{
  "file": "hympavzi_1.pdf",
  "num_pages": 198,
  "pages": [
    {
      "page_number": 1,
      "text": " \n \n \n \n \n \n19 September 2024 \nEMA/464842/2024 \nCommittee for Medicinal Products for Human Use (CHMP) \n \n \n \nAssessment report \nHympavzi \nInternational non-proprietary name: Marstacimab \n \n \nProcedure No. EMEA/H/C/006240/0000 \n \n \n \nNote \nAssessment report as adopted by the CHMP with all information of a commercially confidential nature \ndeleted. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOfficial address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands \nAddress for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us \nSend us a question Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000 \n \nAn agency of the European Union \n \n© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged. \n"
    },
    {
      "page_number": 2,
      "text": "Assessment report \nEMA/464842/2024 \nPage 2/198 \n \nTable of contents \n1. Background information on the procedure ................................................................. 11 \n1.1. Submission of the dossier ......................................................................................................................... 11 \n1.2. Legal basis, dossier content ..................................................................................................................... 11 \n1.3. Information on Paediatric requirements .............................................................................................. 11 \n1.4. Information relating to orphan market exclusivity .......................................................................... 12 \n1.4.1. Similarity ...................................................................................................................................................... 12 \n1.5. Applicant’s request for consideration .................................................................................................... 12 \n1.5.1. New active Substance status ............................................................................................................... 12 \n1.6. Scientific Advice / Protocol assistance .................................................................................................. 12 \n1.7. Steps taken for the assessment of the product ................................................................................ 14 \n2. Scientific discussion.................................................................................................................. 16 \n2.1. Problem statement ....................................................................................................................................... 16 \n2.1.1. Disease or condition................................................................................................................................. 16 \n2.1.2. Epidemiology............................................................................................................................................... 16 \n2.1.3. Aetiology and pathogenesis .................................................................................................................. 17 \n2.1.4. Clinical presentation, diagnosis ........................................................................................................... 17 \n2.1.5. Management ............................................................................................................................................... 18 \n2.2. About the product ......................................................................................................................................... 19 \n2.3. Type of Application and aspects on development ............................................................................ 19 \n2.4. Quality aspects .............................................................................................................................................. 20 \n2.4.1. Introduction ................................................................................................................................................. 20 \n2.4.2. Active Substance ....................................................................................................................................... 20 \n2.4.3. Finished Medicinal Product – Prefilled Syringe .............................................................................. 25 \n2.4.4. Finished Medicinal Product - Prefilled Pen ....................................................................................... 29 \n2.4.5. Discussion and conclusions on chemical, pharmaceutical and biological aspects ........... 31 \n2.4.6. Conclusions on the chemical, pharmaceutical and biological aspects .................................. 33 \n2.5. Non-clinical aspects ..................................................................................................................................... 34 \n2.5.1. Introduction ................................................................................................................................................. 34 \n2.5.2. Pharmacology ............................................................................................................................................. 34 \n2.5.3. Pharmacokinetics ...................................................................................................................................... 41 \n2.5.4. Toxicology .................................................................................................................................................... 41 \n2.5.5. Ecotoxicity/environmental risk assessment ................................................................................... 45 \n2.5.6. Discussion on non-clinical aspects ..................................................................................................... 45 \n2.5.7. Conclusion on the non-clinical aspects ............................................................................................. 52 \n2.6. Clinical aspects .............................................................................................................................................. 53 \n2.6.1. Introduction ................................................................................................................................................. 53 \n2.6.2. Clinical pharmacology.............................................................................................................................. 54 \n2.6.3. Discussion on clinical pharmacology ................................................................................................. 81 \n2.6.4. Conclusions on clinical pharmacology ............................................................................................... 90 \n2.6.5. Clinical efficacy .......................................................................................................................................... 91 \n"
    },
    {
      "page_number": 3,
      "text": "Assessment report \nEMA/464842/2024 \nPage 3/198 \n \n2.6.6. Discussion on clinical efficacy ............................................................................................................ 156 \n2.6.7. Conclusions on the clinical efficacy .................................................................................................. 164 \n2.6.8. Clinical safety ........................................................................................................................................... 164 \n2.6.9. Discussion on clinical safety ............................................................................................................... 183 \n2.6.10. Conclusions on the clinical safety .................................................................................................. 186 \n2.7. Risk Management Plan.............................................................................................................................. 187 \n2.7.1. Safety concerns ....................................................................................................................................... 187 \n2.7.2. Pharmacovigilance plan ........................................................................................................................ 187 \n2.7.3. Risk minimisation measures ............................................................................................................... 187 \n2.7.4. Conclusion .................................................................................................................................................. 188 \n2.8. Pharmacovigilance ...................................................................................................................................... 188 \n2.8.1. Pharmacovigilance system .................................................................................................................. 188 \n2.8.2. Periodic Safety Update Reports submission requirements ..................................................... 188 \n2.9. Product information.................................................................................................................................... 188 \n2.9.1. User consultation..................................................................................................................................... 188 \n2.9.2. Additional monitoring ............................................................................................................................ 188 \n3. Benefit-Risk Balance ..............................................................................................................189 \n3.1. Therapeutic Context .................................................................................................................................. 189 \n3.1.1. Disease or condition............................................................................................................................... 189 \n3.1.2. Available therapies and unmet medical need .............................................................................. 189 \n3.1.3. Main clinical studies ............................................................................................................................... 189 \n3.2. Favourable effects ...................................................................................................................................... 190 \n3.3. Uncertainties and limitations about favourable effects ................................................................ 190 \n3.4. Unfavourable effects .................................................................................................................................. 191 \n3.5. Uncertainties and limitations about unfavourable effects ........................................................... 191 \n3.6. Effects Table ................................................................................................................................................. 192 \n3.7. Benefit-risk assessment and discussion ............................................................................................ 193 \n3.7.1. Importance of favourable and unfavourable effects ................................................................. 193 \n3.7.2. Balance of benefits and risks ............................................................................................................. 193 \n3.7.3. Additional considerations on the benefit-risk balance .............................................................. 194 \n3.8. Conclusions.................................................................................................................................................... 194 \n4. Recommendations ....................................................................................................................194 \n"
    },
    {
      "page_number": 4,
      "text": "Assessment report \nEMA/464842/2024 \nPage 4/198 \n \nList of abbreviations \n \n \nAbbreviation \nTerm \n%CV \npercent coefficient of variation \nABR \nannualised bleeding rate(s) \nACCR \nAccumulation ratio \nADA \nanti-drug antibody \nADCC \nAntibody-dependent cell-mediated cytotoxicity \nADR \nadverse drug reaction \nAE \nadverse event \nAESI \nadverse event of special interest \nAPCC \nActivated prothrombin complex concentrate \naPTT \nactivated partial thromboplastin time \nAST \naspartate aminotransferase \nATP \nActive Treatment Phase \nAUC \narea under the concentration-time curve \nAUC48 \nAUC time curve from time zero to 48 hours \nAUC168 \nAUC time curve from time zero to 168 hours \nAUCinf \narea under the concentration-time curve from 0 to infinity \nAUClast \narea under the concentration-time curve from 0 to time of last \nmeasurable concentration \nAUCss \narea under the concentration-time curve at steady-state \nAUCtau \nAUC time curve during a dosing interval \nBID \nTwice daily \nBLQ \nBelow limit of quantification \nBP \nBlood pressure \nBU \nBethesda Units \nC1q \nComplement component 1q \nCBER \nCenter for Biologics Evaluation and Research \nCDC \nUS Centers for Disease Control and Prevention \n"
    },
    {
      "page_number": 5,
      "text": "Assessment report \nEMA/464842/2024 \nPage 5/198 \n \nCDER \nCenter for Drug Evaluation and Research \nCDRH3 \nthird complementarity-determining region of the heavy chain \nCDRL3 \nthird complementarity-determining region of the light chain \nCHMP \nCommittee for Medicinal Products for Human Use \nCI \nconfidence interval \nCL \nclearance \nCL/F \napparent clearance \nCLIA \nClinical Laboratory Improvement Amendments \nCmax \nmaximum observed concentration \nCmax,ss \nmaximum observed concentration at steady state \nCNS \nCentral nervous system \nCO \nClinical Overview \nCOVID-19 \ncoronavirus disease 2019 \nCRA \nCytokine release assay \nCRO \nContract Research Organisation \nCSR \nClinical Study Report \nCV \nCardiovascular \nCWRES \nConditional weighted residuals \nCYP \ncytochrome p450 \nDC-T \ndendritic cell-CD4 T-cell assay \nDDI \ndrug-drug interaction \ndPT \ndilute prothrombin time \nDVT \ndeep vein thrombosis \nD180 \nDay 180 \nEBE \nEmpirical Bayes estimate \nEC50 \n50% effective dose \nECG \nelectrocardiogram \nECL \nelectrochemiluminescence \neGFR \nestimated glomerular filtration rate \nEHL \nextended half-life \n"
    },
    {
      "page_number": 6,
      "text": "Assessment report \nEMA/464842/2024 \nPage 6/198 \n \nEMA \nEuropean Medicines Agency \nEmax \nmaximal effect \nEQ-5D-5L \nEuropean Quality of Life-5 Dimensions 5 Level version \nEQ-VAS \nEQ visual analogue scale \nEU \nEuropean Union \nF \nbioavailability \nFc \nFragment crystallizable region of an antibody \nFcgR \nFc gamma receptor \nFEIBA \nFactor Eight Inhibitor Bypassing Activity \nFDA \nFood and Drug Administration \nFIH \nfirst-in-human \nFIX \nFactor IX \nFVIIa \nFactor VII activated \nFVIII \nFactor VIII \nFX \nFactor X \nFXa \nFactor X activated \nGLP \nGood Laboratory Practice \nGOF \nGoodness of fit \nHaem-A-QoL \nHaemophilia Quality of Life Questionnaire for Adults (≥17 years \nof age) \nHaemo-QoL \nHaemophilia Quality of Life Questionnaire for Children \n(Adolescents 12 to <17 years of age) \nHAL2 \nHaemophilia Activities List \nHEPES \n4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid \nHJHS \nHaemophilia Joint Health Score \nHRQoL \nhealth-related quality-of-life \nHTC \nHemophilia Treatment Centers \nIFN-g/-g \ninterferon gamma \nICH \nInternational Conference on Harmonisation \nIgG \nimmunoglobulin G \nIgG1 \nimmunoglobulin G1 \n"
    },
    {
      "page_number": 7,
      "text": "Assessment report \nEMA/464842/2024 \nPage 7/198 \n \nIgG4 \nImmunoglobulin G4 \nIHC \nImmunohistochemical \nIIV \nInter-individual variance \nIL-6 \ninterleukin 6 \nIM \nintramuscular(ly) \nIND \nInvestigational New Drug \nINR \ninternational normalized ratio \nIPRED \nIndividual predictions \nISI \nIntegrated Summary of Immunogenicity \nISR \ninjection site reaction \nISR \nincurred sample reanalysis \nIU \ninternational unit \nIV \nintravenous \nIVM \nIntravital Microscopy \nIWRES \nIndividual weighted residuals \nK \nClot formation time \nK1 \nKunitz domain 1 \nK2 \nKunitz domain 2 \nK3 \nKunitz domain 3 \nka \nfirst-order absorption rate constant \nKD \ndissociation constant \nLC/MS \nliquid chromatography/mass spectrometry \nLDT \nlaboratory developed test \nLLOQ \nLower limit of quantification \nLPLV \nlast participant last visit \nMAA \nMarketing Authorisation Application \nmAb \nMonoclonal antibody \nMAD \nMultiple ascending dose \nMAD \nMutual Acceptance of Data \nmITT \nModified Intent-to-Treat \n"
    },
    {
      "page_number": 8,
      "text": "Assessment report \nEMA/464842/2024 \nPage 8/198 \n \nN \ntotal number, total sample size \nn \nnumber (subgroup or subpopulation) \nNAb \nneutralizing antibody \nNCA \nNon-compartmental \nNOAEL \nNo-observed-adverse-effect level \nNOEL \nNo-observed-effect-level \nNONMEM \nNon-linear mixed-effects modeling \nOECD \nOrganisation for Economic Co-operation and Development \nOD \non-demand \nOLE \nopen-label extension \nOP \nObservational Phase \nPBS \nPhosphate buffered saline \nPD \npharmacodynamic(s) \nPDCO \nPaediatric Committee (Committee for Medicinal Products for \nHuman Use [CHMP] of European Medicines Agency [EMA]) \npedHAL \nPediatric Haemophilia Activities List \nPGIC-H \nPatient’s Global Impression of Change-Haemophilia \nPF 1+2 \nprothrombin fragment 1 +2 \nPFP \npre-filled pen \nPFS \npre-filled syringe \nPI \nprincipal investigator \nPIP \nPediatric Investigation Plan \nPK \npharmacokinetic(s) \nPMAR \nPopulation Modeling and Analysis Report \nPRED \nPopulation predictions \nPRO \npatient-reported outcome \nPT \n(MedDRA) Preferred Term; prothrombin time \nQ \nInter-compartmental clearance \nQoL \nquality of life \nQD \nOnce per day \n"
    },
    {
      "page_number": 9,
      "text": "Assessment report \nEMA/464842/2024 \nPage 9/198 \n \nQW \nonce weekly \nR \nDose dependent decrease in clotting time \nrFVIIa \nActivated recombinant Factor VII \nrFVIII \nRecombinant Factor VIII \nRSE \nRelative standard error \nRU \nRelative unit \nSAE \nserious adverse event \nSAP \nStatistical Analysis Plan \nSBS \nSummary of Biopharmaceutic Studies and Associated Analytical \nMethods \nSC \nsubcutaneous(ly) \nSCE \nSummary of Clinical Efficacy \nSCP \nSummary of Clinical Pharmacology \nSCS \nSummary of Clinical Safety \nSD \nstandard deviation \nSEM \nStandard error of the mean \nSHL \nstandard half-life \nSMQ \nStandardised MedDRA Query \nSOC \nSystem Organ Class \nSPR \nSurface Plasmon Resonance \nSS \nSteady state \nt½ \nHalf-life \nTCR \nTissue Cross Reactivity \nTEAE \ntreatment-emergent adverse event \nTEG \nThromboelastography \nTF \nTissue factor \nTFPI \ntissue factor pathway inhibitor \nTGA \nthrombin generation assay \nTK \nToxicokinetic \nTmax \ntime of occurrence of Cmax \n"
    },
    {
      "page_number": 10,
      "text": "Assessment report \nEMA/464842/2024 \nPage 10/198 \n \nTMDD \nTarget Mediated Drug Disposition \nTNF-a \ntumour necrosis factor a \nUK \nUnited Kingdom \nULN \nupper limit of normal \nULOQ \nUpper limit of quantification \nUS \nUnited States \nVc \ncentral volume of distribution \nVp \nperipheral volume of distribution \nVss \nsteady state volume of distribution \nVWH \nvon Willebrand Factor \nVz/F \napparent volume of distribution \nWFH \nWorld Federation of Hemophilia \n"
    },
    {
      "page_number": 11,
      "text": "Assessment report \nEMA/464842/2024 \nPage 11/198 \n \n1. Background information on the procedure \n \n1.1. Submission of the dossier \n \nThe applicant Pfizer Europe Ma EEIG submitted on 6 October 2023 an application for marketing authorisation \nto the European Medicines Agency (EMA) for Hympavzi, through the centralised procedure falling within the \nArticle 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. \nMarstacimab was designated as an orphan medicinal product EU/3/16/1752 on 14.10.2016 in the following \ncondition: Treatment of haemophilia A. \nMarstacimab was designated as an orphan medicinal product EU/3/23/2866 on 13.12.2023 in the following \ncondition: Treatment of haemophilia B. \nFollowing the CHMP positive opinion on this marketing authorisation and at the time of the review of the \norphan designation by the Committee for Orphan Medicinal Products (COMP), this product was removed from \nthe Union Register of designated orphan medicinal products on 10 October 2024. More information on the \nCOMP’s review can be found in the orphan withdrawal assessment report published under the ‘Assessment \nhistory’ tab on the Agency’s website: https://www.ema.europa.eu/en/medicines/human/EPAR/hympavzi \nThe applicant applied for the following indication: \nHympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, \nweighing at least 35 kg, with: \n• \nsevere haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or \n• \nsevere haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. \n \n1.2. Legal basis, dossier content \n \nThe legal basis for this application refers to: \nArticle 8.3 of Directive 2001/83/EC - complete and independent application \nThe application submitted is composed of administrative information, complete quality data, non-clinical and \nclinical data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting \ncertain test(s) or study(ies). \n \n1.3. Information on Paediatric requirements \n \nPursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decisions \nP/0443/2022 on the agreement of a paediatric investigation plan (PIP). \nAt the time of submission of the application, the PIP P/0443/2022 was not yet completed as some measures \nwere deferred. \n"
    },
    {
      "page_number": 12,
      "text": "Assessment report \nEMA/464842/2024 \nPage 12/198 \n \n1.4. Information relating to orphan market exclusivity \n \n1.4.1. Similarity \n \nPursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No \n847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan \nmedicinal products. \n \n1.5. Applicant’s request for consideration \n \n1.5.1. New active Substance status \n \nThe applicant requested the active substance Marstacimab contained in the above medicinal product to be \nconsidered as a new active substance, as the applicant claims that it is not a constituent of a medicinal \nproduct previously authorised within the European Union. \n \n1.6. Scientific Advice / Protocol assistance \n \nThe Applicant received the following Scientific Advice and Protocol Assistance on the development relevant \nfor the indication subject to the present application: \n \nDate \nReference \n21 July 2016 \nEMEA/H/SA/3363/1/2016/I \n20 July 2017 \nEMEA/H/SA/3363/2/2017/PA/II \n26 July 2018 \nEMEA/H/SA/3363/2/FU/1/2018/PA/II \n31 January 2019 \nEMEA/H/SA/3363/4/2018/II \n31 January 2019 \nEMEA/H/SA/3363/3/2018/PA/III \n19 May 2022 \nEMA/SA/0000086196 \n19 May 2022 \nEMA/SA/0000086197 \n \n \nThe Scientific Advice and Protocol Assistance pertained to the following quality, non-clinical, and clinical \naspects. \nEMEA/H/SA/3363/1/2016/I – Non-clinical development \n• \nThe need for a chronic toxicity study in monkeys; the proposed juvenile toxicity studies; the proposed \ncombination pharmacology study with PF-06741086 and eptacog alfa; the need for a fertility study in \nfemale animals and embryo fetal developmental toxicity studies; the proposed waiver for carcinogenicity \nstudies. \nEMEA/H/SA/3363/2/2017/PA/II – Clinical development \n"
    },
    {
      "page_number": 13,
      "text": "Assessment report \nEMA/464842/2024 \nPage 13/198 \n \n• \nThe proposed clinical development plan to characterise the PK, PD, safety, immunogenicity and efficacy of \nPF-06741086 for prophylaxis treatment of young children, adolescent, and adult individuals with \nhaemophilia A (with/without inhibitors); characterisation of PD and PK of PF-06741086 across the \nanticipated range of ages to be treated; the adequacy of the proposed safety data package to characterise \nthe overall safety of routine prophylactic treatment with PF-06741086; the proposed plan to characterise \nthrombotic safety of PF-06741086 in haemophilia patients with inhibitors during concomitant treatment \nwith eptacog alfa; the proposed characterisation of immunogenicity; the approach to flat clinical dosing for \nPF-06741086; the proposed primary endpoint for prophylaxis efficacy to show an effect in subjects \nreceiving routine prophylaxis treatment with PF-06741086 compared to on-demand treatment; the \nproposed phase 3 programme to support the initial MAA for individuals aged 12 to <65 years with and \nwithout inhibitors; the proposed paediatric development and staggered approach for inclusion of paediatric \npatients in clinical trials; the proposed justification to not study paediatric patients <2 years with inhibitors \nand without inhibitors; the proposed timing of conducting the paediatric study and strategy for MAA; the \nneed for a separate clinical study in paediatric patients ages 2 to <12 years without inhibitors; the \nproposed data packages to support the initial indication of prophylaxis in adolescent and adult patients \nwith haemophilia A (and B) patients with inhibitors, and subsequent extensions of the indication to include \na) adolescent and adult haemophilia A (and B) patients without inhibitors and b) young paediatric \nhaemophilia A (and B) patients with inhibitors (and without inhibitors if supported by analysis of available \ndata). \n \n \nEMEA/H/SA/3363/2/FU/1/2018/PA/II – Clinical development \n• \nUsability evaluation of the prefilled pen; clinical bridging between delivery presentations (prefilled syringe \nto prefilled pen). \n \nEMEA/H/SA/3363/4/2018/II – Clinical development \n• \nThe design of the pivotal Phase 3 study B7841005 in haemophilia A or B subjects aged 12 years and older \nwith and without inhibitors and, in particular, the staged enrollment of non-inhibitor patients on prior \nprophylaxis, dosing regimen, primary endpoint, and statistical analysis; the strategy to submit an initial \nMAA in haemophilia A or B inhibitor patients at the time of an interim analysis; adequacy of the overall \nclinical development plan to characterise the safety, tolerability, efficacy, PK, PD, and immunogenicity of \nPF-06741086; the proposed paediatric development strategy. \n \nEMEA/H/SA/3363/3/2018/PA/III – Quality, Non-clinical and Clinical development \n• \nThe proposed potency assay. \n• \nThe design of the proposed combination pharmacology study in rats with PF 06741086 and FEIBA; the \nproposed waiver for carcinogenicity studies; appropriateness of the overall non-clinical development \nprogramme for MAA. \n• \nThe same clinical questions as for procedure EMEA/H/SA/3363/3/2018/PA/III. \n \nEMA/SA/0000086196 - Clinical development \n• \nProposal to file an initial MAA in patients with haemophilia A without inhibitors, upon completion of 12 \nmonths of active dosing for participants in the non-inhibitor cohorts, in particular adequacy of the safety \nanalyses, and inclusion of adolescent patients aged 12 and above. \n"
    },
    {
      "page_number": 14,
      "text": "Assessment report \nEMA/464842/2024 \nPage 14/198 \n \nEMA/SA/0000086197 - Clinical development \n• Proposal to file an initial MAA in patients with haemophilia B without inhibitors, upon completion of 12 \nmonths of active dosing for participants in the non-inhibitor cohorts, in particular adequacy of the safety \nanalyses, and inclusion of adolescent patients aged 12 and above. \n \n1.7. Steps taken for the assessment of the product \nThe Rapporteur and Co-Rapporteur appointed by the CHMP were: \nRapporteur: Daniela Philadelphy \nCo-Rapporteur: Robert Porszasz \nTheapplicationwasreceivedbytheEMA on \n6October 2023 \nTheprocedurestartedon \n26October 2023 \nTheCHMPRapporteur'sfirstAssessmentReportwascirculatedtoall CHMP \nand PRAC members on \n15 January2024 \nTheCHMPCo-Rapporteur'sfirstAssessmentReportwascirculatedtoall CHMP \nand PRAC members on \n30 January2024 \nThePRACRapporteur'sfirstAssessmentReportwascirculatedtoall PRAC \nand CHMP members on \n29 January2024 \nTheCHMPagreedontheconsolidatedListofQuestionstobesentto the \napplicant during the meeting on \n22February 2024 \nTheapplicantsubmittedtheresponsestotheCHMPconsolidatedListof \nQuestions on \n23May2024 \nTheCHMPRapporteurscirculatedtheCHMPandPRACRapporteursJoint \nAssessment Report on the responses to the List of Questions to all \nCHMP and PRAC members on \n1 July2024 \nThePRACagreedonthePRACAssessmentOverviewandAdviceto CHMP \nduring the meeting on \n11 July2024 \nThe CHMP Rapporteurs circulated the updated CHMP and PRAC \nRapporteursJointAssessmentReportontheresponsestotheListof Questions \nto all CHMP and PRAC members on \n18 July2024 \nTheCHMPagreedonalistofoutstandingissuesinwritingtobesentto the \napplicant on \n25 July2024 \nTheapplicantsubmittedtheresponsestotheCHMPListofOutstanding Issues \non \n19August 2024 \nTheCHMPRapporteurscirculatedtheCHMPandPRACRapporteursJoint \nAssessment Report on the responses to the List of Outstanding Issues \nto all CHMP and PRAC members on \n4September2024 \nTheCHMP,in thelightoftheoveralldatasubmittedandthescientific \n19September2024 \n"
    },
    {
      "page_number": 15,
      "text": "Assessment report \nEMA/464842/2024 \nPage 15/198 \n \ndiscussion within the Committee, issued a positive opinion for granting \na marketing authorisation to Hympavzi on \nThe CHMP adopted a report on similarity of Hympavzi with Alprolix, \nIdelvion, Roctavian and Hemgenix \n19 September 2024 \nFurthermore, the CHMP adopted a report on New Active Substance \n(NAS) status of the active substance contained in the medicinal product \n19 September 2024 \n"
    },
    {
      "page_number": 16,
      "text": "Assessment report \nEMA/464842/2024 \nPage 16/198 \n \n2. Scientific discussion \n \n2.1. Problem statement \n \n2.1.1. Disease or condition \n \nHaemophilia A and B are bleeding disorders caused by a deficiency of coagulation Factor VIII (FVIII) or \ncoagulation Factor IX (FIX) respectively, each of which is a key component of the intrinsic pathway. Blood \ncoagulation is achieved by a highly regulated cascade of plasma proteins, which ensures that bleeding can be \nrapidly stopped and that once bleeding is stopped, the cascade is shut down to prevent thrombosis. This \nregulation is achieved by 2 overlapping pathways, the extrinsic (initiation) and intrinsic (amplification) \npathways, which converge in a final common pathway of coagulation. \nThe Applicant proposes the following indication: Hympavzi is indicated for routine prophylaxis of bleeding \nepisodes in patients 12 years of age and older with: \n• \nsevere haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or \n• \nsevere haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors \n \n \nFOR CHILDREN under 15 years : \n \nChemical Formula: C6304H9766N1678O2006S44 \nMolar Mass: 529694.5200000001 \n \n \nAtoms of carbon present in Hympavzi = a,                       \nAtoms of hydrogen present in Hympavzi = b,           \nAtoms of nitrogen present in Hympavzi =  c, \nAtoms of oxygen present in Hympavzi = d, \nAtoms of sulphur present in Hympavzi = e,    \na = 6304, b=9766, c=1678, d=2006, e=44  \n \nsub total mass of carbon present = v \nsub total mass of hydrogen present = w \nsub total mass of nitrogen present = x \nsub total mass of oxygen present = y \nsub total mass of sulphur present = z \nv =63.11, w= 6.90, x=16.49, y=22.51, z=0.99 \n \nMolar Mass = (v*a)+(w*b)+(x*c)+(y*d)+(z*e) \nMolar Mass = Atoms to the particular element * sub total mass  \nMolar Mass = (63.11*6304)+(6.09*9766)+(16.49*1648)+(22.51*2006)+(0.99*44) \nMolar Mass = 529694.5200000001 \n \n \n2.1.2. Epidemiology \n \n"
    },
    {
      "page_number": 17,
      "text": "Assessment report \nEMA/464842/2024 \nPage 17/198 \n \nIncidence \nGlobally, haemophilia A occurs at a rate of approximately 17.1 cases per 100,000 males7. The estimated \naverage incidence rate was 1 in 5,617 male births for haemophilia A in the US in a study using the \nHaemophilia Treatment Centers (HTC) network, with an incidence rate at birth of 17.9 per 100,000 male \nbirths10. According to the US Centers for Disease Control and Prevention (CDC), approximately 400 boys are \nborn with haemophilia A each year in the US9. The prevalence at birth was 24.6 cases per 100,000 male \nbirths for all severities of haemophilia A and 9.5 cases for severe haemophilia based on data from the 3 most \nestablished registries (Canada, France, and the United Kingdom)10. \nHaemophilia B occurs globally at an annual rate of approximately 1 in 30,000 (3.33 per 100,000) male live \nbirths3 and the incidence rate in the US is 5.3 per 100,000 male births8. While the CDC doesn’t report an \nestimate for how many boys are born annually with haemophilia B, haemophilia B is estimated to be about \n3.4 times less common than haemophilia A8. The prevalence at birth was 5 cases per 100,000 male births for \nall severities of haemophilia B and 1.5 cases for severe haemophilia B in an international study including \nAustralia, Canada, France, Italy, New Zealand, and the United Kingdom10. \nPrevalence \nThe prevalence (per 100,000 males) is 6.0 cases for severe haemophilia A, and 1.1 cases for severe \nhaemophilia B12. The current worldwide population of patients with a diagnosis of haemophilia A, as \ndetermined by the World Federation of Hemophilia (WFH) 2021 survey (representing data reported from \napproximately 7.14 billion persons or roughly 91% of the world population), is estimated to be 185,318 \nindividuals. An estimated 37,998 individuals have a diagnosis of haemophilia B7. \n"
    },
    {
      "page_number": 18,
      "text": "Assessment report \nEMA/464842/2024 \nPage 18/198 \n \nData from the 2021 WFH Annual Global Survey collected from 118 countries show that males represented \n81% of haemophilia A cases, females represented 3% of haemophilia A cases, and gender unknown \nrepresented 5% of haemophilia A cases. For haemophilia B, males represented 79% of cases, females \nrepresented 6% of cases, with 5% with gender unknown (note that numbers do not add up to 100% as not \nall countries provided gender data)7. \nEurope: \nAccording to the WFH Annual Global Survey 2021, the reported number of patients with a diagnosis of \nhaemophilia A (all severities) in various countries is as follows: United Kingdom (UK), n = 7,064; Germany, n \n= 3,793; France, n = 7,623; and the Netherlands, n = 1,376.7 \nFor haemophilia B, the distribution of patients in Europe differs from that of haemophilia A. The WFH Annual \nGlobal Survey 2021 reported that the number of patients with a diagnosis of haemophilia B (all severities) in \nvarious European countries is as follows: UK, n = 1,607; France, n= 1,841; Poland, n = 477; and Ireland, n \n= 223.9 \nThe prevalence at birth (per 100,000 males) is 24.6 and 24.0 cases for all severities of haemophilia A, and \n10.2 and 8.6 cases for severe haemophilia A in the UK and in France, respectively.10 \n \n2.1.3. Aetiology and pathogenesis \n \nThe genes encoding FVIII and FIX are on the long arm of the X chromosome. Haemophilia A and B are the \nonly hereditary clotting diseases inherited in a sex-linked recessive pattern. The genetic mutations cause a \nquantitative decrease in protein expression, a qualitative decrease in protein activity, or both. Approximately \n5% to 10% of patients with haemophilia A and 40% to 50% of patients with haemophilia B make a \ndysfunctional protein, which results in decreased protein activity without a quantitative decrease. More than \n1000 mutations in either the factor VIII or factor IX genes have been identified to cause clinical haemophilia. \nThere is a high rate of spontaneous mutation (approximately one-third of cases) such that even in the \nabsence of a family history, haemophilia should be suspected in a newborn with bleeding and a prolongation \nin the PTT.1 \n \n2.1.4. Clinical presentation, diagnosis \n \nHaemophilia A and B are bleeding disorders caused by a deficiency of coagulation Factor VIII (FVIII) or \ncoagulation Factor IX (FIX) respectively, each of which is a key component of the intrinsic pathway. Blood \ncoagulation is achieved by a highly regulated cascade of plasma proteins, which ensures that bleeding can be \nrapidly stopped and that once bleeding is stopped, the cascade is shut down to prevent thrombosis. This \nregulation is achieved by 2 overlapping pathways, the extrinsic (initiation) and intrinsic (amplification) \npathways, which converge in a final common pathway of coagulation. \nIndividuals with haemophilia A have a FVIII activity level below the normal range 4,5, while those with \nhaemophilia B have a FIX activity level below the normal range. Severity of haemophilia A or B is defined into \n3 categories based on circulating FVIII or FIX activity levels in the plasma, each of which is characterised by \ndifferent bleeding profiles as presented in Table 1. \n"
    },
    {
      "page_number": 19,
      "text": "Assessment report \nEMA/464842/2024 \nPage 19/198 \n \nTable 1: Relationship of bleeding to factor activity level for Haemophilia A and B \n \n \nThe most common haemophilia bleeds are prolonged spontaneous and/or traumatic bleeding within the \nmusculoskeletal system and joints, as well as in the muscle and mucosal soft tissues. While less common, \nsome types of bleeds, including intracranial and gastrointestinal bleeds, can be life-threatening. An \nindividual's bleeding phenotype is the result of their genotype, joint health status and behaviour. Even among \npatients with severe haemophilia there can be considerable heterogeneity in bleeding phaenotypes6. \n \n2.1.5. Management \n \nTreatment of haemophilia is primarily through replacement of the missing FVIII or FIX. The replacement \nfactor products are commonly standard half-life (SHL) or extended half-life (EHL) recombinant factor \nproducts, but plasma-derived products of various purities are still in use. Treatment with the replacement \ncoagulation factor can either be episodic, treating bleeding episodes on-demand as they occur, or \nprophylactic, preventing bleeding episodes by a regular schedule of FVIII or FIX infusions to maintain factor \nlevels in a range >1%. Significant evidence exists that prophylactic treatment prevents bleeding episodes \nand the associated joint damage that is a major morbidity in haemophilic patients.11,12,13,14,15 \nDue to the relatively short half-lives of FVIII and FIX, effective prophylactic treatment in patients without \ninhibitors may require frequent intravenous (IV) administration, with the most frequent administration being \nevery 2 days for SHL FVIII products, and up to twice weekly for SHL FIX products.6,13,14,15 The recent \ndevelopment of EHL factor replacement products have helped reduce treatment burden for patients with \nhaemophilia by lowering prophylactic infusion rates and maintaining higher trough levels.16,17,18 However, \ndespite the approval of newer EHL products, patients still may require regular factor replacement IV infusions \nat frequencies ranging from twice weekly to once every 2 weeks.23,24 \nEmicizumab (Hemlibra) is a bi-specific antibody that bridges activated coagulation Factor IXa and Factor X (to \nreplace the function of missing activated FVIII). Hemlibra received approval by the EMA on 23 February 2018 \nfor “routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) \nwith factor VIII inhibitors”, \"Hemlibra can be used in all age groups”22 and on 11 March 2019 received \napproval for “routine prophylaxis of bleeding episodes in patients with severe haemophilia A (congenital \nfactor VIII deficiency, FVIII <1%) without factor VIII inhibitors”, and is currently approved for once weekly \n(QW) administration for the first 4 weeks, followed by SC administration weekly, or every 2 or 4 weeks.23,24 \nSeveral newer treatments for haemophilia A or B are available in some markets or have submissions \ncurrently under regulatory review. Hemgenix (etranacogene dezxaparvovec) is a gene therapy treatment \nconditionally approved in the EU for treatment of adults with haemophilia B.25,26 Roctavian (valoctocogene \nroxparvovec) is a gene therapy treatment that has been conditionally approved in the EU for the treatment of \nhaemophilia A.28 Alhemo (concizumab) is a new monoclonal humanised IgG4 antibody that targets the K2 \ndomain of TFPI. Concizumab was approved in Canada in March 202329 and Australia in July 202330 for use in \n"
    },
    {
      "page_number": 20,
      "text": "Assessment report \nEMA/464842/2024 \nPage 20/198 \n \nhaemophilia B patients with inhibitors and was approved in Canada in July 2023 for use in haemophilia A \npatients with inhibitors.31 Concizumab is under regulatory review in the US and EU. \n \n2.2. About the product \n \nMarstacimab is a human monoclonal IgG1 antibody directed against the Kunitz domain 2 (K2) of tissue factor \npathway inhibitor (TFPI), the primary inhibitor of the extrinsic coagulation cascade. TFPI initially binds to and \ninhibits the factor Xa active site via its second Kunitz inhibitor domain (K2). Thus, neutralising the activity of \nTFPI may serve to enhance the extrinsic pathway and reduce or eliminate the need for replacement FVIII or \nFIX. \nMarstacimab is intended for routine prophylaxis of bleeding episodes in patients 12 years of age and older \nwith: severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or \nsevere haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. \nThe recommended dose for patients 12 years of age and older, weighing at least 35 kg, is an initial loading \ndose of 300 mg by subcutaneous (SC) injection followed thereafter by 150 mg by subcutaneous injection \nonce weekly. \n \nFOR Teenagers of age between 16 years to 21 years : \n \nChemical Formula: C6904H9786N1978O2506S47 \nMolar Mass:  13132954273.31001 \n \nAtoms of carbon present in Hympavzi = a,  \nAtoms of hydrogen present in Hympavzi = b, \nAtoms of nitrogen present in Hympavzi =  c, \nAtoms of oxygen present in Hympavzi = d, \nAtoms of sulphur present in Hympavzi = e,  \na = 6904, b=9786, c=1978, d=2506, e=47 \nsub total mass(g/mol) of carbon present = v \nsub total mass(g/mol) of hydrogen present = w \nsub total mass(g/mol) of nitrogen present = x \nsub total mass(g/mol) of oxygen present = y \nsub total mass of sulphur present = z \nv =82921.87, w= 9863.31, x=27705.25, y=40094.50, z=1507.05 \n \nMolar Mass = (v*a)+(w*b)+(x*c)+(y*d)+(z*e) \nMolar Mass = Atoms to the particular element * sub total mass(g/mol)  \nMolar Mass = (82921.87*6904) +(9863.31*9786) +(27705.25*1978) +(40094.50*2506) \n+(1507.05*47) \nMolar Mass = 13132954273.31001  \n \n \n"
    },
    {
      "page_number": 21,
      "text": "Assessment report \nEMA/464842/2024 \nPage 21/198 \n \n \n2.3. Type of Application and aspects on development \n \nScientific advice was provided by CHMP during several protocol assistance procedures for non-clinical and \nclinical topics, please see section 1.6. \n"
    },
    {
      "page_number": 22,
      "text": "Assessment report \nEMA/464842/2024 \nPage 22/198 \n \n2.4. Quality aspects \n \n2.4.1. Introduction \n \nThe finished product (FP) is presented as solution for injection containing 150 mg/mL of marstacimab as \nactive substance (AS). Other ingredients are: Disodium edetate, L-Histidine, L-Histidine monohydrochloride, \nPolysorbate 80 (PS80), sucrose, water for injections. The product is available in a prefilled syringe and a \nprefilled pen containing 1 mL solution for injection. \n \n2.4.2. Active Substance \n \n2.4.2.1. General Information \n \nMarstacimab (INN) is a new active substance for the treatment of haemophilia A and haemophilia B. It is a \nrecombinant human monoclonal IgG1 lambda antibody directed against the Kunitz 2 (K2) domain of tissue \nfactor pathway inhibitor (TFPI) and produced in Chinese Hamster Ovary cells (CHO). The Applicant described \nthe features of the antibody, its glycosylation, disulfide bonds and modifications to minimise Fc effector \nfunctions. The annotated primary amino acid sequence and the theoretical and experimental molecular mass \nis presented. Molecular formula as well as the element number of cysteine residues and disulfide bonds are \nlisted. \n2.4.2.2. Manufacture, process controls and characterisation \nManufacturers and GMP \nThe active substance is manufactured at Wyeth BioPharma, Division of Wyeth Pharmaceuticals LLC, 1 Burtt \nRoad, Andover, MA 01810, USA. All relevant GMP certificates are valid according to EudraGMDP database. QP \ndeclaration concerning GMP compliance of the active substance manufacture has been presented. \nDescription of Manufacturing Process and Process Controls \nThe manufacturing process for marstacimab active substance uses a recombinant Chinese hamster ovary \n(CHO) cell line that contains the DNA encoding the sequence for marstacimab and is grown in suspension \nculture. Chemically defined, animal-derived component-free media is used. Upon thawing of a working cell \nbank (WCB) vial, the cell culture is expanded in several steps from shake flasks/bags to a seed bioreactor. \nCells from the seed bioreactor are then used as inoculum for a production bioreactor. The duration of an \ninoculum/campaign can vary but cannot exceed the established limit of in vitro cell age (LIVCA). A production \nbioreactor culture is harvested and clarified by centrifugation and depth filtration to remove cells and debris. \nFollowing the harvest step, the pool is processed by a Protein A affinity chromatography step, a low pH virus \ninactivation step, and an anion exchange (AEX) chromatography step. The material is then processed through \na virus retaining filter followed by concentration and buffer exchange in an ultrafiltration/diafiltration (UF/DF) \nstep. The final formulation of active substance is followed by final filtration (0.2 µm), filling, and freezing. \nOverall, sufficiently detailed flow charts were provided, and the manufacturing process is appropriately \ndescribed. Critical and non-critical process parameters (CPP, non-CPP) and critical material attributes (CMA) \nand their established acceptable range as well as in-process tests (IPCs) are listed for every process step. \n"
    },
    {
      "page_number": 23,
      "text": "Assessment report \nEMA/464842/2024 \nPage 23/198 \n \n1Control of materials tails of compendial and non-compendial raw materials are provided. Raw materials used \nfor cell culture and purification process are listed with their respective quality standard and their intended \nuse. Acceptable acceptance criteria are provided for the non-compendial raw materials. The composition of \nthe cell culture media is described. Description of the filters and chromatography resins are provided. Overall, \nthe provided information is sufficient. \nThe construction of the expression plasmid and their genetic elements are described in sufficient detail. The \nexpression plasmid used for transfection was confirmed by sequencing. The information provided on origin \nand history of the CHO cell line and generation of the cell line clone is satisfactory. The host cell bank was \nadequately tested for contaminants. Chemically defined animal component-free medium was used to prepare \nthe host cell bank. \nA two-tiered cell bank system consisting of MCB and WCB has been established in accordance with ICH Q5D \nand GMP requirements. The cell banking system is adequately described with sufficient details on \nmanufacture and storage of the MCB and WCB. Vials of both MCB and WCB are stored at multiple sites. \nThe cell banks have been adequately characterised. The Applicant has established a LIVCA from the MCB, \nphenotypic stability and comparability was confirmed for MCB, WCB and end of production (EOP) LIVCA cells. \nMCB and WCB stability is monitored; the proposed intervals are acceptable. A protocol for introduction of \nfuture WCBs has been included and considered acceptable. \nIn conclusion, the characterisation of the cell banks satisfactorily demonstrates identity, purity, suitability, \nand genetic stability. \nControl of critical steps and intermediates \nDetails of process controls and CPPs have been provided. The process controls for cell culture and harvest \ninclude a combination of CPPs, non-CPPs, CMAs, and in-process tests. Operational parameter results outside \ncontrol limits will be investigated. \nIn the upstream process, IPCs are established over the whole cell culture process. \nIn the downstream process, tests for bioburden and endotoxin are performed throughout the purification \nprocess. The purification process contains virus clearance and inactivation steps. \nOverall, a holistic approach to the control strategy has been taken, where both active substance and finished \nproduct elements were considered in totality to ensure final finished product quality through shelf-life. For \nboth cell culture/harvest and the downstream purification processes, the process controls include a \ncombination of critical process parameters (CPP), non-critical process parameters (non-CPP), critical material \nattributes (CMA), and in-process tests. Overall, the control strategy in terms of CPPs and process controls is \nconsidered acceptable to ensure adequate control of the active substance manufacturing process. Hold times \nare supported by appropriate data. \nProcess Validation \nProcess performance qualification (PPQ) of the marstacimab commercial manufacturing process has been \nperformed. Pre-defined acceptance criteria for performance were presented for the upstream and \ndownstream processes. All PPQ batches met the pre-defined acceptance criteria when run within defined \nprocess parameters and met the release acceptance criteria, demonstrating the adequacy of the \nmanufacturing process controls for consistent batch production. Overall, it is agreed that the PPQ showed \nthat the manufacturing process is able to consistently produce active substance with predefined quality. The \ncontrol strategy proved to be effective. Deviations were appropriately followed up. \n"
    },
    {
      "page_number": 24,
      "text": "Assessment report \nEMA/464842/2024 \nPage 24/198 \n \nImpurities \nRemoval of host cell-derived DNA and protein as well as process-derived and media-derived impurities has \nbeen demonstrated.. The results from the PPQ batches showed consistent capability of the purification steps \nto remove such impurities. \nAt the Active Substance level, all impurities were in a range that does not pose a safety concern. \nTo conclude, validation of the removal of impurities was appropriately performed and no issues are raised. \nHold times \nIn-process hold times to demonstrate biochemical stability were validated in small scale models \nrepresentative of the commercial scale manufacturing, which is acceptable. The hold-times with respect to \nmicrobiological control were demonstrated on all PPQ batches. Overall, the in-process hold times for the \ncommercial process were appropriately established and no issues are raised. \nColumn and Membrane Studies \nResin lifetime was appropriately established at small-scale and an acceptable protocol for monitoring resin \nlifetime at commercial scale was provided. For UF/DF membrane lifetime a concurrent validation protocol will \nbe executed at commercial scale, which is acceptable. Overall, establishment of resin and membrane lifetime \nis appropriate. \nReprocessing \nReprocessing has been appropriately evaluated at small-scale for both filters and an appropriate protocol was \nprovided to confirm reprocessing at commercial scale in case it is needed in the future. Overall, the \nApplicant´s strategy to implement reprocessing is accepted. \nShipping validation \nThe shipping validation supports shipment of marstacimab active substance in the container closure was \nprovided. \nManufacturing Process Development \nManufacturing-scale runs and process characterisation studies, including design of experiments (DoE) \nstudies, using scale-down models of individual unit operations has been applied to establish an understanding \nof the marstacimab manufacturing process. \nComparability Assessment \nComparability assessments have been performed to support the process changes The overall strategy to \ncomparability assessment is appropriate. \nOverall, based on the presented results, it is agreed that the material derived from the different processes \ncan be regarded comparable. Thus, a bridge between material used from different processes in clinical \nstudies was appropriately established. \nQuality Attributes and Analytical Methods \nA summary of the quality attribute criticality assignment rationale for the marstacimab active substance was \npresented. The results of the criticality assessment and justifications is reasonable. \n"
    },
    {
      "page_number": 25,
      "text": "Assessment report \nEMA/464842/2024 \nPage 25/198 \n \nEvolution of analytical method was described and does not give rise to questions. \nIn-Process Extractables and Leachables \nA risk assessment was performed for all marstacimab active substance in-process contact materials. The \nresults of the assessment show an overall low potential total daily intake (TDI) of the extractables compared \nto the permissible daily exposure or recommended dietary allowances. Overall, it is agreed that that the \npotential leachables associated with each process contact component of the marstacimab active substance \nmanufacturing process pose negligible risk to humans. \nUpstream Process Development and Characterisation \nA risk assessment was performed to identify important unit operations, process parameters, and material \nattributes that could affect the critical quality attributes (CQAs) of the active substance and/or could \nsignificantly affect process performance. \nA qualified bioreactor model was used to test the impact of process parameters on quality attributes of the \nproduct . The DoE studies appear well designed and reasonable process parameters and sufficient and critical \nquality attributes were assessed. \nThe Applicant summarised the experimental ranges applied in the multivariate DoE and the resulting \nacceptable range and whether the process parameter is regarded critical or non-critical. \nOverall, the upstream process development was appropriately performed according to ICH Q8/Q9, and no \nissues have been identified. \nDownstream Process Development and Characterisation \nBased on multivariate DoE, characterisation studies, and risk assessments, several CPPs were identified due \nto their impact on CQAs. \nAs applicable, based on characterisation studies, platform knowledge and risk assessments, reasonable \ncritical process parameters were identified for all other downstream process steps. Overall, the downstream \nprocess development was appropriately performed according to ICH Q8/Q9, and no issues have been \nidentified. \nControl Strategy \nThe final control strategy was summarised in a table identifying every process parameter/in-process test, its \ncriticality assignment, the characterised range in development studies, the target/control limit/observed \nrange for process validation, the acceptable range/control limit for process validation and the respective \njustification for acceptable rang/control limit for commercial manufacturing. Overall, the section on \ndevelopment of the control strategy was well addressed. \nCharacterisation \nAnalytical characterisation was performed with the material derived from the commercial active substance \nmanufacturing. A panel of analytical methods was used to evaluate primary structure, post-translational \nmodifications, charge and size heterogeneity, higher order structure, and biological activity of marstacimab... \nThus, it is agreed that the presented characterization of the material in this section can be regarded \nrepresentative of the material used during the development process and clinical studies. \nOverall, the characterisation results demonstrate that marstacimab has the expected structure and target \nbinding properties. \n"
    },
    {
      "page_number": 26,
      "text": "Assessment report \nEMA/464842/2024 \nPage 26/198 \n \nImpurities \nProcess-related impurities (residual DNA, HCP, cell culture derived impurities, protein A) were appropriately \nidentified and characterised over the whole development process from manufacturing process. It was shown \nthat impurity removal is consistent and will remove process-related impurities below the specified limits. This \nwas also validated during the PPQ runs. Thus, it is agreed that expect for HCP no routine testing of process- \nrelated impurities is warranted. \nIt is agreed that routine in-process testing, and active substance release testing ensures control over \npotential contaminants and adventitious agents. \n \n2.4.2.3. Specification \n \nThe specification for marstacimab active substance at release and during stability studies is provided and \nincludes control of identity, purity and impurities, potency and other general tests. The acceptance criteria \nare applicable from batch release to end of shelf-life. \nThe specification is based on development experience with marstacimab, process characterisation and \nprocess validation data as well as data from active substance batches used in non-clinical and clinical studies. \nThe specification is based on understanding of the control strategy to ensure that critical quality attributes \n(CQAs) are controlled to appropriate levels. In general, the strategy for justification of the specification is \nacceptable and the presented limits can be regarded acceptable. \nAnalytical Procedures \nCompendial methods were appropriate established. \nThe non-compendial methods are described in sufficient detail. Used equipment, operating parameters, \nreagents and standards, buffers/solutions are listed. Furthermore, the sample preparation and procedure are \ndescribed. The system suitability, assay and sample acceptance criteria are listed as well and found suitable \nto confirm that the methods are performing as expected during release testing. Were applicable, \nrepresentative figures and results were presented. The Applicant confirmed that method validation is \napplicable on the facility where the AS testing is accomplished. Overall, the non-compendial analytical \nmethods have been appropriately validated for their suitability for intended use according to ICH Q2(R1). \nReference Standard \nFor commercial manufacturing, the Applicant established a two-tiered reference standard system. The \nprimary reference material (PRM) and the working reference material (WRM) are derived from the active \nsubstance (AS) by the commercial manufacturing process. . A bridging study was performed to ensure \ncorrect potency/biological activity assignment of the PRM against the previous clinical reference material \n(CRM). Thus, the traceability of potency values from clinical material to commercial material is appropriately \nestablished. Furthermore, an acceptable protocol for the preparation of future reference materials was \nprovided. \nBatch Analyses \nRelease results of all manufactured batches were provided and conformed to release criteria that were in \nplace at the respective time. Overall, the results appear consistent. Comparability between process variants \nwas appropriately established. \n"
    },
    {
      "page_number": 27,
      "text": "Assessment report \nEMA/464842/2024 \nPage 27/198 \n \nContainer Closure \nThe container closure system used for the marstacimab active substance are ethylene vinyl acetate (EVA) \nbags.. The choice of the container/closure is justified and supported by pharmacopoeial compliance of the \nmaterials and stability data. \nThe bags are provided sterile by the manufacturer meeting the sterility assurance level of 10-6 according to \nISO 11137. Overall, the container closure specification covers all expected attributes and is acceptable. \n \n2.4.2.4. Stability \n \nThe Applicant is claiming a marstacimab active substance shelf life of 48 months when stored at the \nrecommended temperature in EVA bags. \nThe shelf-life claim is based on the real-time, real-temperature data from the primary stability studies, \ntherefore, can be regarded acceptable. \nIn addition, data from supportive stability batches at long term and accelerated conditions are provided.. \nThe real-time stability data of the primary stability batches over 48 months at frozen condition show that all \ntested quality attributes conform to their clinical and commercial stability specification at all tested time- \npoints. It is agreed that there are no apparent trends over time. Real-time stability data of supportive \nbatches confirm the data established for primary stability batches. \nThe proposed shelf-life of 48 months stored at frozen conditionfor the active substance is acceptable. \n \n \n \n2.4.3. Finished Medicinal Product – Prefilled Syringe \n \nDescription of the product and Pharmaceutical Development \n \nMarstacimab finished product (FP) is provided at pH 5.8 in a strength of 150 mg/mL. The finished product is a \ncolourless to light yellow solution supplied in a 1 mL glass (Type I) prefilled syringe. The finished product \ncontains no preservative. Container closure system is adequately outlined. An overfill is included to (ensure \nthat a 1 mL nominal volume can be delivered from the prefilled syringe. A successful confirmatory study was \nconducted looking at the delivery system hold-up (DSHU) and delivered volume of marstacimab in the \nsyringe. \nThe formulations of marstacimab active substance and bulk finished product (prior to filling) are the same. \nThe active substance is formulated in L-histidine, L-histidine monohydrochloride, sucrose, disodium edetate, \npolysorbate 80 and water for injections in the same excipient concentrations as in the finished product. There \nare no novel excipients used in the manufacture of marstacimab finished product are of human or animal \norigin. All excipients are compendial grade according to Ph. Eur. \nThe robustness of the marstacimab formulation was evaluated through multiple studies to assess the \ncapability of the formulation to protect the drug against various stresses. \n"
    },
    {
      "page_number": 28,
      "text": "Assessment report \nEMA/464842/2024 \nPage 28/198 \n \nThe physicochemical and biological properties relevant to the safety, efficacy, quality, or manufacturability of \nthe finished product were investigated from early development through process validation (PV, also referred \nto as process performance qualification (PPQ)), using a range of analytical procedures. \nThe formulation was used throughout pre-clinical and clinical development varying only the concentration of \nmarstacimab to enable subcutaneous administration and dose adjustments that occurred during clinical \ndevelopment. The experimentally measured levels of excipients tested in a robustness study showed that \nduring commercial manufacturing, the release testing of pH and osmolality is sufficient to ensure the control \nof excipients. Submitted long-term and accelerated stability data provided evidence that the marstacimab \nfinished product quality is robust to variations in excipient concentrations. \nManufacturing process development history and site changes are described with sufficient detail, the finished \nproduct lots used in each stage of development and the clinical studies provided. Manufacturing process \ndevelopment was performed extensively. \nThe process development and characterisation studies represent a combined experience derived both from \nlaboratory scale studies using scale-down models as well as from full-scale studies and manufacturing \nconducted within the commercial production environment. Scale-down models to characterise the \nmanufacturing process are sufficiently described in the Process Development and Characterisation Studies . \nThe choice of excipients (histidine, sucrose, disodium edetate, polysorbate 80, pH 5.8) have remained the \nsame throughout development history of marstacimab including inclusion in the pivotal phase 3 clinical \nstudies.Process development to support operations related to the drug product manufacture, from active \nsubstance thaw to filling and inspection were performed. \nIn addition, studies were also performed to support finished product storage and finished product shipping. \nInformation about these studies were sufficient and results within these studies met the appropriate \nacceptance criteria. \nHold time studies were performed to establish hold times for marstacimab active substance and bulk finished \nproduct within the finished product manufacturing process in terms of physicochemical stability. The hold \ntimes are supported from a physicochemical stability perspective. \nA risk-based approach as described in ICH Q9 Quality Risk Management was employed to guide the selection \nof process parameters to be investigated during process characterization studies. \nProduct attributes categorised as elemental impurities or extractables/leachables were evaluated in dedicated \nrisk assessment/experimental programs. \nQAs relevant to finished product and their classifications are presented and justified. Quality attributes (QAs) \nwere assessed during development with methods that were intended to be used for commercial release and \nstability testing. \nCriticality assessment of quality attributes is explained in detail. \nOverall, the approach for identification of CQAs and the criticality assignment appears reasonable and \nsufficiently justified. The strategy for controlling of CQAs, relevant for the finished product, is deemed \nsatisfactory. \nThe finished product consists of the marstacimab finished product within the container closure system \n(syringe barrel), a PFS plunger rod (non-product contact), and a PFS finger grip (back stop) (non-product \ncontact). Primary packaging materials with contact to the finished product are of Ph. Eur. quality. No \n"
    },
    {
      "page_number": 29,
      "text": "Assessment report \nEMA/464842/2024 \nPage 29/198 \n \nsubstance of safety concern is leaking into the finished product as indicated by results of leachables and \nextractables testing. \nA Notified Body Opinion for the PFS was submitted by the applicant, confirming full compliance with the \nrelevant GSPRs. \nSyringeability refers to the force required for the injection of a given solution at a given injection rate. The \ndesign and user requirements set for the marstacimab fully assembled PFS have been met. \nCompatibility of marstacimab FP with its excipient and primary packaging materials has been shown in \nformulation studies and confirmed by stability data. \n \n2.4.3.1. Manufacture of the product and process controls \n \nAll sites involved in manufacture, control and storage of the finished product operate in accordance with EU \nGMP. \nThe finished product manufacturing process consists of thawing of the active substance, followed by transfer \nto a manufacturing vessel to begin bulk finished product (FP) manufacturing. A formulation buffer is prepared \nand used to dilute the AS, in an optional one-step dilution, to the target protein concentration of 150 mg/mL. \nThe formulated bulk FP is then filtered through a bioburden reduction filter into a holding vessel and \nsubsequently filtered through redundant sterile filters on the filling line and aseptically filled into syringes. \nAfter visual/ automatic inspection, the PFS are labelled and packaged and stored at a defined temperature \nrange. \nMaximum hold times of the finished product in-process materials are provided. These hold times are \nsupported by data generated during process development and process validation. \nRegarding reprocessing, a single bioburden reducing refiltration step of bulk product using a new 0.2 μm \nbioburden reducing filter is allowed in the event of technical failure. Repeated bioburden reducing filtration \nstep is validated. \nIn-process hold times and time out of refrigeration (TOR) hold time is deemed acceptable, based on stability \nstudies demonstrating that FP is stable under out-of-refrigeration conditions in excess of the time required for \nroutine manufacturing operations. \nProcess validation was performed on three consecutive PPQ or PV lots \nValidation data are submitted from active substance (AS) thawing, formulation of bulk finished product \n(pooling and dilution of pooled AS with buffer), bioburden filtration and re-filtration, sterile filtration, aseptic \nfilling, and inspection of the FP syringes. Refreeze and rethaw and refiltration steps were adequately \nvalidated. Stability studies were performed, monitoring the effect of in-process hold times and cumulative \nhold times on the microbiological and physicochemical quality. Sterilisation methods of filter membranes and \nother product contact equipment, media filling process and shipping is also adequately validated. All \nvalidation results were within predefined acceptance criteria. \nBased on the data provided the manufacturing process of marstacimab FP seems to be robust and provides a \nproduct that meets quality and stability attributes. \n"
    },
    {
      "page_number": 30,
      "text": "Assessment report \nEMA/464842/2024 \nPage 30/198 \n \n2.4.3.2. Product specification \n \nSpecification for the finished product in pre-filled syringe includes control of identity, purity and impurities, \npotency and other general tests. \nQuality attributes are adequate, analytical procedures are well chosen and partly compendial. Acceptance \ncriteria are based on data gained during development- and stability studies and are thoroughly justified. \nCompendial analytical procedures were verified, non-compendial methods) were validated against reference \nmaterial. \nA summary of marstacimab finished product lots is provided, along with all the parameters tested within \nspecifications. \nAnalytical procedures: \nFor all test methods SOPs and for the non-compendial assays for the FP , validation studies were performed \nin line with current compendial Ph. Eur. methods and ICH Q2(R1). Relevant validation parameters for each \ntest method were taken into consideration. Test methods seem to be validated appropriately and can be \naccepted. \nFurthermore, documents of the analytical method transfer exercises (AMTE), where appropriate, were \nsubmitted. Validation of Analytical Procedures, and the results from comparative testing are presented. All \nmethod system suitability/assay acceptance and transfer acceptance criteria were met. The results obtained \nby the receiving lab were within the performance of the analytical procedures and seems acceptable. \nBatch analysis: \nBatch analysis data from all Marstacimab finished product lots used for clinical trials, stability, and process \nvalidation are submitted. All parameters tested were within the defined specifications. The data submitted \ndemonstrate consistency and conformity in the manufacturing process of Marstacimab finished product. \nCharacterisation of impurities: \nAn evaluation of the potential for N-nitrosamine impurity formation by review of process chemistry used to \nmanufacture the active substance and finished product and the container closure system was conducted. No \nrisk for small molecule nitrosamine (cohort of concern) formation was identified. From the toxicological \nperspective, there is no risk of the marstacimab molecule itself forming a nitrosamine requiring cohort of \nconcern control. Sufficient information about the potential N-nitrosamines risk was submitted. \nAn elemental impurities risk assessment on marstacimab was performed according to ICH Q3D. The three \nprocess performance qualification finished product lots (PPQ) showed that all elements were below the \ncontrol threshold and required no further assessment or control. Furthermore, the applicant states that no \nadditional impurities arise from the finished product process. Therefore, the product related impurities in \nmarstacimab finished product are the same as those found in the active substance. \n \n2.4.3.3. Stability of the product \n \nTo support the shelf-life claim of 24 months at 2-8 °C and up to 7 days at 8-30 °C (within the 24-month \nshelf-life), Stability studies were performed in accordance with ICH guidelines. \n"
    },
    {
      "page_number": 31,
      "text": "Assessment report \nEMA/464842/2024 \nPage 31/198 \n \nA photostability study was performed according to ICH Q1B. The results demonstrated that the product is \nphotolabile, but stable if stored in secondary packaging. This information has been included in SmPC. \nThe data provided supports the shelf-life claim of 24 months when stored at the recommended temperature \nof 2-8 °C and short-term storage between 8-30 °C for up to 7 days (within the 24-month shelf-life). \n \n \n \n2.4.4. Finished Medicinal Product - Prefilled Pen \n \n2 . 4 . 4 . 1 . \nDescription of the product and Pharmaceutical Development \n \nThe prefilled pen (PFP) is a single-dose, disposable pen that encloses a 1 mL long Type I glass prefilled \nsyringe as described in 3.2.P Prefilled Syringe sections. Together they form a single integral product, \nintended exclusively for use in the given combination. The final assembled pen consists of a prefilled syringe, \na syringe clip and two subassemblies (power pack and front assembly). \nThe description and composition of the PFP presentation and container closure system is adequately \ndescribed. \nThe applicant has provided a comprehensive overview of the pharmaceutical development of the medicinal \nproduct combined with an integral medical device and has included a Notified Body Opinion confirming full \ncompliance with the relevant GSPRs. The assembly of the pen is an automated process. \nThe applicant defined the quality target profile (QTPP) for the Prefilled Pen. The Prefilled Pen assembly \nprocess is adequately described. \nThe design verification was adequate and demonstrated to be compliant with ISO 11608. Critical quality \nattributes were defined for attributes that directly relate to usability and the safety of the user and will be \nroutinely tested as part of release and stability. \nHuman factors testing on participants representative of the intended marstacimab pen user population \nincluded iterative evaluations of the marstacimab user interface, including the pen and label, the instructions \nfor use with and without training. . The prefilled pen was validated to be safe and effective when used by the \nintended users in the intended use environment. \nA risk analysis was performed using FMEA (failure mode effect analysis). The overall residual risk associated \nwith the product has been reduced as far as possible and is acceptable when balanced against the benefit of \nits intended use, which is supported. \n \n2.4.4.2. Manufacture of the product and process controls \n \nAppropriate evidence of GMP compliance of the site responsible for pen manufacture has been provided. \nEach prefilled pen lot can be manufactured using a single lot of prefilled syringes. The manufacturing process \nis adequately described in the dossier and in-process tests are considered sufficient. \nThe Process validation was performed. It consisted of in-process controls and release tests at the end of \nmanufacture. \n"
    },
    {
      "page_number": 32,
      "text": "Assessment report \nEMA/464842/2024 \nPage 32/198 \n \nA shipping validation was performed to assess all possible conditions that are expected to arise during the \nshipping process. The validation demonstrated that the pen is not impacted by the shipping hazard conditions \nthat could occur during the transportation process. \nOverall, the manufacturing process was adequately described and validated. \n \n2.4.4.3. Product specification \n \nThe release and stability specification for the marstacimab 150 mg/mL pen is provided. \nAnalytical methods are described, and the methods appear to be appropriately validated. Adequate method \nvalidation was performed. \nBatch analysis was performed on clinical, stability and process validation material. All lots were within \npredefined acceptance criteria. \nThe specification limits were justified based on lot release, process validation and stability testing and \nconsidered acceptable. \nThe sample numbers for release and post-stability testing are calculated using binomial principles based on \nacceptable risk-based quality limits, which is supported.In summary, the set of quality attributes tested is \nacceptable. \nThe section on the container closure system is considered to be sufficient and no questions are raised. \n \n2.4.4.4. Stability of the product \n \nThe Applicant has performed several stability studies including long-term, accelerated, time out of \nrefrigeration, thermal stress, and thermal cycling. \nIt is accepted that for the assembled pen, the stability studies only focus on appearance and functionality \nparameters since the marstacimab finished product is not in contact with the device. Results were within \nacceptance criteria. \nThe 24 months shelf-life claim for the prefilled pen (at recommended storage conditions of 2-8 °C with a \nmaximum of 30 °C for a single period of up to 7 days within the shelf-life), is sufficiently justified with \nprovided long-term stability data. \nThe Applicant has provided a commitment to perform post-approval annual stability studies. \n \n2.4.4.5. Adventitious agents \n \nMultiple measures are implemented to ensure product safety with regards to non-viral and viral adventitious \nagents. The measures include evaluation and testing of raw material, testing of cell banks and process \nintermediates for microbial and viral contaminants, testing of microbial attributes as in-process controls and \nrelease. Implementation and validation of virus clearance steps and steps contributing to virus reduction. \nNon-viral adventitious agents \nMCB, WCB and end-of-production cell bank (EOPCB) were tested for the absence of bacterial, fungal and \nmycoplasma contamination according to Ph. Eur. 2.6.1 and 2.6.7 at appropriate steps of manufacture. Tests \n"
    },
    {
      "page_number": 33,
      "text": "Assessment report \nEMA/464842/2024 \nPage 33/198 \n \nfor bioburden, mycoplasma and endotoxin are performed at multiple steps during the manufacturing process \nfor active substance and finished product. No animal-derived materials were used in MCB and WCB \nmanufacture or during active substance and finished product manufacturing. During establishment of the \nparental CHO cell line, cells were exposed to animal derived components (i.e. FBS) and the Applicant referred \nto valid certificates of suitability issued by the EDQM. \nIn conclusion, the risk for microbial contamination is adequately controlled and the risk with regard to TSE is \nminimal. \nAdventitious viruses \nCell banks were tested with various assays. Unprocessed bulk harvest was tested for the absence of \nadventitious viruses \nIn conclusion, testing of cell banks and unprocessed bulk was performed according to guideline ICH Q5A. No \nadventitious viruses were detected except for A-type particles. \nVirus clearance studies \nThe virus clearance capacity of the manufacturing process was assessed with virus clearance studies using \nsmall scale models of the respective large-scale manufacturing process steps. The design of the studies \nappears to be in line with guideline ICH Q5A. Tabular comparison of the process parameters for the \nmanufacturing scale and the small-scale process steps were provided. Details on small scale models are \nadequately described. \nA number of process steps were evaluated using a selected panel of viruses that represents a broad range of \nvirus types with different physicochemical characteristics. It is agreed that the chosen viruses represent \nrelevant models that may possibly contaminate the active substance. \nThe total process clearance determined by summation of removal/inactivation methods implies an acceptable \nsafety margin regarding retrovirus-like particles. \nIn conclusion, the inactivation/clearance steps provide for an effective and robust overall clearance capacity \nfor adventitious viruses. The risk of potential contamination and transmission of bacterial, viral or TSE agents \nappears to be acceptably low. \n \n2.4.5. Discussion and conclusions on chemical, pharmaceutical and biological \naspects \n \nAn extensive and well organised Module 3 of overall good quality for Hympavzi was provided by the \nApplicant. The product is a monoclonal IgG1 antibody that binds and neutralises tissue factor pathway \ninhibitor (TFPI) to enhance the extrinsic pathway and reduce or eliminate the need for replacement of \ncoagulation factors FVIII or FIX. Appropriate confirmation of GMP compliance of the active substance and \nfinished product manufacturing and testing sites was shown. The product is indicated for children > 12 years \nof age, therefore paediatric aspects related to formulation and the presentations provided are not of concern. \nActive substance \nThe marstacimab active substance manufacturing process and control strategy was described in detail. \nProcess parameters (CPP and non-CPPs), CMA and in-process tests and their respective acceptance ranges \n"
    },
    {
      "page_number": 34,
      "text": "Assessment report \nEMA/464842/2024 \nPage 34/198 \n \nare presented for every manufacturing process step. Sufficient detail on raw and starting materials including \ninformation on quality and control of these materials is provided. \nThe active substance is manufactured in a bioreactor. The purification process provides two dedicated virus \nreduction steps in combination with chromatography steps. Virus clearance studies were performed at small- \nscale. Overall, an effective and robust clearance capacity for enveloped and non-enveloped adventitious \nviruses was confirmed. The risk of potential contamination and transmission of bacterial, viral, or TSE agents \nappears acceptably low. \nThe active substance specification is acceptable. \nProcess validation of the intended commercial upstream and downstream active substance manufacturing \nwas appropriately performed. Impurity clearance, hold times, resin and membrane lifetime, reprocessing and \nshipping were also validated either at small-scale and/or commercial scale. \nProcess development for selected manufacturing steps was performed in qualified small-scale models. \nProcess parameters with expected influence on CQAs were studied using DoE studies. Overall, the process \nwas appropriately developed. Comparability between the process variants was appropriately established. The \nmaterial used in (pre-)clinical studies can be regarded representative of the commercial scale material. \nThe active substance was characterised with an extensive set of analytical methods. \nThe layout for the control of AS is generally approvable. The selection of analytical techniques is considered \nadequate. Detailed method descriptions have been provided. Validation of the methods is considered \nacceptable. An adequate two-tiered reference standard system has been established. \nThe description of the Container Closure System is considered acceptable. \nThe shelf-life claim of 48 months at -20°C for marstacimab AS is approvable as the shelf-life claim is \nsupported by the submitted stability study results. \nFinished product (Syringe) \nThe presentation and content of the dossier of FP (syringe) is satisfactory. Marstacimab finished product (FP) \nis provided at pH 5.8 in a strength of 150 mg/mL. The finished product is a colourless to light yellow solution \nsupplied in a 1 mL single-dose glass (Type I) prefilled syringe. The finished product contains no preservative \nand is for single-dose only. An overview of formulation development is provided supporting the proposed \ncomposition. \nThe FP of marstacimab is well characterised. The finished product is manufactured with a validated process \nand satisfactorily controlled to ensure consistent quality. Quality attributes chosen for release and stability \nspecification are approvable, the choice of analytical procedures as well. An elemental impurities risk \nassessment on marstacimab was performed according to ICH Q3D. Results showed that all elements were \nbelow the control threshold and required no further assessment or control routinely for finished product \nrelease by the company. An appropriate N-nitrosamines risk assessment was submitted confirming no risk for \nnitrosamine formation. \nThe container closure system has been adequately described and appears to be suitable for the intended use. \nThe Applicant has provided a comprehensive overview of the pharmaceutical development of the medicinal \nproduct combined with an integral medical device and has included a Notified Body Opinion. \nMany stability studies with different conditions were performed by the company. The Applicant is claiming a \nmarstacimab finished product shelf life of 24 months when stored at the recommended temperature of 2-8 \n"
    },
    {
      "page_number": 35,
      "text": "Assessment report \nEMA/464842/2024 \nPage 35/198 \n \n°C. Additionally it is proposed that marstacimab finished product can undergo short term storage between 8- \n30°C for up to 7 days (within the 24 months shelf life). The proposed shelf life is acceptable. \nAll raised other concerns were appropriately addressed. \nFinished product (Prefilled Pen) \nThe prefilled pen is a single-dose, disposable pen that encloses a prefilled syringe. Together they form a \nsingle integral product, intended exclusively for use in the given combination. The final assembled pen \nconsists of a prefilled syringe, a syringe clip and two subassemblies (power pack and front assembly). The \nprovided information in the finished product section for the prefilled pen is satisfactory. Notified body opinion \non the prefilled pen as a device has been submitted. Description and composition of the Finished product has \nbeen sufficiently described. Details on the individual components and functions of the prefilled pen are \nprovided. The pharmaceutical development section provides an overview of the manufacturing process \ndevelopment including a process characterization study. \nA design verification study demonstrated compliance with ISO 11608 and the product validation included a \nhuman factors testing, validating the pen to be safe and effective when used by the intended users in the \nintended use environment. \nThe pen manufacturing process consists of pen assembly, labelling and packaging. A flow chart and a brief \nsummary of the IPCs is provided. The process and shipping validation are sufficiently described. \nThe control strategy of the prefilled pen appears appropriate, and the proposed release and stability \nspecifications are acceptable. Analytical methods used for release and stability have been sufficiently \ndescribed. Analytical methods appear appropriately validated. \nThe container closure system has been adequately described and appears to be suitable for the intended use. \nBased on the provided stability data, the proposed shelf-life of 24 months when stored at 5 ± 3 °C with \nstorage at a maximum of 30 °C for a single period of up to 7 days is considered acceptable. A commitment to \nperform post-approval annual stability studies is provided. \nAll raised concerns were appropriately addressed. \n \n2.4.6. Conclusions on the chemical, pharmaceutical and biological aspects \n \nThe overall quality of Hympavzi is considered acceptable when used in accordance with the conditions defined \nin the SmPC. The different aspects of the chemical, pharmaceutical and biological documentation comply with \nexisting guidelines. \nNo further recommendations for future quality development have been made. \nIn conclusion, based on the review of the quality data provided, it is considered that the marketing authorisation \napplication for Hympavzi is approvable from the quality point of view. \n"
    },
    {
      "page_number": 36,
      "text": "Assessment report \nEMA/464842/2024 \nPage 36/198 \n \n2.5. Non-clinical aspects \n \n2.5.1. Introduction \n \nMarstacimab (PF-06741086) is a human mAb that binds to and inhibits the activity of TFPI, an endogenous \ninhibitor of coagulation. TFPI is a Kunitz-type protease inhibitor that negatively regulates thrombin generation \nwithin the extrinsic pathway of coagulation by rapidly inactivating the protease functions of FXa and the \nFactor VIIa/Tissue Factor (FXa/FVIIa/TF) complex (Baugh et al, 1998; Girard et al, 1989). TFPI initially binds \nto and inhibits the FXa active site via its second Kunitz inhibitor domain (K2). This complex then binds to and \ninhibits the Factor VIIa active site through its first Kunitz inhibitor domain (K1) to form a quaternary complex \nwith full inhibitory activity (Broze & Girard, 2012). In haemophilia, the production of FXa and thrombin via \nthe extrinsic pathway is insufficient to overcome the intrinsic pathway deficiencies of FVIII (haemophilia A) or \nFactor IX (haemophilia B), due to the tight negative regulation of the pathway by TFPI. Neutralising the \nactivity of TFPI may serve to enhance the extrinsic pathway and bypass deficiencies in the intrinsic pathway \nof coagulation. \nThe nonclinical PK strategy supported the nonclinical pharmacology and nonclinical safety evaluation of \nmarstacimab. Single-and repeat-dose PK were characterised following SC or IV dosing of marstacimab in \nWistar Han rats and Cynomolgus monkeys. Repeat-dose PK were also characterised after dosing of \nmarstacimab co-administered with NovoSevenRT, or FEIBA, or Byclot. Validated ligand binding assays were \nused to support the TK and ADA evaluations in repeat-dose GLP toxicity and TK studies in Wistar Han rats (up \nto 6 months) and Cynomolgus monkeys (up to 3 months). The toxicity of marstacimab was evaluated in \nWistar Han rats and Cynomolgus monkeys in GLP-compliant repeat-dose studies of up to 3 months \n(monkeys) or 6 months (rats) in duration. A fertility and early embryonic toxicity study in male rats and a \nsingle-dose SC local tolerance study in rats were also conducted. Doses in these studies were administered \nby SC and/or IV injection since they were the routes of administration used during clinical development. The \nnonclinical toxicity program for marstacimab also included a GLP-compliant TCR study, and non-GLP in vitro \nhuman C1q and FcR binding assays and a CRA. \n \n2.5.2. Pharmacology \n \n2.5.2.1. Primary pharmacodynamic studies \n \nPharmacological activity of marstacimab was assessed in nine in vitro studies, investigating binding of \nmarstacimab to its target, the Tissue Factor Pathway Inhibitor (TFPI), and its functional activity, inhibition of \nTFPI and therefore neutralisation of TFPI activity, resulting in promotion of the TF/FVIIa extrinsic pathway of \nthe coagulation cascade. \nTwo in vitro binding studies were conducted with marstacimab to confirm binding to the K2 domain of Tissue \nFactor Pathway Inhibitor (TFPI). In study PF-06741086_28APR15_072904, binding affinity and kinetics of \nmarstacimab to human, mouse, rat, rabbit and Cynomolgus monkey TFPI K1K2 was investigated by Surface \nPlasmon Resonance (SPR), whereas in study PF-06741086_14Nov22_121926, the same technique was used \nto confirm binding of marstacimab to human TFPI K1K2 and TFPI K1 and non-binding to TFPI K1. SPR \nanalysis in study PF-06741086_28APR15_072904 revealed low dissociation constant (KD) values of \nmarstacimab for human (3.7 nM  0.28), mouse (0.575 nM  0.05), rat (1.57 nM  0.04), rabbit (4.25 nM  \n0.05) and Cynomolgus monkey (1.22 nM  0.03) TFPI K1K2 within the nanomolar or even sub-nanomolar \n"
    },
    {
      "page_number": 37,
      "text": "Assessment report \nEMA/464842/2024 \nPage 37/198 \n \nrange. Binding kinetics of marstacimab to human and rabbit TFPI K1K2 were most similar, when compared to \nthe other species. The lack of binding to TFPI K1 could be confirmed in study PF- \n06741086_14Nov22_121926, where a KD of 2.63 nM  0.08 to TFPI K2 and a KD of 7.91 nM  0.33 to \ncombined TFPI K1K2 domains was achieved. The almost three-fold higher dissociation constant of the \ncombined domains TFPI K1K2 compared to the single TFPI domain K2 was discussed by the Applicant and \nexplained by the higher (slower) on-rates (ka) of TFPI K1K2, maybe due to its larger size. \nTwo enzymatic chromogenic-based assays (study PF-06741086_06APR15_085202), the FXa Inhibition \nReversal Assay and the TF-FVIIa-FX Inhibition Reversal Assay, were conducted to verify inhibition of TFPI by \nmarstacimab (0-80000 ng/mL and 0-32000 ng/mL, respectively) and the resulting increase in Factor Xa \nactivity. In both assays of study PF-06741086_06APR15_085202, a dose-dependent response was observed \nby marstacimab, with estimated EC50 values of 1312 ng/mL (8.75 nM) in the FXa Inhibition Reversal Assay \nand 1985 ng/mL (13.23 nM) in the TF-FVIIa-FX Inhibition Reversal Assay. \nThromboelastography (TEG) was used to examine the effect of marstacimab [up to 32 g/mL (213.3 nM) in \ndonor 2 and 3, up to 16 g/mL (106.7 nM) in donor 1 blood) on clot formation dynamics (as speed and \nstrength determined by the clotting/reaction time (R), clot formation time/clot firmness (K), alpha angle and \nmaximum amplitude) in non-haemophilic human whole blood of three different donors (study PF- \n06741086_01Apr15_142056). TEG analysis of non-haemophilic human whole blood of all 3 donors revealed \ndose-dependent decreases in clotting time (R) and clot formation time (K), no changes in maximum \namplitude and an increase in alpha angle, with increasing concentrations of marstacimab. It is to note, that a \nhigh donor-to-donor variability was observed. \nIn study PF-06741086_07APR15_123404, three haemostatic assays were performed to investigate the \ninhibitory activity of marstacimab on TFPI in non-haemophilic human plasma of healthy volunteers, the \nactivated partial thromboplastin time (aPTT) assay, which targets on the intrinsic pathway of the coagulation \ncascade, the dilute prothrombin time (dPT) assay targeting the extrinsic pathway and the thrombin \ngeneration assay (TGA). Marstacimab was used in concentrations ranging from 0.8 to 56000 ng/mL (373.3 \nnM) in the aPTT and dPT assay and from 1.6 ng/mL to 16000 ng/mL in the TGA assay. The dPT assay was \nconducted as well in non-haemophilic rabbit and Cynomolgus monkey plasma, using similar or the same \nconcentrations of marstacimab, respectively. As expected, no effect on the aPTT clotting time was observed, \nwhereas in contrast, a dose-dependent shortening of the dPT clotting time was seen in the dPT assay in non- \nhemophilic human, rabbit and Cynomolgus monkey plasma, with EC50 values of 406 ng/mL (2.7 nM), 629 \nng/mL (4.2 nM) and 273 ng/mL (1.7 nM), respectively. In the TGA assay, thrombin generation increased with \nincreasing doses of marstacimab in non-haemophilic human plasma, accompanied by several changes in the \nquantitative parameters of the TGA assay (e.g. increase in velocity index and decrease in lag time). \nStudy PF-06741086_07APR15_135025 describes the influence of marstacimab on coagulation in the presence \nof haemophilic plasma, as this reflects the condition of disease. Therefore, an aPTT, a dPT and a TGA assay \nwere performed using the plasma of four severe haemophilia A patients, one severe haemophilia A patient \nwith inhibitor (BU=176) and one severe haemophilia B patient (all below 1% Factor VIII or IX activity, \nrespectively). \nMarstacimab was used at concentrations ranging from: \n- 0.8 ng/mL (0.0053 nM) to 56000 ng/mL (373.3 nM)] in the aPTT and dPT assay \n- 0.16 g/mL (1.07 nM) to 80 g/mL (533.3 nM) were applied in the TGA assay. \n"
    },
    {
      "page_number": 38,
      "text": "Assessment report \nEMA/464842/2024 \nPage 38/198 \n \n- 20 to 0.0002 g/mL when FVIIa was added to plasma of one haemophilia A donor in concentrations \nranging, marstacimab was added at a final concentration of 16 g/mL (106.7 nM) and a TGA was conducted \nagain. \nUnexpectedly, slight decreases in aPTT clotting times were observed in all haemophilic plasmas at the three \nhighest concentrations of marstacimab (56000 ng/mL, 16000 ng/mL and 8000 ng/mL) but were obviously far \nfrom the normal range of non-haemophilic, normal plasma. As observed in non-haemophilic human plasma \n(study 123404), dose-dependent shortening of the dPT clotting time was seen in all haemophilic plasmas as \nwell, with similar EC values ranging from 380.5 to 471.4 ng/mL (2.3 to 3.1 nM). The thrombin generation \nassay revealed dose-dependent increases in thrombin generation with increasing doses of marstacimab in all \nhaemophilic plasma samples. The presence of increasing doses of rFVIIa, without marstacimab, led to a \ndose-dependent increase in thrombin generation. Addition of marstacimab further increased thrombin \ngeneration, even to normal plasma levels or above and showed to be dose-dependent at lower rFVIIa \nconcentrations (up to 0.02µg/ml). \nIn study PF-06741086_31Mar16_122443, the effect of marstacimab on thrombin generation with and without \nthe combination of rFVIIa (NovoSevenRT, eptacog alfa) was investigated in haemophilic plasma (from 6 \nhaemophilia A donors, 3 haemophilia A donors with an inhibitor and one haemophilia B donor) by a thrombin \ngeneration assay. Following samples were analysed: vehicle-treated haemophilic plasma; 2µg/mL rFVIIa- \ntreated haemophilic plasma; 0.5, 1, 2, 4, 8 or 16µg/mL marstacimab-treated haemophilic plasma; 0.5, 1, 2, \n4, 8 or 16µg/mL marstacimab-treated haemophilic plasma in addition of 2µg/mL rFVIIa; untreated non- \nhaemophilic plasma and non-haemophilic plasma dosed with 16 µg/mL marstacimab. Increasing doses of \nmarstacimab at 0.5, 1, 2, 4, 8 and 16µg/mL to haemophilic plasma increased peak thrombin levels and \ndecreased lag time, when compared to vehicle control. Addition of rFVIIa at 2µg/mL to marstacimab at 0.5, \n1, 2, 4 and 8µg/mL in haemophilic plasma led to similar peak thrombin levels as seen with marstacimab \nalone, whereas a slight additive effect of rFVIIa at 2µg/mL and marstacimab at 16µg/mL was observed after \nco-treatment. Overall, in haemophilic plasma, marstacimab at 16µg/mL with and without co-treatment of \n2µg/mL rFVIIa reached comparable peak thrombin levels as observed in untreated non-haemophilic plasma. \nAddition of 16µg/mL marstacimab to non-haemophilic plasma led to the highest increase in thrombin \ngeneration. Summary of observed peak thrombin levels: (1) vehicle control: 26-76nM in Haemophilia A, 24- \n66nM in Haemophilia A with Inhibitor, 81nM in Haemophilia B; (2) rFVIIa at 2µg/mL: 45-113nM in \nHaemophilia A, 46-89nM in Haemophilia A with Inhibitor, 131nM in Haemophilia B; (3) marstacimab at \n16µg/mL: 82-172nM in Haemophilia A, 88-166nM in Haemophilia A with Inhibitor, 174nM in Haemophilia B; \n(4) marstacimab at 16µg/mL and rFVIIa at 2µg/mL: 102-178nM in Haemophilia A, 99-157nM in Haemophilia \nA with Inhibitor, 167nM in Haemophilia B; (5) untreated non-haemophilic plasma: 128-143nM; (6) non- \nhaemophilic plasma treated with marstacimab at 16µg/mL: 171-198nM. \nA thrombin generation assay was performed in study PF-06741086_26Jul18_045123 to evaluate individual \nand combined treatment of plasma derived activated prothrombin complex concentrate (aPCC; FEIBA) and \nmarstacimab in haemophilic inhibitor plasmas (from four haemophilia A donors and one Factor IX immune- \ndepleted plasma with the addition of an inhibitory antibody as haemophilia B plasma). For individual \ntreatments, aPCC was dosed at 0.063, 0.125, 0.5 or 1 U/mL and marstacimab at 0.5, 1, 2, 4, 8, or 16 \nµg/mL, whereas the highest dose of 1 U/mL aPCC or 16µg/mL marstacimab was used in combination with \nincreasing doses of marstacimab or aPCC, respectively. Human non-haemophilic plasma with and without \naddition of marstacimab at 16µg/mL was used for comparison. Peak thrombin values increased dose- \ndependently in haemophilic plasmas with increasing doses of either aPCC or marstacimab, the latter \nindicating to reach a plateau at >0.5µg/mL marstacimab. After addition of 1 U/mL aPCC to increasing doses \nof marstacimab in haemophilic plasma, an additional increase in thrombin generation was observed, reaching \n"
    },
    {
      "page_number": 39,
      "text": "Assessment report \nEMA/464842/2024 \nPage 39/198 \n \na plateau at marstacimab >0.5µg/mL. Addition of 16µg/mL marstacimab to increasing doses of aPCC led to a \ndose-dependent increase in peak thrombin values. Focusing on a combined treatment with aPCC at 1 U/mL \nand 16µg/mL marstacimab, each expected plasma levels which could be achieved after clinical \nadministration, the latter corresponding to a Cmax following a single SC dose of 300mg marstacimab, an \nadditive increase in peak thrombin generation, but no additive decrease in lag time were observed, whereas \neach single treatment led to an increase in peak thrombin and decrease in lag time itself. Reported values for \npeak thrombin: (1) untreated haemophilic inhibitor plasma A (HA): 14.6-19.05nM, untreated haemophilic \ninhibitor plasma B (HB): 30.51nM; (2) untreated non-haemophilic plasma: 89.62-135.23nM; (3) HA treated \nwith 1 U/mL aPCC: 74.73-110.08nM, HB treated with 1 U/mL aPCC: 163.08nM; (4) non-haemophilic plasma \nwith 16µg/mL marstacimab: 160.43-256.73nM; (5) HA with 16µg/mL marstacimab: 72.92-109.69nM, HB \nwith 16µg/mL marstacimab: 70.14nM; (6) HA with combined treatment of 1 U/mL aPCC and 16µg/mL \nmarstacimab: 209.26-240.57nM, HA with combined treatment of 1 U/mL aPCC and 16µg/mL marstacimab: \n254.11nM. \nStudy PF-06741086_14Oct22_103228 investigated combined treatment of Byclot at concentrations of \nFVIIa/FX at 2/20, 1/10, 0.5/5 µg/mL and marstacimab at 16µg/mL in haemophilia A and haemophilia B \nplasma with inhibitor (for the latter, haemophilia B plasma was spiked with a FIX inhibitory monoclonal \nantibody) by a thrombin generation assay. Non-haemophilic plasma and haemophilia A and B plasma with \ninhibitor, each with and without 16µg/mL marstacimab, were used as controls for comparison. Furthermore, \nthe dose-response relationship of increasing doses of Byclot (0.25/2.5µg/mL to 8/80µg/mL) was examined in \nhaemophilia A and B plasma with inhibitor. A dose-response relationship for Byclot at all concentrations \ntested was observed in haemophilia A and B plasma with inhibitor and mirrored by increases in peak \nthrombin (peak thrombin values ranging dose-dependently from 42.79 to 260.99 nM and 25.65 to 209.12 \nnM, respectively), ETP and VelIndex. Byclot led to a similar shortening of lag time at all concentrations in \nboth, haemophilia A and B plasmas with inhibitor (decrease from 4.17min in untreated haemophilic plasma to \n2.0 minutes in HA and 5.50 to 2.67 minutes in HB). After addition of 16µg/mL marstacimab to haemophilia A \nand B plasma with inhibitor or non-haemophilic plasma, an increase in thrombin generation, reflected by an \nincrease in peak thrombin (102.25nM in HA, 64.59nM in HB and 220.97/219.56nM in non-haemophilic \nplasma) and decrease in lag time (3.83min, 4.83min and 3.50min, respectively) was observed, when \ncompared to corresponding plasmas without addition of marstacimab (haemophilia A and B: peak thrombin of \n15.20nM and 6.15nM, respectively; lag time of 4.17min and 5.50min, respectively; non-haemophilic plasma: \npeak thrombin of 99.13 and 91.36 nM, lag time of 4.50min). A dose-dependent increase in thrombin \ngeneration was observed as well for the combined treatment of Byclot (2/20, 1/10, 0.5/5 µg/mL) and \nmarstacimab (16µg/mL) in haemophilia A and B plasma with inhibitor, which showed an additive effect in \npeak thrombin (ranging from 209.85 to 291.22 nM in HA and from 156.22 to 228.61 nM in HB). A decrease in \nlag time with the combined treatment in haemophilia A and B plasma with inhibitor was observed (ranging \nfrom 1.83min to 2min and 2.17min to 2.33min, respectively). \nPharmacological activity of marstacimab was assessed in six in vivo studies conducted in male Cynomolgus \nmonkeys, male haemophilia A and B mice or male Wistar Han rats. \nStudy 8299672 was conducted to investigate pharmacokinetics and pharmacodynamics of marstacimab in \nmale Cynomolgus monkeys. Therefore, the animals (2/group) received either intravenous (IV) marstacimab \nat 1mg/kg, 3mg/kg and 1mg/kg on day 1, day 8 and day 22, respectively (group 1), or IV marstacimab at \n10mg/kg on day 1 and at 3mg/kg on day 22 but subcutaneous (SC) marstacimab at 10mg/kg on day 8 \n(group 2), or IV marstacimab at 1mg/kg, at day 1 and day 22 but SC marstacimab at 3mg/kg on day 8 \n(group 3). Plasma concentrations for marstacimab and for total TFPI (by LC-MS) were determined pre and \npost dose [day 1: pre-dose, and at 0.083, 6, 24, 48, 72, 96, 120, 144, and 168 (just prior to the next dose) \n"
    },
    {
      "page_number": 40,
      "text": "Assessment report \nEMA/464842/2024 \nPage 40/198 \n \nhours post-dose; day 8: 0.083, 6, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312 (just prior to \nthe next dose) and 336 hours post-dose; day 22: 0.083 hours post-dose] and a dilute prothrombin time \nassay (dPT) was conducted pre-and post-dose at various time points for group 1 at 1mg/kg IV marstacimab \non day 1, for group 2 at 10mg/kg SC marstacimab on day 8 and group 3 at 3mg/kg SC marstacimab on day \n8. A dose dependent increase in marstacimab plasma concentrations was observed. Mean Cmax (20400, \n54600 and 289000ng/mL), AUC168 (386000, 1950000 and 14100000ng*hrs/mL) and t1/2 (12.3, 35 and 118 \nhours) increased with increasing doses of IV marstacimab at 1, 3 and 10mg/kg/dose, respectively. After SC \nadministration of marstacimab at 3 and 10mg/kg/dose, an increase in mean Cmax (18500 and 148000ng/mL, \nrespectively), AUC336 (2360000 and 28200000 ng*hrs/mL, respectively) and t1/2 (36.5 and 163 hours, \nrespectively) was observed as well. Systemic plasma clearance (CL, in mL/min/kg) decreased with increasing \ndoses after IV marstacimab administration. Furthermore, increases in marstacimab plasma concentrations \ncorrelated with increases in total TFPI concentrations in plasma and the other way round, total TFPI \ndecreased with elimination of marstacimab. The dPT assay revealed a decrease in dPT clotting time after IV \nor SC administration of marstacimab at the respective doses tested in all groups, compared to baseline pre- \ndose values. At 3 mg/kg SC marstacimab, dPT clotting time decreased gradually up to 24 hours and then \nremained stable up to approximately 240 hours. In intravenously dosed animals at 1mg/kg marstacimab a \nmore rapid decrease in dPT clotting time was noticed at 5 minutes post-dose, but with dPT values returning \nto baseline values approximately after 72-96 hours. At 10mg/kg SC marstacimab, mean baseline pre-dose \nvalues for both animals tested (animal 102447:107.7s and animal 102448: 106.8s) decreased as well, \nmeasured at 0.083, 24, 192 and 336 hours post dose (animal 102447: 90.8, 92.7, 91.1 and 92.5s, \nrespectively and animal 102448: 88.5, 92.0, 90.1 and 89.9s, respectively). \nIn study PF-06741086_07APR15_135244, male haemophilia A and B mice (5 animals/group) were used as \nacute tail clip injury model and the duration of marstacimab’s efficacy in the reduction of tail bleeding after \ninjury at certain time points (0.5 hours in HB; 0.5, 24, 96, 189 and 240 hours in HA mice) postdosing \nintravenous marstacimab (6 mg/kg) or vehicle was assessed. Dose-response on tail bleeding obtained with \nincreasing IV doses of marstacimab (0.5, 1, 2 or 6 mg/kg) administered to haemophilia A mice was \ninvestigated after 0.5 hours. Blood was collected for 10 minutes after tail clip, then blood volume as well as \nhaemoglobin content, which was then converted to total blood loss (µL), were determined for each mouse. \nAdditionally, male haemophilia A and non-haemophilic WT C57BL6/J mice were used in the laser induced \ninjury model using intravital microscopy imaging, detecting platelet accumulation and fibrin deposition with \nfluorescent labelled antibodies to platelet CD42c (Dylight 649) and fibrin (Alexa 488). Haemophilia A mice \nwere intravenously dosed with 6 mg/kg of marstacimab, PBS saline (as negative control) or 200 IU/kg of \nrFVIII (as positive control) and 0.5 hours post-dose the cremaster arteriolar endothelium of the mice was \ninjured by laser (7 to 12 injuries/mouse, 3 mice/group). Non-haemophilic WT C57BL6/J mice received saline \nbefore injury and served as control. Blood loss after tail clip injury showed to decrease dose-dependently with \nincreasing doses of marstacimab in haemophilia A mice. At 0.5, 1, 2 or 6 mg/kg a decrease of 6.1%, 51%, \n63.2% and 77.7% in bleeding was observed in haemophilia A mice. In haemophilia B mice, a decrease of \n74% was noticed at 6 mg/kg marstacimab. Furthermore, a high reduction in blood loss was observed at 0.5 \nhours, which finally returned to baseline and control values after 240 hours in haemophilia A mice treated \nwith 6mg/kg marstacimab (e.g. 77.9% reduction at 0.5 hours, 27.3% reduction at 189 hours). The laser \ninduced injury model revealed a similar increase in platelet accumulation and fibrin deposition for \nhaemophilia A mice treated with 6 mg/kg marstacimab or 200 IU/kg rFVIII but were far from the maximal \nlevel observed in non-haemophilic control animals. The haemostatic effect of marstacimab persisted to 168 \nhours. \n"
    },
    {
      "page_number": 41,
      "text": "Assessment report \nEMA/464842/2024 \nPage 41/198 \n \nIn study number PF-06741086_31Mar16_121321, the effect of marstacimab on bleeding was investigated in \nhaemophilic mice by using acute tail clip injury or laser-induced injury to provoke active bleed. Therefore, \nhaemophilia B mice (5 mice/group) were intravenously treated with marstacimab at 6 mg/kg or vehicle and \nthe volume of blood loss and haemoglobin content were determined 0.5 (marstacimab group and vehicle \ncontrol), 72 and 192 (marstacimab groups only) hours post-dose, when bleeding was induced by tail clip. \nHaemophilic A mice received either IV marstacimab at 6 mg/kg (n=10), vehicle (n=11), or recombinant FVIII \nat 200 U/mg (n=5) immediately after tail clip or marstacimab at 1, 3 and 6 mg/kg (n=11, n=6 and n=8, \nrespectively), recombinant FVIII at 200 U/mg (n=8) or vehicle (n=14) two minutes after bleeding onset \ncaused by tail clip. In the laser-induced injury model, bleeding was investigated by intravital microscopy \nimaging in haemophilia A mice (n=18), where each mouse was injured twice, at first without and then with \nintravenous administration of marstacimab (at 6 mg/kg), immediately given after injury. In haemophilia B \nmice, a significant reduction of blood loss (65%) was observed at 0.5 hours post-dose marstacimab (6mg/kg) \nand to a less extend at 72 hours post-dose. In haemophilia A mice, immediate infusion of marstacimab \n(6mg/kg) or recombinant FVIII led to a decrease in blood loss of 60% or 84%, respectively. A dose- \ndependent reduction was observed due to IV administration two minutes after bleeding onset of 1, 3 (51%) \nand 6 mg/kg (76%) marstacimab. An increase in platelet accumulation (1.8-fold) and fibrin deposition (6- \nfold), analysed by area under the curve after laser injury in haemophilia A mice, was observed, when \ncompared to untreated mice. \nA non-GLP 10-day intravenous repeat dose administration study, number 16MA086, was conducted in male \nWistar Han rats to investigate potential additive effects of a combined treatment of marstacimab at 50 mg/kg \nonce daily on Days 1 and 8 and NovoSeven RT (eptacog alfa, activated), a blood coagulation factor VIIa \n(FVIIa), at 3 mg/kg once daily (QD) or 0.8 mg/kg (0.4 mg/kg twice daily (BID)) on day 8, 9 and 10. \nMarstacimab (at 50 mg/kg QD on Days 1 and 8) and NovoSeven RT (0.4, 1, or 3 mg/kg (QD) or 0.8 mg/kg \n(0.4 mg/kg BID) on Days 8-10) were also administered alone. Only combined once daily administrations of \nmarstacimab at 50 mg/kg QD (Days 1 and 8) and NovoSeven RT at 3 mg/kg indicated an enhanced effect, \nreflected microscopically by an increased incidence and /or severity of minimal to mild, acute thrombi/emboli \nin the lung and injection site (tail). Treatment with Novoseven RT resulted in non-dose-related lower group \nmeans for PT, which were not changed by concomitant administration of marstacimab. Combined treatment \nof marstacimab and NovoSeven RT at 0.4 mg/kg BID led to slightly higher glucose values (1.17x-1.28x \nrespective vehicle control group mean). Co-administration of marstacimab (50mg/kg QD) and NovoSeven RT \n(3mg QD or 0.4mg BID) did not alter systemic exposure, reflected by similar Cmax and AUCt values when \ndosed alone. After dosing with NovoSeven RT, a delay in Tmax was noticed. For marstacimab (50 mg/kg), \nmarstacimab (50 mg/kg)/NovoSeven RT (3 mg/kg), and marstacimab (50 mg/kg)/NovoSeven RT (0.8 [0.4 \nBID] mg/kg) at Day 8 following values data were reported, respectively: Cmax: 1670, 1690 and 1750 µg/mL; \nmean AUCt: 41800, 45400 and 43200 µg•h/mL; mean Tmax: 0.083, 1 and 1 hour. \nPotential additive effects of a combined treatment of subcutaneous administered marstacimab at 30 mg/kg \nonce daily on day 1 and 8 and twice daily intravenous injections of FEIBA, a freeze-dried sterile human \nplasma fraction with Factor VIII inhibitor bypassing activity, at 10, 50, or 100 U/kg/day on day 8, 9 and 10 \nwas investigated within the scope of the non-GLP compliant study 19GR258, which was conducted in male \nWistar Han rats (5/group in main and 4/group in PK study). Vehicle groups for marstacimab and FEIBA were \nincluded and both test articles were also administered alone at the same doses as used in combination \n(marstacimab: 30mg/kg QD on D1 and D8; FEIBA: 10 (5 BID), 50 (25 BID), or 100 (50 BID) U/kg/day on \nDays 8-10). Subcutaneous administration of marstacimab at 30 mg/kg once daily on day 1 and 8 resulted in \nhigher mean concentrations of thrombin-antithrombin complexes (TAT) (2.06x of vehicle control), but \nwithout any further test-article related findings (e.g. clinical, macroscopic and or microscopic observations). \n"
    },
    {
      "page_number": 42,
      "text": "Assessment report \nEMA/464842/2024 \nPage 42/198 \n \nIntravenous administration of FEIBA alone led to higher TAT concentrations, activated partial thromboplastin \ntime and lower prothrombin time, correlating with clinical signs as well as macroscopic and microscopic \nobservations (e.g. abnormal colour and increased incidence and/or severity of thrombi/emboli at the IV \ninjection site, etc.) at the highest dose of 100 (50 BID) U/kg/day. Combined treatment of marstacimab and \nFEIBA showed similar results as reported for FEIBA alone, with the exception of higher TAT concentrations \n(2.30x-10.84x of vehicle control), slightly higher mean platelet volume values (1.05x-1.11x of control) and \nno increased incidence for test article-related thrombi/emboli in the lung, observed for concomitant \ntreatment. Co-administration of marstacimab (30mg/kg QD) and FEIBA (5, 25 or 50 BID) did not alter \nsystemic exposure of marstacimab, reflected by similar Cmax, Tmax and AUC48 values when dosed alone \n(marstacimab at 30mg/kg: day 1: 196µg/mL, 72hrs and 4100µg*hrs/mL, respectively; day 8: 219µg/mL, \n48hrs and 7990µg*hrs/mL, respectively). Accumulation ratios of mean AUC48 values after marstacimab \nadministration with and without combined treatment of FEIBA at various doses ranged from 1.8 to 2.1. \nIn the non-GLP compliant study 22GR075, potential additive effects of a combined treatment of subcutaneous \nadministered marstacimab at 30 mg/kg once daily on day 1 and 8 and intravenously dosed Byclot, a freeze- \ndried activated human blood coagulation factor VII concentrate containing factor X, at 60 (30 BID), 120 (60 \nBID), or 180 (120/60 BID) µg/kg/day on Day 8 and at 60, 120, or 120 µg/kg/day QD on Day 10, were \ninvestigated in male Wistar Han rats (5/group in main and 4/group in PK study). Treatment with Byclot alone \nrevealed shortened prothrombin times (0.45x-0.50x of respective control mean) and prolonged activated \npartial thromboplastin times (1.35x-1.51x of respective control mean) at all doses, whereas administration of \nmarstacimab at 30 mg/kg alone did not result in any test-article related effects. Combined treatment of \nByclot at all doses and marstacimab at 30mg/kg showed similar shortened prothrombin times and prolonged \nactivated partial thromboplastin times (0.50x-0.52x and 1.45x-1.46x of respective control mean, \nrespectively) as observed with Byclot alone, but led to an increase in thrombin:antithrombin-complex \nconcentrations (1.41x-1.89x of respective control mean), which was not achieved by each individual \ntreatment. Addition of various doses of Byclot did not alter mean systemic exposures (Cmax and AUC) of \nmarstacimab at 30mg/kg (marstacimab alone: day 1: Cmax 156µg/mL, Tmax 54hrs and AUC48 \n4370µg*hrs/mL; day 8: Cmax 140µg/mL, Tmax 42hrs and AUC48 4690µg*hrs/mL). \n \n2.5.2.2. Secondary pharmacodynamic studies \n \nNo Secondary pharmacodynamic studies were performed with marstacimab. \n \n2.5.2.3. Safety pharmacology programme \n \nNo dedicated safety pharmacology studies were conducted, however safety pharmacology parameters were \nassessed within the scope of the GLP-compliant 13-week subcutaneous repeat-dose toxicity study in \nCynomolgus monkeys (study 20062114), where no test article-related changes were observed in neurological \nparameters, respiration rate, ECG parameters and hemodynamic endpoints. \n \n2.5.2.4. Pharmacodynamic drug interactions \n \nPharmacodynamic drug interaction studies, in vitro and in vivo, with available bypass agents as \nNovoSevenRT, FEIBA, or Byclot, were provided as part of the primary pharmacology section of this dossier. \n"
    },
    {
      "page_number": 43,
      "text": "Assessment report \nEMA/464842/2024 \nPage 43/198 \n \n2.5.3. Pharmacokinetics \n \nMarstacimab PK/TK profile was characterised following intravenous (IV) and subcutaneous (SC) \nadministration to rats (IV: 3-1000 mg/kg, SC: 3-180 mg/kg) and Cynomolgus monkeys (IV: 1-500 mg/kg, \nSC: 3-90 mg/kg). \nLigand-binding assays were used for quantification of marstacimab in rats and monkeys. Validated assays (in \naccordance to GLP) were used to support the bioanalysis of plasma samples from GLP toxicity studies. \nValidation reports were submitted and analytical methods used adequate for the measurement of \nmarstacimab in plasma of rat and monkey, respectively. \nFor detection of anti-drug antibodies in plasma of rat and monkey, ligand-binding assays were validated \nbased on the MSD assay platform. A rabbit anti-marstacimab anti-serum polyclonal antibody spiked into rat \nor Cynomolgus monkey plasma was used as positive control, while normal pooled rat or Cynomolgus monkey \nplasma, respectively, was used as negative control. Samples were tested using a tiered strategy (Screening, \ntitre determination). \n \nFOR Adults of age between 22 years to 41 years : \n \nChemical Formula: C6905H9789N1979O2509S49 \nMolar Mass:  824890856.54 \n \nAtoms of carbon present in Hympavzi = a,  \nAtoms of hydrogen present in Hympavzi = b, \nAtoms of nitrogen present in Hympavzi =  c, \nAtoms of oxygen present in Hympavzi = d, \nAtoms of sulphur present in Hympavzi = e,  \na = 6905, b=9789, c=1979, d=2509, e=49 \n \nsub total mass(g/mol) of carbon present = v \nsub total mass(g/mol) of hydrogen present = w \nsub total mass(g/mol) of nitrogen present = x \nsub total mass(g/mol) of oxygen present = y \nsub total mass of sulphur present = z \nv = 82933.88, w= 9866.33, x= 27719.26, y=40142.49, z=1571.18 \n \nMolar Mass = (v*a)+(w*b)+(x*c)+(y*d)+(z*e) \nMolar Mass = Atoms to the particular element * sub total mass(g/mol)  \nMolar Mass = (82933.88*6905) +(9866.33*9789)+(27719.26*1979) \n+(40142.49*2509)+(1571.18*49) \nMolar Mass = 824890856.54 \n \n \n \n"
    },
    {
      "page_number": 44,
      "text": "Assessment report \nEMA/464842/2024 \nPage 44/198 \n \n \n2.5.4. Toxicology \n \nThe Applicant filed a suite of toxicology studies. In total, five repeated dose toxicity studies, a male fertility \nand early embryonic development study, a weight of evidence carcinogenicity assessment, a local tolerance \nstudy, two immunotoxicity studies and two additional “other” toxicity studies were submitted. In general, this \ntoxicology programme complies with recommendations in the current regulatory guidelines ICH M3(R2) and \nICH S6(R1); justifications were provided for instances in which studies were waived. \n \n2.5.4.1. Single dose toxicity \n \nNo single dose toxicity studies were submitted, as the toxicity profile of marstacimab was characterised in the \nrepeated dose toxicity studies in rats and Cynomolgus monkeys in line with ICH M3(R2) and ICH S6(R1). \n \n2.5.4.2. Repeat dose toxicity \n \nIn total, five repeated dose toxicity studies were submitted. At first, the toxicity profile and toxicokinetics of \nmarstacimab were examined in a non-GLP compliant study in male Wistar Han (CRL:WI [HAN]) rats (n=5 per \nvehicle and dosing group, n=3 (vehicle) or 6 (test-article) in TK satellite groups) during and after two \nintravenous or subcutaneous administration (day 1 and 8 of the study) at 0, 3, 30 and 90 mg/kg/week and at \n0 or 3 mg/kg/week, respectively (Study 13MA067). Similarly, in the non-GLP compliant Study 13MA070, the \ntoxicity and toxicokinetics of marstacimab were evaluated in male and female Cynomolgus monkeys (n=1 per \ngroup and sex) that received 0, 3, 30 and 90 mg/kg/week marstacimab intravenously (bolus injection) and 0 \nand 3 mg/kg/week subcutaneously at day 1 and 8 of the study. Then, the toxicity and toxicokinetics of \nmarstacimab were further examined in the GLP-compliant Study 20064198 in which male and female \nCrl:WI(Han) rats (n=10 per sex and vehicle/dosing group, and n= 3 (vehicle) or 6 (test-article) per sex and \nTK satellite group) received intravenous or subcutaneous marstacimab at 0, 60, 180 and 1000 mg/kg/week \nand 0 and 180 mg/kg/week, respectively. In this study, marstacimab was administered on a weekly basis for \n3 months. Additionally, reversibility of potential test-article related effects was examined in the i.v. 0 and \n"
    },
    {
      "page_number": 45,
      "text": "Assessment report \nEMA/464842/2024 \nPage 45/198 \n \n1000 mg/kg/week groups after a 6-week recovery period. In the GLP-compliant Study 20089324, the toxicity \nand toxicokinetics of marstacimab were examined in male and female Crl:WI(Han) rats (n=15 per sex in \nvehicle and dosing groups, and n=3 (vehicle) and 4 (test-article) per sex in test-article TK satellite groups) \nvia intravenous injections of 0, 60, 180, or 1000 mg/kg/week for 26 weeks. Also in this study, the \ntoxicokinetics of the test-article was assessed in a follow-up test-article free 6-week recovery phase (only in \nthe 60 mg/kg/week toxicokinetic cohort). Finally, in the GLP-compliant Study 20062114, marstacimab was \nadministered to male and female Cynomolgus monkeys (n=3 per group and sex) at 0, 30, 90 or 500 \nmg/kg/week (i.v., slow bolus) and 0 or 90 mg/kg/week (s.c.) for 13 concomitant weeks. Reversibility of test- \narticle related effects was examined in n=2 male and female 0 and 500 mg/kg/week animals after a 6-week \nperiod. \nMarstacimab was very well tolerated in rats and Cynomolgus monkeys. Importantly, all test-article related \neffects identified in the repeated dose toxicity studies pertained to the pharmacologic mode of action of \nmarstacimab (enhancement of the extrinsic clotting pathway) or the presence of marstacimab itself. In all \nstudies, the highest applied doses (i.v. and s.c.) turned out to be the studies’ NOAELS. \nSpecifically, decreases in fibrinogen, increases in D-dimer, prolonged activated partial thromboplastin time \nand increases in prothrombin time were generally observed in the animal toxicity studies, all of which were \npresumably related to the pharmacologic mode of action of marstacimab. Importantly, in the 6-month rat \nStudy 20089324, marstacimab-related microscopic findings in the lung, specifically minimal acute and \norganizing thrombi/emboli, minimal infiltrates with refractile material, and minimal basophilic or non- \nbasophilic foreign materials were observed. The occurrence of thrombi and emboli did not follow a dose- \nresponse relationship and did not lead to clinical and microscopic adversities in the affected animals. \nAltogether, it therefore appears unlikely that these findings bear clinical relevance, especially considering the \nconsiderable supra-therapeutic exposures of marstacimab applied in this study. Additionally, similar \nmicroscopic findings were observed in vehicle control animals, potentially demonstrating that the rat model \nused in this study is susceptible to such micro-coagulation events, even in the absence of test-article. Apart \nfrom the lungs, also in the tail vein (the site oT bolus injection) minimal acute and organising thrombi or \nemboli were identified and classified as test-article related. Again, these were characterised as non-adverse. \nTogether with the considerable supra-therapeutic marstacimab doses used in this study, also no concern was \nraised on this finding. \nAdditionally, increases in globulin, total protein, and decreases in albumin:globulin ratios in both rats and \nCynomolgus monkeys were correlated with the high amounts of administered marstacimab (being a IgG1 \nlambda antibody and a protein itself). \nIn terms of toxicokinetics, after intravenous administration, systemic marstacimab exposures increased with \nincreasing dose, generally in a dose-proportional manner. No sex-specific differences in systemic exposure \nwere observed, and maximally a small potential for accumulation was noted. After intravenous \nadministration, marstacimab generally did not lead to the formation of ADAs. However, in Study 20064198, \nsubcutaneous administration of marstacimab clearly led to an increased formation of ADAs. Finally, \nsubcutaneous administration of marstacimab led to lower systemic exposures (in terms of Cmax and AUC168) \nthan intravenous administration of the same dose (e.g. rat Study 20064198). \nExposure margins were sufficiently large when compared to clinical exposures. Importantly, the \nsubcutaneous clinical route of administration was only examined in some of the submitted non-clinical animal \nstudies. However, also for this route of administration, sufficient exposure margins were realised, e.g. in the \n3-month rat repeated dose toxicity Study 20064198 (5-fold exposure margin in the s.c. arm, and 212-fold \nexposure margin in the highest i.v. arm), and in the 3-month Cynomolgus monkey study (40-fold exposure \n"
    },
    {
      "page_number": 46,
      "text": "Assessment report \nEMA/464842/2024 \nPage 46/198 \n \nmargin in the s.c. arm, and 219-fold exposure margin in the highest i.v. arm). The highest applied doses (i.v. \nand/or s.c.) translated to the NOAELs in all submitted studies, demonstrating a low toxicity potential of \nmarstacimab in rats and Cynomolgus monkeys. \nThe absence of a 6-month repeated dose toxicity study in a non-rodent animal species (in the case of \nmarstacimab a 6-month Cynomolgus monkey study) had prior to this MAA submission already been \ncommunicated with CHMP (in the scientific advice procedure EMA/H/SA/3363/1/2016/I, 21 July 2016). Even \nthough ICH M3(S2) specifies that in the EU/EEA 6-months studies in rodents and non-rodents are required, \nICH S6(R1) specifies that there might also be derivations from this principle when scientifically justified. \nJustification on this aspect was provided in the scientific advice procedure EMA/H/SA/3363/1/2016/I, 21 July \n2016. \n \n2.5.4.3. Genotoxicity \n \nAccording to ICH S6(R1), genotoxicity studies were not performed. \n \n2.5.4.4. Carcinogenicity \n \nStandard carcinogenicity studies are not required for biotechnology-derived medicinal products as laid down \nin the Guideline ICH S6 (R1) EMA/CHMP/ICH/731268/1998. Instead, the decision for the need of \ncarcinogenicity studies should be based on a case-to-case evaluation considering the biologic activity of the \nmedicinal product. \nConsidering that Marstacimab is a monoclonal antibody, a direct pro-oncogenic effect is not anticipated. The \nApplicant states that a definitive link between TFPI and mechanisms of carcinogenesis has not been \nestablished but suggests potential of some tumour suppressive properties from literature references. Based \non these data, it cannot be fully excluded that inhibition of TFPI could hinder these tumour suppressive \neffects. However, a thorough weight of evidence evaluation, in combination with data from the repeat dose \ntoxicity studies, which included exposure to marstacimab up to 26 weeks, does not suggest any carcinogenic \npotential. Furthermore, marstacimab is expected to be administered intermittently (once weekly) in humans. \n \n2.5.4.5. Reproductive and developmental toxicity \n \nA male rat fertility and early embryonic development study (Study 00655204) was submitted. Haemophilia A \nand B are X-chromosome linked disorders are with extremely low prevalence in women, this non-clinical \nsubmission strategy has been accepted by CHMP in the EMA scientific advice procedure \nEMA/H/SA/3363/1/2016/I. \nIn Study 00655204, the potential effects of marstacimab on male fertility in Crl:WI(Han) rats after \nintravenous injection of 0, 60, 180 and 1000 mg/kg/week were assessed. Specifically, marstacimab dosing \nwas initiated 4 weeks prior to mating, throughout mating, and was subsequently continued until euthanasia. \nDuring this period, 11 injections were administered. Per dosing group, n=20 male rats were used. Also n=20 \nmarstacimab-naïve female rats (Crl:WI(Han) were used for determining the effects of marstacimab on siring \nperformance and subsequently early embryonic development. Additionally, the toxicokinetics of marstacimab \nwere examined (at exclusively 5 minutes post-dose). \n"
    },
    {
      "page_number": 47,
      "text": "Assessment report \nEMA/464842/2024 \nPage 47/198 \n \nNo test-article related changes in male reproductive performance, spermatogenesis, embryonic survival and \norgan weights or macroscopic findings were observed. Consequently, marstacimab did not impose effects on \nmale reproduction in Study 00655204. \nIn terms of juvenile toxicity, marstacimab will be indicated in patients of 12 years of age and older. \nTherefore, in principle, a juvenile toxicity study could be needed for adequately covering the non-clinical \nsafety of marstacimab. However, the Applicant argued that in the 3-month repeat-dose toxicity Study \n20062114 in Cynomolgus monkeys, the age of some of the animals aligned with the age of adolescent \npatients (monkeys were 3.7 to 7.2 years at dosing initiation). \n \n2.5.4.6. Toxicokinetic data \n \nSee section 2.5.4.2. Repeat dose toxicity. \n \n2.5.4.7. Local Tolerance \n \nIn line with the ICH S6(R1) guideline, local tolerance was assessed in a dedicated single dose SC study in \nrats and as part of the 6-month tail vein IV RDT study in rats. Injection site reactions, typical for mAb \ntherapeutics, were observed after s.c. administration of marstacimab and were characterised by \nhistopathological observations. These predominantly included minimal to mild mixed cell infiltration \nassociated with minimal oedema and/or haemorrhage at the injection site, which were reversible, and slightly \nreduced food consumption which was not accompanied by any additional clinical signs, thus regarded as non- \nadverse. In addition, non-adverse test article-related microscopic findings of minimal acute and organizing \nthrombi/emboli at the tail vein IV injection site was observed at all doses in the 6-month rat repeat-dose \ntoxicity study. No adverse local tolerance findings were observed in the 3-month rat RDT or the 8-day or 3- \nmonth monkey RDT studies at the IV or SC injection sites, respectively. \n \n2.5.4.8. Other toxicity studies \n \nAssessment of ADAs was conducted as part of the repeat-dose toxicity studies in rats and Cynomolgus \nmonkey. ADAs were only observed in the 3-month rat study and did not impact on PK. Please refer also to \nthe discussion provided on repeat-dose toxicity studies. \nNo C1q or FcγR binding was observed with marstacimab, suggesting a low potential to elicit CDC or ADCC \nactivity. Marstacimab did not induce TNF-α, IL-6, or IFN-γ in vitro. \nStudies on marstacimab metabolites have not been conducted. Marstacimab is expected to be metabolised by \nproteolytic catabolism and cleared by receptor-mediated and target-mediated mechanisms. \nStudies on marstacimab impurities have not been conducted because of this type of medicinal product. \nBesides staining with marstacimab in anticipated tissues in rat, monkey and human, TFPI expression was also \nfound in the mesothelium, epithelium, and islet cells. However, it is agreed that in vitro binding of \nmonoclonal antibodies to cytoplasmic sites is generally considered to be of low toxicological concern due to \nlack of in vivo relevance. \n"
    },
    {
      "page_number": 48,
      "text": "Assessment report \nEMA/464842/2024 \nPage 48/198 \n \n2.5.5. Ecotoxicity/environmental risk assessment \n \nIn accordance with the CHMP guideline for Environmental risk assessment of medicinal products for human \nuse” [EMEA/CHMP/SWP/4447/00 corr 2], as the proposed product falls within the classification of a products \ncontaining vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids as active \npharmaceutical ingredient(s), an environmental risk assessment (ERA) is not required. \n \n2.5.6. Discussion on non-clinical aspects \n \nPharmacology \n \nOverall, the in vitro primary pharmacology program conducted by the Applicant is adequate to elucidate \nmarstacimab’s mode of action, being a fully human IgG1 monoclonal antibody directed against an epitope in \nthe K2 domain of human Tissue Factor Pathway Inhibitor (TFPI), which is itself a Kunitz-type protease \ninhibitor, binding to Factor Xa via Kunits domain 2 (K2), and further triggering binding of this complex to \nTissue Factor bound Factor VIIa via Kunitz domain 1 (K1). Inhibition of TFPI by marstacimab therefore leads \nto further Thrombin generation via the extrinsic pathway of the coagulation cascade, which is known to be \nnot affected in patients with Haemophilia A (deficiency of FVIII) and B (deficiency of FIX). \nThe in vitro studies were performed using purified TFPI protein, non-haemophilic whole blood or plasma and \nhaemophilic plasma. \nIn study PF-06741086_28APR15_072904, binding affinity and kinetics of marstacimab to human, mouse, rat, \nrabbit and Cynomolgus monkey TFPI K1K2 were investigated by Surface Plasmon Resonance (SPR) and \nbinding was confirmed for each species in this assay. As it was published by Hansen et al 2014, that the \nmonoclonal KPI-2 binding antibody concizumab cross reacted with rabbit TFPI but not with rat TFPI, the \nApplicant was asked for discussion regarding binding of marstacimab to rat TFPI K1K2, since this species had \nbeen used in non-clinical in vivo studies with marstacimab. To support the assumption that marstacimab is \nbinding to rat TFPI, the Applicant provided further data in Memo 1 and Memo 2, indicating that concizumab \nand marstacimab are binding to different TFPI epitopes, by crystallography of TFPI-23 (the precursor of \nmarstacimab) bound to Cynomolgus monkey TFPI K2 (which differs to human TFPI K2 by only two amino \nacids far from the TFPI-23 epitope), to the one of humanised 4F36 (a humanised mouse antibody on a \nhuman IgG4 Fc containing a sequence matching that of concizumab) bound to human TFPI K2 obtained from \na NCBI structure database entry (Hilden et al., 2012) (Memo 1). An overlap in contact residues was found \ntwice (D102 and R107) but allows the antibodies to bind simultaneously since TFPI-23 and 4F36 bind TFPI-K2 \nfrom opposite sides. Furthermore, simultaneous binding of TFPI-23 and 4F36 huIgG4m to human TFPI (K1 \nand K2) was observed by surface plasmon resonance using a sandwich assay (Memo 2). Further SPR \ninvestigations endorsed binding to human TFPI K2 and non-binding to human TFPI K1 (study PF- \n06741086_14Nov22_121926). \nA dose-dependent response of marstacimab to restore Factor Xa activity by inhibition of TFPI was shown in \nstudy PF-06741086_06APR15_085202. In the TF-FVIIa-FX Inhibition Reversal Assay a minor increase in \nFactor Xa activity was even observed in IgG control samples at higher concentrations. TEG analysis (study \nPF-06741086_01Apr15_142056) revealed dose-dependent changes in some clot formation dynamic \nparameter, indicating improvement in clot formation speed and strength. \nStudy PF-06741086_07APR15_123404 confirmed marstacimab’s inhibitory effect on TFPI in the extrinsic \npathway, leading to dose-dependent shortening of dPT clotting times in non-haemophilic human, rabbit and \n"
    },
    {
      "page_number": 49,
      "text": "Assessment report \nEMA/464842/2024 \nPage 49/198 \n \nCynomolgus monkey plasma, increasing thrombin generation with increasing doses in non-haemophilic \nhuman plasma and no effect on aPTT clotting time, which is focused on the intrinsic pathway of the \ncoagulation cascade. Similar results were obtained in severe haemophilia A (with and without inhibitor) and \nhaemophilia B plasma samples (study PF-06741086_07APR15_135025), with EC50 values akin to the ones \nseen in non-haemophilic plasma of study 123404. Combination of marstacimab with rFVIIa further increased \nthrombin generation compared to rFVIIa alone, reaching non-haemophilic plasma control levels or even \nabove. In this study (135025), the thrombin generation assay was performed in haemophilia A plasma from \nfour different donors with increasing concentrations of marstacimab. In a separate assay, thrombin \ngeneration was investigated after addition of increasing doses of rFVII to haemophilia A plasma from donor \nGK-897-3292, with and without addition of 16µg/ml marstacimab. Untreated haemophilia A and normal \nplasma were used as control. No haemophilia A plasma with marstacimab alone was added for direct \ncomparison with rFVII alone or combined treatment with marstacimab and rFVII in this assay, which would \nhave been of interest in this context. When the same plasma from the severe haemophilia A donor Lot GK- \n897-3292 was used to determine the dose-response relationship for marstacimab, rFVIIa, and the \ncombination of rFVIIa with a fixed 16 ug/mL concentration of marstacimab, not only the measured absolute \nvalues of lag time and peak thrombin were significantly different for the controls (lag time 23.08 min and \n5.68 min; peak thrombin 3.2 nM and 38.4 nM) during the two measurements but also the effect size of 16 \nµg/mL marstacimab: the lag time decrease was approximately 75% vs. 20%, and the peak thrombin \nincrease was ~12-fold vs. ~4-fold. Literature data provided showed substantial susceptibility of thrombin \ngeneration assay for preanalytical errors explaining the observed large interexperimental variability. \nAdditionally, it was shown that the inherent limitations of the thrombin generation assay were reduced by the \ncoherent results of multiple independent non-clinical studies. \nTable 2: Thrombin generation parameters in severe Haemophilia A plasma (GK-897-3292). Data \nfrom appendix 12.1, 12.8 and 12.9 in study report PF-06741086_07APR15_135025. \n \nLot No \ntable No in \nreport \n135025 \nmarstacimab \nconcentration \n(µg/mL) \nlag time (min) \npeak thrombin \n(nM) \nLot GK-897-3292 \n12.1 \n0 \n23.08 \n3.2 \nLot GK-897-3292 \n12.1 \n16 \n5.85 \n39.81 \nLot GK-897-3292 \n12.8 \n0 \n5.68 \n38.4 \nLot GK-897-3292 \n12.9 \n16 \n4.51 \n152.1 \nHowever, further extensive in vitro assays were conducted investigating concomitant dosing of marstacimab \nand rFVII (see study 122443 below). As mentioned above, in study 123404, the dilute prothrombin time \n(dPT) assay was conducted in human non-haemophilic human, rabbit and Cynomolgus monkey plasma, but \nnot in rat plasma. Thrombin generation was investigated in human haemophilic inhibitor plasmas in the \ncombination study 045123 with aPCC. Within the scope of the scientific advice from 2019 (CHMP Protocol \nAssistance, EMEA H SA 3363 3 20 18 PA III, 31 January 2019), the conduct of an in vitro study with rat \nplasma similar to that performed in human haemophilia plasma with activated prothrombin (study 045123) \nwas proposed, to further help with the translation of any or the lack of effects seen in vivo in rats. Therefore, \nthe Applicant was asked why haemophilic assays as dPT and TGA were not conducted with rat plasma, since \nthis animal species had been used in in vivo combination studies with Byclot, FEIBA and Novoseven. It was \nthen asserted that pharmacological activity of marstacimab in rats was sufficiently demonstrated in vitro, by \nassessing marstacimab’s binding affinity to recombinant rat TFPI K1K2 (by SPR), as well as in vivo, since all \ntest-article related effects observed in the repeated dose toxicity study in rats pertained to the pharmacologic \nmode of action of marstacimab. \n"
    },
    {
      "page_number": 50,
      "text": "Assessment report \nEMA/464842/2024 \nPage 50/198 \n \nAn increase in thrombin generation in haemophilia A (with and without inhibitor) and haemophilia B plasma \nwith increasing doses of Marstacimab with or without co-treatment of rFVIIa was observed in study PF- \n06741086_31Mar16_122443 as well, overall, obtaining physiological peak thrombin values, similarly as \nmeasured in untreated non-haemophilic plasma, at 16µg/mL marstacimab. Combined treatment of \nMarstacimab with a plasma derived activated prothrombin complex concentrate (aPCC), at systemic \nexposures expected to occur after clinical administration, was investigated in study PF- \n06741086_26Jul18_045123, showing an additive increase in thrombin generation, even exceeding non- \nhaemophilic plasma control levels, but no additive decrease in lag time. \nStudy PF-06741086_14Oct22_103228 investigated the effect of a possible combined treatment of \nmarstacimab and Byclot (FVIIa/FX), which resulted in, including but not limited to, an additive increase in \npeak thrombin, whereas a decrease in lag time was observed as well, but without any additive effect. Overall, \nthe concentration of 16µg/mL marstacimab used in various non-clinical in vitro assays was chosen to mirror \nexpected Cmax steady state concentrations following subcutaneous dosing of marstacimab at 2mg/kg, based \non modelling. A comparable Cmax (18.5µg/mL) was observed in the Cynomolgus monkey study (number \n8299672) after SC administration of marstacimab at 3mg/kg. Similar values were reported following single \ndose subcutaneous administrations of 300mg to healthy study participants (Cmax 16490ng/mL and \n12870ng/mL in study B7841001 and B7841009, respectively) and patients with haemophilia (17110ng/mL \nand 15610ng/mL in study B7841002 and B7841010, respectively). \nOverall, the performed in vitro studies provided evidence for selective and high affinity binding of \nmarstacimab to the K2 domain of TFPI with broad species cross reactivity and for the increased activation of \nthe extrinsic pathway in both non-haemophilic whole blood / plasma and haemophilia A and B plasmas \nwithout and with inhibitors. The combination of marstacimab and bypass agents in haemophilic plasmas (A \nand B) sometimes resulted in slight additivity in thrombin generation (peak thrombin level) but the \nconcentration was within the range in studies reported for non-haemophilic normal plasmas. In this context it \nis worth to note that the intended clinical indication of marstacimab is prophylaxis of bleeding episodes in \npatients with severe haemophilia A without factor VIII inhibitors, or severe haemophilia without factor IX \ninhibitors. \nPharmacodynamic \nPharmacodynamic in vivo studies to assess non-clinical efficacy of marstacimab were conducted in \nCynomolgus monkeys, Haemophilia A and B mice and Wistar Han rats. \n \nPharmacodynamics after repeated intravenous and/or subcutaneous dosing of marstacimab, observed as a \ndecrease in dPT clotting time, and dose-dependent pharmacokinetics, correlating with target concentrations \n(total TFPI) in plasma, were investigated in male Cynomolgus monkeys in study 8299672. In group 1 \nanimals, plasma concentrations of marstacimab after IV administrations of 1mg/kg marstacimab at day 1 \nwere not quantifiable at 144 hours post-dose and therefore, animals receiving their second dose IV or SC of \n3mg/kg on day 8 assumed to have no or negligible marstacimab concentrations prior to dosing. Animals of \ngroup 2, which received 10mg/kg IV marstacimab at day 1 still had high plasma concentrations of \nmarstacimab at 168 hours post-dose and therefore prior to their second dose of 10mg/kg SC marstacimab on \nday 8. Recalculations of the PK parameters of the 10mg/kg SC marstacimab treatment group at day 8 using \nthe pre-dose sample values taken from the prior time course (ie 168 hour) as C0 instead of setting C0 to 0.00 \nng/ml as done before, showed to have no impact on evaluated PK parameters when compared to each other. \nTotal TFPI concentrations in Cynomolgus monkey plasma increased with increasing concentrations of \nmarstacimab and decreased with elimination of marstacimab. Because a strong correlation between free TFPI \n"
    },
    {
      "page_number": 51,
      "text": "Assessment report \nEMA/464842/2024 \nPage 51/198 \n \nand TFPI inhibitory mAb concentrations is expected in plasma, mirrored by a decrease of free TFPI with \nincreasing concentrations of TFPI inhibitory mAbs (e.g.: Eichler H. et al, 2018; Chowdary P. et al, 2015) the \nApplicant was asked to provide data for free TFPI concentrations in Cynomolgus monkey plasma or discuss \nand justify the lack of those. A thorough explanation was provided by the Applicant that due to several \nreasons (observed issues due to e.g. sample dilution requirements, reagent competition leading to \ndissociation of TFPI from the drug-target complex and/or marstacimab’s target affinity) efforts to develop an \nassay for the detection of free TFPI failed. \nHaemophilia A and B mice were used as animal models of disease in study PF-06741086_07APR15_135244, \nwhere a dose-dependent reduction in blood loss after tail clip injury was observed, which was supported by \nthe laser induced injury model in haemophilia A mice, where an increase in platelet accumulation and fibrin \ndeposition was detected by intravital microscopy imaging. Results of study PF-06741086_31Mar16_121321, \nwhere further and similarly experiments in haemophilic mice were conducted, support the data from study \n135244. The Applicant provided a rationale regarding the broad variation in sample sizes used in study \n135244 and 121321, necessary to confirm marstacimab’s mode of action and to support respective primary \nendpoints of each exploratory study. Haemophilia A and B mice were used as animal model of disease in \nstudy 135244 and 121321, which are generally considered an appropriate species for this purpose. Mice were \ndosed with intravenous marstacimab only, whereas the clinical route of administration, the subcutaneous \nroute, was not investigated, neither in haemophilic mice, nor in other animal models of disease (e.g. \nhaemophilic dogs or rabbits). (see also Clinical Efficacy discussion). However, the Applicant refers to the \nclinical study B7841001. In this trial pharmacodynamic effects and pharmacokinetics of marstacimab were \ninvestigated at different dose levels following subcutaneous (SC) or intravenous (IV) administration in \nhealthy adults (first in-human study B7841001) and treatment related changes were observed for all PD \nendpoints (e.g. increases in total TFPI, peak thrombin, D-Dimer, and PF1+2 and shortening of TGA lag time \nand dilute prothrombin time) in both SC and IV treated subjects. \nStudy 16MA086 investigated the combined treatment of marstacimab with NovoSeven RT in rats. \nConcomitant administration of marstacimab and NovoSeven RT did not alter systemic exposures (Cmax and \nAUCt) of each other. Enhanced efficacy by co-administration, reflected by an increased incidence and /or \nseverity of minimal to mild, acute thrombi/emboli in the lung and injection site (tail), was only seen in the \nNovoSeven RT high dose group. In study 19GR258, combined treatment of marstacimab and FEIBA was \ninvestigated and did not reveal any changes in systemic exposure (Cmax and AUC48) of marstacimab. \nFurthermore, combined treatment of marstacimab and FEIBA showed similar results as reported for FEIBA \nalone (e.g. increase in TAT concentrations and activated partial thromboplastin time and decrease in \nprothrombin time, correlating with clinical signs as well as macroscopic and microscopic observations), but \nwith an additive increase in TAT concentrations, slightly higher mean platelet volume values, and no \nincreased incidence for test article-related thrombi/emboli in the lung. Combined treatment of \nsubcutaneously administered marstacimab and intravenously dosed Byclot® was assessed in study 22GR075, \nwhere an increase in thrombin:antithrombin-complex concentrations was observed in rats after co-treatment, \nwhereas marstacimab alone did not result in any test-article-related effects. Overall, to summarise, \ntreatment of rats with marstacimab alone led to no test-article related changes in Prothrombintime (PT), \nactivated partial thromboplastin time (aPTT; as expected) and Thrombin-antithrombin complexes (TAT) in the \ncombination study with Byclot, higher TAT values (about 2x of control) in the FEIBA study and no changes in \nPT in the Novoseven combination study, indicating only low pharmacodynamic response to marstacimab in \nthis animal model. It is to note, that the use of marstacimab is indicated for the treatment of adult and \nadolescent patients with haemophilia A or B without inhibitors. The combination studies of marstacimab with \nNovoSeven RT (study 16MA086), FEIBA (study 19GR258) or Byclot (study 22GR075) in male Wistar Han rats \n"
    },
    {
      "page_number": 52,
      "text": "Assessment report \nEMA/464842/2024 \nPage 52/198 \n \nwere mainly conducted to support the inclusion of patients with inhibitors in clinical studies. A concomitant \nstudy with FEIBA in rats was discussed within the scope of a scientific advice (CHMP Protocol Assistance, \nEMEA/H/SA/3363/3/20-18/PA- III, 31 January 2019), where the conduct of an in vitro study with rat plasma \nsimilar to that performed in human haemophilia plasma with activated prothrombin (study 045123) was \nproposed, to further help with the translation of any or the lack of effects seen in vivo. No such study was \nsubmitted with this MAA. Furthermore, scientific advice was provided in 2016 (CHMP Scientific Advice, EMEA \nH SA 3363 1 20161, 21 July 2016), where the use of marstacimab and eptacog alfa was discussed for the \nsame purpose. It was pointed out by the CHMP, that any pivotal safety study should be conducted according \nto GLP, or thoroughly justified if not, that exposures should reflect clinical exposures and that the proposed \nnumber of animals (n=5/group) was thought to be minimal and could be adapted. In study 16MA086, group \nsizes remained 5 animals/group in the main study but were increased to at least 8 animals/group in the PK \nstudy arm. All combination studies with marstacimab were not conducted according to GLP. \nOverall, the pharmacodynamic effect of iv or sc marstacimab in Cynomolgus monkeys was demonstrated by \nshortening of dPT with a stable decrease in dPT clotting time from 24 to 240 hours. Additionally, efficacy of \nintravenously administered marstacimab was shown in a model of disease, using acute tail clip injury and/or \nlaser induced injury in haemophilia A and B mice. Combination studies in rats with marstacimab and \nbypassing agents (NovoSevenRT, FEIBA, or Byclot) were conducted to investigate the cumulative \npharmacodynamics and potential additive effects of co-administration of these treatments. It is of note that \nthese combination studies are relevant primarily in the context of patients with inhibitors but marstacimab's \nindication in this application is only for haemophilia A and B patients without inhibitors. In summary, the \nresults of these in vivo combination studies did not raise major concerns regarding the combined effects of \nmarstacimab and bypassing agents but with signs of enhanced efficacy for some combinations and doses. \nSecondary pharmacodynamics \nNo dedicated secondary pharmacodynamic studies were conducted with marstacimab, since tissue cross- \nreactivity studies did not raise concern for any off-target effect, which is accepted. \nSafety pharmacology \nNo dedicated safety pharmacology studies were conducted, whereat safety pharmacology parameters were \nassessed within the scope of the GLP-compliant 13-week subcutaneous repeat-dose toxicity study in \nCynomolgus monkeys (study 20062114), where no test article-related changes were observed in neurological \nparameters, respiration rate, ECG parameters and hemodynamic endpoints. \nPharmacodynamic drug interaction studies  \nPharmacodynamic drug interaction studies, in vitro and in vivo, with available bypass agents as \nNovoSevenRT, FEIBA, or Byclot, are covered in the primary pharmacology section. \nPharmacokinetics \nPharmacokinetics were determined after single and repeated dosing using SC and IV administration of \nmarstacimab in rats and Cynomolgus monkey. \nSeveral ligand binding assay methods were developed and validated for the determination of marstacimab \nconcentration in rat and monkey plasma. A part of these validations was performed by the Applicant, and \nanother part by CROs. The methods were validated according to the current requirements, including the \nquantification range, sensitivity, intra-batch and inter-batch precision and accuracy, dilutional linearity, \nselectivity, bench-top stability, long-term storage stability, freeze-thaw stability, and incurred sample \n"
    },
    {
      "page_number": 53,
      "text": "Assessment report \nEMA/464842/2024 \nPage 53/198 \n \nreanalysis (ISR). Out of the methods used for the determination of marstacimab in pivotal (GLP) toxicological \nstudies, only the method 160918vlim-pgc was validated in accordance with GLP. \nLigand binding methods were also developed and validated for the detection of ADAs in rat and monkey \nplasma. \nThe methods used for the determination of PK/TK parameters were adequate for the assays (however, with \nfurther discussion of the non-GLP studies 13MA067 and 13MA070 studies - see below). \nPK parameters were determined in a PK/PD study (Study number: 8299672) and in single and repeated dose \ntoxicological studies (13MA067, 13MA070, 16MA86, 19GR258, 22GR075), following IV or SC administration. \nThe assays were performed at the same test site where the analytical methods were validated, thus no cross- \nvalidation was necessary. \nSufficient in-study validations were done, and the results were reported sufficiently, except in the 8299672 \nnon-GLP PK/PD study, and in 13MA067 and 13MA070 non-GLP TK/PK studies. In the case of 8299672 PK/PD \nstudy the in-study validation data were not reported. The study reports of 13MA067 and 13MA070 PK/TK \nstudies do not contain sufficient information about the methods used. However, the Applicant provided \nsufficient information on the methods in its answer to the questions. \nThe bioanalytical phases of the pivotal toxicological studies were carried out in accordance with GLP. \nIn 20089324 and 655204 studies the samples were analysed out of the long-term stability range determined \nwithin the method validation study (160918vlim-pgc), but sufficient stability of marstacimab during long- \nterm freeze storage was determined in other method validation studies (e.g.: 15-1828 or 154029). \nIn Cynomolgus monkey the PK increased with dose and TMDD was observed at low doses. The mean t½ was \nbetween ~12 and 118 hours across doses in the nonclinical species. \nToxicokinetics were evaluated as part of the RDT GLP studies in rats and Cynomolgus monkeys. \nSubcutaneous as well as intravenous administration of marstacimab was used. While accumulation was only \nobserved in monkeys after repeated IV administration, systemic exposure after IV dosing increased dose- \ndependently in both species. No significant differences in PK parameters with regard to sex of the animals \nwere observed in either species. Quantifiable levels of marstacimab were detected in rats through the \nrecovery period in the 3- as well as the 6-month study, and in the 3-month RDT monkey study after 6 weeks \nof recovery. \nADAs were only observed in the 3-month rat study after SC dosing and at the lowest IV dose (60 \nmg/kg/week), but not at higher IV doses which may indicate that higher plasma levels of marstacimab may \nhave interfered with ADA detection. However, ADAs did not appear to impact on marstacimab exposure in \nADA-positive rats, as exposure was similar to ADA-negative animals. No ADAs were detected in monkeys. \nPK was also evaluated in investigative pharmacodynamic studies in male rats to assess potential additive \neffects of combined, repeated dosing of marstacimab together with NovoSeven RT, FEIBA, or ByClot. The \nmean systemic exposure (AUC) was similar in all dose groups when marstacimab was administered alone or \nin combination with NovoSevenRT, FEIBA or ByClot. These data suggest there was no DDI effect on \nnonclinical PK after coadministration with these products. \nDedicated tissue distribution and protein binding studies were not conducted with marstacimab, which is \nagreed. Consistent with the known biodistribution of monoclonal antibodies, marstacimab showed low volume \n"
    },
    {
      "page_number": 54,
      "text": "Assessment report \nEMA/464842/2024 \nPage 54/198 \n \nof distribution, with Vss of marstacimab in Cynomolgus monkeys ranging from ~34 to 65 mL/kg), suggesting \na distribution to plasma and extravascular fluid commonly observed for IgGs. \nNo metabolism studies with marstacimab were conducted in animals. The absence of metabolism studies is in \naccordance with ICH S6(R1). \nAs marstacimab is a monoclonal antibody, it is expected to be proteolytically digested into peptides and \namino acid. No specific studies to measure excretion of marstacimab were conducted. The absence of \nexcretion studies in accordance with ICH S6(R1). \nDedicated drug-drug interaction studies were not conducted for marstacimab as DDI is not expected. \nPharmacodynamic studies in rats showed that the mean systemic exposure (AUC) after repeated dosing was \nsimilar in all dose groups when marstacimab was administered alone or in combination with NovoSeven RT, \nFEIBA or ByClot, respectively. These data further indicate no DDI effect on nonclinical PK after \ncoadministration. \nToxicology \nThe toxicologic profile of marstacimab was adequately examined with the submitted studies and therefore \ngenerally supports marketing of marstacimab in the EU/EEA. \nImportantly, no groups in which marstacimab was subcutaneously injected were included in the 6-month rat \nrepeated dose toxicity Study 20089324 even though subcutaneous injection is the clinical route of \nadministration. In general, repeated dose toxicity studies are expected to be carried out in the clinically \nintended route of administration. The lacking investigation of the repeated dose toxicity of marstacimab after \nsubcutaneous administration in Study 20089324 could therefore – in principle – be problematic. Apart from \nregulatory considerations, this is e.g. supported by the fact that in the 3-month rat repeated dose toxicity \nStudy 20064198, marstacimab was considerably more immunogenic after subcutaneous administration than \nafter intravenous administration. Consequently, Study 20089324 did not adequately address the \nimmunogenic potential of marstacimab in the rat after long-term (6 month) subcutaneous administration. \nNonetheless, as already sufficient experience with subcutaneously administered marstacimab has been \ngathered in the clinical trials, it is not considered that an additional repeated dose toxicity rat study in which \nmarstacimab would be subcutaneously administered for 6-months would add additional relevant information \nto the overall hazard characterisation and risk mitigation of marstacimab. Therefore, no concern was raised \non this aspect. \nGenotoxicity \nGenotoxicity studies for marstacimab were not conducted; this omission is justified according to the ICH \nS6(R1) guideline. \nCarcinogenicity \nIt is accepted that complete product-specific assessment of the carcinogenic potential of marstacimab was \nsubmitted in accordance with the requirements of ICH S6(R1) guideline. During scientific advice the CHMP \nagreed that a 2-year rodent carcinogenicity study is not warranted. \nBased on the carcinogenicity risk assessment there are data suggesting tumour suppressive properties of \nTFPI in vitro and in vivo tumour models, there are no non-clinical or clinical reports of TFPI inhibition and \nincreased cancer risk. In addition, no evidence for effects of TFPI inhibition on hormonal or immune \nmodulation has been identified. Therefore, a definitive link between TFPI inhibition with intermittent \nadministration of marstacimab and risk of carcinogenesis has not been established. \n"
    },
    {
      "page_number": 55,
      "text": "Assessment report \nEMA/464842/2024 \nPage 55/198 \n \nIn the repeat-dose toxicity studies in rats and monkeys, there were no marstacimab-related \nproliferative/hyperplastic lesions or tumours, and no evidence of immunosuppression or immunostimulation, \nhormonal modulation, or chronic tissue injury. Further, there was no evidence of infection and there were no \neffects on any organ weight or microscopic findings in tissues/organs of the immune or endocrine systems. \nTherefore, marstacimab-related findings in the toxicity studies do not present a specific carcinogenicity \nconcern. In summary, the weight of evidence indicates the carcinogenic risk of marstacimab is low and \nadditional studies are not warranted. \nReproductive and developmental toxicity \nThe absences of other than male FEED studies in this submission is acceptable, no concerns were identified \non the scope of the submitted developmental and reproductive toxicity studies. As no unexpected test-article \nrelated effects were observed in this study, marstacimab administration can be considered safe in adolescent \npatients. Additionally, the Applicant referred to literature and summarised that coagulation is already fully \nfunctioning 6 months post-partum. Therefore, adverse safety effects of marstacimab that would be specific to \nthe adolescent patient population are not expected. These aspects are considered sufficient for waiving a \njuvenile animal toxicity study; it is not expected that such a study would contribute to a risk assessment in \nthe adolescent patient population. The same conclusion had already been confirmed in prior consultations \nwith EMA, specifically in the CHMP protocol assistance procedure EMA/H/SA/3363/3/2018/PA/III and the EMA \nPIP decision EMEA-002285- PIP02-19. \nNo test-article related changes in male reproductive performance, spermatogenesis, embryonic survival and \norgan weights or macroscopic findings were observed. Consequently, marstacimab did not impose effects on \nmale reproduction in Study 00655204. \nLocal tolerance \nNo adverse local tolerance findings were observed in the 3-month rat RDT or the 8-day or 3-month monkey \nRDT studies at the IV or SC injection sites, respectively. \nEnvironmental risk assessment \nThe active substance is a monoclonal antibody (i.e. of protein structure), susceptible to physical and \nbiological degradation. Therefore, marstacimab is not expected to pose a risk to the environment. \n \nAssessment of paediatric data on non-clinical aspects \n \nThis product is intended to be used in patients 12 years of age and older. Considering non-clinical aspects, a \nsufficient justification was provided why no juvenile toxicity studies were conducted. \n \n2.5.7. Conclusion on the non-clinical aspects \n \nOverall, marstacimab’s mode of action, being a human monoclonal antibody directed against human Tissue \nFactor Pathway Inhibitor (TFPI), was demonstrated by in vitro and in vivo pharmacodynamic studies, with no \nconcerns raised regarding safety pharmacology. \nThe PK/TK profile of marstacimab was adequately examined using validated ligand-binding assays. Potential \ninduction of ADAs was investigated using the same assay system. The toxicologic profile of marstacimab was \nadequately studied. All relevant information has been reflected in sections 4.6 and 5.3 of the SmPC. \n"
    },
    {
      "page_number": 56,
      "text": "Assessment report \nEMA/464842/2024 \nPage 56/198 \n \n2.6. Clinical aspects \n \n2.6.1. Introduction \n \nGCP aspects \nThe Clinical trials were performed in accordance with GCP as claimed by the applicant \nThe applicant has provided a statement to the effect that clinical trials conducted outside the Community \nwere carried out in accordance with the ethical standards of Directive 2001/20/EC. \n• \nTabular overview of clinical studies \nTable 3: Marstacimab Studies contributing Clinical Data \n \nStudy \nidentifier \nStudy design \nPopulation \n(incl number of subjects, \nhealthy vs patient and gender \nratio) \nDosing regimen \nB7841001 \nPhase 1 first-in-human, single \nascending dose, randomised, \ndouble-blind, sponsor open, \nplacebo-controlled study \ninvestigating the safety, \ntolerability, PK, and PD of SC \nand IV administration of \nmarstacimab. \n7 cohorts of healthy male adults and \nan additional cohort of healthy \nJapanese male participants. \nRandomised/Treateda/Completed: \n41/41/40 \nTreatment by Cohortb \n(marstacimab/placebo): \nCohort 1: 4/1 \nCohort 2: 6/2 \nCohort 3: 6/2 \nCohort 4: 6/2 \nCohort 5: 6/2 \nCohort 8 (Japanese): 4/0 \nPresentation: Marstacimab solution for \ninjection, 100 mg/mL vial \nMarstacimab or placebo \nMarstacimab dose SC: \nCohort 1: 30 mg \nCohort 2: 100 mg \nCohort 3: 300 mg \nCohort 8: 300 mg \nMarstacimab dose IVb: \nCohort 4: 150 mg \nCohort 5: 440 mg \nB7841002 \nPhase 1b/2 open-label study \ninvestigating the safety, \ntolerability, PK, PD, and \nefficacy of multiple SC doses \nof marstacimab. \nMale adult participants (18 to <65 \nyears) with severe haemophilia A or B \nwith and without inhibitors to FVIII or \nFIX. \nEnrolled/Treated/Completed: \n27/26/24 \nTreatment by Cohort: \nCohort 1: 7 \nCohort 2: 6 \nCohort 3: 6 \nCohort 4: 7 \nPresentation: Marstacimab solution for \ninjection, 100 mg/mL vial \nCohort 1 (non-inhibitor): 300 mg SC \nQW \nCohort 2 (non-inhibitor): 300 mg SC \nloading dose, 150 mg SC QW \nCohort 3 (non-inhibitor): 450 mg SC \nQW \nCohort 4 (inhibitor): 300 mg SC QW \nB7841003 \nPhase 2 open-label extension \nstudy of B7841002 assessing \nthe safety, tolerability, and \nefficacy of marstacimab as a \nprophylactic treatment \nregimen. \nMale participants with haemophilia A \nor B, with or without inhibitors to FVIII \nor FIX. \nEnrolled/Treated/Completed: \n20/20/18 \n(2 de novo participants, 18 from Study \nB7841002) \nTreatment by Cohort: \n300 mg SC QW: 10 \n150 mg SC QW: 10 \nPresentation: Marstacimab solution for \ninjection, 150 mg/mL vial \nDoses: 150 mg and 300 mg QW \nRoute of administration: SC \nB7841005 \nPhase 3 one-way, cross-over, \nopen-label, multi-center \nstudy. Treatment on factor \nreplacement or bypass \ntherapy during the 6-month \nObservational Phase is \ncompared with a 12-month \nActive Treatment Phase. \nAdolescent and adult participants \nbetween ages 12 to <75 years with \nsevere haemophilia A or moderately \nsevere to severe haemophilia B \n(defined as FVIII activity <1%, or FIX \nactivity ≤2%, respectively) with or \nwithout inhibitors. \nNon-inhibitor Cohort: \nPresentation: Marstacimab solution for \ninjection, 150 mg/mL, PFS \nMarstacimab 300 mg SC for initial \nloading dose followed by 150 mg SC \nQW. \nDose escalation to 300 mg SC QW \nallowed for participants meeting \nprotocol-defined criteria. \n"
    },
    {
      "page_number": 57,
      "text": "Assessment report \nEMA/464842/2024 \nPage 57/198 \n \nEnrolled/Treated/Completed: \nObservational phase: \n128/na/118 \nActive treatment phase: \n116/116/111 \nHaemophilia A: n = 101 \nHaemophilia B: n = 27 \nB7841007 \nPhase 3 open-label extension \nstudy of B7841005 to \nevaluate the long-term safety, \ntolerability, and efficacy of \nmarstacimab prophylaxis \nParticipants with severe haemophilia A \nand B with or without inhibitors who \ncompleted Studies B7841005 or \nB7841008. \nNon-inhibitor Cohort: \nEnrolled/Treated/Completed: \n88/87/na \nHaemophilia A: n = 67 \nHaemophilia B: n = 20 \nPresentation: Marstacimab solution for \ninjection, 150 mg/mL, PFS and PFP \nMarstacimab 150 mg SC QW. \nDose escalation to 300 mg SC QW \nallowed for participants meeting \nprotocol-defined criteria \nB7841009 \nPhase 1 open-label, \nrandomised, 4-period, 2 \nsequence, crossover study to \nevaluate the bioequivalence of \nmarstacimab prefilled syringe \nand prefilled pen following \nsingle-dose subcutaneous \nadministration. \nHealthy adult male participants. \nRandomised/Treated/Completed: \n22/22/10 \nPresentation: Marstacimab solution for \ninjection, 150 mg/mL, PFS and PFP \nDose: 300 mg single dose \nRoute of administration: SC \nB7841010 \nPhase 1 single-arm, open- \nlabel, non-randomised, non- \ncontrolled multicentre study \nto evaluate the PK, PD, \nsafety, and tolerability of a \nsingle subcutaneous dose of \nmarstacimab. \nChinese adult participants with severe \nhaemophilia. \nEnrolled/Treated/Completed: 6/6/6 \nPresentation: Marstacimab solution for \ninjection, 150 mg/mL, PFS \nDose: 300 mg single dose \nRoute of administration: SC \na. Treated with study intervention; marstacimab for all studies except Study B7841001 which included placebo. \nb. Planned Cohort 6 (1000 mg IV) and Cohort 7 (2000 mg IV) were not evaluated in Study B7841001 as dose escalation was terminated as \nsafety, tolerability, PK, and PD data through Cohort 5 was determined to be sufficient for progression to the next study (B7841002). \n \n \n \n \n2.6.2. Clinical pharmacology \n \n2.6.2.1. Pharmacokinetics \n \n \nAbsorption \n \nPK results of phase 1 first-in-human Study B7841001 (single SC/IV dose in healthy adults) \n"
    },
    {
      "page_number": 58,
      "text": "Assessment report \nEMA/464842/2024 \nPage 58/198 \n \nFigure 1: Median Marstacimab plasma concentration-time profiles (linear scale) following \nadministration of single SC or IV doses to healthy participants (B7841001) \n \n \n \n \nTable 4: Descriptive summary of plasma marstacimab pharmacokinetics parameters following \nsingle SC and IV doses (B7841001) \n \n"
    },
    {
      "page_number": 59,
      "text": "Assessment report \nEMA/464842/2024 \nPage 59/198 \n \nPK results of phase 1 Study B7841009 (single SC dose, 4-period, 2-sequence, bioequivalence comparing the \nPK of a pre-filled pen with a pre-filled syringe in healthy male adults) \nBased on the statistical analysis performed using completer data (N = 11), PK of marstacimab administered \nvia PFS versus PFP were demonstrated to be bioequivalent with test/reference ratios of adjusted geometric \nmeans of marstacimab AUClast and Cmax values of 107.5% (95.2%, 121.4%) and 104.1% (93.7%, 115.6%) \nrespectively. \nTable 5: Statistical summary of Log transformed plasma marstacimab PK parameters – PK \nparameter analysis set, participants who completed all 4 periods (completers), protocol B7841009 \n \nSensitivity analysis (N = 15) also showed the geometric mean ratios (test/reference) of AUClast and Cmax \nfor N = 15 to be completely contained within the 80% - 125% acceptance criteria for BE (AUClast: 111.9% \n[101.1%, 123.9%] and Cmax: 107.7% [98.8%, 117.5%]). \nFigure 2: Median marstacimab plasma concentration-time profiles (linear and semi-Log scales) by \ntreatment group following single dose SC administration of 300 mg marstacimab to healthy \nparticipants using PFS and PFP (B7841009) \n \n"
    },
    {
      "page_number": 60,
      "text": "Assessment report \nEMA/464842/2024 \nPage 60/198 \n \nTable 6: Descriptive summary of average plasma marstacimab PK parameters – PK parameter \nanalysis set, protocol B7841009 \n \nParameter (Unit)a \nMarstacimab PFP 300mg \n(N=18) \nMarstacimab PFS 300mg \n(N=18) \nN2, N3 \n18, 15 \n18, 13 \nAUCinf (ng*hr/mL) \n2523000 (56) \n2482000 (49) \nAUClast (ng*hr/mL) \n2018000 (69) \n2015000 (50) \nCL/F (L/hr) \n0.1215 (57) \n0.1218 (48) \nCmax (ng/mL) \n12550 (54) \n12870 (43) \nt1/2 (hr) \n61.29 ± 20.073 \n60.24 ± 13.687 \nTmax (hr) \n72.00 (60.0 - 146) \n72.00 (60.0 - 146) \nVZ/F (L) \n10.19 (37) \n10.21 (39) \nSource: Module 5.3.1.2 B7841009 – Table 14.4.5.1.1 \nAverages of PK parameter values for replicate treatment had been used in this table. \nN = total number of participants in the treatment group in the indicated population. \nN2 = number of participants contributing to the summary statistics. \nN3 = number of participants contributing to the summary statistics for t1/2, AUCinf, VZ/F and CL/F. \nOne participant was not included in this presentation. \nPK parameter analysis set was defined as all participants randomised and treated who had at least 1 of the PK parameters of primary interest in at least 1 \ntreatment period. \na. Geometric mean (geometric CV (%)) for all except median (range) for Tmax and arithmetic mean ± standard deviation for t½. \nPFIZER CONFIDENTIAL SDTM Creation: 26JAN2022 (05:06) Source Data: adpp Table Generation: 26JAN2022 (05:09) \nOutput File: ./nda1_cdisc/B7841009_PK2/adpp_s101_im \n \n \nPK results of phase 1 Study B7841010 (single SC dose in adult Chinese haemophilia patients) \nTable 7: Descriptive summary of plasma marstacimab PK parameters in Chinese Haemophilia \nparticipants following single dose SC administration of marstacimab 300 mg (B7841010) \n \nParameter (Unit)a, b \nMarstacimab 300mg SC \n(N=6) \nN2, N3 \n6, 4 \nAUCinf (ng*hr/mL) \n4549000 (7) \nAUClast (ng*hr/mL) \n2917000 (60) \nCmax (ng/mL) \n15610 (35) \nTmax (hr) \n73.15 (71.9 - 167) \nt1/2 (hr) \n90.48 ± 26.025 \nCL/F (L/hr) \n0.06595 (7) \nVz/F (L) \n8.305 (29) \nSource: Module 5.3.3.2 B7841010 – Table 14.4.5.1 \nPK parameter analysis set was defined as all participants treated who had at least 1 of the PK parameters. \nN = Total number of participants in the actual treatment group in the indicated population. \nN2 = Number of participants contributing to the summary statistics. \nN3 = Number of participants contributing to the summary statistics for AUCinf, t½, CL/F and Vz/F. \na. Geometric mean (geometric coefficient of variation (%)) for all except median (range) for Tmax and arithmetic \nmean ± standard deviation for t½. \nb. Cmax was included in the terminal phase to calculate kel derived PK parameters AUCinf, t½, CL/F and Vz/F. \n \n \n \n \n \n \nFigure 3: Median plasma marstacimab concentration-time profile (linear and semi-Log scales) in \nChinese Haemophilia participants following single dose SC administration of marstacimab 300 mg \n(B7841010) \n"
    },
    {
      "page_number": 61,
      "text": "Assessment report \nEMA/464842/2024 \nPage 61/198 \n \n \n \n \nPK results of phase 1b/2 Study B7841002 (multiple SC doses in adult haemophilia patients) \nTable 8: Descriptive summary of marstacimab plasma PH parameters (study B7841002) \nMarstacimab \n300 mg SC \nLoading + 150 \nmg SC QW \nNon-Inhibitorc \n(N=6) \nMarstacimab \n300 mg SC QW \nNon-Inhibitor \n(N=7) \nMarstacimab \n450 mg SC QW \nNon-Inhibitor \n(N=6) \nMarstacimab \n300 mg SC QW \nInhibitor \n(N=7) \nOverall - \nMarstacimab \n300 mg SC \n(N=14) \nParameter \n(Unit)a \nDay 1 \n(Week 1) \nn \n6 \n7 \n6 \n7 \n14 \nAUClast \n(ng*hr/mL) \n2675000 (41) \n1818000 (79) \n2806000 (37) \n2495000 (40) \n2130000 (61) \nCmax \n(ng/mL) \n19480 (42) \n14880 (70) \n23070 (37) \n19680 (51) \n17110 (61) \nCmin \n(ng/mL) \n13040 (43) \n7980 (112) \n15660 (44) \n11140 (41) \n9429 (78) \nTmax (hr) \n69.7 (68.2, \n71.1) \n70.0 (69.1, 72.8) 71.6 (67.6, 72.3) 70.7 (22.8, 167) \n70.1 (22.8, 167) \nDay 29 \n(Week 5) \nn \n6 \n5 \n4 \n5 \n10 \nAUCtau \n(ng*hr/mL) \n3309000 (50) \n9045000 (49) \n11090000 (43) \n9248000 (38) \n9146000 (41) \nCmax \n(ng/mL) \n24150 (44) \n61850 (47) \n73490 (38) \n66070 (44) \n63930 (43) \nCmin \n(ng/mL) \n15000 (59) \n42120 (52) \n53630 (61) \n39490 (37) \n40790 (42) \nCL/F \n(mL/hr) \n45.34 (50) \n33.16 (49) \n40.60 (43) \n32.43 (38) \n32.79 (41) \nTmax (hr) \n23.7 (22.0, \n71.7) \n23.7 (23.1, 94.2) 58.5 (23.3, 97.0) 22.8 (22.1, 94.7) \n23.3 (22.1, 94.7) \n"
    },
    {
      "page_number": 62,
      "text": "Assessment report \nEMA/464842/2024 \nPage 62/198 \n \nMarstacimab \n300 mg SC \nLoading + 150 \nmg SC QW \nNon-Inhibitorc \n(N=6) \nMarstacimab \n300 mg SC QW \nNon-Inhibitor \n(N=7) \nMarstacimab \n450 mg SC QW \nNon-Inhibitor \n(N=6) \nMarstacimab \n300 mg SC QW \nInhibitor \n(N=7) \nOverall - \nMarstacimab \n300 mg SC \n(N=14) \nParameter \n(Unit)a \nDay 85 \n(Week 13)b \nn \n5 \n6 \n6 \n5 \n11 \nCmin \n(ng/mL) \n20630 (43) \n57050 (58) \n37310 (656) \n61140 (51) \n58880 (52) \nSource: Module 5.3.5.2 B7841002 - Table 14.4.5.2 \nThe dose of 1 participant was modified from 450 mg to 300 mg due to multiple severe injection site reactions; the subject was analyzed \nin the Marstacimab 450 mg SC QW \nnon-inhibitor dose cohort. The overall Marstacimab 300 mg SC group combined subjects from both the Marstacimab 300 mg SC QW \nnon-inhibitor and inhibitor dose cohorts. \nPK parameters for 4 subjects (1 subject from the Marstacimab 300 mg SC QW non-inhibitor dose cohort, 2 subjects from the \nMarstacimab 450 mg SC QW non-inhibitor \ndose cohort and 1 subject from the Marstacimab 300 mg SC QW inhibitor dose cohort) on Day 29 (Week 5) were excluded from the \npresentation. \na. Geometric mean (geometric %CV) for all except median (range) for Tmax. \nb. Cmin of Day 85 (Week 13) represents plasma Marstacimab concentration of Day 85 (Week 13). Data points were excluded if there \nwas a dose missed within 4 weeks prior to Day 85 (Week 13). \nc. Day 1 (Week 1): 300 mg SC (loading dose); Day 29 (Week 5): 4th weekly dose of 150 mg SC following a loading dose of 300 mg \nSC. \n"
    },
    {
      "page_number": 63,
      "text": "Assessment report \nEMA/464842/2024 \nPage 63/198 \n \nFigure 4: Median Marstacimab Plasma Concentration-Time Profiles Following Single and Multiple \nDose SC Administration of Marstacimab to Haemophilia A and B Participants With or Without \nInhibitors (B7841002) \n \n \n \n \nUpper and lower panels are linear and semi-logarithmic scales, respectively. \nThe lower limit of quantification was 100 ng/mL. Study Visit “Day 113/Follow-up” located at tick 113 on Xaxis. \nThe overall Marstacimab 300 mg SC group combined participants from both the marstacimab 300 mg SC QW noninhibitor and inhibitor \ndose cohorts. \nSummary statistics were calculated by setting concentration values below the lower limit of quantification to 0. \nThe dose of 1 participant was modified from 450 mg to 300 mg due to multiple severe injection site reactions; the participant was \nanalyzed in the marstacimab 450 mg SC QW non-inhibitor dose cohort. \nPK concentrations for 4 participants (1 participant from the marstacimab 300 mg SC QW noninhibitor dose cohort, 2 participants from the \nmarstacimab 450 mg SC QW non-inhibitor dose cohort and 1 participant from the marstacimab 300 mg SC QW inhibitor dose cohort) on \nDays 29, 30 and 33 were excluded from the presentation. Unplanned readings were excluded from this presentation. \n"
    },
    {
      "page_number": 64,
      "text": "Assessment report \nEMA/464842/2024 \nPage 64/198 \n \nPK results of phase 2 Study B7841003 (extension of Study B7841002) \nMarstacimab PK parameters for two newly enrolled participants were in agreement with those seen in Study \nB7841002. \n \n \nPK results of phase 3 Study B7841005 (multiple SC doses in adult and adolescent haemophilia patients) \nThe 150 mg dose group consisted of participants who received 150 mg SC once weekly marstacimab \nthroughout the entire study whereas the 300 mg dose group consisted of participants who were dose \nescalated to 300 mg SC once weekly marstacimab after Day 180 (Visit 14) following administration of 150 \nmg SC once weekly marstacimab up to that visit. \nFollowing once-weekly subcutaneous administration of 150 mg, plasma concentrations of marstacimab \nappeared to have reached steady state by approximately 60 days (ie, by the 8th or 9th dose of weekly \nmarstacimab dosing). Median steady-state marstacimab plasma concentrations in adults receiving 150 mg \nweekly were approximately 10,000 - 11,000 ng/mL whereas median steady-state marstacimab plasma \nconcentrations in adolescents were approximately 25,000 – 30,000 ng/mL. For the most part, individual \nconcentration-time profiles for adults and adolescents appeared to lie within a similar range of \nconcentrations. In general, marstacimab concentrations are highly variable (% CV of approx. 62% - 92% in \nadults and 40% - 85% in adolescents for 150 mg SC QW). \nFigure 5: Median marstacimab plasma concentration-time profiles (linear scale) following multiple \ndose SC administration of marstacimab to Haemophilia A and B participants without inhibitors \n(B7841005) by dose group and age group \n \n"
    },
    {
      "page_number": 65,
      "text": "Assessment report \nEMA/464842/2024 \nPage 65/198 \n \nMarstacimab PK profiles in Figure 6 show summary data over the entire study duration based on \ncategorization of participants by non-escalated (150 mg SC QW) and escalated (300 mg SC QW) dosegroups. \nTo provide clarity for the 300 mg SC dose and take into account the different times at which doseescalation \noccurred, plasma concentration profiles starting from the time point of dose escalation only are shown in \nFigure 6A. Following escalation to 300 mg SC QW, in general, marstacimab concentrations are seen to be at \nor near steady-state. \nFigure 6A. \nMedian Marstacimab Plasma Marstacimab Concentration Versus Time Profiles by \nAge Group [Starting from the Time of Dose Escalation] for Dose-Escalated Participants Receiving \nMarstacimab 300 mg SC QW (B7841005) \n \n \n \n"
    },
    {
      "page_number": 66,
      "text": "Assessment report \nEMA/464842/2024 \nPage 66/198 \n \nFigure 7: Plot of individual plasma marstacimab concentration – time plot by dose group and age \ngroup (linear scale) – marstacimab safety set \n \n \n \n \nBioavailability \nBA of SC dosing compared to the IV reference dose following single dose administration was 27%. Population \nPK analysis estimated marstacimab BA following SC administration to be approximately 71%. The \nmultiplicative factor estimates for bioavailability for arm and thigh were both close to 1, ie 0.951 and 0.959 \nrespectively, relative to the abdomen, resulting in bioavailability estimates of 67.0% and 67.6% for arm and \nthigh, respectively (based on Fabdomen estimate of 70.5%) As such, no differences are seen in marstacimab \nbioavailability between arm and thigh. The difference in the BA estimate between single dose administration \n(NCA analysis) and multiple dose administration (pop PK) is likely attributed to the nonlinearity in \nmarstacimab PK at higher concentrations. For drugs that exhibit nonlinear PK, estimation of BA using ratio of \ndose-normalised AUCs following IV and SC may lead to significant under- or over-estimation of BA. \n"
    },
    {
      "page_number": 67,
      "text": "Assessment report \nEMA/464842/2024 \nPage 67/198 \n \nTable 9: Breakdown of injection sites for 150 mg dose group of B7841005 \n \n \nFigure 8: Forest plot of ratio of arm and thigh bioavailability as compared to abdomen \n \nFigure 9: Empirical Bayesian estimates of bioavailability with site of injection \n \nNo statistically significant difference in bioavailability was detected, based on bioavailability ratios between \nabdomen vs. arms and abdomen vs. thigh. \n \nDistribution \n \nFollowing single dose IV administration in healthy participants marstacimab Vss was 3.5 - 3.9 L. Following \nsingle dose SC administration in healthy participants and haemophilia patients, marstacimab Vz/F values \nranged from 8.3 - 18.4 L. \n"
    },
    {
      "page_number": 68,
      "text": "Assessment report \nEMA/464842/2024 \nPage 68/198 \n \nPopulation PK analysis estimates (%RSE) for central volume of distribution (Vc), peripheral volume of \ndistribution (Vp) and volume of distribution at steady-state (Vss) were 3.6 (9.2%) L, 5 (10.5%) L and 8.6 L, \nrespectively. This limited extravascular distribution suggests that marstacimab is restricted to the \nintravascular space. \n \nElimination \n \nExcretion studies were not conducted with marstacimab. Based on the molecular weight, marstacimab is \nexpected to undergo catabolic degradation and is not expected to be renally cleared. \nMarstacimab total CL/F following weekly SC administration to haemophilia patients ranged from 0.03 - 0.05 \nL/hr, based on NCA. For the population PK analysis, marstacimab elimination was divided into linear and non- \nlinear clearance (Figure below). \nFigure 10: Schematic of the final population PK model \n \n \nThe non-linear part was added to account for the drug binding to bound forms of TFPI. The estimated linear \nCL, Michaelis-Menten constant (Km) for the drug’s non-linear clearance and maximum saturable elimination \nrate (Vmax) for the drug’s nonlinear clearance (presented as population value (RSE%) in the final population \nPK analysis were 0.019 (11.3%) L/hr, 4.31 (9.94%) nM and 0.53 (7.96%) nM/hr, respectively. \nMarstacimab effective t½ (geometric mean), calculated from the accumulation ratios, ranged from \napproximately 16 – 18 days across both adults and adolescents and across dose groups. \n \nDose proportionality and time dependencies \n \nFollowing single dose administration to healthy participants in Study B7841001, under the same dosing \nroute, exposures appeared to increase greater than proportionally with dose based on dose-normalized \nAUCinf and Cmax, which suggests that marstacimab may undergo target-mediated drug disposition. \nPopulation PK analysis using a power model [AUCss = mDoseb or log AUCss = b*log(Dose) + m] as \ndescribed by Wolfsegger et al was used to assess the dose proportionality of marstacimab in haemophilia \npatients over a range of 3 doses (150 mg, 300 mg and 450 mg. Results showed point estimate value of m \n(intercept) to be 5.47 (95% CI: 2.14 – 8.81) and point estimate value of b (the proportionality exponent or \nslope in the linearised equation) to be 1.81 (95% CI: -2.15 – 5.77). Based on the point estimate of 1.81 for \nslope (p-value = 0.1087), an approximately 3.5-fold increase in AUCss is expected for a 2-fold increase in \ndose. Due to the high variability in the data, the 95% CI for b contained 1 and as such, deviation from \n"
    },
    {
      "page_number": 69,
      "text": "Assessment report \nEMA/464842/2024 \nPage 69/198 \n \nlinearity cannot be concluded even though greater than proportional increases are seen in AUCss in the 150 \nmg to 450 mg dose range. \nModel-predicted estimates (median) for marstacimab AUCss in adults were 2110 μg*hr/mL (2.5 – 97.5 \npercentile: 214 – 8530 μg*hr/mL) and 9200 μg*hr/mL (2.5 – 97.5 percentile: 2970 – 17500 μg*hr/mL) for \n150 mg SC QW and 300 mg SC QW respectively; approximately a 4.36-fold increase for a 2-fold increase in \ndose. Similar trends were also seen for model-predicted estimates of Cmax,ss. \nIn general, marstacimab exposures (AUCss and Cmax,ss) were seen to increase with slightly greater than \nproportional increases over the 150 mg to 450 mg SC dose range. \nFigure 11: AUCss with Dosing Regimen for Dose Proportionality Analysis \n \n \nAUCss is shown in mg/mL* hr units. Left panel shows AUCss as a box-plot with dosing regimens of 150 mg, 300 mg and 450 mg \nSC weekly dosing. Right panel shows the same as a line plot. The blue line represents the linear regression fit with standard error. \n \n \nEffect of anti-drug antibodies (ADAs) on PK data \nADA and NAb were determined using validated bioanalytical methods. \n"
    },
    {
      "page_number": 70,
      "text": "Assessment report \nEMA/464842/2024 \nPage 70/198 \n \nTable 10: Overall incidence of anti-marstacimab antibody (ADA) and neutralising antibody (Nab) \nfor phase 1b/2 studies B7841002/B7841003 and phase 3 studies B7841005/B7841007 – \nmarstacimab dataset \n \n \nThe data from the phase 1/2 trial do not allow any conclusions due to the small number of participants in \nrelevant dose groups. \nMarstacimab concentration time profiles (by age group) following weekly SC administration of 150 mg \nmarstacimab to haemophilia participants from the Phase 3 study (B7841005) were compared between ADA \npositive and ADA-negative participants for assessment of differences in marstacimab PK between the 2 \ngroups. Consistently lower mean/median marstacimab concentrations were reported in ADA-positive \nparticipants throughout all study visits. \nOut of the 14 participants who dose escalated to 300 mg SC QW, only 3 were ADA positive (3 out of total 23 \nADA positive; 2/21 adults and 1/2 adolescents). All 3 ADA-positive participants were ADA positive before \ndose escalation. None of the 14 dose escalated participants had new ADAs develop after dose escalation. \n"
    },
    {
      "page_number": 71,
      "text": "Assessment report \nEMA/464842/2024 \nPage 71/198 \n \nFigure 12: Boxplot of marstacimab plasma concentration vs time(150 mg) by ADA status by age \nfor study B7841005 -marstacimab dataset \n \n \n \n \n \n \nSpecial populations \n \nPopulation PK and PK/PD analyses were conducted using marstacimab PK (concentration) and PD (total TFPI \nand peak thrombin) data from all Phase 1 (B7841001, B7841009, B7841010), Phase 2 (B7841002, \nB7841003) and Phase 3 (B7841005) studies to evaluate the effect of relevant intrinsic and extrinsic factors \nie, demographics, creatinine clearance, ADA status, on marstacimab PK and to support dosing regimens in \nvarious populations (eg, haemophilia type) of different ages and weights (adolescents vs adults). A two- \ncompartment model with TMDD and first order absorption was used to estimate PK parameters. \n"
    },
    {
      "page_number": 72,
      "text": "Assessment report \nEMA/464842/2024 \nPage 72/198 \n \nTable 11: Parameter Estimates of the Final Population PK Model \n \n \nBootstrap estimates were obtained from a bootstrap run with N = 1000 samples using a PsN Bootstrap routine. SE - Standard Error; RSE - \nRelative Standard Error; CV - Coefficient of Variation; TFPI - Tissue Factor Pathway Inhibitor; KSS - Quasi-steady State Parameter; IIV - \nInter-individual Variance. %RSE is provided for population (theta) parameters, %CV is provided for IIV parameters. Some of the IIVs were \nfixed to 15%CV. Residual variability was calculated on PK and TFPI via an additive error model on the log-scale with a thetarized (fixed) \nsigma parameter. \n"
    },
    {
      "page_number": 73,
      "text": "Assessment report \nEMA/464842/2024 \nPage 73/198 \n \nTable 12: Absolute and Weight-normalised Linear Clearance and Central Volume \n \nCL - Linear Clearance (L/hr); Vc - Central Volume (L); CL/W - Weight adjusted Linear Clearance (L/hr/kg); Vc/W - Weight \nadjusted Central Volume (L/kg). For calculating hepatic impairment type, participants who had Bilirubin ≤ 40 umol/L and \nAST ≤ 20 umol/L were considered as having no hepatic impairment. \n"
    },
    {
      "page_number": 74,
      "text": "Assessment report \nEMA/464842/2024 \nPage 74/198 \n \nTable 13: Summary of Secondary PK Parameters by Dosing Regimen \n \nN- number of participants in the sub-group; SS - Steady State; ACCR - Accumulation Ratio Table 13 shows that the mean Cmin,ss, \nCmax,ss and Cavg,ss were close to each other, indicating a low peak to trough ratio in drug concentrations at steady state for the \n150 mg (Adults) and 300 mg (Adults) sub-groups. \n \n \n \nHaemophilia Type \nPopulation PK analysis did not show haemophilia type to be a clinically relevant covariate (11.8% higher CL in \nhaemophilia B compared to haemophilia A; 95% CI: --15% to 40%); there were no relevant differences in \nmarstacimab PK between haemophilia A and B patients. \n"
    },
    {
      "page_number": 75,
      "text": "Assessment report \nEMA/464842/2024 \nPage 75/198 \n \nFigure 13: Plot of induvial plasma marstacimab concentration – time plot by dose group and \nhaemophilia type (linear scale) – marstacimab safety set \n \n \n \n \nImpaired renal function \nClinical studies have not been conducted to evaluate the effect of renal impairment as renal clearance is not \nconsidered important for elimination of mAbs due to their large size and inefficient filtration through the \nglomerulus. \nAll patients with haemophilia A and B in the population pharmacokinetic analysis had normal renal function \n(N = 128; eGFR ≥90 mL/min/1.73 m2) or mild renal impairment (N = 22; eGFR of 60-89 mL/min/1.73 m2). \nPopulation analysis of the effect of renal impairment on marstacimab CL showed a 16.8% lower CL with mild \nrenal impairment (95% CI: -34% to 12.1%). \nThere are no data available on the use of marstacimab in patients with moderate or severe renal impairment. \n \n \nImpaired hepatic function \nClinical studies have not been conducted to evaluate the effect of hepatic impairment on the PK of \nmarstacimab, as it is generally not considered clinically relevant for mAbs. \nAll patients with haemophilia A and B in the clinical studies had normal hepatic function (N = 135, total \nbilirubin and AST ≤ ULN) or mild hepatic impairment (N = 15, total bilirubin > ULN, AST > ULN). Mild hepatic \nimpairment did not affect the pharmacokinetics of marstacimab. There are no data available on the use of \nmarstacimab in patients with moderate or severe hepatic impairment. \n"
    },
    {
      "page_number": 76,
      "text": "Assessment report \nEMA/464842/2024 \nPage 76/198 \n \nGender \nOnly male individuals were recruited for the trials. Considering that haemophilia is an X linked congenital \nbleeding disorder that affects almost exclusively males with very rare cases of female patients suffering from \na severe form of the disease. \nEthnic factors \nEffect of race on marstacimab PK was evaluated using population PK analysis with race as a covariate. \nPopulation PK analysis showed that marstacimab CL (L/hr) was estimated to be approximately 35% (RSE of \n54.8%) higher in Asian haemophilia participants. After adjusting for weight, marstacimab CL (L/hr/kg) was \nestimated to be approximately 31.9% higher in Asian participants. \nWeight \nWeight was an important covariate to describe the pharmacokinetics of marstacimab. Normalised weight was \nincluded as a structural covariate on Vc, and CL, Q and Vp. The allometric constants for CL and Vc were \nestimated to be 1.14 and 1.86 respectively. \nWeight was able to account for most of the differences in PK between adults and adolescents, as described \nbelow. The studied weight range was 35 - 120 kg. \nPaediatric population \nMedian steady-state marstacimab plasma concentrations in adults receiving 150 mg weekly were \napproximately 10,000 - 11,000 ng/mL whereas median steady-state marstacimab plasma concentrations in \nadolescents were approximately 25,000 – 30,000 ng/mL. For the most part, individual concentration-time \nprofiles for adults and adolescents appeared to lie within a similar range of concentrations. In general, \nmarstacimab concentrations are highly variable (% CV of approximately 62% - 92% in adults and 40% - \n85% in adolescents for 150 mg SC QW). \nThe difference in marstacimab CL and Vc between adolescent and adult patient populations was \napproximately 29% and 43%, respectively, however, the weight-adjusted difference in CL and Vc between \nadolescents and adults was 3.1% and 25.9% respectively, indicating that weight explains most of the \ndifferences observed in CL between these two age groups. \nModel estimated steady state Cmax,ss, Cmin,ss, Cavg,ss, AUCtau, accumulation ratio and effective t½ for \nmarstacimab by age groups was presented. Accumulation ratio (geometric mean), calculated as ratio of AUC \nat steady state to the AUC for the first dose, was approximately 4 (across both dose groups and age groups). \nElderly \nEffect of age was not included as a covariate in the model since the haemophilia population in the clinical \nstudies was a young population with median age of 31 years (range: 13 – 66 years) and expected differences \nin marstacimab PK between adolescents and adults were mostly accounted by including weight as a covariate \nin the model. \n \nAge 65-74 \n(Older subjects number \n/total number) \nAge 75-84 \n(Older subjects number \n/total number) \nAge 85+ \n(Older subjects number \n/total number) \nPK Trials \n1 \n0 \n0 \n"
    },
    {
      "page_number": 77,
      "text": "Assessment report \nEMA/464842/2024 \nPage 77/198 \n \nPharmacokinetic interaction studies \n \nClinical PK DDI studies have not been conducted for marstacimab to date. \nIn vitro \nIn an in vitro human whole blood cytokine release assay, marstacimab did not elicit test article-related \ncytokine release of 3 human pro-inflammatory cytokines (TNF- alpha, IL-6, or IFN-gamma). Therefore, DDIs \nresulting from cytokine-mediated effects on CYP enzymes or transporters are not anticipated. Also, CYP \nenzymes are not anticipated to impact the clearance of marstacimab since the primary CL mechanisms of \nmarstacimab are receptor-mediated endocytosis following binding to its target (TFPI) as well as regular IgG \ncatabolism pathways. Thus, no risk of DDI is expected for marstacimab. \nMany therapeutic proteins belonging to the cytokine class appear to differentially affect CYP activities. \nCytokine modulators may affect CYP enzyme activities by altering cytokine effects on CYP enzymes. \nMarstacimab does not belong to the cytokine class. Marstacimab binds to the human TFPI K2 domain with \nlow-nanomolar affinity, but it does not bind to the human TFPI K1 domain. It is therefore not expected to \nbind to cytokines and modulate their concentrations. Thus, changes in cytokine-dependent expression of CYP \nenzymes are not anticipated. \nIn vivo \nIn an investigative pharmacodynamic studies in rats, the mean systemic exposure (AUC) after repeat dosing \nwas similar in all dose groups when marstacimab was administered alone or in combination with NovoSeven \nRT or FEIBA or ByClot. These data suggest there was no DDI effect on nonclinical PK after coadministration. \n2.6.2.2. Pharmacodynamics \nMechanism of action \nMarstacimab is a human monoclonal antibody directed against TFPI, the primary inhibitor of the extrinsic \ncoagulation cascade. TFPI is a protease inhibitor which acts as an antagonist of the extrinsic coagulation \npathway via inhibition of tissue FVIIa and FXa. Marstacimab inhibits TFPI and bypasses the need for \nreplacement of FVIII or FIX. Marstacimab is capable of promoting haemostasis in human haemophilic plasma \nand in non-clinical models of haemophilia. The binding affinity (KD) of marstacimab for TFPI in human is 3.7 \nnM. \nNon-clinical evidence identifies marstacimab’s mechanism of action in the well-defined extrinsic coagulation \npathway: The two major coagulation pathways (intrinsic and extrinsic pathways) both ultimately lead to \nactivation of Factor X, which in turn leads to thrombin generation. FVIII and FIX form a single enzymatic \ncomplex and thus deficiency of either component, in patients with haemophilia A and B, respectively, \nmanifests in similar coagulation deficits. In in vitro spike-in assays, marstacimab similarly promoted \nhaemostasis in haemophilic plasma from haemophilia A, B, and haemophilia inhibitor plasma in haemostatic \nassays, including TGA. \nNon-clinical efficacy demonstrates basis for effectiveness in bleeding control utilising the extrinsic coagulation \npathway. The foundational nonclinical evidence is demonstrated in male haemophilia A (FVIII deficient) or \nhaemophilia B (FIX deficient) mice in a severe tail clip injury model (a standard and validated [accepted] \nanimal model in assessments of bleeding control). Marstacimab restored haemostasis in haemophilia mouse \ninjury models when administered before and after the onset of a severe bleeding injury. \n"
    },
    {
      "page_number": 78,
      "text": "Assessment report \nEMA/464842/2024 \nPage 78/198 \n \nBased on the mechanism of action and pharmacology of marstacimab, the in vivo endpoints PF 1+2 and D- \ndimer, as well as the ex-vivo endpoints dPT and TGA (composed of thrombin generation lag time, \nendogenous thrombin potential (also referred to as endogenous thrombin generation potential) and peak \nthrombin [also referred to as TGA peak]) were monitored as pharmacologic effects reflective of coagulation \npathway activation. Total plasma TFPI levels were measured to reflect target binding. Inhibition of TFPI is \nexpected to be associated with an increase in PF 1 +2, D-dimer, peak thrombin, and endogenous thrombin \npotential, as well as a shortening of dPT and thrombin generation lag time. An increase in total TFPI, due to \nbinding of marstacimab with free TFPI thus resulting in delayed elimination of TFPI (bound to marstacimab), \nis also expected with the anti-TFPI pharmacology. The relationship between free TFPI and peak thrombin is \ninverse as free TFPI is highest at baseline (without any drug) and is expected to decrease as a result of \nmarstacimab binding to TFPI. \n \n \nPrimary and Secondary pharmacology \n \nPD in Phase 1 studies \n \nPD results of phase 1 first-in-human Study B7841001 (single SC/IV dose in healthy adults) \nFollowing marstacimab SC and IV single dose administration, treatment related changes were observed for all \nPD endpoints and generally the response was exposure-dependent. These changes included increases in total \nTFPI consistent with binding of free TFPI with marstacimab, increases in PF 1+2, D-dimer, peak TGA, TGA \nendogenous thrombin generation potential, shortening of TGA lag time, and shortening of dPT. \nPharmacologic effects on total TFPI as well as a number of PD biomarkers (eg, PF 1+2, TGA lag time and \npeak thrombin generation, and D-dimer) were seen to persist >7 days following administration of a single \n300 mg SC dose. Weekly SC dosing was supported by effects seen on change from baseline calculated from \nDays 1-7. Effects were seen at all dose levels for some endpoints (eg, TGA lag time and TGA peak thrombin \ngeneration), and at a higher dose level for other endpoints (eg, D-dimer, PF 1+2 and dPT at 100 mg and \nabove, and total TFPI at 150 mg and above). Maximum or near maximum effect occurred most frequently \nfollowing a single dose of 300 mg SC based on values of maximum change from baseline as well as AUC. \n"
    },
    {
      "page_number": 79,
      "text": "Assessment report \nEMA/464842/2024 \nPage 79/198 \n \nFigure 14: Plot of median absolute values vs time for PF endpoints by cohort and dose following \nadministration of single SC or IV doses of marstacimab to healthy participants (B7841001) \n \n \n \nPD results of phase 1 Study B7841010 (single SC dose in adult Chinese haemophilia patients) \nFollowing administration of a single SC dose of marstacimab 300 mg in Chinese participants with severe \nhaemophilia A or B without inhibitors, treatment-related changes were observed for all PD endpoints. \nIncreases were observed in plasma total TFPI, PF 1+2, D-dimer, peak thrombin, and TGA endogenous \nthrombin generation potential. A shortening of dPT and TGA lag time were also observed. Pharmacologic \neffects on total TFPI as well as all other PD biomarkers persisted >7 days following administration of a single \n"
    },
    {
      "page_number": 80,
      "text": "Assessment report \nEMA/464842/2024 \nPage 80/198 \n \nSC dose of marstacimab 300 mg. For all PD biomarkers, maximum or near maximum effect occurred most \nfrequently within the first week based on maximum change from baseline. \nPD in Phase 2 and 3 Studies \nPD results of phase 1b/2 Study B7841002 (multiple SC doses in adult haemophilia patients) \nTreatment-related changes were observed for all PD endpoints in all dose cohorts as expected. These \nchanges included increases in total TFPI consistent with binding of free TFPI with marstacimab resulting in \ndelayed elimination of TFPI (bound to marstacimab) due to much longer half-life of marstacimab compared to \nthe target TFPI, shortening of TGA lag time, increases in peak TGA, TGA endogenous thrombin potential, PF \n1+2, and D-dimer, and shortening of dPT. There were no clinical findings suggesting that these PD changes \nwere reflective of excessive pharmacology. PD responses were mostly consistent between participants with \nand without inhibitors and between participants with haemophilia A and B. \nFigure 15: Plot of median absolute values vs time for PF endpoints following single and multiple \ndose administration of marstacimab to haemophilia A and B participants with or without inhibitors \n(study B7841002) \n"
    },
    {
      "page_number": 81,
      "text": "Assessment report \nEMA/464842/2024 \nPage 81/198 \n \nPD results of phase 2 Study B7841003 (extension of Study B7841002) \nConsistent with the PD results seen in Study B7841002, treatment-related changes were observed for all PD \nendpoints in the newly enrolled 300 mg loading + 150 mg inhibitor dose cohort except TGA lag time. These \nchanges included increases in total TFPI consistent with binding of free TFPI with marstacimab, increases in \npeak TGA level, and increases in PF 1+2. \n \n \nPD results of phase 3 Study B7841005 (multiple SC doses in adult and adolescent haemophilia patients) \nA total of 116 participants with haemophilia A and B had at least one evaluable PD concentration and \ncontributed data for the PD analyses. \nThe 150 mg dose group included participants who received 150 mg SC once weekly marstacimab through the \nentire study whereas the 300 mg dose group included participants who were dose escalated to 300 mg SC \nonce weekly marstacimab after Day 180 (Visit 14) following administration of 150 mg SC once weekly \nmarstacimab up to that visit. \na) Peak Thrombin (TGA Peak): \nFigure 16: Plot of median absolute values vs time for peak TGA (nM) by dose group and age group \n(B7841005) \n \n \nPost-treatment variability (geometric %CV) in peak TGA ranged from 33% - 52% across adults and \nadolescents (150 mg SC). The median peak thrombin values were lower in adolescents compared to adults, \nbut for the most part, there was an overlap of the individual peak thrombin values between adults and \nadolescents. \n"
    },
    {
      "page_number": 82,
      "text": "Assessment report \nEMA/464842/2024 \nPage 82/198 \n \nb) PF 1+2: \nFigure 17: Plot of median absolute values vs time for PF 1+2 (pmol/L) by dose group and age \ngroup (B7841005) \n \nPost-treatment variability (geometric %CV) in PF 1+2 data ranged from 25% - 99% across adults and \nadolescents (150 mg SC). \nc) D-dimer: \nFigure 18: Plot of median absolute values vs time for D-dimer (µg/mL) by dose group and age \ngroup (B7841005) \n \n"
    },
    {
      "page_number": 83,
      "text": "Assessment report \nEMA/464842/2024 \nPage 83/198 \n \nPost-treatment variability (geometric %CV) in D-dimer data ranged from 40% - 76% across adults and \nadolescents (150 mg SC). \n \n \nd) Total TFPI: \nFigure 19: Plot of median absolute value vs time for Tissue Factor Pathway Inhibitor (ng/mL) by \ndose group and age group (b7841005) \n \n \nPost-treatment variability (geometric %CV) in TFPI ranged from 19% - 58% across adults and adolescents \n(150 mg SC). \n \n \nEffect of ADA and NAb on PD Data \nProfiles of key pharmacodynamic endpoints ie, TFPI (total), TGA peak, PF1+2, dPT and D-dimer following \nweekly SC administration of 150 mg of marstacimab to haemophilia participants from the Phase 3 study \n(B7841005) were compared between ADA positive and ADA-negative participants for assessment of \ndifferences in PD between the 2 groups (only TFPI data shown, Figure below). For adults, there were \nconsistently lower mean and median values for TFPI concentrations in ADA positive subjects at nearly all \nstudy visits. The remaining PD parameters (peak thrombin, PF 1+2, D-Dimer) were more comparable \nbetween ADA positive and ADA negative participants. \n"
    },
    {
      "page_number": 84,
      "text": "Assessment report \nEMA/464842/2024 \nPage 84/198 \n \nFigure 20: Boxplot of Tissue Factor Pathway Inhibitor over Time (150 mg) by ADA status by age \nfor study B7841005 – marstacimab dataset \n \n \n2.6.3. Discussion on clinical pharmacology \n \nThe submitted dossier includes PK/PD data from six clinical trials. \nHealthy male adults were recruited for the phase 1 first-in-human single ascending dose Study B7841001 and \nfor the phase 1 bioequivalence Study B7841009. Study B7841001 investigated the PK/PD of Marstacimab at \ndifferent dose levels (30 to 440 mg) in 6 cohorts with either SC or IV administration (cohort 1: 30 mg SC, N=4; \ncohort 2: 100 mg SC, N=6; cohort 3: 300 mg SC, N=6; cohort 4: 150 mg IV, N=6; cohort 5: 440 mg IV, N=6; \ncohort 6: 300 mg SC, 4 Japanese participants). A total of 9 healthy individuals received Placebo. Study \nB7841009 was a Phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate crossover \nstudy in healthy adult male participants and compared the PK of a pre-filled syringe (used for the phase 3 trial) \nwith a pre-filled pen. Both presentations are intended for marketing. Only PK data were collected during this \nbioequivalence study. While 38 participants (19 participants per sequence) were planned to be enrolled to have \napproximately 34 evaluable participants, only 22 participants were actually enrolled due to the occurrence of \nan event of deep vein thrombosis and pulmonary embolism leading to termination of the study. A total of 18 \nparticipants completed at least 1 period and contributed data for the calculation of PK parameters for PFS and \nPFP. A total of 11 participants completed all 4 periods and contributed data for the statistical analysis of the PK \nparameters. \nThe phase 1b/2 Study B7841002 was a first-in-patients safety, efficacy and pharmacology study and recruited \npatients with haemophilia A or B, with or without inhibitors. The study consisted of 4 dose cohorts (cohort 1: \nnon-inhibitors, 300 mg SC QW, N=7; cohort 2: non-inhibitors, 150 mg SC QW with a 300 mg loading dose, \n"
    },
    {
      "page_number": 85,
      "text": "Assessment report \nEMA/464842/2024 \nPage 85/198 \n \nN=6; cohort 3: non-inhibitors, 450 mg SC QW, N=6; cohort 4: inhibitors, 300 mg SC QW, N=7). The \nparticipants received weekly doses until up to Day 85, while blood samples were taken until Day 113. \nThe extension Study B7841003 was an open-label long-term study on the safety, tolerability and efficacy of \nmarstacimab during up to 365 days of treatment. The study included a total of 20 participants out of which 18 \nwere rollovers from Study B7841002 and 2 were newly enrolled. Participants from Cohorts 1 and 4 of Study \nB7841002 kept their dose regimen of 300 mg SC QW, while all other participants (including the 2 newly enrolled \nparticipants and those who previously received 450 mg SC QW) received 150 mg SC QW with a loading dose \nof 300 mg SC. \nThe phase 1 Study B7841010 investigated the PK/PD of a single SC dose of 300 mg marstacimab in Chinese \nadults with severe haemophilia A or B, with or without inhibitors (N=6, 5 with haemophilia A, 1 with haemophilia \nB). \nThe phase 3 Study B7841005 was a one-way, cross-over, open-label, multi-centre study in adolescent and \nadult participants between ages 12 to <75 years with severe haemophilia A or moderately severe to severe \nhaemophilia B (defined as FVIII activity <1%, or FIX activity ≤2%, respectively) with or without inhibitors. The \ndossier only includes data from non-inhibitor patients (97 adult and 19 adolescent patients, 91 with haemophilia \nA and 25 with haemophilia B). All participants started treatment with an initial loading dose of 300 mg SC \nfollowed by 150 mg SC QW. If certain dose escalation criteria were met (patients weighing ≥ 50 kg and \nexperiencing 2 or more breakthrough bleeds), an increase of the weekly dose to 300 mg was allowed at any \ntime after 6 months (D180 visit). \nIn Study B7841007 (=extension of the phase 3 trial), blood samples for PK and PD assessments are only \ncollected on a conditional basis as soon as possible for any participant who tested positive for both ADA and \nNAb during their participation in the study. This criterion was not met so far and therefore, no PK/PD data are \navailable from the phase 3 extension study. \nInvestigated PD parameters and PK/PD sampling schedule \nThe main PD parameters investigated in the development program included plasma total TFPI, peak thrombin \n(via thrombin generation assay), prothrombin fragments 1+2 (PF 1+2), D-Dimer, and dilute prothrombin time \n(dPT). \nConcentration of total TFPI in plasma (bound and free TFPI) is expected to increase after binding of marstacimab \ndue to the longer half-life of the monoclonal antibody leading to delayed clearance of the complex. Therefore, \ntotal plasma TFPI levels reflect target binding. \nThe generation of thrombin (by cleavage of prothrombin) is an important step of the coagulation cascade. \nThrombin is a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, which is able to \nform fibrin-based blood clots. The thrombin generation assay is an established method and considered as a \nsuitable biomarker to investigate the procoagulant effect of marstacimab. \nThe commonly used safety laboratory parameters D-Dimer and PF 1+2 are both markers for activation of the \ncoagulation system and considered relevant additional PD endpoints. The dilute prothrombin time (dPT) is an \nadditional informative method to further characterise the effect of marstacimab on the coagulation status of \nthe investigated subjects. \nOverall, the choice of PD biomarkers is considered suitable to characterise the procoagulant effect of \nmarstacimab. However, no data. on the effect of marstacimab on free TFPI are available. \n"
    },
    {
      "page_number": 86,
      "text": "Assessment report \nEMA/464842/2024 \nPage 86/198 \n \nEfforts were made to develop and validate a free TFPI assay, however, free TFPI measurement from clinical \nsamples was not possible. It was argued that the low nanomolar affinity of marstacimab with TFPI increases \nthe risk of disassociation of the complex during analysis leading to unreliable free TFPI measurements. It should \nbe noted that free TFPI measurements were performed for a very comparable development program (Chowdary \net al. 2015, DOI: 10.1111/jth.12864). Lack of data showing the extent of inhibition of free TFPI is not optimal, \nconsidering that this constitutes the main mechanism of action of marstacimab. Such data were also considered \nimportant in earlier EMA scientific advice (Procedure No.: EMEA/H/SA/3363/2/2017/PA/II), especially because \na flat dose regimen is foreseen. The Applicant was asked to further elaborate on the problems to obtain reliable \nfree TFPI measurements. In the response, the Applicant pointed out that there are different isoforms and \nmultiple binding partners of TFPI, which can have high binding affinity. The Applicant explained their attempts \nof developing a method to measure free TFPI. All strategies failed due to (1) sample dilution requirements and \n(2) reagent competition leading to dissociation of TFPI from the drug-target complex which would lead to an \noverestimation of free TFPI. The Applicant provided high-level data of two respective experiments, which is \nacknowledged. The Applicant further argued that marstacimab has a lower binding affinity for human TFPI, \ncompared to other known TFPI inhibitors. A higher affinity for TFPI would significantly reduce the effect of \nsample dilution and reagent competition. Due to the lower nanomolar binding affinity of Marstacimab for TFPI \nand the large pool of TFPI bound with picomolar affinity to other endogenous proteins, the process of \nbioanalytical measurement, including both reagent binding and even minimal sample dilution disrupts TFPI- \nMarstacimab complex equilibrium thus releasing bound TFPI and resulting in inaccurate and overestimated free \nTFPI values. This justification is considered acceptable. \nIn the medical literature, under the term “free TFPI” they mean TFPI which is circulating (not membrane- \nbound) and not lipoprotein-bound. For a pharmacokinetics free TFPI means TFPI molecules with empty binding \nsites available to marstacimab binding. In fact, it seems that the POP-PK/PD report uses the term “free TPFI” \nin this sense. It was clarified that the \"free TFPI\" denotes all TFPI molecules with empty binding sites available \nto bind marstacimab. This definition is exact but strongly linked to this submission and differs from the standard \nterminology. In principle, this could be misleading, but not in this case because there are no references to the \nfree TFPI molecules in the SmPC. Therefore, this is considered acceptable. \nOut of the presented studies, the first-in-human Study B7841001 had the most extensive sampling schedule, \nwith blood samples collected at 0 (predose), 1, 2 (IV cohort only), 4, 8 (IV cohort only), 12, 24, 48, 72 hours \nand on Days 7, 14, 21, 28, 35, 42, 56, 70 and 84 after administration of marstacimab. Such a long sampling \nperiod (up to Week 12) was necessary due to the long half-life of marstacimab. Depending on the dose, the \nhalf-life ranged from 33.3 to 98.35 hours after single dose administration in Study B7841001. Based on the \npopulation PK model, the mean effective steady state half-life (for weekly administrations) of marstacimab was \nestimated to be approximately 16 to 18 days for both adults and adolescents and across dose groups. Until \nDay 84, all measured PK/PD markers returned to baseline. During the first week, the sampling schedule was \nrelatively dense. Overall, the sampling schedule of this first-in-human trial appears adequate. \nThe multiple dose studies had less frequent blood sampling schedules but in principle sufficient to determine \nthe long-term effect on PD parameters. \nPopulation PK and PK/PD modelling \nThe objectives of the population pharmacokinetic and pharmacodynamic modelling analyses were to develop \nan integrated, predictive population pharmacokinetic (PK) model for marstacimab plasma drug and total tissue \nfactor pathway inhibitor (TFPI) concentrations, to identify potential covariates which impact marstacimab \nconcentration levels, and to explore the relationship between free target (TFPI) and the key biomarker (peak \nthrombin) using pharmacokinetic-pharmacodynamic (PKPD) modelling. \n"
    },
    {
      "page_number": 87,
      "text": "Assessment report \nEMA/464842/2024 \nPage 87/198 \n \nThere are two Population PK/PD reports. The first (report PMAR-EQDD-B784a-DP3-1021) uses data from the \nPhase 1 and Phase 2 studies, while the second (report PMAR-EQDD-B784a-DP3-1331) uses data from the Phase \n3 study (study B7841005). Of note, an updated version of the second report was submitted with the responses \nto the D120 LoQ due to an input error. For the second report, a \"full modelling approach\" was used, i.e. all \ncovariates considered relevant were included in the final model. Age (being an adolescent) as a factor was not \nincluded in the model because this variable strongly correlates with body weight. However, using the obtained \nmodel parameters, separate simulations were performed for the adolescent age group. Overall, from a \nmethodological point of view, the POP-PK/PD model is properly validated, and the presentation of the POP- \nPK/PD report is in line with the requirements of the CHMP (Guideline On Reporting The Results Of Population \nPharmacokinetic Analyses, CHMP/EWP/185990/06). The PK part of the combined POP PK/PD model is \nbiologically meaningful: a target mediated drug disposition (TMDD) model with additional non-linear elimination \nof the drug was assumed. The model assumes that binding of the drug to the free receptor and dissociation of \nthe drug-receptor complex are several orders of magnitude faster than the remaining system processes. This \nassumption allows the estimation of free (in pharmacokinetic sense) and bound concentrations of soluble TFPI \n(sTFPI). \nApproximately half of the data points are derived from healthy volunteers. Although the percentage of BLQ \nsamples is in total about 17%, it is still acceptable since this is mainly due to data from healthy volunteers and \nonly about 5% of samples obtained from patients are BLQ. \nThe Applicant was questioned on regarding the fact that ADA positivity was only implemented as a baseline \ncovariate (as opposed to a time-varying covariate) or the observation that the provided R-script detailing the \nsimulations for the paediatric dose selection does not match the results provided. The Applicant tried to include \nADA status as a time-varying variable in the model but either the estimates were unreliable (RSE 628%), or \nthe model could not converge (all other parameters fixed). This was most likely also influenced by the limited \ndata. If the model will be updated in the future, it is recommended to further investigate ADAs as the time- \nvarying variable. \nOverall, the provided updated population PK model seems to describe the observed data well for doses of 150 \nmg SC QW and lower and much better for the 300mg dose compared to the previously submitted model. \nHowever, the predicted values diverge from the observed values especially for higher concentrations and seem \nto underpredict higher concentrations. Although this is a shortcoming of the model, this might also be due to \nthe limited data and could improve if further data might be integrated in the future. \nThe updated PK/PD model describes the data well also for higher concentrations. \nHigher variability was noted in adolescent patients, but this might be due to the low number of patients in this \nage group. The Applicant did not discuss a potential effect of any other covariates nor were any explicitly tested \nin the PKPD model, which might be acceptable, if no effect is expected but no justification was provided. \nHowever, differences in free, total TFPI or peak thrombin might be explained by covariates also already included \nin the popPK model. \nResults of the covariate analysis based on the popPK model are described further below (PK in special \npopulations). \nBioanalytical assays \nFully validated assays were used for determination of marstacimab drug concentrations (PK), total plasma TFPI \n(PD) and detection of ADA and NAb. In principle, the presented bioanalytical methods were well described and \n"
    },
    {
      "page_number": 88,
      "text": "Assessment report \nEMA/464842/2024 \nPage 88/198 \n \nestablished. They were set up correctly and fully validated according to current EMA guidelines. Performance \nof the assays during clinical studies is considered acceptable. \nThe remaining PD parameters (thrombin generation, dPT, D-Dimer and prothrombin fragments 1+2) were \nmeasured using laboratory developed tests validated under CLIA requirements. \nPK/PD in healthy adults \nFollowing single dose SC administrations in Study B7841001, the marstacimab exposure increased in a more \nthan proportional manner. For example, when comparing SC doses of 100 mg with 300 mg (3-fold dose \nincrease, cohort 2 vs. cohort 3, N=6 each), the geometric mean Cmax increased from 1183 ng/mL to 16490 \nng/mL (nearly 14-fold increase), and the geometric mean AUClast increased from 81890 ng*hr/mL to 3120000 \nng*hr/mL (38-fold increase). Depending on the SC dose, the Tmax ranged from 48 to 108 hours and the t1/2 \nranged from 33.3 to 98.35 hours. After single IV administrations (150 mg IV vs. 440 mg IV), the geometric \nmean Cmax increased in a roughly proportional manner (45640 ng/mL vs. 152800 ng/mL), while the geometric \nmean AUClast did also increase more than proportional (2346000 ng*hr/mL vs. 14290000 ng*hr/mL, 6-fold \nincrease). It is assumed that marstacimab undergoes target-mediated drug disposition. Based on AUCinf, the \nbioavailability of SC dosing compared to the IV reference dose was 27%. \nAfter single administrations of different dose levels in Study B7841001 in healthy adults, treatment related \nchanges were observed for all PD endpoints and the response was roughly dose dependent. As expected, \nincreases in total TFPI, peak thrombin, D-Dimer, and PF1+2 and shortening of TGA lag time and dilute \nprothrombin time were detected. The duration of the effect of the relevant dose levels did in principle support \nthe intended weekly administrations of marstacimab. \nAdditional data on SC administrations of 300 mg (consisting of 2 injections of 150 mg each) are available from \nthe bioequivalence Study B7841009, which compared the PK of a pre-filled pen (PFP) with a pre-filled syringe \n(PFS, used during the phase 3 trial). The descriptive analysis of the 18 participants who contributed data for \nthe calculation of PK parameters for PFP and PFS showed comparable results for both administration devices \n(PFP vs PFS: geometric mean AUCinf [ng*hr/mL]: 2523000 vs. 2482000; geometric mean AUClast [ng*hr/mL]: \n2018000 vs. 2015000; geometric mean Cmax [ng/mL]: 12550 vs. 12870; median Tmax [hr]: 72.00 vs. 72.00; \narithmetic mean t1/2 [hr]: 61.29 ± 20.073 vs. 60.24 ± 13.687). As mentioned above, the study was terminated \nprematurely because of the occurrence of a deep vein thrombosis and pulmonary embolism. A statistical \nanalysis using data from 11 participants who completed all 4 PK periods revealed test (PFP)/reference (PFS) \nratios of adjusted geometric means for marstacimab AUClast and Cmax values of 107.5% (95.2%, 121.4%) \nand 104.1% (93.7%, 115.6%), respectively. The confidence intervals are within the pre-specified acceptance \nrange of 80% ‑ 125%. This result was confirmed by a sensitivity analysis of 15 participants who completed at \nleast 2 periods (which means that they have received each treatment at least once) and also supported by the \ndescriptive PK results of 18 participants who contributed PK data. While the early termination of the study is \nnot optimal, one could argue that this led to a more challenging scenario for meeting the acceptance criteria \ndue to the lower sample size. \nPK/PD in patients \nIn the phase 1 single dose (300 mg SC) Study B7841010 in Chinese haemophilia patients, the PK parameters \nof Tmax and Cmax were comparable with results from both studies in healthy adults (Study B7841001, Study \nB7841009) in cohorts using the same dose. The AUC and t1/2 values were higher in Chinese patients, but \nconsistent with a small cohort of Japanese healthy adults (n=4) from Study B7841001 (detailed results for \nstudies B7841010, B7841001 and B7841009 are shown in the results section). In line with the single dose trial \nin healthy adults (B7841001), changes in PD parameters (increased plasma total TFPI, PF 1+2, D-Dimer, peak \n"
    },
    {
      "page_number": 89,
      "text": "Assessment report \nEMA/464842/2024 \nPage 89/198 \n \nthrombin, and TGA endogenous thrombin generation potential, shortening of dPT and TGA lag time) were \nmaintained for more than a week. For most of these PD parameters, the maximum effect was observed within \nthe first week, except for total plasma TFPI and D-Dimer, which peaked later (during week 2 or 3, respectively). \nIn the phase 1b/2 Study B7841002, weekly administration of marstacimab led to an increasing plasma \nconcentration up to the Day 29 visit. The plasma concentrations at the following visits (Day 57, Day 85) were \nlower or comparable, suggesting that a steady state may have been reached. This should however be \ninterpreted with caution due to the small sample size and reference is made to the discussion of the longer- \nterm data of the phase 3 trial B7841005 were accumulation of marstacimab was noted for the weekly dose of \n300 mg. At Day 29, PK parameters such as AUCtau, Cmax, and Cmin seemed to be dose-dependent, with the \nhighest values observed for the 450 mg SC QW group and the lowest values for the 150 mg SC QW (+300 mg \nSC loading dose) group. Importantly, the more than proportional increase in PK parameters such as Cmax and \nAUC (as described for the first-in-human single dose study in healthy adults) was not observed during the \nmultiple dose study in haemophilia patients, at least not to the same extent. It should however be noted that \nthe lower dose levels of Study B7841001 (30 mg SC, 100 mg SC) were not investigated during Study B7841002 \nand that the 150 mg SC QW cohort received a loading dose of 300 mg. A possible explanation for the roughly \ndose-dependent increase in PK parameters could be that the linear elimination likely dominates at the dose \nlevels (and plasma concentrations) investigated during the multiple dose trials due to a saturated drug target \n(TMDD). \nWhile Study B7841002 suggested that steady state concentration of marstacimab might have been reached \nuntil Day 85, the PK data of the extension Study B7841003 do not allow a clear conclusion on this aspect \nfor the higher dose regimen (300 mg SC QW). Among the participants who received weekly doses of 300 mg \n(participants with or without inhibitors combined) throughout the study, the mean plasma concentrations of \nmarstacimab were higher at later time points compared to Day 85 (Day 85: 41720 ng/mL, N=10; Day 169: \n60690 ng/mL, N=9; Day 253: 58420 ng/mL, N=9, Day 365: 60930 ng/mL, N=4). Of note, for non-inhibitor \npatients, the plasma concentrations of marstacimab did continue to increase until D365, while the levels were \nstable or decreasing for inhibitor patients. The interpretability of these one-year PK data seems limited due to \nthe small number of participants in the different dose cohorts of this study. \nDuring the multiple dose Study B7841002 and its extension Study B7841003, the effects on PD parameters \ntended to increase until either Day 85 (increased PF1+2) or Day 169 (total TFPI, increased peak thrombin, \nshortened TGA lag time, increased endogenous thrombin generation potential) and remained roughly \ncomparable until the end of the extension study. \nIn the phase 3 Study B7841005, 102 participants (85 adults, 17 adolescents) received a weekly dose of 150 \nmg SC marstacimab (after an initial loading dose of 300 mg) throughout the whole study duration of one year. \nFor 14 participants (12 adults, 2 adolescents), the weekly dose was escalated to 300 mg SC after the D180 \nvisit. \nAmong the 102 participants who remained on the 150 mg SC WQ dose regimen throughout the study, the \nmarstacimab plasma concentration seemingly reached a steady state around Day 60. Adolescents reached \nhigher mean plasma concentrations (roughly around 21000-27000 ng/mL, SD ~ 12000-18000) than adults \n(roughly around 12000-14000 ng/mL, SD ~ 10000-13000) throughout the visits at Day 60, Day 120, Day 180, \nDay 240, Day 300 and Day 360. A higher plasma concentration in adolescents was predicted by the population \nPK model. The variability of these PK measurements was high, as shown by the standard deviation values. In \nthe phase 3 study, the coefficients of variation were approximately between 40% - 85% in adolescents and \nbetween 62% - 92% in adults. In the CSR it is argued that the variability was likely caused by differences in \nsampling time points. In order to support this hypothesis, the Applicant was asked to provide an overview with \n"
    },
    {
      "page_number": 90,
      "text": "Assessment report \nEMA/464842/2024 \nPage 90/198 \n \nmore details on the variability of the sampling time points. The Applicant clarified that blood samples were \ncollected at any time during the clinical visit, regardless of the time of dose administration. While \nrecommendation was made in the protocol that the PK sample be collected prior to dose administration, this \nwas not mandatory. Approximately 50% of samples were obtained pre-dose (at around 6 days post dose or \nlater), while 50% of samples were obtained anytime between 1 – 5 days post dose. Besides patient weight, \nvariable soluble and cell surface levels of TFPI may also contribute to variability. \nBased on how the data were presented in the initial submission, it seemed that marstacimab and TFPI were \ncontinuously increasing in those 14 participants who had a dose escalation to 300 mg SC QW during the phase \n3 Study. In addition, the population PK/PD model did not adequately describe the data observed for the 300 \nmg SC QW dosing. This issue was raised as a major objection in the D120 LoQ since accumulation of \nmarstacimab and a potential risk for thrombosis could not be excluded. A more detailed presentation of the \ndata in dose-escalated particpants was requested. \nIn the response to this major objection, the Applicant provided detailed tables and figures describing all data \npoints (marstacimab concentration, total TFPI) in participants who switched to the higher dose regimen, an \nupdate of the population PK/PD model (correcting an input error), and updated discussions on the safety and \nefficacy of marstacimab based on a later data cut-off of the extension study B7841007. \nAmong the 14 participants who received 300 mg SC QW during the phase 3 Study B7841005, 6 participants \nhad 3 PK data points (marstacimab concentration in plasma) after dose escalation, covering a period of \n~120 days between the sampling time points. Importantly, there was no sign of accumulation in these \nparticipants. For the remaining 8 participants, only one or two PK data points were available, because they \nswitched their dose at later time points during the study. The measured marstacimab concentrations were \nwithin the observed range of the overall study population. The mean plasma concentration in all participants \nwho had a dose escalation did only slightly increase between D300 and D360, while the median concentrations \nremained stable. Based on the provided data, it seems that the data in the initially provided Figure above were \nbiased due to different time points of dose escalations, leading to the wrong impression of a continued increase \nof marstacimab in plasma over time. This could not be assessed in the previous round based on how the data \nwere presented in the initial submission. The same observation was made for total TFPI. \nIn addition, the Applicant provided an amended population PK and PK/PD model, including an updated report. \nThe Applicant claimed that this was made to correct an error in the dosing record inputs for the 300 mg dose \n(150 mg input instead of 300 mg) in Study B7841005 in the NONMEM dataset used for population PK modelling. \nThe data cutoff remained the same as previously (ie, all data up to Day 300 was included). The modelling \npredictions (marstacimab concentration, total TFPI) for the 300 mg SC QW dose now show better agreement \nwith the observed data. The amended model is now considered more suitable for use with the higher dose (300 \nmg SC QW). \nUpdated safety & efficacy data from a more recent data cut (09 Oct 2023 vs. 10 Mar 2023 in the previous \nsubmission) from the extension Study B7841007 were provided. Additional participants had a dose escalation \nduring the extension study. At the new data cut-off, there were a total of 23 participants who have been dose \nescalated from 150 mg marstacimab to 300 mg marstacimab, either in Study B7841005 or Study B7841007 \n(13 HA participants, 10 HB participants). No PK/PD data are collected during the ongoing extension study. \nThere were no SAEs in dose escalated participants and importantly also no thromboembolic events in any \nhaemophilia patient treated with marstacimab (regardless of the dose level). While this is reassuring, the very \nsmall safety database needs to be considered. The Applicant provided additional efficacy data based on the \nlater data cut-off (09 Oct 2023) and there was no sign of reduced efficacy in this population. \n"
    },
    {
      "page_number": 91,
      "text": "Assessment report \nEMA/464842/2024 \nPage 91/198 \n \nBased on the more detailed data, the major concern regarding a potential accumulation of marstacimab (and \ntotal TFPI) was considered resolved. The presented data support the proposed dose regimen, which allows a \ndose escalation to 300 mg SC QW when control of bleeding events is judged to be inadequate by the healthcare \nprofessional. \nFor patients who remained on the 150 mg SC QW dose level, the peak thrombin values seemed to have \nreached a steady state at Day 60, with median values ranging from 63 – 66 nM in adults (N=85) compared to \nto 41 - 54 nM in adolescents (N=17). Paradoxically, for the 14 participants who underwent dose escalation to \n300 mg SC QW during the trial, the median peak thrombin levels started to continuously decrease over time \nafter every subsequent visit. The median peak thrombin levels decreased from >70 nM at Day 180 to around \n30 nM at Day 360. This is unexpected and contradicts the results of a previous smaller study (Study B7841003, \nFigure 5 in the Clinical AR). Potential reasons and consequences of this unexpected observation and whether it \ncan be excluded that this might have been caused by some form of drug tolerance or by development of \nantibodies against marstacimab were discussed. Only 3 of the 14 dose-escalated participants contributed to \nthe median peak thrombin. In addition, these 3 data points were incorrectly assigned as post-dose data at this \ntime point and that the actual number contributing data at the D180 time point for 300 mg SC QW is 0. \nHowever, an updated figure (not included in this report), which only includes data starting from D240, still \nshows a downward trend for median TGA peak values that is similar to the trend shown (from ~55 nM to ~30 \nnM). The Applicant argued that efficacy was maintained during the extension of the phase 3 study, that the \npeak thrombin values were stable over time during the phase 2 study, that other PD biomarkers remained \nstable during phase 3, that the “n” in the concerned population of dose-escalated participants was small, and \nthat the variability of PD measurements was generally high. For the few concerned participants who developed \nADA, no meaningful impact on peak thrombin was noted. The totality of the provided arguments was considered \nreassuring. \nOverall, the median thrombin peak levels remained within a physiological range throughout the study. A \nsummary on how often the thrombin peak values were elevated above the upper limit of normal (by subject \nincidence and individual occurrences), whether the values returned to normal until the end of the study and a. \nsummary and discussion on the PD parameters of D-Dimer and PF 1+2 were requested. These data should be \ndiscussed with respect to potential safety risks. It was clarified that ~50% of the blood samples were collected \npre-dose (Day 6 after last administration of Hympavzi), whereas the remaining samples were obtained anytime \nbetween 1 – 5 days post dose (multiple dose Tmax = 23 – 59 hours). For contextualization of the analyses of \nthe PD marker (peak thrombin, D-Dimer, PF1+2) values measured during the phase 3 trial, the Applicant \nprovided not only physiological ranges for these markers from the literature, but also an analysis of pre-dose \n(baseline, n=41 participants) and post-dose (n=27 participants) values of the healthy volunteers recruited for \nthe phase 1 trial B7841001. \nThree out of 116 participants of the phase 3 trial had peak thrombin values above 176 nM, which is the 97.5th \npercentile for normal range in healthy participants of the phase 1 study. The elevated levels were only transient \nand returned to normal. For one of these 3 cases, sample collection occurred within 2 days of a bleed. \nIn the phase 3 study, 33 out of 116 haemophilia participants had at least 1 D-Dimer value > 0.52 µg/mL, the \n97.5th percentile for normal range in healthy participants. The maximum observed post-dose value in the \nhaemophilia population was 1.9 µg/mL (97.5th percentile = 0.81 µg/mL), in comparison to a maximum post- \ndose value of 6.1 ug/mL in the healthy population (97.5th percentile = 2.5 ug/mL). Out of the 33 participants, \n20 participants had D-Dimer > 0.52 µg/mL at more than 1 timepoint (range = 2 – 8 timepoints) after which \nvalues returned to normal. Ten (10) participants had D-Dimer > 0.52 µg/mL at Day 360, i.e. at the end of \nstudy. \n"
    },
    {
      "page_number": 92,
      "text": "Assessment report \nEMA/464842/2024 \nPage 92/198 \n \nNearly all (112 out of 116) haemophilia participants of the phase 3 Study had PF1+2 values > 181 pmol/L, \nwhich is the 97.5th percentile for normal range in healthy participants. Values greater than 181 pmol/L were \nseen at 2 or more time points (between 2 – 9 time points) post dose. The maximum value seen in haemophilia \nparticipants was 12801 pmol/L (at 1 time point in 2 participants before end of study). The 97.5th percentile \nfor post-dose PF1+2 was 1290 pmol/L in haemophilia participants in comparison to the 97.5th percentile of \n961 pmol/L in healthy participants. \nThe applied exact thresholds for peak thrombin, D-Dimer and PF1+2 may be debatable. It is reassuring that \nno thromboembolic events occurred in any of the clinical trials which recruited haemophilia patients, including \nthe latest data cut-off of the extension study B7841007. In order to inform the prescriber, a statement was \nincluded in section 5.1 of the SmPC describing that potentially elevated values (above the physiological range) \nmay occur for D-Dimer or PF1+2. \nFor the PD parameters of PF 1+2 and D-dimers, steady state was also reached at Day 60. The median values \nfor absolute PF 1+2 ranged from 492 – 579 pmoL/L in adults (N = 85) in comparison to 557 – 874 pmoL/L in \nadolescents (N = 17). The median values for absolute D-dimer were around 0.3 μg/mL in adults (N = 85) in \ncomparison to roughly 0.25 – 0.45 µg/mL (with a decreasing trend over time) in adolescents (N = 17). In \ncontrast to peak thrombin, the PF 1+2 and D-dimer levels remained on comparable levels after dose escalation \nto 300 mg SC QW. \nImmunogenicity \nIn the pooled Phase 2 studies (Studies B7841002/B7841003), the total incidence of ADA was 10.7%. None of \nthe participants tested positive for marstacimab NAb. \nIn the pooled Phase 3 studies (Study B7841005/B7841007), the total incidence of ADA was 19.8% (23/116 \nparticipants). Overall, ADA titres were low, transient in the majority of the participants and resolved in all but \none (i.e., 22/23 = 95.7%) ADA-positive participant by the end of the parent study. The NAb incidence was \n5.2%, all NAbs were transient in nature and no participants were NAb positive at end of the parent study or \nduring the OLE study. \nThe Applicant summarised PK/PD data by ADA status. The data from the phase 1/2 trial do not allow any \nconclusions due to the small number of participants in relevant dose groups. For the phase 3 study, upon \nrequest, the Applicant provided detailed tables including descriptive statistics for plasma marstacimab and PD \nparameters by ADA status. The mean marstacimab concentrations were lower in ADA positive participants \ncompared to negative participants throughout all clinical visits. At Day 360, mean marstacimab concentration \nwas 10550 ng/mL in ADA positive participants, and 15570 ng/mL in ADA negative participants (median 8340 \nng/mL vs. 12300 ng/mL). The same pattern was seen for total TFPI in plasma with lower mean and median \nvalues observed in ADA negative participants compared to ADA positive participants throughout all visits (e.g., \nDay 360 mean TFPI values; ADA+: 258.4 ng/mL; ADA-: 322.2 ng/mL). A comparable but less consistent trend \nwas seen for PF1+2. ADA status did not seem to influence TGA peak values and Dilute Prothrombin Time (sec). \nEven if an impact on efficacy is not necessarily expected based on data presented, information about the \nobserved influence of ADA on PK was included in the SmPC. \nPK in special populations \nBased on the population PK analysis, haemophilia type did not seem to significantly influence the PK of \nmarstacimab. Effect of age was not included as a covariate in the model because of the young age of the \nhaemophilia population with median age of 31 years (range: 13 – 66 years) in the studies. Lack of data in \n"
    },
    {
      "page_number": 93,
      "text": "Assessment report \nEMA/464842/2024 \nPage 93/198 \n \nelderly is reflected in the SmPC. The data on ethnic factors is very limited. After adjusting for weight, \nmarstacimab clearance was estimated to be approximately 31.9% higher in Asian participants. \nSome individuals with mild renal (N=22; eGFR of 60-89 mL/min/1.73 m2) or hepatic (N = 15, total bilirubin > \nULN, AST > ULN) impairment were recruited. Population analysis of the effect of renal impairment on \nmarstacimab CL showed a 16.8% lower CL with mild renal impairment (95% CI: -34% to 12.1%). No clinically \nsignificant impact is expected in these patients. The lack of data in patients with moderate or severe forms of \nrenal/hepatic impairment is reflected in the SmPC. \nBased on population PK analysis, weight was the most important covariate which seemed to influence the PK \nof marstacimab. Lower weight seems to cause lower clearance (and higher exposure). For example, differences \nin clearance between adults and adolescents were noted, with lower clearance (~32%) and higher median \nmarstacimab plasma concentrations reported for adolescents. After weight-adjustment, the difference in \nclearance was only ~3%. This is reflected in section 5.2 of the SmPC. \nThe Applicant was asked to discuss and justify why no dose adjustment is recommended for obese and \nunderweight subjects in section 4.2 of the SmPC. Simulated steady-state individual post-hoc PK exposure \nusing the amended population PK model and simulations for peak thrombin using the same PK/PD model were \nperformed. Based on limited data from obese participants (n=11), the simulated marstacimab exposure \nlevels were lower compared to healthy weight or overweight participants. However, the simulated TGA peak \nvalues were comparable between the groups, with a trend for slightly higher values in these few obese \nparticipants. In contrast, the simulated exposure was higher in underweight participants (n=24) compared \nto healthy weight or overweight participants. There seemed to be a trend for slightly lower simulated TGA peak \nvalues compared to the other weight groups. No inconsistencies or outliers were detected with respect to \nannualised bleeding rates in obese participants. In underweight participants, there were 3 participants with an \nABR above 10, but the rate of outliers was comparable to the healthy weight or overweight participants. \nNo thromboembolic events were reported, but the sample size is too low to make any firm conclusions based \non safety data. The absence of a narrow therapeutic window is acknowledged. \nBased on the provided PK/PD and efficacy data, it can be agreed that there seems to be no need for dose \nadjustment of the 150 mg SC QW dose in obese or underweight patients. The Applicant has adequately \ndiscussed the effects of the 300 mg dose on PK, safety and efficacy in underweight subjects with a view to \njustify why there is no need for dose adjustment in this setting, considering that these individuals seem to have \nnotably higher simulated mean steady state marstacimab concentrations (but lower peak thrombin levels) with \nthe 150 mg SC QW dose, compared to healthy weight participants. Estimated Cmax values for marstacimab as \nwell as estimated TGA values overlap between normal weight/overweight subjects and underweight subjects \nwho have been escalated to the higher dose. No safety signals were observed in patients who were treated \nwith 300 mg, irrespective of bodyweight. As dose escalation is permitted only for those subjects with a minimum \nbodyweight of 50 kg and only if the observed bleeding control is not deemed sufficient, no additional warnings \nare considered necessary in the SmPC. \n \n2.6.4. Conclusions on clinical pharmacology \n \nThe methodology and conduct of the clinical pharmacology studies are acceptable. Clinical pharmacology \nparameters and pharmacodynamics markers have been adequately studied and relevant information has been \nreflected in SmPC sections 4.2, 4.4 and 5.2. After weekly SC administration of 150 mg study drug (after a 300 \nmg loading dose) in the phase 3 trial, the concentrations of marstacimab and total TFPI in plasma reached a \n"
    },
    {
      "page_number": 94,
      "text": "Assessment report \nEMA/464842/2024 \nPage 94/198 \n \nsteady state at the Day 60 visit. The PD biomarker of peak thrombin increased to physiological values and the \nmeasured downstream biomarkers for coagulation (PF 1+2, D-Dimer) showed consistent response throughout \nthe study. The proposed dose regimen in section 4.2 of the SmPC includes the option of a dose escalation to \n300 mg SC QW in patients with inadequate control of bleeding events, as judged by the healthcare professional. \nAlthough only limited data are available for this dose escalation setting, the Applicant provided sufficient \nreassurance that there are no signs for accumulation of marstacimab. There were no thromboembolic events \nin haemophilia patients in any of the clinical studies. \nSeveral PD markers were measured during the clinical program. The relationship between the levels of these \nbiomarkers and the primary efficacy parameter (ABR) has not been investigated. Measuring TFPI activity would \nhave been the most straightforward way to connect pharmacodynamics and clinical efficacy. The Applicant \nargued that all strategies of developing a method to measure free TFPI failed because of (1) sample dilution \nrequirements and (2) reagent competition leading to dissociation of TFPI from the drug-target complex due to \nthe relatively low binding affinity of marstacimab to TFPI compared to other known binding partners, which \nwould lead to an overestimation of free TFPI. \n \n2.6.5. Clinical efficacy \n \nClinical efficacy data from 4 studies are provided in the MAA for Hympavzi, which include a single pivotal \nPhase 3 study and its Phase 3 OLE study, as well as one Phase 1b/2 study and its Phase 2 OLE. \nThe single pivotal study B7841005 investigating both non-inhibitor and inhibitor cohorts is currently ongoing, \nhowever efficacy data from the completed non-inhibitor cohort are available for review. The Phase 3 OLE \nstudy B7841007 is ongoing with an interim analysis for the non-inhibitor cohort provided with a cut-off date \nof 10 March 2023. Further, supportive efficacy data are provided from the completed studies B7841002 \n(Phase 1b/2) and B7841003 (Phase 2 OLE). \nThe indication applied for with this MAA is restricted to the non-inhibitor patient population only. \nData provided from patients who were previously on routine prophylaxis during OP are considered the pivotal \nevidence for this MAA. Comparison of marstacimab prophylactic treatment and previous on-demand \ntreatment is considered to be of decreased regulatory importance and is viewed as supportive evidence. \n"
    },
    {
      "page_number": 95,
      "text": "Assessment report \nEMA/464842/2024 \nPage 95/198 \n \nTable 14: Clinical efficacy studies included in the marstacimab MAA \n \n \n \n2.6.5.1. Dose response study(ies) \n \nB7841002: Phase 1b/2 Study \nStudy B7841002 was a Phase 1b/2, open-label, multiple ascending dose clinical study in male participants \nwith severe haemophilia A or B, with or without inhibitors. \nThe dose progression scheme and treatment duration of the study is described in Figure below. \nFigure 21: dose progression scheme \n \n"
    },
    {
      "page_number": 96,
      "text": "Assessment report \nEMA/464842/2024 \nPage 96/198 \n \nTwenty-seven (27) participants were enrolled at 8 study sites. Subcutaneous (SC) multiple dose cohorts were \nenrolled starting at the 300 mg SC dose. Intravenous (IV) routes of administration were not evaluated in the \nstudy. Participants were enrolled and assigned to the study treatments in four cohorts: Cohort 1 (non- \ninhibitor, n = 8) with 300 mg weekly s.c. dosing, Cohort 2 (non-inhibitor, n = 6) with 300 mg loading dose \nfollowed by 150 mg weekly s.c. dosing, Cohort 3 (non-inhibitor, n = 6) with 450 mg weekly s.c. dosing. The \ninhibitor cohort (Cohort 4) was treated with 300 mg weekly s.c. dosing, which was assessed as safe and well- \ntolerated in participants without inhibitors before treatment of inhibitor patients was initiated. \nCohorts were followed for at least 29 days. If available safety, tolerability and pharmacokinetic (PK) data \nthrough Day 29 were permissive for dose escalation, a cohort at a higher dose level was to be opened for \nenrollment. Alternatively, a cohort at a lower dose level was to be opened if data were supportive. In \naddition, if the dose level under review was safe and well tolerated through Day 29, treatment was to \ncontinue for the participants in that respective cohort during the subsequent 2 months (Day 30 to Day 85). \nEligible participants were patients with severe haemophilia A or B (FVIII or FIX activity ≤1%) with on- \ndemand treatment regimen, including those with inhibitors to FVIII or FIX. \nFor efficacy evaluation, frequency and annualised rate of bleeding episodes from day 1 to day 85 were \ninvestigated as the key secondary endpoint of the study. Information on bleeding episodes over the 6 months \nprior to the study were collected at screening, information on new bleeding episodes after screening were \ncollected continuously to day 113 (FU/EOS). Additionally, a historical on-demand group was constructed \nusing data from the following internal Pfizer studies: ReFacto AF 3082B2-4432 (B1831004), BeneFIX \nB1821010, and BeneFIX 3090A1-400 (B1821004). \n \n \nResults \nSubject Disposition and Demography: \n38 individuals were screened, of which, 11 individuals failed at screening. Among the 27 participants who \nmet the eligibility criteria and were assigned to the study treatment, 26 (96.3%) participants were treated \nwith PF-06741086, and 1 (3.7%) participant assigned to the PF-06741086 300 mg SC QW non-inhibitor \ndose cohort was not treated due to consent withdrawal prior to dosing on Day 1. \nAmong 26 participants treated with PF-06741086, 24 (92.3%) participants completed the study, and 2 \n(7.7%) participants discontinued from study due to AEs. One (1) participant from the PF-06741086 300 mg \nSC loading + 150 mg SC QW non-inhibitor dose cohort discontinued from study due to a Grade 2 non- \nserious AE of hypertension, which was determined to be treatment related by the investigator. 1 participant \nfrom the PF-06741086 300 mg SC QW inhibitor dose cohort discontinued from study due to a Grade 3 non- \nserious AE of decreased blood fibrinogen, which was determined to be treatment related by the investigator. \nAll 26 participants were male. The majority of participants (19/26, 73.1%) were in the 18-44 age range. \nAll 26 participants were of White (14/26, 53.8%) or Black/African American race (12/26, 46.2%). The \nmedian weight ranged from 61.60 kg (PF-06741086 300 mg SC loading + 150 mg SC QW non-inhibitor \ndose cohort) to 82.85 kg (PF-06741086 450 mg SC QW non-inhibitor dose cohort) and individual values \nranged from 50.2 to 96.0 kg. The median body mass index (BMI) ranged from 21.26 kg/m2 (PF- \n06741086 300 mg SC loading + 150 mg SC QW non-inhibitor dose cohort) to 26.30 kg/m2 (PF- \n06741086 450 mg SC QW non-inhibitor dose cohort) and individual values ranged from 17.8 to 30.4 \nkg/m2. \n"
    },
    {
      "page_number": 97,
      "text": "Assessment report \nEMA/464842/2024 \nPage 97/198 \n \nAmong 26 treated participants, 23 (88.5%) participants had haemophilia A and 3 (11.5%) participants had \nhaemophilia B. All 7 (100%) participants in the PF-06741086 300 mg SC QW inhibitor dose cohort had \nhaemophilia A and inhibitors to FVIII. \nEfficacy results \nA descriptive summary of ABR data is presented by study phase in below Table. \nTable 15: description summary of annualised bleeding rate by dose cohort -PPAS \n \n \n \nThe comparisons for ABR between the PF-06741086 dose cohorts and the historical On Demand group \nusing a negative binomial model are provided in the table below. There was a statistically significant \nreduction in ABR in the pooled PF-06741086 dose cohorts (24 participants) versus that in the historical \nOn Demand group (ratio [test/reference] = 0.10, 80% CI = 0.07 to 0.14, p <0.0001). The reduction in \nABR remained statistically significant in each PF-06741086 dose cohort versus that in the historical On \nDemand group. \n"
    },
    {
      "page_number": 98,
      "text": "Assessment report \nEMA/464842/2024 \nPage 98/198 \n \nTable 16: statistical summary of annualised bleeding rate versus historical on demand group \nbased on negative binomial model – PPAS \n \nThe comparisons between on-study ABR and pre-treatment ABR in the PF-06741086 dose cohorts using a \nnegative binomial model are provided below. There was a statistically significant reduction in ABR in the on- \nstudy phase versus that in the pre-treatment phase in the pooled PF-06741086 dose cohorts (ratio [on- \nstudy/pre-treatment] = 0.14, 80% CI = 0.09 to 0.22, p <0.0001). The reduction in ABR in the on-study \nphase versus that in the pre-treatment phase remained statistically significant in each PF-06741086 dose \ncohort. \nTable 17: Statistical summary of on-study versus pre-treatment annualised bleeding rate based \non negative binomial model - PPAS \n \n"
    },
    {
      "page_number": 99,
      "text": "Assessment report \nEMA/464842/2024 \nPage 99/198 \n \n2.6.5.2. Main study \n \nPivotal Phase 3 study B7841005 \n \nMethods \nStudy B7841005 is an ongoing, one-way, cross-over, open-label, multi-centre study planned for \napproximately 145 adolescent and adult participants between 12 to <75 years of age with severe haemophilia \nA or moderately severe to severe haemophilia B (defined as FVIII activity <1%, or FIX activity ≤2%, \nrespectively) with or without inhibitor, with approximately 20% of participants as adolescents (ages between \n12 to <18 years old). Study B7841005 originally allowed for enrolment of participants with severe \nhaemophilia A and severe haemophilia B. Protocol Amendment 6 added the inclusion of participants with \nmoderately severe haemophilia B. In the non-inhibitor cohort, only severe haemophilia B participants have \nenrolled. The non-inhibitor cohort of this study is complete, whereas the inhibitor cohort is ongoing. \nThis study compared treatment with the participant’s prescribed factor replacement therapy or bypass \ntherapy during an OP with a 12-month ATP, during which participants were to receive marstacimab \nprophylaxis (defined as treatment by SC injection of marstacimab). \nThe dosing regimen was marstacimab 300 mg SC for the initial loading dose followed by 150 mg SC QW. \nIndividual participants who met protocol-specified dose escalation criteria based upon breakthrough \nbleeding were eligible for dose escalation to 300 mg SC QW. \nTreatment during the 6-month OP consisted of the following: \nPrior On-Demand Treatment: Participants with either haemophilia A or B, with or without inhibitors, and \nwho were prescribed an on-demand treatment regimen during the OP, transitioned to the ATP after 6 \nmonths. \nPrior Prophylaxis Treatment: Participants without inhibitors who were on prior prophylactic \ntreatment with FVIII- or FIX-replacement during the OP transitioned to the ATP after 6 months. \nThe study duration for an individual participant was approximately 21 months, including an approximately \n45-day screening period, an OP of 6 months, a 12-month ATP during which the participant was to receive an \ninitial loading dose followed by prophylaxis treatment with marstacimab, and a 1-month follow-up for safety \nmonitoring. \nFigure 22: Study schema \n \n"
    },
    {
      "page_number": 100,
      "text": "Assessment report \nEMA/464842/2024 \nPage 100/198 \n \n• \nStudy Participants \nEnrolled in this study were adult or adolescent male participants (12 to <75 years of age) with a diagnosis of \nsevere haemophilia A or moderately severe to severe haemophilia B (FVIII activity <1% or FIX activity ≤2%, \nrespectively) who consented to participate in the study. \n \n \nInclusion Criteria \n \nParticipants are eligible to be included in the study only if all of the following criteria apply: \nAge \n▪ \nParticipant must be male and 12 to <75 years of age with a minimum body weight of 35 kg at the \ntime of signing the informed consent. \nType of Participant and Disease Characteristics \n▪ \nParticipants with a diagnosis of severe haemophilia A or moderately severe to severe haemophilia B \n(FVIII activity <1% or FIX activity ≤2%, respectively) documented by a clinical laboratory prior to \nEnrollment. The severity of haemophilia may be confirmed either by documented historical evidence \nfrom a clinical laboratory prior to Screening or by factor activity obtained from a clinical laboratory \n(which may include the central laboratory for this study) prior to Enrollment. \n▪ \nParticipants who are enrolled into the Non-Inhibitor Cohort must also meet the following criteria: \no \nNo detectable or documented history of inhibitors (≥0.6 BU/mL or greater than the upper \nlimit of normal [ULN] for the testing laboratory) against FVIII or FIX prior to enrollment \n(Baseline of Observational Phase). \no \nParticipants receiving routine prophylaxis (defined as treatment by IV injection of factor \nconcentrate to prevent bleeding) treatment with FVIII/FIX replacement, have demonstrated \nat least 80% compliance with scheduled prophylaxis regimen during 6 months prior to \nenrollment, and willing to continue to receive routine prophylaxis treatment with FVIII/FIX \nreplacement during the Observational Phase. \n(OR) \no \nParticipants with on-demand treatment regimen with ≥6 acute bleeding episodes \n(spontaneous or traumatic) that required coagulation factor infusion during the 6 months \nperiod prior to Enrollment into Observational Phase and willing to continue to receive on- \ndemand treatment during the Observational Phase. Surgical bleeding episodes do not apply \nto this criterion. \nSex \n▪ \nMale \n \n \nInformed Consent \n▪ \nParticipant or legally authorised representative, or participant’s caregiver capable of giving signed \ninformed consent (or minor assent, when applicable) which includes compliance with the \nrequirements and restrictions listed in the informed consent document (ICD) and in this protocol. \n"
    },
    {
      "page_number": 101,
      "text": "Assessment report \nEMA/464842/2024 \nPage 101/198 \n \nExclusion Criteria \n \nParticipants are excluded from the study if any of the following criteria apply: \n \n \nMedical Conditions \n▪ \nPrevious or current treatment for or history of coronary artery diseases, venous or arterial thrombosis \n(Common Terminology Criteria for Adverse Events [CTCAE]14 Grade >1), or ischemic disease (except \nfor catheter-associated thrombosis). \n▪ \nKnown planned surgical procedure during the planned study period. \n▪ \nKnown hemostatic defect other than haemophilia A or B. \n▪ \nAbnormal renal or hepatic function as defined by the following laboratory results at Screening: \no Alanine transaminase (ALT) >2 × upper limit of normal (ULN) \no Bilirubin >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated \nand direct bilirubin <35%) \no Current unstable liver or biliary disease per investigator assessment defined by the presence of \nascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, \npersistent jaundice, or cirrhosis. NOTE: Stable chronic liver disease (including Gilbert’s \nsyndrome, asymptomatic gallstones, and chronic stable hepatitis B or C -eg, presence of \nhepatitis B surface antigen [HBsAg] or positive hepatitis C antibody test result at screening or \nwithin 3 months prior to starting study intervention) is acceptable if the participant otherwise \nmeets entry criteria \no Serum albumin less than the lower limit of normal (LLN). \no Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2. \n \n \n▪ \nAbnormal hematology values as defined by the following laboratory tests at Screening: \no Platelet count <100,000/uL \no Hemoglobin level <10 g/dL \n▪ \nOther acute or chronic medical or psychiatric condition including recent (within the past year) or active \nsuicidal ideation or behaviour or laboratory abnormality that may increase the risk associated with \nstudy participation or investigational product administration or may interfere with the interpretation of \nstudy results and, in the judgment of the investigator, would make the participant inappropriate for \nentry into this study. \n▪ \nQTcF >450 msec for male participants or QTcF >480 msec in participants with bundle branch block. \n▪ \nIndividuals with hypersensitivity or an allergic reaction to hamster protein or other components \nof the study intervention. \n"
    },
    {
      "page_number": 102,
      "text": "Assessment report \nEMA/464842/2024 \nPage 102/198 \n \nPrior/Concomitant Therapy \n▪ \nCurrent routine prophylaxis with bypassing agent (eg, aPCC, BYCLOT, Prothrombin Complex \nConcentrates [PCC], or rFVIIa), non-coagulation non-factor replacement therapy (eg, \nemicizumab), or any previous treatment with a gene therapy product for treatment of haemophilia. \no Participants with inhibitors who are being treated using a prophylaxis treatment regimen with a \nbypass agent will be considered on a case-by-case basis, only after discussion and agreement \nbetween the investigator and the Pfizer medical monitor. \no Participants who have previously received non-factor-based haemophilia therapy (eg, fitusiran, \nconcizumab, emicizumab) will be considered on a case-by-case basis, only after discussion and \nagreement between the investigator and the Pfizer medical monitor. \n▪ \nRegular, concomitant therapy with immunomodulatory drugs (eg, IV immunoglobulin [IVIG], and \nroutine systemic corticosteroids, rituximab). \n▪ \nOngoing or planned use of immune tolerance induction during the Observational Phase or Active \nTreatment Phase, or prophylaxis with FVIII or FIX replacement at any time after initiation of treatment \nwith study intervention during the Active Treatment Phase. \n \n \nPrior/Concurrent Clinical Study Experience \n▪ \nParticipation in other studies involving investigational drug(s) or investigational vaccine(s) within 30 \ndays (or as determined by local requirements) or 5 half-lives prior to study entry or during study \nparticipation. \n▪ \nPrevious exposure to PF-06741086 during to participation in Studies B7841002 and B7841003. \n \n \nDiagnostic assessments \n▪ \nCD4 cell count ≤200/uL if human immunodeficiency virus (HIV)-positive \n▪ \nScreening 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant \nsafety or interpretation of study results. \n \n \nOther Exclusions \n▪ \nInvestigator site staff members directly involved in the conduct of the study and their family \nmembers, site staff members otherwise supervised by the investigator, or participants who are Pfizer \nemployees, including their family members, directly involved in the conduct of the study. \n \n \n• \nTreatments \nThe study intervention marstacimab (PF-06741086) was administered as 300 mg SC (2 × 150 mg SC \ninjections) for the initial loading dose followed by a single 150 mg SC QW injection via PFS. Individual \nparticipants who met protocol-specified dose escalation criteria based upon breakthrough bleeding may \nhave had their dose increased to 300 mg SC QW at any time after completion of ATP Day 180 (Visit 14). All \nparticipants were provided the PFS for administration of marstacimab in the study. \n"
    },
    {
      "page_number": 103,
      "text": "Assessment report \nEMA/464842/2024 \nPage 103/198 \n \nModification of study intervention dose is not required but, under certain circumstances, is allowed. Any \ndecisions related to dose modification due to meeting bleed event criteria will exclude any bleeding data from \nthe first 72 hours of a 300-mg loading dose with study intervention. \nFollowing 6 months of active treatment with PF-06741086, and at any time after completion of Visit 14 \n(Active Treatment Phase Day 180), the dose may be escalated from 150 mg SC QW to 300 mg SC QW if the \nfollowing criterion is met and following discussion with the medical monitor: \n▪ \nThe participant must weigh at least 50 kg in order to escalate to the 300 mg SC QW dose. Any \nparticipant weighing between 35 kg and <50 kg, including adolescents, must remain on the 150 \nmg dose. \n▪ \nNon-Inhibitor Cohort: Two or more spontaneous (atraumatic) bleeds (consisting of joint bleeds \nor significant soft tissue/muscle or other site bleeds) treated with infusion(s) of coagulation FVIII \nor FIX over a 6-month period in the absence of a confirmed FVIII or FIX inhibitor, respectively. \nSignificant spontaneous bleeds were defined as those that lead to a transient or persistent loss of function. \nThe loss of function may be transient and may evidence itself by a reluctance of the participant to utilise the \naffected body part in usual activities be it on account of pain, associated swelling or limitation in motion. This \nspecification was intended to prevent regimen escalation based upon clinically insignificant or minor bleeding \nepisodes (eg, ecchymoses, epistaxis). \nThe investigator will review this criterion with the participant/caregiver at the time study intervention is first \ndispensed and again at study visits and visits conducted by phone. In the event that this criterion for regimen \nescalation is met, the participant/caregiver must contact the investigator as soon as possible, and the \ninvestigator will confirm that the participant has met the criterion. The investigator will discuss planned \nregimen escalation with the sponsor’s medical monitor and determine new dosing regimen for the participant. \nThe investigator will provide the participant/caregiver with instructions for the new prophylaxis regimen. The \nparticipant will now follow the protocol assigned regimen escalation, and arrangements for adequate study \nintervention supplies will be made. \n \n \nConcomitant and rescue therapies \nAny medication or vaccine (including over-the-counter or prescription medicines, vitamins, or herbal \nsupplements) that the participant is receiving at the time of Screening or receives during the study had to be \nrecorded along with reason for use, dates of administration including start and end dates, and dosage \ninformation including dose and frequency. The medical monitor was to be contacted if there were any \nquestions regarding concomitant or prior therapy. In case a participant was scheduled to undergo a surgical \nprocedure, the investigator was to contact the medical monitor and discuss further participation for the \nparticipant, as well as any other action which may be required. \n"
    },
    {
      "page_number": 104,
      "text": "Assessment report \nEMA/464842/2024 \nPage 104/198 \n \nPermitted Haemostatic Medication \n \nTable 18: Haemostatic medication allowed for use during the study \n \nCohort \nAllowed During Observational \nPhase \nAllowed During Active \nTreatment Phase \nDuration \n6 Months \n12 Months \nNon- \nInhibitor \nWashout 3-4 \ndays prior to \nfactor activity on \nDay 1a \nFVIII, FIX \nOn-Demand, preventatived, \nor Prophylaxis (prophylaxis \ntreatments are permitted \nuntil initiation of treatment \nwith study intervention) \nPF-06741086 Prophylaxisb,c \nBreakthrough bleeding: \nFVIII or FIX, at minimum \neffective dose according to \nproduct label; \n \n \na. \nDuration of washout of participant’s prior haemophilia treatment prior to factor activity laboratory assessments is dependent upon \nprior treatment as follows: \n- From FVIII replacement therapy for at least 72 hours; \n- From extended half-life FVIII replacement therapy for at least 4 × half-life; \n- From FIX replacement therapy for at least 96 hours; \n- From extended half-life FIX replacement therapy for at least 4 × half-life; \n- From bypass agent therapy (either rFVIIa, PCC, aPCC, FEIBA, or BYCLOT) for at least 72 hours. \nNote: If a participant experiences an acute bleeding episode during this washout period requiring treatment with a FVIII or FIX \nreplacement therapy, or bypass agent therapy, the participant is to be stabilised utilizing this regimen and a new washout period \nshould be initiated. \nb. If a participant required a change of factor-replacement treatment regimen during the Observational Phase, the participant will be \ndiscontinued. These participants may be screened again, at the discretion of the investigator. \nc. Systemic antifibrinolytic agents or medications known to influence platelet function (eg, aspirin or certain non-steroidal anti- \ninflammatory drugs) washout of ≥120 hours prior to administration of study intervention on Day 0 through completion of \nATP Day 360 (Visit 20) in the Active Treatment Phase. \nd. Preventative treatments prior to planned activity (eg, sports participation, physical therapy, surgical/medical procedure, etc) \nshould only be given/prescribed to participants after the investigator has discussed these planned treatments with the \nmedical monitor. Agreement of planned preventative treatment/prescription between investigator and medical monitor will \nbe documented. Reasons for preventative treatment will be categorised as either: a) Medical/Dental procedure; or b) Other. \n \n \nProhibited Medications \nObservation and Active Treatment Phases \nThroughout all phases of the study, the following medications were prohibited: immunomodulatory \nmedications (eg, IVIG, routine systemic corticosteroids, rituximab) and emicizumab. Bypassing \nagent therapy is not permitted at any time for the Non-Inhibitor Cohort. \nSystemic antifibrinolytic agents or medications known to influence platelet function (eg, aspirin or certain \nnon-steroidal anti-inflammatory drugs) require a washout of ≥120 hours prior to administration of study \nintervention on Day 0 through completion of ATP Day 360 (Visit 20) in the Active Treatment Phase. Use of \nthese medications is permitted thereafter and other times during the study period. \nActive Treatment Phase \nThe following therapies are prohibited during the Active Treatment Phase unless required for the emergency \nmanagement of acute breakthrough bleeds in the opinion of the investigator or treating physician. \n• \nNon-Inhibitor Cohort: Prophylaxis treatment with FVIII- or FIX-replacement, or any use of \nbypassing agent therapy (rFVIIa, PCC, aPCC, or BYCLOT). \n"
    },
    {
      "page_number": 105,
      "text": "Assessment report \nEMA/464842/2024 \nPage 105/198 \n \no \nProphylaxis treatments with regularly prescribed haemostatic medication are permitted \nuntil initiation of treatment with study intervention at Visit 7. \n• \nInhibitor Cohort: Prophylaxis, on-demand, or preventative treatment with FVIII- or FIX- \nreplacement. Prophylaxis treatment with bypassing agent therapy (rFVIIa, PCC, aPCC, or BYCLOT). \no \nWhen agreed between investigator and Pfizer medical monitor, current routine prophylaxis \nwith bypassing agent are permitted until initiation of treatment with study intervention at \nVisit 7. \nPausing or withdrawal of treatment with PF-06741086 was not required in the event of a breakthrough \nbleed but could be considered at the discretion of the investigator. \nAll bleeding episodes and products used for treatment of these bleeding episodes were to be recorded in the \nparticipant’s diary. \n \n \n• \nObjectives \nPrimary objective \nThe primary objective of this study was to demonstrate the efficacy and safety of PF-06741086 for routine \nprophylaxis in severe haemophilia A or moderately severe to severe haemophilia B (FVIII activity <1% or FIX \nactivity ≤2%, respectively) participants 12 to <75 years of age with or without inhibitors. \nNon-Inhibitor Cohort \nFor the EU, the statistical hypothesis was the demonstration of non-inferiority of PF-06741086 prophylaxis \nobserved over the 12-month Active Treatment Phase compared to routine prophylaxis during 6 months prior \nto receiving study intervention, on the difference in the ABR of treated bleeds (non-inferiority margin of 2.5) \nusing a repeated measures model to account for participant’s experience in the OP and ATP, in participants \n≥12 years of age with severe haemophilia A or moderately severe to severe haemophilia B (FVIII activity \n<1% or FIX activity ≤2%, respectively) without inhibitors who receive routine prophylaxis treatment during \nthe 6 months prior to receiving study intervention. Non-inferiority will be declared if the two-sided 95% \nconfidence interval of the estimated ABR difference (PF-06741086 prophylaxis – prior prophylaxis) lies below \n2.5. If non-inferiority is demonstrated on ABR, subsequent testing for superiority will be conducted on this \nendpoint. \n \n \nSecondary objectives \nAdditional efficacy evaluation of PF-06741086 \nFor the Non-Inhibitor Cohort, the primary endpoint with respect to comparisons with prior on-demand \ntherapy for regions outside EU will be a secondary endpoint for the EU. \nThe following parameters were assessed for comparison between PF- 06741086 prophylaxis observed over \nthe 12-month Active Treatment Phase versus prior prophylaxis therapy or versus prior on-demand therapy. \n- \nIncidence of joint bleeds \n- \nIncidence of spontaneous bleeds \n- \nIncidence of target joint bleeds \n"
    },
    {
      "page_number": 106,
      "text": "Assessment report \nEMA/464842/2024 \nPage 106/198 \n \n- \nIncidence of total bleeds (treated and untreated) \n- \nChange in joints as measured by the Haemophilia Joint Health Score (HJHS) \n \n \nEvaluation of the effect of PF-06741086 on health-related quality of life (HRQoL) \n- \nHaemophilia Quality of Life Questionnaire for Adults (Haem- A-QoL) (≥17 years of age)/Haemophilia \nQuality of Life Questionnaire for Children (Haemo-QoL); (Adolescents 12 to <17 years of age); \n- \nHaemophilia Activities List (HAL) (Adult ≥17 years of age)/Pediatric Haemophilia Activities List \n(pedHAL) (Adolescents 12 to <17 years of age) \n- \nPatient Global Impression of Change – Haemophilia (PGIC-H) (Observational Phase and Active \nTreatment Phase) \n- \nHealth Utilities Measure (EuroQol 5 Dimensions 5 Level [EQ-5D-5L]) \n \n \n• \nOutcomes/endpoints \nTable 19: Estimands for primary objective \n \nPopulation \nAdult and adolescent patients (12 to <75 years of age) with severe \nhaemophilia A or moderately severe to severe haemophilia B (FVIII \nactivity <1% or FIX activity ≤2%, respectively) without inhibitors. \nBased on the mITT: All participants who completed OP and received at \nleast 1 dose of PF-06741086 in ATP (excluding participants with \ninhibitors who are treated with routine prophylaxis in the OP). \nParticipants who changed from a non-inhibitor to an inhibitor on or \nbefore ATP Day -7 testing were excluded from mITT. \nTreatment \ncondition \nPF-06741086 for routine prophylaxis during 12-month Active Treatment Phase \n(ATP) compared to 6-month Observational Phase (OP), regardless of receiving \nrescue medication in the form of factor replacement or bypass therapy. \nEndpoint \n(variable) \nThe annualised bleeding rate (ABR) of treated bleeding events over a 12-month \nActive Treatment Phase (ATP) compared to a previous 6-month Observational \nPhase (OP). \nPopulation-level \nsummary \nThe mean ABR difference (marstacimab prophylaxis – prior prophylactic \ntreatment) based on adult and adolescent participants meeting the entry criteria \nwith prior prophylaxis therapy. \nIntercurrent events and strategy to handle them \nReceiving rescue \nmedication in the \nTreatment policy \n"
    },
    {
      "page_number": 107,
      "text": "Assessment report \nEMA/464842/2024 \nPage 107/198 \n \nPopulation \nAdult and adolescent patients (12 to <75 years of age) with severe \nhaemophilia A or moderately severe to severe haemophilia B (FVIII \nactivity <1% or FIX activity ≤2%, respectively) without inhibitors. \nBased on the mITT: All participants who completed OP and received at \nleast 1 dose of PF-06741086 in ATP (excluding participants with \ninhibitors who are treated with routine prophylaxis in the OP). \nParticipants who changed from a non-inhibitor to an inhibitor on or \nbefore ATP Day -7 testing were excluded from mITT. \nform of factor \nreplacement or \nbypass therapy \nPreventative \ntreatment for \nmedical/dental \nprocedures, sport \nactivity, or \nphysical therapy \n(plus 72 hours), \nor dose \nmodification \nand/or \ndiscontinuation of \ntreatment \nWhile-on-treatment \n \n \nThe hypothesis testing of the primary endpoint is listed below. Type I error rate will be separately controlled \nwithin each statistical testing. \n \nFor the EU: to demonstrate non-inferiority of PF-06741086 prophylaxis observed over the 12-month Active \nTreatment Phase compared to routine prophylaxis during 6 months prior to receiving study intervention, on \nthe difference in the ABR of treated bleeds (non-inferiority margin of 2.5) using a repeated measures model \nto account for participant’s experience in the OP and ATP, in participants ≥12 years of age with severe \nhaemophilia A or moderately severe to severe haemophilia B (FVIII activity <1% or FIX activity ≤2%, \nrespectively) without inhibitors who receive routine prophylaxis treatment during the 6 months prior to \nreceiving study intervention. Non-inferiority will be declared if the two-sided 95% confidence interval of the \nestimated ABR difference (PF-06741086 prophylaxis – prior prophylaxis) lies below 2.5. If non-inferiority is \ndemonstrated on ABR, subsequent testing for superiority will be conducted on this endpoint. Note this is a \nsecondary endpoint for regions outside the EU. \n"
    },
    {
      "page_number": 108,
      "text": "Assessment report \nEMA/464842/2024 \nPage 108/198 \n \nThe primary objective is addressed via the primary endpoint of ABR of treated bleeds. For the Non-Inhibitor \nCohort aiming for the EU, the difference in mean ABRs is estimated between the PF-06741086 prophylaxis \nfor the 12-month Active Treatment Phase during Active Treatment Phase and routine prophylaxis. \nThe analyses include those participants who receive at least 1 dose of PF-06741086 prophylaxis after \ncompleting the Observational Phase. The ABR for each participant is derived based on the number of \ntreated bleeding events; during the 12-month Active Treatment Phase for PF-06741086 prophylaxis and \nduring the Observational Phase for the respective control group. \nWith an anticipated trial completion rate of 90%, the derived ABR is expected to closely represent the entire \nduration of the Observational Phase and the Active Treatment Phase with a minimal rate (<10%) of missing \nendpoints. Missing values will not be imputed in the primary efficacy analysis. Furthermore, the ABR is \nderived without regard to the administration of rescue medication use (in the form of coagulation factor \nreplacement or bypass therapy) while any bleeding events after dose increase of PF-06741086 during PF- \n06741086 prophylaxis are excluded to avoid an inflated efficacy estimate for the 150 mg QW dose of PF- \n06741086. All data during the preventative medical/dental treatment (plus 72 hours) are also excluded. \nRescue medication use is assessed directly via a secondary endpoint of total coagulation factor or bypass \nproduct consumption. \nIntercurrent events: For all cohorts and regions, all data collected while receiving rescue medication in the \nform of factor replacement or bypass therapy are included. However, all data during the preventative \ntreatment for medical/dental procedures, sport activity, or physical therapy (plus 72 hours), or collected after \ndose modification and/or discontinuation of treatment will not be included. \n \n \nSecondary Objectives Estimands \nFor incidences of joint bleeds, spontaneous bleeds, target joint bleeds, and total bleeds, the estimand will \nutilise the same population summary and intercurrent event handling as in the primary endpoint. \nFor HJHS, the difference in mean changes from baseline at 6 months between the marstacimab prophylaxis \nin ATP versus the respective reference therapy in OP will be presented using the data irrespective of rescue \nmedication use, dose modification, and/or the preventative treatment for medical/dental procedures. \nObservations after discontinuation of treatment, if collected, will not be included. \nThe estimand for all HRQoL endpoints will utilise the same population summary and intercurrent event \nhandling as in the HJHS. \n \n \n• \nSample size \nA sample size of 60 evaluable participants were derived via simulation under a range of scenarios. In the \nsimulation, bleeding counts were generated from a negative binomial distribution with the mean bleeds over \n6 months of initially assumed as 2.5. An added scenario of 2.35 was obtained as the weighted average of \nHaemophilia A and B ABRs based on a meta-analysis of selected historical data among Pfizer haemophilia \nstudies, B1821010 (BeneFIX), B1821002 (BeneFIX), and B1831004 (Xyntha/ReFacto) (5.1 • 0.8 + 3.1 • 0.2 \n= 4.7 ABR); the weights were based on the prevalence of each haemophilia type. The mean bleeds over 12 \nmonths for PF-06741086 prophylaxis was initially assumed as 4 with 2 additional scenarios of 2.67 and 3.46, \nthe point estimate and the upper bound of the 1-sided 80% CI from Study B7841002, respectively. \n"
    },
    {
      "page_number": 109,
      "text": "Assessment report \nEMA/464842/2024 \nPage 109/198 \n \nThe variance was assumed as 6 times the mean for each scenario; the correlation between the 2 bleeding \ncounts at OP and ATP from the same participant was assumed as 0.2. The simulation further accounted for \ndifferent follow-up times due to drop-out or lost-to follow-up. To simulate 10% discontinuation during the \nATP, a uniform (0, 1) random number Ui was generated for each subject; when Ui <0.1, the duration of \ntreatment was curtailed into 10 • Ui years; the number of bleeding 𝑿𝒊 in this reduced duration was newly \ngenerated from a negative binomial distribution with the expected value of 𝝁𝒊 = 𝟏0 𝑼𝒊 𝝁 and variance of 𝟔 𝝁𝒊 \nwhere 𝝁 represents the mean bleeding for PF-06741086 prophylaxis for complete follow up. The Table below \ndemonstrates that the planned sample sizes maintain adequate power (>90%) for all scenarios except for \nthe most pessimistic case. \nTable 20: Power simulations with different follow-up \n \nTesting/ \nSample Size \nAssumed \nPF-06741086 \nMean Bleeding \nfor 12 Months1 \nAssumed \nReference \nMean Bleeding \nfor 6 Months2 \nSimulated \nPower3 (%) \nNon-inferiority vs \nprior prophylaxis \nwith N=60 \n4 \n2.5 \n90.1 \n3.46 \n96.9 \n2.67 \n>99 \n4 \n2.35 \n86.9 \n3.46 \n95.4 \n2.67 \n>99 \n1. \nInitial assumption 4; then 3.46 and 2.67 as the upper bound of 80% CI and the point estimate from B7841002. \n2. \nInitial assumption 12.5 and 2.5; then 2.35 as the weighted average (80% and 20%) of haemophilia A and B ABRs \nfrom an internal meta-analysis. \n3. \n5,000 simulations per each scenario where bleed counts were generated from a negative binomial distribution; \neach variance was assumed to be 6 times the mean with correlation coefficient of 0.2 between 2 bleed counts \nfrom the same participants. To simulate 10% discontinuation during the ATP, a uniform (0, 1) random number Ui \nwas generated for each subject; when Ui <0.1, the year of observation was curtailed into 10* Ui years with the \nnumber of bleeding Xi newly generated from a negative binomial distribution with the expected value of 𝜇𝑖 = 10 𝑈𝑖 \n∙ 𝜇 and variance 6 𝜇𝑖. \n \n \n• \nRandomisation and Blinding (masking) \nThis was an open-label study; however, the specific cohort assignment to which a participant was assigned \nwas to be reported using an IVRS/IWRS. The site was to contact the IVRS/IWRS prior to the start of study \nintervention administration for each participant. The site was to record the cohort assignment on the \napplicable CRF, if required. \n \n \n• \nStatistical methods \nAnalysis Set \nFor purposes of efficacy analyses, a modified Intent-to-Treat (mITT) Population was defined for this open- \nlabel, single arm, 1-way crossover study including all participants who completed OP and received at least 1 \ndose of PF-06741086 in ATP (excluding participants with inhibitors who are treated with routine prophylaxis \n"
    },
    {
      "page_number": 110,
      "text": "Assessment report \nEMA/464842/2024 \nPage 110/198 \n \nin the OP). Participants who changed from a non-inhibitor to an inhibitor on or before ATP Day -7 testing was \nexcluded from mITT. \nThe “All Safety” Analysis Set was used in certain Sensitivity Analyses and included all participants who \nreceived at least 1 prophylaxis treatment at OP. Participants who changed from a non-inhibitor to an inhibitor \non or before ATP Day -7 testing will be excluded from this population. \n \n \nAnalysis Method \nWhen PF-06741086 prophylaxis treatment is compared with prior routine prophylaxis for various bleeding \ncount endpoints (treated, spontaneous, joint, target joint[s], and all bleeds), a repeated measure negative \nbinomial regression model via GEE approach was used with identity link function. In the model, the number \nof bleeds will be a response variable, and duration (in years) and the interaction by treatment (PF-06741086 \nprophylaxis or routine prophylaxis) and duration will be factors with no intercept. The working correlation will \nbe set as Unstructured. Treatment difference in the mean ABRs were obtained using a contrast within the \ninteraction term. Non-inferiority is demonstrated if the upper bound of the 2-sided 95% CI for the mean ABR \ndifference (PF-06741086 prophylaxis – routine prophylaxis) lies below the pre-set non-inferiority margin for \neach endpoint. If the non-inferiority is established, subsequent testing for superiority may be conducted. \nDerivation of non-inferiority Margin for treated bleeds \nThe derivation followed the methodology outlined in FDA (Food and Drug Administration) Guidance for Non- \nInferiority Clinical Trials to Establish Effectiveness. \nHistorical data were selected among Pfizer haemophilia studies. This enabled selection of individual \nparticipant level data that would closely match the inclusion/exclusion criteria of Study B7841005 The \nfollowing 3 studies satisfied these criteria: B1821010 (BeneFIX), B1821002 (BeneFIX), and B1831004 \n(Xyntha/ReFacto). \n• \nB1821010 was an open-label 1-way crossover study intended to compare the efficacy and safety \nbetween the on-demand treatment and prophylactic therapy using BeneFIX in haemophilia B patients \nwith ages 12-65 years old and the factor IX activities not greater than 2%. This study comprised \nPeriod 1 (on-demand treatment at a dosage determined by principal investigator, 6 months) and \nPeriod 2 (100 IU/kg once-weekly dose, 12 months). \n• \nB1821002 was an open-label, randomised, 4-period crossover study on males with haemophilia B \nwith ages 6-65 years old and the factor IX activities not greater than 2% to compare on-demand \nadministration and 2 prophylaxis regimens. Study was conducted following 4 periods: \no \nPeriod 1: On-demand administration per dose directed by investigators, 16 weeks. \no \nPeriod 2: 50 IU/kg/ twice weekly or 100 IU/kg/once weekly (randomised), 16 weeks. \no \nPeriod 3: On-demand administration per dose directed by investigators, 8 weeks. \no \nPeriod 4: 50 IU/kg/twice weekly or 100 IU/kg/once weekly (different regimen than that \napplied during Period 2), 16 weeks. \n• \nB1831004 evaluated safety and efficacy of ReFacto AF in haemophilia A patients switching to ReFacto \nAF from ReFacto or other factor VIII products in usual care settings. The patients were of ages 12 \nand greater and had factor XIII activities <1%. All participants were treated under standard care with \n"
    },
    {
      "page_number": 111,
      "text": "Assessment report \nEMA/464842/2024 \nPage 111/198 \n \nReFacto AF at a dose and frequency prescribed by the treating physician. The duration of treatment \ndepended on the frequency of infusions (to achieve 100 exposure days) with mean (SD) of 336 (223) \ndays. \nThe analyses included subjects with matching age (12-74 years old) and factor level (<1%) criteria to Study \nB7841005. The mean ABR difference between prophylaxis and on-demand treatment was estimated using 3 \nanalyses: t-test allowing for non-homogeneous variances, Hodges-Lehman location-shift parameter \nestimation, and additive negative binomial model. All analyses resulted in similar estimated mean differences \nand lower bound of 2-sided 95% confidence intervals. \nBased on the lower bound of the confidence interval of this estimate, the on-demand ABR was assumed to be \nhigher than M1 in the non-inferiority test setting. \nGiven the large effect size of prophylaxis treatment, an appropriate value for M2 was considered in order to \npreserve a sufficiently large proportion of this effect. A value of 2.5 for M2 was selected as both clinically \nmeaningful and yielding a reasonable sample size. M1 and M2 are derived from the notation used in the FDA \nGuidance document, Non-Inferiority Clinical Trials to Establish Effectiveness. \nThe process of deriving the non-inferiority margin and the selected magnitude of the margin also satisfy the \nprinciples delineated in the EMA/CHMP Guideline on the Choice of the Non-inferiority Margin. \no \nThe estimated effect of factor replacement therapy versus on-demand and its most \nconservative lower bound of the 95% CI is estimated mean difference and M1, respectively. \no \nThe margin of 2.5 preserves a large portion of the most conservative estimated effect. \no \nIn meta-analyses of factor replacement products to 2017, the weighted mean ABR was 5.1 \nfor factor VIII prophylaxis and 3.1 for factor IX prophylaxis for factor IX prophylaxis, all \nproducts have participants with factor level activity ≤2%, the planned phase 3 <1%; \ntherefore, the non-inferiority margin of 2.5 should be interpreted in the background \ncomparator mean ABR of ~4.5. \no \nExpected half-width of 95% CI is 2.1 applying the parameter assumptions for the sample size \ncalculation (ABR of 2.5 for 6 months for prior prophylaxis, 4 for 1 year for PF06741086 \nprophylaxis, variance = 6*mean, correlation = 0.2); therefore, meeting the non-inferiority \nmargin of 2.5 requires that the point estimate for the difference is close to 0; further \nestablishing acceptable efficacy of PF06741086 relative to factor replacement therapy. \no \nIn addition, PF-06741086 has an advantage via once weekly subcutaneous dosing versus up \nto 2 or 3 times weekly IV dosing of the active comparators. Per guidance, it may be possible \nto justify a wider non-inferiority margin for efficacy in this case. \nClinically, the planned non-inferiority hypothesis will be met if the difference between PF-06741086 and \nfactor-based prophylaxis regimens does not exceed 2.5. The pooled ABR observed across the 4 cohorts \nstudied in the 3 month phase 2 B7841002 study of PF-06741086-based prophylaxis was 2.6 (N=24).3 \nReproducing this result in B7841005 during the active treatment period, and assuming a factor-based \nprophylaxis ABR of ~4.5 during the observation period, would place the upper bound of the 95% CI \ndifference at around and ABR of 5, which is comfortably within the range of ABR achieved with approved \nfactor XIII and IX-based prophylaxis regimens \n"
    },
    {
      "page_number": 112,
      "text": "Assessment report \nEMA/464842/2024 \nPage 112/198 \n \nFurther non-inferiority margins for other bleed count and key secondary HRQoL endpoints \nTable 21: Key Secondary Endpoints and Decision Rules \n \nEndpoints \nNon-Inferiority vs. \nPrior Prophylaxis for Non-inhibitors \nIncidence of spontaneous bleeds \n2.5 ABR Difference \nIncidence of joint bleeds \n2.5 ABR Difference \nIncidence of target joint bleeds \n1.2 ABR Difference \nIncidence of total bleeds \n2.9 ABR Difference \nPhysical health domain in Haem-A-QoL at 6 months \nMedian Difference: 10 units \nTotal score in Haem-A-QoL at 6 months* \nMedian Difference: 7 units \nEQ-5D-5L Index score at 6 months* \nMedian Difference: 0.1 units \nEQ-VAS score at 6 months* \nMedian Difference: 9.5 units \n*: These endpoints are key secondary only for the EU, but not for regions outside the EU \n \n \nHandling Missing Data \nThe table below describes possible reasons for incomplete treatment duration and how each of these are \nhandled in analyses of endpoints related to bleeding counts. \nTable 22: Handling Intercurrent Events in Bleed Count Analyses \n \nReason \nPrimary analysis of the \nprimary endpoint; \nanalyses of all key \nsecondary endpoints \nSensitivity/supplementary analysis of \nthe primary endpoint \nPreventative treatment for \nmedical/dental procedures, \nsport activity or physical \ntherapy (plus 72 hours) \nExclude \nInclude \nDose increase of PF-06741086 \nExclude \n1. Include the portion after dose \nincrease. \n2. Impute the prorated duration and \nthe bleeding counts using the data \nin the primary analysis. \n3. Tipping point analysis where the \nobserved data are combined with \nmultiples of successively larger \n"
    },
    {
      "page_number": 113,
      "text": "Assessment report \nEMA/464842/2024 \nPage 113/198 \n \n(>1) portion to determine the \ntipping point. \nTreatment discontinuation \nData collected after \ntreatment \ndiscontinuation will be \nexcluded; Analyze \nobserved data during \ntreatment only \n1. Impute the prorated duration and \nthe bleeding counts using the data \nin the primary analysis. \n2. Tipping point analysis where the \ndata in the primary analysis are \ncombined with multiples of \nsuccessively larger (>1) portion to \ndetermine the tipping point. \n \n \nA tertiary endpoint of the number of target joints was derived during the treatment duration excluding the \nperiod of preventative treatment for medical/dental procedures, sport activity or physical therapy (plus 72 \nhours) and the increased dose of PF-06741086. \nFor the Wilcoxon signed rank test used to analyse physical health domain and the total score of Haem-A-QoL, \nas well as EQ-5D-5L index score and EQ-VAS scores, a multiple imputation approach with 10 imputations \nwere applied via monotone or fully conditional specification (FCS) regression approach utilizing the ‘missing \nat random’ assumption. \nThe same approach was used for the following endpoints: HJHS total score, Haemo-QoL total score, \nHAL/pedHAL total score, and PGIC. A single imputation procedure using the month 6 OP value was used for \nthe Wilcoxon signed rank test for the domain and component scores of PRO endpoints. \n \n \nSensitivity and Supplementary analyses \nSupplemental Analyses \nSupplemental analyses used the same methodology and summary as the main analysis but used the \nfollowing approaches after the intercurrent events of study drug dose increase or discontinuation. \n1. To assess the impact of preventative treatment for medical/dental procedures, sport activity or \nphysical therapy (plus 72 hours): include data. \n2. To assess the impact of PF-06741086 dose increase, the main analysis was repeated with the same \nmodel, using the following approaches: \na. Including the portion of dose increase \nb. Imputing the portion after a dose increase using the data before the dose increase to give full \nweight in the negative binomial regression to the observations from participants with such \ntreatment. \nc. \nTipping point analysis using ABRs calculated combining bleeds during the intervention dose \nand assuming the bleed rate after the dose increases as multiples of successively larger (>1) \nfactors of the former to determine the tipping point. \n"
    },
    {
      "page_number": 114,
      "text": "Assessment report \nEMA/464842/2024 \nPage 114/198 \n \n3. To assess the impact of treatment discontinuation, the main analysis was repeated with the same \nmodel, using the following approaches: \na. Imputing the portion after treatment discontinuation using the data during treatment to give \nfull weight in the negative binomial regression to the observations from those participants. \nb. Tipping point analysis using ABRs calculated combining bleeds during the treatment and \nassuming the bleed rate after the treatment discontinuation as multiples of successively \nlarger (>1) factors of the former to determine the tipping point. \nSensitivity Analysis \n1. The following analyses assessed the impact of carryover effect from the Observational Phase. \na. The main analysis was repeated with the main model, excluding the first month data after \ninitiation of PF-06741086. \nb. Bleed rates during the early part of the treatment period (Months 1-6 in ATP) and the latter \npart of the treatment period (Months 7-12 ATP) were descriptively summarised and \ncompared. \n2. The following analysis was performed to assess the seasonal effect on bleeding; it used the same \nmethodology and summary as the main analysis but will include only the observations that match the \ncalendar time between OP and ATP. \n3. The following summary was provided to assess a potential impact on efficacy assessment due to a 1- \nway cross-over study design where some participants are excluded from mITT via not successfully \ncompleting the OP and/or not meeting the eligibility criteria to enter the ATP. \na. disposition of participants who are excluded from mITT \nb. demography by mITT status – All Safety Set \nc. \nsubject characteristics by mITT status – All Safety Set \nd. descriptive summary of the ABR of treated bleeds during OP by mITT status – All Safety Set \nNo sensitivity or supplemental analyses will be performed for the bleeding-related secondary endpoints. \n \nPlanned subgroup analyses \nSubgroup analyses were conducted for the primary endpoint for the following variables: Haemophilia A and \nB, age (12-17 and >=18), race, ethnicity, and geographic region. \n \n \nError probabilities, adjustment for multiplicity and interim analyses \nType I error rate for the primary analysis of the primary endpoints were separately controlled for the non- \ninhibitor cohort for the EU based on participants and each of the other 2 cohorts. \nWithin each cohort, the familywise Type I error rate for the secondary endpoints was controlled using \nhierarchical testing method at the 1-sided 0.025 level following the ordering of statistical testing: \n"
    },
    {
      "page_number": 115,
      "text": "Assessment report \nEMA/464842/2024 \nPage 115/198 \n \nTable 23: Ordering of Statistical Testing in Non-Inhibitor Cohort for EU \n \nEndpoints \nNon-Inferiority vs. \nPrior Prophylaxis \nSuperiority vs. Prior \nProphylaxis \nTreated bleeds (primary) \n1 \n6 \nIncidence of spontaneous bleeds \n2 \n12 \nIncidence of joint bleeds \n3 \n13 \nIncidence of target joint bleeds \n5 \n15 \nIncidence of total bleeds \n4 \n14 \nPhysical function domain in Haem-A-QoL \n7 \n11 \nTotal score in Haem-A-QoL at 6 months \n8 \n16 \nEQ-5D-5L Index score at 6 months \n9 \n17 \nEQ-VAS score at 6 months \n10 \n18 \n \n \nInterim Analyses \nUpon completion of the 12-month ATP for the Non-Inhibitor Cohorts (with prior On-Demand therapy as well \nas with prior Prophylaxis), analyses of the primary endpoint of interest along with secondary endpoints in the \ncorresponding participant populations were performed to assess respective efficacy and safety for a potential \ninitial registration filing regardless of whether or not follow-up is ongoing in the Inhibitor cohort. These \nanalyses were considered the final analyses for these participant populations. The study will continue until \nthe completion of participants from all cohorts. \nType I error rate of 2-sided 0.05 is allocated separately to each of the 3 populations (Inhibitor Cohort; Non- \nInhibitor Cohort with prior On-Demand therapy as well as with prior Prophylaxis). Therefore, analyses upon \ncompletion of the Non-Inhibitor Cohorts (with prior On-Demand therapy as well as with prior Prophylaxis) do \nnot impact the Type I error for the Inhibitor Cohort. \n \n \nResults \n• \nParticipant flow \n"
    },
    {
      "page_number": 116,
      "text": "Assessment report \nEMA/464842/2024 \nPage 116/198 \n \nTable 24: Disposition events summary \n \n"
    },
    {
      "page_number": 117,
      "text": "Assessment report \nEMA/464842/2024 \nPage 117/198 \n \n \n"
    },
    {
      "page_number": 118,
      "text": "Assessment report \nEMA/464842/2024 \nPage 118/198 \n \n \n \n• \nRecruitment \nFirst patient first visit (FPFV): 09 March 2020 \nData Cutoff Date (LPLV for Non-inhibitor cohort): 17 April 2023 \n \n \n• \nConduct of the study \nThe study protocol was amended a total of 7 times. Notably, 5 of the amendments were introduced after the \nstudy initiation date (FPFV) of 09 March 2020. \nTable 25: Protocol amendments summary of changes table \n \n \nA brief summary of the most important protocol amendment changes is provided below: \nAmendment 1 and Amendment 2 included changes to the protocol before study initiation (09 March 2020). \nAmendment 3: Included participation of prior prophylaxis participants in the US and Canada following a \nread-out of safety data provided from the Phase 2 program. \nAmendment 4: For dose modification requirements a minimum body weight of 50 kg was added to allow \ndose escalation to 300 mg QW. New appendix added to the protocol detailing alternative study procedures to \nbe followed during the COVID-19 global pandemic. \n"
    },
    {
      "page_number": 119,
      "text": "Assessment report \nEMA/464842/2024 \nPage 119/198 \n \nAmendment 5: Added the option to conduct safety assessments at a non-study centre when necessary to \nallow more flexibility in the event that an in-clinic visit could not be completed due to the COVID-19 global \npandemic. \nAmendment 6: Due to recruitment challenges and feedback received from clinical study sites, inclusion \ncriteria were updated to enable recruitment of participants with moderately severe haemophilia B based on \nbaseline factor activity level (factor activity level ≤2%) and hemorrhagic phenotype (≥4 bleeding episodes in \nthe 6 months prior to study entry). \nAllowed additional participants (approximately 20%) in order to provide sufficient enrollment into regions \nwhich had experienced delays created by the COVID-19 global pandemic. \nBased on eDMC recommendation, revised to add that treatment with study intervention was to be suspended \nif a participant developed a presumed or confirmed symptomatic COVID-19 infection due to the potential for \nthrombotic events. \nAmendment 7: removal of the interim analysis for futility within each participant population of interest \nplanned after 50% of participants within each population of interest have completed the study as the interim \nanalysis data cut time would be very close to the non-inhibitor cohort completions Endpoint “total coagulation \nfactor or bypass product consumption” moved from secondary endpoints to tertiary/exploratory endpoints \nand removal of “percentage of participants with no treated bleeding episodes” from secondary endpoints, \nwhich will however be presented as part of descriptive analysis for the primary endpoint \nImportant protocol deviations \n \n74 (57.8%) participants had important protocol deviations reported, including those related to \nprocedures/tests (31 participants), investigational product (25 participants), concomitant medications \n(22 participants), informed consent (18 participants), inclusion/exclusion criteria (10 participants), safety \nreporting (8 participants), laboratory (4 participants), and randomization (1 participant). Participants \nwith dosing administration error protocol deviations reported a variety of different deviations that \noccurred typically one time and had no impact on overall efficacy or safety. Participants who did not \nadhere to the protocol-specified washout period prior to Visit 7 (1st dose of marstacimab) had no bleeds \nin the 4 weeks following Visit 7, with the exception of 1 participant who had 1 treated bleed. The \npotential impact of this is addressed in the analysis to assess the impact of carryover effect from the OP. \nThere were no observed efficacy or safety effects for participants with concomitant medication or \ndosing/administration error protocol deviations. PROs questionnaires not completed resulted in missing \nPRO data, however, the impact of the missing data was minimal on the overall analysis of the PRO data. \nOverall, there was no observed impact to safety or efficacy due to the important protocol deviations. \n \n \n• \nBaseline data \nStudy B7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 years of age) study \nconducted in male participants with severe haemophilia A or moderately severe to severe haemophilia B. The \nseverity of haemophilia was confirmed either by documented historical evidence from a clinical laboratory \nprior to screening or by factor activity obtained from a clinical laboratory prior to study enrollment. \nParticipants in Study B7841005 were primarily White (65, 50.8%) and Asian (61, 47.7%), with 1 \nBlack/African American (0.8%) participant and 1 participant's race not reported. 42.2% and 36.7% of \nparticipants were from Asia and Europe, respectively. \n"
    },
    {
      "page_number": 120,
      "text": "Assessment report \nEMA/464842/2024 \nPage 120/198 \n \nDemographic characteristics for participants are summarized in Table 26 below. Table 27 summarises \nparticipant haemophilia history by haemophilia type, target joint, and geographical region. \nTarget joints are defined as major joints (eg, hip, elbow, wrist, shoulder, knee, and ankle) into which \nrepeated bleeds occur (3 or more spontaneous bleeds into a single joint within a consecutive 6-month \nperiod). Target joints are a contributing factor to bleeding phenotype, eg, the bleeds from a single target \njoint would count toward a participant having an ABR of at least 6, the bleeds from 2target joints would count \ntoward a participant having an ABR of at least 12, and the bleeds from 3 or more target joints would count \ntoward a participant having an ABR of at least 18. \nOverall, across participants without inhibitors in Study B7841005: \n▪ \n101 (78.9%) participants had haemophilia A and 27 (21.1%) participants had \nhaemophilia B. \n▪ \n108 (84.4%) participants were adults (≥18 to <75 years of age) and 20 (15.6%) \nparticipants were adolescents (≥12 to <18 years of age). \n▪ \n38 (41.8%) participants with prior prophylactic treatment had no target joints at baseline. The \nremaining 53 out of 91 participants with prior prophylactic treatment had one or more target \njoints at baseline. \n▪ \n1 (2.7%) participant with prior on-demand treatment had no target joints at baseline. The \nremaining 36 out of 37 participants with prior on-demand treatment had one or more target joints \nat baseline. \n \n \nAll 128 participants were male with a median age of 30.0 years and individual values ranged from 13.0 to \n66.0 years. The majority of participants (78, 60.9%) were in the 18-44 age range. \nThe median participant weight was 70.7 kg (range: 35.0 to 120.0 kg) and the median participant BMI was \n24.1 kg/m2 (range: 15.2 to 38.8 kg/m2). The median participant height was 170.1 cm (range: 141.0 to 190.0 \ncm). \nMost participants (100, 78.1%) had normal renal function (eGFR ≥90 mL/min/1.73 m2), while 24 (18.8%) \nparticipants had mild renal impairment (eGFR ≥60 to <90 mL/min/1.73 m2) and 1 (0.8%) participant had \nmoderate renal impairment (eGFR 30 to <60 mL/min/1.73 m2). \nTable 26: Baseline and demographic characteristics – all safety set \n \n"
    },
    {
      "page_number": 121,
      "text": "Assessment report \nEMA/464842/2024 \nPage 121/198 \n \n \n"
    },
    {
      "page_number": 122,
      "text": "Assessment report \nEMA/464842/2024 \nPage 122/198 \n \nTable 27: Participants characteristics – all safety set \n \n"
    },
    {
      "page_number": 123,
      "text": "Assessment report \nEMA/464842/2024 \nPage 123/198 \n \nMedical History and Concurrent Illnesses \nThe most common conditions in study participants (≥5%) were hepatitis (27 [21.1%] with hepatitis C, 8 \n[6.3%] with hepatitis B, and 4 [3.1%] with chronic hepatitis C), haemophilic arthropathy (20, 15.6%), \nhypertension (16, 12.5%), circumcision (13, 10.2%), synoviorthesis (10, 7.8%), and arthropathy (7, 5.5%: \n6 of whom also reported haemophilic arthropathy and 1 participant had unspecific arthropathy). One \nparticipant in the prior prophylaxis group with a medical history of cerebral venous sinus thrombosis was \ndiscontinued during the OP due to this inclusion/exclusion protocol deviation. \n \n \n• \nNumbers analysed \n \nOverall, 179 participants were screened, of whom 50 participants discontinued (47 participants failed at \nscreening, 1 participant withdrew, 1 participant due to AE, and 1 participant was withdrawn by \nparent/guardian). Among the 129 participants who completed screening, 128 entered the OP (1 participant \ncompleted screening but did not enter the OP: At the time of the data cut-off, the inhibitor cohort data was \nmissing because the participant had their enrollment/cohort assignment visit after the data cut-off date). \n \nAs of 17 April 2023, the LPLV for the non-inhibitor cohort: \n• \n37 participants with prior on-demand treatment using factor replacement entered the study, of whom \n34 (91.9%) completed the 6-month OP and 3 (8.1%) discontinued during the OP (2 participants due \nto protocol deviations and 1 participant due to other reason of moving to a different country). Of the \n34 participants who completed the OP, 33 participants entered the ATP and all 33 (100%) \nparticipants completed the 12-month ATP. No participants discontinued during the ATP. \n• \n91 participants with prior prophylactic treatment using factor replacement entered the study, of \nwhom 84 (92.3%) completed the 6-month OP and 7 (7.7%) discontinued during the OP (5 \nparticipants no longer met eligibility criteria and 2 participants due to protocol deviations). Of the 84 \nparticipants who completed the OP, 83 participants entered the ATP, of whom 78 (94.0%) completed \nthe 12-month ATP and 5 (6.0%) discontinued (4 participants withdrew and 1 participant due to AE). \n• \n108 of 111 participants who completed the 12-month marstacimab ATP planned to participate in the \nlong-term extension Study B7841007. \n• \n1 participant with prior on-demand treatment and 8 participants with prior prophylactic treatment \nentered the follow-up phase of Study B7841005. Note: participants who planned to participate in the \nlong-term extension Study B7841007 were not required to enter the follow-up phase. \n• \nTwo participants (1 in the prior on-demand cohort and 1 in the prior prophylaxis cohort) completed \nthe OP, but discontinued before entering the ATP and marstacimab dosing due to not meeting \neligibility criteria to enter the ATP. \n"
    },
    {
      "page_number": 124,
      "text": "Assessment report \nEMA/464842/2024 \nPage 124/198 \n \n• \nOutcomes and estimation \nPrimary Efficacy Endpoint \nABR of Treated Bleeds (Routine Prophylaxis at OP) \nTable 28: Primary analysis of the ABR for treated bleeds for non-inhibitor cohort with routine \nprophylaxis at OP -MITT set \n \n"
    },
    {
      "page_number": 125,
      "text": "Assessment report \nEMA/464842/2024 \nPage 125/198 \n \nABR of Treated Bleeds (On-Demand at OP) \nTable 29: primary analysis of the ABR for treated bleeds for non0inhibitor cohort with on demand \nof OP- MITT set \n \n"
    },
    {
      "page_number": 126,
      "text": "Assessment report \nEMA/464842/2024 \nPage 126/198 \n \nSecondary Efficacy Endpoints \n \nIncidence of Joint Bleeds (Routine Prophylaxis at OP) \nTable 30: Analysis of incidence of joint bleeds for non-inhibitor cohort with routine prophylaxis at \nOP-MITT set \n \n"
    },
    {
      "page_number": 127,
      "text": "Assessment report \nEMA/464842/2024 \nPage 127/198 \n \nIncidence of Spontaneous Bleeds (Routine Prophylaxis at OP) \n \nTable 31: analysis of incidence of spontaneous bleeds for non-inhibitor cohort with routine \nprophylaxis at OP- MIIT set \n \n"
    },
    {
      "page_number": 128,
      "text": "Assessment report \nEMA/464842/2024 \nPage 128/198 \n \nIncidence of Target Joint Bleeds (Treated) (Routine Prophylaxis at OP) \nTable 32: Analysis of incidence of target joint bleeds for non-inhibitor cohort with routine \nprophylaxis at OP- MIIT set \n \n"
    },
    {
      "page_number": 129,
      "text": "Assessment report \nEMA/464842/2024 \nPage 129/198 \n \nIncidence of Total Bleeds (Treated and Untreated) (Routine Prophylaxis at OP) \nTable 33: Analysis of incidence of total bleeds (treated and untreated) for non-inhibitor \ncohort with routine prophylaxis at OP -MITT set \n \n"
    },
    {
      "page_number": 130,
      "text": "Assessment report \nEMA/464842/2024 \nPage 130/198 \n \nHaemophilia Joint Health Score (HJHS) (Routine Prophylaxis at OP) \n \nTable 34: Non-parametric analysis of change from baseline in haemophilia joint health score \n(HJHS)* for non-inhibitor cohort with routine prophylaxis at OP – MITT set \n \n"
    },
    {
      "page_number": 131,
      "text": "Assessment report \nEMA/464842/2024 \nPage 131/198 \n \nHealth-Related Quality-of-Life Outcomes (Routine Prophylaxis at OP) \n \nThe reference treatment duration in the OP was 6 months, while marstacimab prophylaxis was \nadministered for 12 months during the ATP, therefore, the main comparison timepoint between the OP \nand ATP is at 6 months, and the 12-month comparison utilises 6-month results from the OP. \nHaem-A-QoL (≥17 Years) and Haemo-QoL (Adolescents 12 to <17 Years) (Routine \nProphylaxis at OP) \nTable 35: Non-parametric analysis of change from baseline in total score and physical health \ndomain in Haem- A- QoL * for non-inhibitor cohort with prophylaxis at OP -MIIT set \n"
    },
    {
      "page_number": 132,
      "text": "Assessment report \nEMA/464842/2024 \nPage 132/198 \n \nTable 36: Non-parametric analysis of change from baseline in total score and physical health \ndomain in Haem-A-QoL* for non-inhibitor cohort with prophylaxis at OP-MITT set \n \n"
    },
    {
      "page_number": 133,
      "text": "Assessment report \nEMA/464842/2024 \nPage 133/198 \n \nEQ-5D-5L (Routine Prophylaxis at OP) \nTable 37: Non-parametric analysis of change from baseline in EQ-5D for non-inhibitor cohort with \nroutine prophylaxis at OP- MITT set \n \n"
    },
    {
      "page_number": 134,
      "text": "Assessment report \nEMA/464842/2024 \nPage 134/198 \n \nTable 38: Non-parametric analysis of change from baseline in EQ-5D for non-inhibitor cohort with \nroutine prophylaxis at OP- MITT set \n \n"
    },
    {
      "page_number": 135,
      "text": "Assessment report \nEMA/464842/2024 \nPage 135/198 \n \n• \nAncillary analyses \n \nSubgroup Analysis: ABR of Treated Bleeds (Routine Prophylaxis at OP) \nABRs of treated bleeds, when compared with prior prophylaxis treatment for participants without inhibitors, \nare summarised by haemophilia types and age groups in the Figure below. \nAll point estimates of the differences across subgroups were consistently under 2.5, the non-inferiority \nmargin for the primary analysis. The upper bound of the CI for some subgroups exceeded 2.5 owing to the \nsmall sample size within subgroups. \nThe descriptive mean ABR of treated bleeds for participants with haemophilia A was 5.30 for marstacimab \nprophylaxis during the ATP compared to the mean ABR of 9.16 for prior routine prophylaxis during the OP. \nOut of 65 participants with haemophilia A, 5 participants increased their dose to 300 mg SC QW, and of \nthese, 4 had reductions in their ABRs and 1 maintained their ABR after the dose increase. The mean ABR for \nall 65 participants with haemophilia A during the entire ATP including the data following the dose increase \nwas 4.95. 60 out of 65 participants completed the ATP. \nThe upper bound of the CI for the ABR difference among adolescent participants (N=17) and participants with \nhaemophilia B (N=18) exceeded 2.5. It should be noted that the sample size within these subgroups is small \nand the study was not powered to draw statistical conclusions on subgroups. \nThe descriptive mean ABR of treated bleeds for adolescent participants was 2.98 for marstacimab prophylaxis \nduring the ATP compared to the mean ABR of 3.30 for routine prophylaxis during the OP. All adolescent \nparticipants in the mITT population (N=17) completed the ATP. \nThe subgroup of haemophilia B adolescents (N=4) displayed significant variability during the ATP, with 2 \nparticipants experiencing zero treated bleeds and 2 participants with ABRs of 19.48 (majority traumatic \nbleeds) and 11.01 (majority traumatic bleeds) during the ATP. All 4 of these participants completed the ATP. \nThe descriptive mean ABR of treated bleeds for participants with haemophilia B was 4.71 for marstacimab \nprophylaxis during the ATP compared to the mean ABR of 3.26 for routine prophylaxis during the OP. Out of \n18 participants with haemophilia B, 6 participants increased their dose and all had reductions in their ABRs \nafter the dose increase. The mean ABR for all 18 participants with haemophilia B during the entire ATP \nincluding the data following the dose increase was 3.88 indicating similar bleed control compared to routine \nprophylaxis. All 18 participants completed the ATP. \nCompliance to the prescribed treatment regimen during the OP and ATP was >90% for all prior prophylaxis \ncohort haemophilia B participants. \nBaseline characteristics of bleeding phenotype severity were similar across haemophilia and age subgroups \nwith the exception of the number of target joints at baseline between the prior prophylaxis cohort adolescent \nand adult subgroups. \nIncidence of ≥1 target joints at baseline for adolescents was 27.8% compared to 65.8% for adults in the \nprior prophylaxis cohort. \n"
    },
    {
      "page_number": 136,
      "text": "Assessment report \nEMA/464842/2024 \nPage 136/198 \n \nFigure 23: Comparison of ABRs for treated bleeds for Haemophilia types and age groups for non- \ninhibitor cohort with routine prophylaxis at OP- MITT set \n \nThe descriptive mean ABRs of treated bleeds during the ATP were generally similar among racial subgroups \n(Black or African American [4.73, N=1], Asian [6.54, N=36], White [4.15, N=45], Not Reported [2.32, \nN=1]). The descriptive mean ABRs of treated bleeds during the ATP are numerically lower in North America \n(2.57, N=11) and Middle East (2.98, N=10) geographic regions, followed by Europe (4.52, N=32), and \nnumerically higher in Asia (7.55, N=30). \n \nSubgroup Analysis: ABR of Treated Bleeds (On-Demand at OP) \n \nA comparison of the ABRs of treated bleeds for participants without inhibitors and with prior on-demand \ntreatment is summarised by haemophilia types and age groups in the Figure below. \nThe descriptive mean ABR of treated bleeds for participants with haemophilia A was 3.61 for marstacimab \nprophylaxis during the ATP compared to the mean ABR of 40.57 for on-demand treatment during the OP. \nWhen the marstacimab dose regimen is considered including the data after the dose increase, the mean \nABR for participants with haemophilia A during the ATP was 3.64. \nThe descriptive mean ABR of treated bleeds for participants with haemophilia B was 1.65 for marstacimab \nprophylaxis during the ATP compared to the mean ABR of 28.67 for on- demand treatment during the OP. \nWhen the marstacimab dose regimen is considered including the data after the dose increase, the mean \nABR for participants with haemophilia B during the ATP was 1.16. \nFigure 24: Comparison of ABRs for treated bleeds for Haemophilia types and age groups for non- \ninhibitor cohort with on- demand at OP -MITT set \n \n"
    },
    {
      "page_number": 137,
      "text": "Assessment report \nEMA/464842/2024 \nPage 137/198 \n \nSupplementary/Sensitivity Analysis: ABR of Treated Bleeds (Routine Prophylaxis at OP) \n \nSupplementary/sensitivity analyses of the ABR of treated bleeds for participants without inhibitors and \nwith prior routine prophylaxis are summarised below. \n \nTable 39: Supplementary analysis/sensitivity analyses of the ABRs for treated bleeds for non- \ninhibitor cohort with routine prophylaxis at OP- MITT set \n \n"
    },
    {
      "page_number": 138,
      "text": "Assessment report \nEMA/464842/2024 \nPage 138/198 \n \nTable 40: Descriptive summary of the ABR for treated bleeds for the first and second half of ATP \nfor completed participants for non-inhibitor with routine prophylaxis at OP-MITT set \n \n \n \nTable 41: Descriptive summary of the ABR for treated bleeds and treatment duration before and \nafter the dose increase for participants with dose for non-inihibtor increase \n \n"
    },
    {
      "page_number": 139,
      "text": "Assessment report \nEMA/464842/2024 \nPage 139/198 \n \nPost-hoc Sensitivity Analyses: ABR of Treated Bleeds (Routine Prophylaxis at OP) \nPost-hoc sensitivity analyses were performed to provide additional context for the results of the ABR of \ntreated bleeds. The figure below compares the ABRs of treated bleeds during the OP versus the ATP by the \nnumber of target joints at the OP baseline. The plot displays the following: \n• \n47 out of 83 participants had at least one target joint at the OP baseline. \n• \nParticipants with target joints at the OP baseline tend to have higher ABRs during both the OP and \nthe ATP compared to those without target joints at the OP baseline. \n• \nMean ABR values were numerically lower in the ATP compared to the OP by number of target joints at \nOP baseline. \nFigure 25: ABRs at OP and ATP by number of target joints at OP baseline for non-inhibitor cohort \nwith prophylaxis at OP-MITT set \n \nFigure 26: ATP versus OP ABRs for treated bleeds by Haemophilia type for non-inhibitor cohort \nwith routine prophylaxis at OP- MITT set \n \n"
    },
    {
      "page_number": 140,
      "text": "Assessment report \nEMA/464842/2024 \nPage 140/198 \n \nFigure 27: ABRs at OP and ATP by number of OP ABR grouping for non0inhibitor cohort with \nroutine prophylaxis at OP – MITT set \n \n \n \n \nPhase 3 OLE study B7841007 \n \nStudy design \nStudy B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy \nof prophylaxis treatment with marstacimab in participants who successfully completed the Phase 3 Study \nB7841005. Approximately 145 adolescent and adult participants 12 to <75 years of age with severe \nhaemophilia A or moderately severe to severe haemophilia B (defined as FVIII activity <1% or FIX activity \n≤2%, respectively) with or without inhibitors were planned to be enrolled in this study during which they \nwould receive prophylactic treatment with marstacimab once weekly (defined as scheduled treatment by \nsubcutaneous (SC) injection of marstacimab) at the dose established during participation in Study \nB7841005. The dosing regimen of marstacimab is 150 mg SC once weekly. Individual participants who \nmeet protocol-specified dose escalation criteria based upon breakthrough bleeding in either this protocol or \nduring participation in the earlier protocol, Study B7841005, may have the dose increased to 300 mg SC \nonce weekly. \n \nThe study will continue until marstacimab is commercially available in each respective country or when the \nparticipants have completed 7 years of participation in Study B7841007, whichever occurs first. Therefore, \nthe duration for each study participant will be variable. Additionally, commercial availability will likely vary \nwithin each respective country between study populations with initial approvals for adolescent/adults ages 12 \nto <75 years, followed by the paediatric population ages 1 to <12 years. Global commercialization of \nmarstacimab is currently anticipated to be completed in 2030, therefore the last participant’s last visit in this \nstudy is estimated to be no later than 2030. \nAll participants were provided the pre-filled pen (PFP) for administration of marstacimab in the study. Use \nof the pre-filled syringe (PFS) was permitted at the investigator’s discretion for those participants who had \ndifficulty with administration of the PFP. Additionally, participants were provided the PFS for use in this \nstudy in countries where the PFS is anticipated to be the only presentation available commercially. \n"
    },
    {
      "page_number": 141,
      "text": "Assessment report \nEMA/464842/2024 \nPage 141/198 \n \nIn addition, an optional, open-label, single arm, sub-study using the PFP included 23 participants rolling over \nfrom Study B7841005 who agreed to participate in the sub-study. This sub-study was implemented at the \nonset of treatment with marstacimab in this study with the primary objective to evaluate the feasibility and \nreal-world effectiveness of marstacimab administration using the PFP device by the sub-study participants or \ntheir caregivers, and a secondary objective to describe difficulties experienced which resulted in unsuccessful \ninjections, and to confirm the correct operation of the PFP by examination of returned devices. \nAt the time of the MAA, an interim analysis including only data from the without inhibitors cohort was \nprovided. \nStudy Objectives and Endpoints of the main study \nStudy objectives and endpoints are summarised in the below table. Evaluation of long-term efficacy was a \nsecondary objective of the main study. \nTable 42: Study B7841007 Objectives and endpoints \n \n"
    },
    {
      "page_number": 142,
      "text": "Assessment report \nEMA/464842/2024 \nPage 142/198 \n \nNumber of Participants (planned and analysed): \n \nThis study was conducted at 36 sites in 14 countries: Canada (2 sites), Croatia (2 sites), France (1 site), \nHong Kong (2 sites), India (2 sites), Japan (2 sites), Korea (3 sites), Mexico (1 site), Oman (2 sites), \nSerbia (3 sites), Spain (4 sites), Taiwan (1 site) Turkey (9 sites), and the United States (2 sites). \nAll 88 participants who met the eligibility criteria entered the treatment phase. Among 88 participants who \nentered the study, 2 discontinued from study due to withdrawal by participant, one of whom entered the \nfollow-up phase. A total of 88 participants enrolled in the study. All 29 participants in the on-demand group \nwere included in the safety analysis set while 58 of 59 participants in the prior prophylaxis group were \nincluded in the safety analysis set. \nDiagnosis and Main Criteria for Inclusion and Exclusion: \n \nEnrolled in this study were adult or adolescent male participants with severe haemophilia A or moderately \nsevere to severe haemophilia B (defined as FVIII activity <1% or FIX activity ≤2%, respectively) with or \nwithout inhibitors who successfully completed the Phase 3 Study B7841005. \nDuration of Study Intervention: \nThe study intervention marstacimab (PF-06741086) was administered on each occasion as a single 150 mg \nSC injection via PFS or PFP as outlined in the Instructions for Use (IFU) (unless the participant required a \n300 mg dose, where 2 × 1 mL injections were used). All participants were provided the PFP for \nadministration of marstacimab in the study. Use of the PFS was permitted at the investigator’s discretion for \nthose participants who have difficulty with administration of the PFP or for use in this study in countries \nwhere the PFS is anticipated to be the only presentation available commercially. Study staff and participants \nreferred to the IFU for specific instructions on the handling and administration of study intervention. \nEfficacy Analysis \nThe efficacy analyses were based on the Safety Analysis Set defined as all participants who received at least \none dose of marstacimab. In the absence of a control group, descriptive summaries were provided without \nany hypothesis testing. \nOnly participants in the non-inhibitor cohort who completed lead-in Study B7841005 as of 10 February \n2023 were included in the provided interim analysis, with a data cutoff of 10 March 2023. \nResults \nStudy population \nDisposition \nAll 88 participants who met the eligibility criteria entered the treatment phase. Among 88 participants \nwho entered the study, 2 discontinued from study due to withdrawal by participant, one of whom entered \nthe follow-up phase. \nA total of 88 participants enrolled in the study. All 29 participants in the on-demand group were included in \nthe safety analysis set while 58 of 59 participants in the prior prophylaxis group were included in the safety \nanalysis set. \nOne enrolled participant from the non-inhibitor prior prophylaxis cohort is not included in the safety analysis \nset because his data was not available by the 10 March 2023 interim data cutoff. \n"
    },
    {
      "page_number": 143,
      "text": "Assessment report \nEMA/464842/2024 \nPage 143/198 \n \nDemographics and baseline characteristics \nWith the exception of weight, height, and eGFR, all demographic information was obtained at the parent \nStudy B7841005 screening. \nStudy B7841007 was an adult and adolescent study (all participants ≥12 years to <75 years of age) with \nprimarily White (43/87, 49.4%) and Asian (42/87, 48.3%) participants. There was 1 Black/African \nAmerican participant (1/87, 1.1%). The race of 1 participant was not reported. \nThe majority of participants were from Asia (39/87, 44.8%) and Europe (30/87, 34.5%). Age was defined \nas the age at the time of providing informed consent at parent study (B7841005) participation. \nOverall, across participants without inhibitors in Study B7841007: \n• \n67 (77.0%) participants had haemophilia A and 20 (23.0%) had haemophilia B \n• \n73 (83.9%) participants were adults ≥18 to <75 years of age and 14 (16.1%) of participants were \nadolescents (≥12 to <18 years of age) \n• \n28 (48.3%) participants with prior prophylaxis had no target joints at baseline, while all 29 (100%) \nparticipants with prior on-demand treatment had 1 or more target joints at baseline. \nAll 87 participants were male with a median age of 29.0 years and individual values ranged from 13.0 to \n66.0 years of age. The majority of participants (54/87, 62.1%) were in the 18-44 age range. \nThe median participant weight was 70.4 kg (range: 39.0 to 128.8 kg) and the median participant BMI was \n23.8 kg/m2 (range: 15.6 to 38.9 kg/m2). The median participant height was 172.0 cm (range: 156.3 to \n193.0 cm). \nMost participants (68, 78.2%) had normal renal function (eGFR ≥90 mL/min/1.73 m2), while 14 (16.1%) had \nmild renal impairment (eGFR ≥60 to <90 mL/min/1.73 m2) and none had moderate renal impairment (eGFR \n≥30 to <60 mL/min/1.73 m2). \n \n \nEfficacy results \nABR of treated bleeds \nThe long-term efficacy of marstacimab administered beyond 12 months in parent Study B7841005 and up to \nan additional approximately 16 months in participants without inhibitors as measured by the ABR of treated \nbleeds was maintained in this long-term extension study. \nOverall, the model-based mean estimated ABR of treated bleeds was 2.79 and the 95% CI was (1.90, \n4.09). \nFor the prior on-demand group, the model-based mean estimated ABR of treated bleeds was 3.86 and the \n95% CI was (2.02, 7.37). For the prior prophylaxis group, the estimated ABR of treated bleeds was 2.27 and \nthe 95% CI was (1.40, 3.67). \nOverall, 49 of 87 participants had no bleeding events over the treatment period ranging from 34.0 to 483.0 \ndays, with a median exposure of 193.0 days. Over the treatment period, in the prior on-demand group 13 of \n29 participants had no bleeding events and in the prior prophylaxis group, 36 of 58 participants had no \nbleeding events. \n"
    },
    {
      "page_number": 144,
      "text": "Assessment report \nEMA/464842/2024 \nPage 144/198 \n \nIncidence of joint bleeds \nThe long-term efficacy of marstacimab in participants without inhibitors, as measured by the incidence of \njoint bleeds, beyond 12 months in parent Study B7841005 and up to an additional approximately 16 months \nwas maintained in the long-term OLE Study B7841007. \nThe overall model-based mean estimate for the annualised incidence of joint bleeds was 1.88 (95% CI \n[1.29, 2.74]), and for the prior on-demand group and prior prophylaxis group was 1.87 (95% CI [1.07, \n3.26]) and 1.87 (95% CI [1.14, 3.08]), respectively. \n \n \nIncidence of spontaneous bleeds \nThe long-term efficacy of marstacimab in participants without inhibitors, as measured by the incidence of \nspontaneous bleeds, beyond 12 months in parent Study B7841005 and up to an additional approximately 16 \nmonths was maintained in long-term OLE Study B7841007. \nThe overall model-based mean estimate for the annualised incidence of spontaneous bleeds was 1.91 \n(95% CI [1.26, 2.89]), and for the prior on-demand group and prior prophylaxis group was 2.54 (95% CI \n[1.22, 5.29]) and 1.62 (95% CI [0.96, 2.73]), respectively. \n \n \nIncidence of target joint bleeds \nThe long-term efficacy of marstacimab in participants without inhibitors, as measured by the incidence of \ntarget bleeds, beyond 12 months in parent Study B7841005 and up to an additional approximately 16 \nmonths was maintained in long-term OLE Study B7841007. \nThe overall model-based mean estimate for the annualised incidence of target joint bleeds was 0.94 (95% CI \n[0.54, 1.63]), and for the prior on-demand group and prior prophylaxis group was 0.90 (95% CI [0.51, \n1.58]) and 0.91 (95% CI [0.36, 2.27]), respectively. \n \n \nIncidence of total bleeds (treated and untreated) \nThe long-term efficacy of marstacimab in participants without inhibitors beyond 12 months in parent Study \nB7841005 and up to an additional approximately 16 months as measured by the incidence of total bleeds \n(treated and untreated), was maintained in long-term OLE Study B7841007. \nThe overall model based mean estimate for the annualised incidence of total bleeds (treated and untreated) \nwas 3.59 (95% CI [2.56, 5.04]), and for the prior on-demand group and prior prophylaxis group was 5.10 \n(95% CI [3.25, 8.00]) and 2.73 (95% CI [1.70, 4.38]), respectively. \n \n \nHaemophilia Joint Health Score (HJHS) \nMarstacimab prophylaxis preserved joint health as assessed by the HJHS in participants without \ninhibitors who contributed Day 180 HJHS values by the interim data cutoff. \nA lower HJHS value is indicative of better joint health. \nThe mean change from Study B7841007 baseline at 180 days in the total HJHS score was -1.0 across all \nparticipants (n=43 with values reported at 180 days). \n"
    },
    {
      "page_number": 145,
      "text": "Assessment report \nEMA/464842/2024 \nPage 145/198 \n \nFor the prior on-demand group (n=19) and the prior prophylaxis group (n=24), the mean change from \nStudy B7841007 baseline in the total HJHS score at 180 days was 1.1 and -2.7, respectively. \n \n \nNumber of target joints \nThe durability of the effect of marstacimab on target joints beyond 12 months in parent Study B7841005 \nand up to an additional approximately 16 months was maintained in long-term OLE Study B7841007 in \nparticipants without inhibitors. \nA target joint is defined as a major joint (eg, hip, elbow, wrist, shoulder, knee, and ankle) into which \nrepeated bleeds occur (3 or more spontaneous bleeds into a single joint within a consecutive 6-month \nperiod). The number of target joints is derived from the eDiary via counting joints that meet the definition of \na target joint during the treatment period. \nThe overall mean for the number of target joints was 0.09. For the prior on-demand group and prior \nprophylaxis group, the mean was 0.07 and 0.10, respectively. \n \n \nTotal coagulation factor consumption \nThe mean total IU (annualised) factor replacement consumption was 9954.9, and for the prior on-demand \ngroup and prior prophylaxis group was 14807.1 and 7528.8, respectively, in participants without inhibitors. \n \n \nHRQoL outcomes \nHaem-A-QoL (≥17 Years) and Haemo-QoL (Adolescents 12 to <17 Years) \nThe treatment effect with marstacimab prophylaxis in the physical health domain and total scores in the \nHaem-A-QoL and Haemo-QoL instrument was preserved with long-term treatment in this study in \nparticipants without inhibitors who contributed Day 180 values by the interim data cutoff. \nParticipants who turned 17 years of age at Study B7841007 rollover and became newly eligible to fill out \nthe Haem-A-QoL did so at Study B7841007 baseline. Participants who aged into a new version of the \nquestionnaire in a given year completed the age-appropriate version of the questionnaire. \nA lower Haem-A-QoL/Haemo-QoL physical health domain or total score is indicative of a better quality of \nlife. \nFor the Haem-A-QoL, across all participants who reported values at 180 days (n=42), the mean change \nfrom Study B7841007 baseline at 180 days in the physical health domain and total scores was -0.7 and - \n0.2, respectively. For the prior on-demand group, across participants who reported values at 180 days \n(n=18) the mean change from Study B7841007 baseline at 180 days in the physical health domain and \ntotal scores was -3.2 and -2.0, respectively. For the prior prophylaxis group, across participants who \nreported values at 180 days (n=24), the mean change from Study B7841007 baseline at 180 days in \nphysical health domain and total score was 1.1 and 1.1, respectively. \nFor the Haemo-QoL, a total of n=3 participants reported physical health domain and total scores at 180 \ndays, all from the prior prophylaxis group. The mean change from Study B7841007 baseline at 180 days \nin the physical health domain and total scores was -4.8 and -3.5, respectively. \n"
    },
    {
      "page_number": 146,
      "text": "Assessment report \nEMA/464842/2024 \nPage 146/198 \n \nEQ-5D-5L \nThe treatment effect with marstacimab prophylaxis in the EQ-5D-5L index and EQ-VAS scores was \npreserved with long term treatment in this study in participants without inhibitors who contributed Day 180 \nvalues by the interim data cutoff. \nA higher value in the EQ-5D-5L index score and EQ-VAS score is indicative of a better health state. \nAcross all participants who contributed Day 180 values, (n=44), the mean change from Study B7841007 \nbaseline at 180 days in the index score was 0.0. Across all participants who contributed Day 180 values \n(n=46), the mean change from Study B7841007 baseline at 180 days in the EQ-VAS score was -1.8. \nFor prior on-demand group participants who contributed Day 180 values (n=18), the mean change at Study \nB7841007 baseline at 180 days in the index score was 0.0, while the mean change in the EQ-VAS score \n(n=19) was -1.4. \nFor prior prophylaxis group participants who contributed Day 180 values (n=26), the mean change at Study \nB7841007 baseline at 180 days in the index score was 0.0, while the mean change in the EQ-VAS score \n(n=27) was -2.1. \n \nPhase 3 OLE Sub-study of B7841007 \n \nThis was an optional, open-label, single arm sub-study for adult or adolescent haemophilia A or B \nparticipants enrolled in the Phase 3 open-label clinical Study B7841007 who agreed to participate in the \nsub-study. All eligible participants had successfully completed participation in the Phase 3 B7841005 parent \nstudy, where marstacimab was administered using a prefilled syringe (PFS) format. This sub-study was \nimplemented at the onset of treatment with marstacimab in this study to evaluate whether sub-study \nparticipants or their caregivers could effectively administer marstacimab using the sponsor’s PFP device. \nApproximately 20 study participants were planned to be enrolled and dosed in this sub-study. Participants \nsigned consent for the sub-study at the Study B7841007 Baseline Visit or during the “Study Completion” \nvisit in the B7841005 study. The sub-study participants continued to follow all the main study procedures. \nThe number of injections and corresponding assessments during the sub-study depended on the dose of \nmarstacimab that the participant was prescribed in Study B7841005, either 150 mg subcutaneously (SC) \nonce weekly or 300 mg SC once weekly (300 mg = 2 × 150 mg injections administered a few minutes \napart in different body sites). Participants (or their caregiver if applicable) were to administer up to 6 \nconsecutive weekly doses of marstacimab as tolerated, using the PFP device. The 1st, 3rd, and 6th \ninjections for participants prescribed 150 mg SC and the 1st/2nd, 5th/6th, and 11th/12th injections for \nparticipants prescribed 300 mg SC were to be administered at the site under the supervision of the \ninvestigator or designated observer. These visits were additional visits for sub-study participants. \nParticipants or their caregiver were to administer their marstacimab dose using the PFP at home for all \nother injections during the sub-study. \nAn assessment of participant’s acceptability of marstacimab injections with the PFP was to be performed \nby the participant or caregiver (person administering the PFP) using the PAT within 10 minutes after each \nPFP injection during sub-study participation throughout the 6-week sub-study period from all participants \nwho had at least 1 attempted administration of study intervention using the PFP device. \nAn assessment of participant’s useability of marstacimab injections with the PFP was to be performed by \nthe investigator or designated observer using the OAT within 10 minutes after the PFP injection at Sub- \n"
    },
    {
      "page_number": 147,
      "text": "Assessment report \nEMA/464842/2024 \nPage 147/198 \n \nstudy Weeks 1, 3, and 6 during sub-study participation from all participants who had at least 1 attempted \nadministration of study intervention using the PFP device. \nThe sub-study participants were required to properly retain and return all used PFPs and any unused PFPs \nwith issues potentially preventing normal function, to support a post-study mechanical evaluation of the \nPFP devices. \nAdditional medical history for all sub-study participants was obtained, including bilateral hand or wrist \ndisability by report (carpal tunnel, proximal/distal interphalangeal flexion contracture/hyperextension, \ntendon rupture, joint replacement, or joint fusion). \nSub-study participants who signed informed consent but never attempted injection with the PFP on Sub- \nstudy Day 1 were to be replaced so as to ensure a sample size of approximately 20 participants. Sub- \nstudy participants who attempted injection with the PFP on Sub-study Day 1 but did not succeed were not \nto be replaced; however, an additional participant was to be enrolled to supplement the exposure and PFP \nperformance data for participants receiving at least one injection by PFP. \nIf the sub-study participant was consistently unable to use the PFP following instruction and observation, the \nparticipant would be discontinued from the sub-study and would return to using the PFS for the remainder \nof their participation in the main study. Following completion of the sub-study, all participants were to \ncontinue use of the PFP for the remainder of the main Study B7841007. \n \n \nNumber of Participants (planned and analysed): \nThis sub-study was conducted at 11 sites in 4 countries: Hong Kong (2 sites), India (2 sites), Republic of \nKorea (1 site), and Turkey (6 sites). All sub-study participants from these sites were the earliest \nparticipants to transition from the parent Study B7841005. \nA total of 23 participants were screened after signing a sub-study informed consent document (ICD), all of \nwhom entered the sub-study and received treatment with marstacimab using the PFP device. All 23 treated \nparticipants completed the sub-study. \n \n \nDiagnosis and Main Criteria for Inclusion and Exclusion: \nEnrolled in this sub-study were a subset of the main Study B7841007 adult or adolescent participants with \nsevere haemophilia A or moderately severe to severe haemophilia B (rolled over from the parent Study \nB7841005), who consented to participate in the PFP sub-study. \n \n \nStudy Interventions, Dose, Mode of Administration, and Batch Number(s): \nThe study intervention marstacimab (PF-06741086) was provided in a sterile liquid solution for injection \npackaged in a PFP for single use, which contained a standard marstacimab PFS. Each package was \nlabelled as required per country requirement. Study intervention information is provided in the table \nbelow. \n"
    },
    {
      "page_number": 148,
      "text": "Assessment report \nEMA/464842/2024 \nPage 148/198 \n \nTable 43: Study intervention(s) administered \n \n \n \n \nDuration of Study Intervention: \nMarstacimab was administered on each occasion as a single 150 mg SC injection (unless the participant \nrequired 300 mg dose, where 2 × 150 mg injections would be used). Study intervention was to be injected \neither into the abdominal wall or upper front thigh. The participant or trained caregiver were to utilise both \ninjection locations during the sub-study. \nIf a participant or trained caregiver failed the first injection attempt at any injection week, the participant or \ntrained caregiver was allowed to make a second attempt only if the full dose was not administered, starting \nwith a new PFP device. \nIf a participant or trained caregiver was unable to physically use the device and inject using the PFP on \nsub-study Day 1 (eg, could not remove the cap, could not exert sufficient force to initiate the injection, \netc), even with repeated assistance and attempts, then the Observer and Participant Assessment tools \nwere to be completed, the participant would be discontinued from the sub-study, and their data would \nbe included in the analysis. The participant was to return to administration of their study treatment \nusing the PFS for the remainder of their participation in the main Study B7841007. \nAll PFPs that were used in the sub-study and all PFPs that were the subject of a Medical Device Complaint \nrecord were to be returned to the sponsor for analysis. The PFP was defined as the pen and its cap, \nwhether the cap had been removed or not. Once the cap had been removed, no attempt was to be made \nto replace it on the pen. All used PFPs (and their caps) were to be immediately placed in the sponsor- \nsupplied individual biohazard disposal containers for secure storage. \nFor all such defined PFPs that were administered at a participant’s home, site personnel instructed the \nparticipant to store the PFPs, as described, until they could be returned to the site for return to the sponsor. \nFor all such defined PFPs that had been administered at the site, site personnel were responsible for \nensuring their correct storage until they could be returned to the sponsor. Instructions for returning all such \ndefined PFPs were provided to the sites by the sponsor and/or designee. \n"
    },
    {
      "page_number": 149,
      "text": "Assessment report \nEMA/464842/2024 \nPage 149/198 \n \nTable 44: Sub study objectives and endpoints \n \n \nAnalysis Sets \nSub-study Intent-to-Treat (ITT) Analysis Set: Sub-study participants who attempted to take at least one \ndose (150 mg or 300 mg) of marstacimab using the PFP device. \nSub-study Safety Analysis Set: Sub-study participants who received at least a portion of a dose of \nmarstacimab using the PFP device. \nAnalysis of the Primary Endpoint \nThe primary sub-study endpoint was DSSR, which was based on participant (actual PFP user, either \nparticipant or participant’s caregiver) and investigator/designated observer observations of the success of \nmarstacimab administration by PFP. \nDelivery success was based on a lack of injection failure reported on the participant assessment \ntool (PAT), as described below: \n• \nQuestion 3 “Do you believe a full dose was injected?”: \no \nA “No” response indicated injection failure. \n• \nQuestion 4 “Did the yellow bar on the pen move across the window as shown below?”: \no \nA “No” response indicated injection failure. \n• \nQuestion 5 “Did you have any difficulties during the injection?”: \no \nA “Yes” response with the difficulty option selected, “Medicine was still flowing out of the pen \nafter it was removed from the skin,” indicated injection failure. \n \n \nNote: A “Yes” response to Question 5 with the following difficulty options selected was not an \nindication of injection failure: \no \nI had trouble removing the cap. \n"
    },
    {
      "page_number": 150,
      "text": "Assessment report \nEMA/464842/2024 \nPage 150/198 \n \no \nI had trouble starting the injection. \no \nI did not hear the 2nd click before removal of the pen from the skin. \n \nWhen the observer assessment tool (OAT) was available, delivery success was also based on a lack of \ninjection failure reported on the OAT, as described below: \n• \nQuestion 2 “Did the user successfully self-administer the full dose without physical assistance?”: \no \nA “No” response indicated injection failure. \n \nIn order to consider “injection success”, delivery of the entire dose (ie, whether 1 × 150 mg PFP required for \n150 mg dose; or 2 × 150 mg PFP required for 300 mg dose) must have been measured as “success” at any \ninjection timepoint/sub-study visit. That is, the DSSR per visit for participants who received 300 mg was to \nbe treated as a composite endpoint, where both the first and second injections needed to meet the criteria \nfor ‘success’ to be determined successful for the DSSR. If any injection during a visit was a ‘failure’, this was \nto be considered a participant failure for the DSSR at this visit. \n \n \nAnalysis of Secondary Endpoints \n• \nCharacterisation of unsuccessful PFP injections was descriptive and based on individual question \nresponses to PAT and OAT. \n• \nIndividual question responses to PAT/OAT were summarised by PFP injection visit using counts and \npercentages. \n• \nDetermination, by inspection, of the correct mechanical function of returned PFP devices was \ndescribed in a separate mechanical report. \n \n \nResults \nDemographic and Other Baseline Characteristics: \nAll 23 participants were male. The median participant age was 25 years and individual values ranged from 14 \nto 44 years. The majority of participants (19/23, 82.6%) were in the 18-44 years age range. All 23 \nparticipants were of Asian (15/23, 65.2%) or White (8/23, 34.8%) race. \nThe median participant weight was 67.0 kg (range: 38.1 to 99.8 kg) and the median participant body mass \nindex (BMI) was 22.4 kg/m2 (range: 15.2-35.3 kg/m2). The median participant height was 169.0 cm (range: \n158.0-178.0 cm). \nOf the 23treated sub-study participants, 20 (87.0%) participants had haemophilia A (16 adult and 4 \nadolescent participants), and 3 (13.0%) participants had haemophilia B (3 adult and 0 adolescent \nparticipants). Participant median number of bleeds in the past 6 months prior to entry into pivotal Study \nB7841005 was 15 bleeds; individual values ranged from 0 to 85 bleeds, with the majority of participants (21 \n[91.3%]) having 6 or more bleeds in the past 6 months. The majority of participants had 1 or more target \njoints at baseline. \n"
    },
    {
      "page_number": 151,
      "text": "Assessment report \nEMA/464842/2024 \nPage 151/198 \n \nExposure: \n \nOf the 23 total sub-study participants, 20 participants were prescribed marstacimab treatment at a dose of \n150 mg SC weekly and 3 participants were prescribed marstacimab treatment at a dose of 300 mg SC \nweekly. \nAmong sub-study participants, the median duration of marstacimab treatment within the sub-study \nperiod was 42 days (range: 35 to 45 days) and the median exposure days of marstacimab treatment \nwas 6 days (range: 5 to 6 days). \n \n \nPFP Device Injection Success Evaluation Results: \n• \nThe DSSR was 100% at all visits except for Week 2, which had a DSSR of 95.0%, with an overall \nDSSR across all visits of 99.2%. The overall DSSR was based on 123 delivery system success \nassessments, of which 122 were considered successful. \n• \nThe inspection of 156 used PFPs returned per the administration schedule, confirmed successful \ninjection of the full contents from the syringe for all returned used PFPs. \n• \nThe following issues were identified for 1 PFP injection attempt noted by the actual PFP User (PAT): \n“trouble starting the injection” and “medicine still flowing after pen removed from the skin.” \n• \nThe following issues were identified for 2 PFP injection attempts noted by the OAT: the user did not \nsuccessfully self-administer the full dose without physical and verbal assistance due to both \nparticipants asking a healthcare professional to administer for them. The following issue was \nidentified for 1 PFP injection attempt noted by the OAT: the user did not successfully self-administer \nthe full dose without verbal assistance due to needing help with Step 7, “Inject Medicine.” \n \n \n• \nSummary of main efficacy results \n \nThe following tables summarise the efficacy results from the main studies supporting the present \napplication. These summaries should be read in conjunction with the discussion on clinical efficacy as well \nas the benefit risk assessment (see later sections). \n \n \nTable 45: Summary of efficacy for trial B7841005 \n \nTitle: An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Haemophilia A \nParticipants With or Without Inhibitors or Moderately Severe to Severe Haemophilia B Participants \n(Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF- \n06741086 Prophylaxis \nStudy \nidentifier \nB7841005; EudraCT Number 2018-003660-31; NCT03938792 \nDesign \nOne-way, cross-over, open-label, multi-centre \n"
    },
    {
      "page_number": 152,
      "text": "Assessment report \nEMA/464842/2024 \nPage 152/198 \n \nDuration of Observation \nPhase (OP): \nDuration of Active Treatment \nPhase (ATP): \nDuration of follow-up: \n6 months \n12 months \n1 month follow-up for safety monitoring \nEfficacy data presented in the initial MAA includes only the completed non-inhibitor cohort; no \nefficacy data is included in the initial MAA for the ongoing inhibitor cohort. \nHypothesis \nNon-Inhibitor Cohort \nNon-inferiority, and superiority if non-inferiority is met, of marstacimab prophylaxis during \nthe active treatment phase (ATP) as compared to prior prophylaxis during the observational \nphase (OP), and superiority of marstacimab prophylaxis over on-demand factor replacement \nduring the OP. \nTreatment \ngroups \nMarstacimab \n(PF-06741086) \n12-month Active Treatment Phase following a 6-month \nObservational Phase: Marstacimab administered 300 mg SC for \nthe initial loading dose followed by 150 mg SC QW. Individual \nparticipants who met protocol-specified dose escalation criteria \nbased upon breakthrough bleeding, may have had their dose \nincreased to 300 mg SC QW \nTreatment for the 6-month observational phase was divided into 2 \ncohorts: \n• \nNon-inhibitor cohort: participants without inhibitors who \nhad prior on-demand or prior prophylaxis factor-based \ntherapy \n• \nInhibitor cohort: participants with inhibitors who were \nreceiving prior on-demand treatment \nEndpoints \nand \ndefinitions \nPrimary Endpoint \nABR of treated bleeds \nStatistical testing was conducted \nfor marstacimab based on \nprespecified ordering for: non- \ninferiority versus prior \nprophylaxis and superiority \nversus prior prophylaxis. In \naddition, superiority versus on- \ndemand was tested outside of the \ntesting hierarchy. \nSecondary Endpoint \nIncidence of joint bleeds \nStatistical testing was conducted \nfor marstacimab based on \nprespecified ordering for: non- \ninferiority versus prior \nprophylaxis and superiority \nversus prior prophylaxis. In \naddition, superiority versus on- \ndemand was tested outside of the \ntesting hierarchy. \nSecondary Endpoint \nIncidence of spontaneous \nbleeds \nStatistical testing was conducted \nfor marstacimab based on \nprespecified ordering for: non- \ninferiority versus prior \n"
    },
    {
      "page_number": 153,
      "text": "Assessment report \nEMA/464842/2024 \nPage 153/198 \n \nprophylaxis and superiority \nversus prior prophylaxis. In \naddition, superiority versus on- \ndemand was tested. \nSecondary Endpoint \nIncidence of target joint bleeds Statistical testing was conducted \nfor marstacimab based on \nprespecified ordering for: non- \ninferiority versus prior \nprophylaxis and superiority \nversus prior prophylaxis. In \naddition, superiority versus on- \ndemand was tested. \nSecondary Endpoint \nIncidence of total bleeds \n(treated and untreated) \nStatistical testing was conducted \nfor marstacimab based on \nprespecified ordering for: non- \ninferiority versus prior \nprophylaxis and superiority \nversus prior prophylaxis. In \naddition, superiority versus on- \ndemand was tested. \nSecondary Endpoint \nChange in joints as measured \nby the Haemophilia Joint Health \nScore (HJHS) \nThe change from baseline in the \ntotal score was measured at 6 \nmonths in the ATP versus during \nthe 6-month OP. The HJHS total \nscore is not included in the \ntesting hierarchy where type I \nerror rate is controlled within \neach statistical objective. \nData Cutoff \nDate (LPLV \nfor non- \ninhibitor \ncohort) \n17 April 2023 (interim analysis for non-inhibitor cohort) \nResults and Analysis \nMarstacimab prophylaxis demonstrated non-inferiority and superiority (2-sided p-value =0.0376) over \nroutine prophylactic treatment as measured by the ABR of treated bleeds. Marstacimab prophylaxis also \ndemonstrated superiority (2-sided p-value <0.0001) over on-demand treatment as measured by the ABR of \ntreated bleeds. Marstacimab prophylaxis demonstrated non-inferiority over prior prophylactic treatment and \nsuperiority over on-demand treatment and reduced the incidence of the following types of bleeds as \ncompared to both on-demand and prior prophylactic treatment: joint bleeds, spontaneous bleeds, target \njoint bleeds, and total bleeds (treated and untreated). \nMarstacimab prophylaxis demonstrated non-inferiority when compared with prior routine prophylaxis for \nHaem-A-QoL physical health domain and total score, and EQ-5D-5L index score and EQ-VAS score. \nAnalysis \ndescription \nPrimary Analysis: ABR of treated bleeds \nAnalysis \npopulation \nand time \npoint \ndescription \nModified intent-to-treat (mITT): participants who completed the OP and received at least 1 \ndose of marstacimab during the ATP. \n"
    },
    {
      "page_number": 154,
      "text": "Assessment report \nEMA/464842/2024 \nPage 154/198 \n \nDescriptive \nstatistics \nand \nestimate \nvariability \nTreatment group \nMarstacimab \nNumber of participants \n116 \nMean estimated ABR \n(95% CI; p value) \nPrior On-Demand (n=33) \nPrior Prophylaxis (n=83) \nATP: 3.18 (2.09, 4.85; \np<0.0001) \nOP: 38.00 (31.03, 46.54) \nATP: 5.08 (3.40, 6.77; \np = 0.0376) \nOP: 7.85 (5.09, 10.61) \nABR Ratio (95% CI) \n0.084 (0.059, 0.119) \nNA \nDifference estimate (95% \nCI) \nNA \n-2.77 (-5.37, -0.16) \nPercentage reduction (95% \nCI) \nNA \n35.2% (5.6, 55.6) \nParticipants without treated \nbleeds (%) \nATP: 10 (30.3%) \nOP: 1 (3.0%) \nATP: 29 (34.9%) \nOP: 33 (39.8%) \nEffect \nestimate per \ncomparison \nPost marstacimab administration for 12 months in the ATP versus the 6-month OP with on- \ndemand or prophylactic factor treatment. \nAnalysis \ndescription \nSecondary analysis: Incidence of joint bleeds \nAnalysis \npopulation \nand time \npoint \ndescription \nModified intent-to-treat (mITT): participants who completed the OP and received at least 1 \ndose of marstacimab in the ATP. \nDescriptive \nstatistics and \nestimate \nvariability \nTreatment group \nMarstacimab \nNumber of participants \n116 \nMean estimate (95% CI) \nPrior On-Demand (n=33) \nPrior Prophylaxis (n=83) \nATP: 2.83 (1.81, 4.44) \nOP: 32.86 (26.15, 41.29) \nATP: 4.13 (2.59, 5.67) \nOP: 5.66 (3.33, 7.98) \nRatio estimate (95% CI) \n0.086 (0.059, 0.125; p \n<0.0001) \nNA \nDifference estimate (95% \nCI) \nNA \n-1.53 (-3.70, 0.64) \nNon-inferiority margin: upper \nbound of 95% CI <2.5 \nParticipants without treated \njoint bleeds (%) \nATP: 10 (30.3%) \nOP: 1 (3.0%) \nATP: 33 (39.8%) \nOP: 40 (48.2%) \nEffect \nestimate per \ncomparison \nPost marstacimab administration for 12 months in the ATP versus the 6-month OP with on- \ndemand or prophylactic factor treatment \nAnalysis \ndescription \nSecondary analysis: incidence of spontaneous bleeds \nAnalysis \npopulation \nand time \nModified intent-to-treat (mITT): participants who completed the OP and received at least 1 \ndose of marstacimab in the ATP. \n"
    },
    {
      "page_number": 155,
      "text": "Assessment report \nEMA/464842/2024 \nPage 155/198 \n \npoint \ndescription \nDescriptive \nstatistics and \nestimate \nvariability \nTreatment group \nMarstacimab \nNumber of participants \n116 \nMean estimate (95% CI) \nPrior On-Demand (n=33) \nPrior Prophylaxis (n=83) \nATP: 2.44 (1.61, 3.69) \nOP: 30.93 (24.12, 39.67) \nATP: 3.78 (2.25, 5.31) \nOP: 5.86 (3.54, 8.19) \nRatio estimate (95% CI) \n0.079 (0.054, 0.114; p \n<0.0001) \nNA \nDifference estimate (95% \nCI) \nNA \n-2.09 (-4.23, 0.06) \nNon-inferiority margin: upper \nbound of 95% CI <2.5 \nParticipants without \nspontaneous bleeds (%) \nATP: 10 (30.3%) \nOP: 2 (6.1) \nATP: 35 (42.2%) \nOP: 40 (48.2%) \nEffect \nestimate per \ncomparison \nPost marstacimab administration for 12 months in the ATP versus the 6-month OP with on- \ndemand or prophylactic factor treatment. \nAnalysis \ndescription \nSecondary analysis: incidence of target joint bleeds (treated) \nAnalysis \npopulation \nand time \npoint \ndescription \nModified intent-to-treat (mITT): participants without inhibitors who completed the OP and \nreceived at least 1 dose of marstacimab in the ATP. \nDescriptive \nstatistics and \nestimate \nvariability \nTreatment group \nMarstacimab \nNumber of participants \nAs indicated below \nPrior On-Demand (n=33) \nPrior Prophylaxis (n=83) \nMean estimate (95% CI) \nATP: 1.84 (1.06, 3.17) \nOP: 23.18 (17.20, 31.24) \nATP: 2.51 (1.25, 3.76) \nOP: 3.36 (1.59, 5.14) \nRatio estimate (95% CI) \n0.079 (0.051, 0.124); p \n<0.0001 \nNA \nDifference estimate (95% \nCI) \nNA \n-0.86 (-2.41, 0.70) \nNon-inferiority margin: upper \nbound of 95% CI <1.2 \nParticipants without any \nbleeds (treated) (%) \nATP: 13 (39.4%) \nOP: 2 (6.1%) \nATP: 54 (65.1%) \nOP: 62 (74.7%) \nEffect \nestimate per \ncomparison \nPost marstacimab administration for 12 months in the ATP versus the 6-month OP with on- \ndemand or prophylactic factor treatment. \nAnalysis \ndescription \nSecondary analysis: incidence of total bleeds (treated and untreated) \nAnalysis \npopulation \nand time \nModified intent-to-treat (mITT): participants who completed the OP and received at least 1 \ndose of marstacimab in the ATP. \n"
    },
    {
      "page_number": 156,
      "text": "Assessment report \nEMA/464842/2024 \nPage 156/198 \n \npoint \ndescription \nDescriptive \nstatistics and \nestimate \nvariability \nTreatment group \nMarstacimab \nNumber of participants \nAs indicated below \nPrior On-Demand (n=33) \nPrior Prophylaxis (n=83) \nMean estimate (95% CI) \nATP: 7.39 (5.08, 10.74) \nOP: 47.76 (39.60, 57.60) \nATP: 5.97 (4.13, 7.81) \nOP: 8.84 (5.97, 11.72) \nRatio estimate (95% CI) \n0.155 (0.116, 0.207; p \n<0.0001) \nNA \nDifference estimate (95% \nCI) \nNA \n-2.87 (-5.61, -0.12) \nNon-inferiority margin: upper \nbound of 95% CI <2.9 \nParticipants without any \nbleeds (treated and \nuntreated) (%) \nATP: 4 (12.1%) \nOP: 0 (0.0%) \nATP: 22 (26.5%) \nOP: 28 (33.7%) \nEffect \nestimate per \ncomparison \nPost marstacimab administration for 12 months versus the 6-month OP with on-demand or \nprophylactic factor treatment. \nAnalysis \ndescription \nSecondary analysis: HJHS \nAnalysis \npopulation \nand time \npoint \ndescription \nModified intent-to-treat (mITT): participants who completed the OP and received at least 1 \ndose of marstacimab in the ATP. The reference treatment duration in the OP was 6 months, \nwhile marstacimab prophylaxis was administered for 12 months during the ATP, therefore, the \nmain comparison timepoint between the OP and ATP is at 6 months, and the 12-month \ncomparison utilises 6-month results from the OP. \nDescriptive \nstatistics and \nestimate \nvariability \nTreatment group \nMarstacimab \nNumber of participants \nAs indicated below \nPrior On-Demand (n=33) \nPrior Prophylaxis (n=83) \nMedian estimate change in \ntotal score from baseline to 6 \nmonths (95% CI) \nATP: -5.2 (-8.7, -1.8) \nOP: -2.6 (-5.7, 0.5) \nATP: -0.6 (-2.2, 1.0) \nOP: 1.3 (-0.7, 3.3) \nEstimated median difference \n(95% CI) \n-2.8 (-7.6, 2.1) \n-2.0 (-4.3, 0.3) \nEffect \nestimate per \ncomparison \nPost marstacimab administration at 6 months in the ATP versus the 6-month OP with on- \ndemand or prophylactic factor treatment. \n \n \n2.6.5.3. Clinical studies in special populations \n \nNo studies were performed investigating Hympavzi in special populations. \nCurrently available efficacy data are limited to patients ≥12 years of age. Efficacy data from elderly patients \nare very limited with only 1 patient ≥65 years of age. \n"
    },
    {
      "page_number": 157,
      "text": "Assessment report \nEMA/464842/2024 \nPage 157/198 \n \nMarstacimab has not been studied in patients with moderate or severe hepatic or renal impairment. \n \n2.6.5.4. In vitro biomarker test for patient selection for efficacy \n \nNot applicable. \n \n2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis) \n \nNot applicable. \n \n2.6.5.6. Supportive study(ies) \n \nB7841003: Phase 2 OLE Study \nStudy B7841003 was an open-label long-term (treatment of up to 365 days) evaluation of marstacimab as a \nprophylactic treatment regimen in participants with severe haemophilia A or B, with or without inhibitors to \nFVIII or FIX. \nApproximately 36 participants (24 participants from Study B7841002 and 12 additional participants not \npreviously enrolled in a study) were planned for enrollment at approximately 20 study sites. Participants \nwho enrolled in Study B7841003 from Cohort 1 or 4 (marstacimab 300 mg SC of Study B7841002 \nparticipants with and without inhibitors) continued with their assigned dose level at the completion of Study \nB7841002. All other participants enrolled in Study B7841003 received 150 mg SC, the lowest dose level \ndetermined to be safe and efficacious in Study B7841002. All participants who successfully completed Study \nB7841002 were eligible for enrollment into Study B7841003. \nFigure 28: B7841003 Dose assignment \n \n"
    },
    {
      "page_number": 158,
      "text": "Assessment report \nEMA/464842/2024 \nPage 158/198 \n \nEfficacy Results \n18 participants were previously enrolled in B7841002 and 2 adult participants with inhibitors were newly \nenrolled. Among these 20 participants, all were treated with marstacimab and 18 participants completed the \nstudy. \nThe table below shows that across all dose cohorts during this study, the mean and median on-study ABR \nranged from 0 to 3.586 and 0 to 2.488 bleeding episodes per participant per year, respectively, \ndemonstrating comparable efficacy observed in the short-term parent Study 1002. \nOut of the 20 participants in Study 1003, there was 1 participant with haemophilia B from the 300 mg \nloading + 150 mg – 300 mg loading + 150 mg non-inhibitor dose cohort, who completed the study and had \nno bleeding events during the study. \nThere was a numerical reduction in ABR in the on-study treatment phase versus that reported for the pre- \ntreatment (pre-study) phase in all dose cohorts. \n \n \nTable 46: PF-06741086 Protocol B7841003 descriptive summary of annualised bleeding rate by \ndose cohort in B7841003 - PPAS \n \n"
    },
    {
      "page_number": 159,
      "text": "Assessment report \nEMA/464842/2024 \nPage 159/198 \n \n2.6.6. Discussion on clinical efficacy \n \nThe intended indication for Hympavzi is for routine prophylaxis of bleeding episodes in patients 12 years of \nage and older, weighing at least 35 kg, with: \n• \nsevere haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or \n• \nsevere haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. \nEfficacy data are available from 4 clinical studies: single pivotal Phase 3 study B7841005 with two completed \nnon-inhibitor cohorts, Phase 3 OLE study B7841007, Phase 1b/2 study B7841002 and Phase 2 OLE study \nB7841003. \nThe pivotal clinical efficacy results are derived from the Phase 3 study B7841005 and its OLE study \nB7841007. Data from the Phase 1b/2 study B7841002 and its OLE study B7841003 are considered \nsupportive evidence. \nDesign and conduct of clinical studies \nPivotal Study B7841005 \nStudy B7841005 is a one-way, cross-over, open-label, multi-centre study planned for approximately 145 \nadolescent and adult participants between 12 to <75 years of age with severe haemophilia A or moderately \nsevere to severe haemophilia B (defined as FVIII activity <1%, or FIX activity ≤2%, respectively) with or \nwithout inhibitor, with approximately 20% of participants as adolescents (ages between 12 to <18 years old). \nParticipants were to be enrolled into either an inhibitor cohort (currently ongoing, no data available at this \ntime) or into a non-inhibitor cohort (completed). For the haemophilia B study population, initially only \npatients with severe disease phenotype were eligible for enrolment, which was changed via amendment of \nthe study protocol due to slow recruitment progress. It is noted that only 1 HB patient with moderately \nsevere disease was included in the study and therefore no conclusions on efficacy in this patient population \ncan be made. This however is of no concern, as only an indication for severe haemophilia B is applied for. \nThe study duration for an individual participant is approximately 21 months, which includes a 45-day \nscreening period, a 6-month observational phase (on-demand or routine prophylactic treatment), a 12-month \nactive treatment phase (initial loading dose of 300mg marstacimab followed by prophylactic weekly \ntreatment with 150mg marstacimab), and a 1-month follow-up for safety monitoring. Participants with \ninsufficient efficacy response were eligible for dose escalation after reaching prespecified criteria. Patients \nweighing at least 50 kg with 2 or more spontaneous (atraumatic) bleeds (consisting of joint bleeds or \nsignificant soft tissue/muscle or other site bleeds) treated with infusion(s) of coagulation FVIII or FIX over a \n6-month period in the absence of confirmed FVIII or FIX inhibitors were eligible for dose escalation to weekly \n300mg marstacimab. \nHA and HB are rare diseases which causes limitations in patient availability for clinical studies. Moreover, \nhaemophilia patients are heterogeneous with regards to clinical signs and symptoms, such as bleeding \nphenotype, bleeding risk due to different lifestyle and individual treatment history, target joints, risk for \ninhibitors etc. In consequence, feasibility of sufficiently informative, randomised, controlled trials to estimate \nefficacy and safety of a novel therapeutic agent is challenging in this disease setting. While a randomised- \ncontrolled study would be the preferred option, conduct of a single arm study with an intra-participant \ncomparison relative to a prospectively captured baseline is considered acceptable. The duration of the active \ntreatment phase of 12 months is acceptable and the overall design is in line with guidance \n(EMA/HAEMWP/136018/2023; currently in draft stage) and previous SA. \n"
    },
    {
      "page_number": 160,
      "text": "Assessment report \nEMA/464842/2024 \nPage 160/198 \n \nImportant protocol deviations were reported for 74 (57.8%) participants in study B7841005. Most deviations \nwere reported related to procedures/tests (31 participants), investigational product (25 participants), \nconcomitant medications (22 participants), informed consent (18 participants), and inclusion/exclusion \ncriteria (10 participants). \nFor the EU, and specifically for the non-inhibitor cohort, the statistical hypothesis was the demonstration of \nnon-inferiority of Hympavzi prophylaxis observed over the 12-month ATP compared to routine prophylaxis \nduring the 6 months prior to receiving study intervention (i.e. the prospectively conducted observational \nperiod), on the difference in the ABR of treated bleeds. The statistical hypothesis of establishing non- \ninferiority against routine prophylaxis is considered the appropriate comparison for the non-inhibitor cohort. \nAdditionally, superiority testing was specified for the comparison of marstacimab prophylaxis compared to \nprevious on-demand factor treatment during the observational period, which is considered supportive \nevidence. \nPrimary endpoints \nThe primary endpoint was the annualised bleeding rate (ABR) of treated bleeding events over a 12-month \nActive Treatment Phase (ATP) compared to a previous 6-month Observational Phase (OP), which is in line \nwith scientific advice and in line with guidance. The primary endpoint is clinically relevant and clearly defined. \nWhile a within subject comparison between the on-treatment duration and the prior observational period has \na risk for bias, the strategy is acceptable in this rare disease. A non-inferiority margin of 2.5 was pre- \nspecified. Regarding its derivation it is unclear in how far the study populations investigated in the three \nstudies used for the non-inferiority margin derivation are comparable to the study population in the pivotal \nmarstacimab study B7841005. This is especially the case for the two included HB Benefix studies, where \nmoderately severe and severe HB patients were enrolled, whereas the HB study population in B7841005 was \nalmost exclusively made up of HB patients with severe disease and a severe phenotype. Further, no \njustification of the clinical irrelevance of 2.5 additional treated bleeding events per year was provided in the \ndossier. However, since in addition to non-inferiority also superiority of marstacimab prophylaxis over routine \nprophylaxis was demonstrated for the primary analysis, these issues are not further pursued. \nThe primary analysis was supplemented with prospectively defined sensitivity analyses aiming to investigate \nthe impact of preventative infusions, marstacimab dose escalation (by including data after dose escalation \ninto the analysis), treatment discontinuation, carryover effect from OP to ATP (by excluding data from the \nfirst month of marstacimab treatment), and seasonal effects (by including only the portion of ATP into the \nanalysis that match the calendar time of the OP). These sensitivity analyses are considered to provide \nimportant additional insight into the generated efficacy data and are acceptable. \nSecondary endpoints \nSecondary endpoints included bleeding rates for different bleeding events, including incidences of joint \nbleeds, spontaneous bleeds, target joint bleeds, and total (treated and untreated) bleeds. These secondary \nendpoints based on bleeding rates provide additional clinically relevant data and supplement the primary \nendpoint. They are in line with guidance and previously provided EMA scientific advice. \nAdditional secondary endpoints include Haemophilia joint health score and PROs Haem-A-QoL for patients \n≥17 years of age and Haemo-QoL for patients 12 to <17 years of age, HAL (≥17y) and pedHAL (12 to \n<17y), PGIC-H, and EQ-5D-5L. Considering the open-label design, the relevance of PRO data is limited. \nOne of the exploratory endpoints includes data on the total coagulation factor product consumption and \ncoagulation factor product consumption unrelated to bleeding events was provided upon request. \n"
    },
    {
      "page_number": 161,
      "text": "Assessment report \nEMA/464842/2024 \nPage 161/198 \n \nImportantly, definitions of bleeding events were pre-specified in the study protocol, are clearly stated and in \nline with ISTH guidelines. \nStatistical methods \nBased on the mITT population (including all patients who completed OP and received at least 1 dose of PF- \n06741086 in ATP, excluding patients that received inhibitors) non-inferiority of PF-06741086 was estimated \nusing a repeated measure negative binomial regression model, which is considered appropriate. The \nderivation of the Non-inferiority (NI) margin of 2.5 for the primary efficacy endpoint can be followed \nstatistically. \nThree supplementary analyses were conducted to assess the impact of preventative treatment for \nmedical/dental procedures, sport activity or physical therapy (plus 72 hours) (1), of PF-06741086 dose \nincrease (2), and of treatment discontinuation (3). Additionally, three sensitivity analyses were conducted to \nassess the impact of carry-over effect from OP to ATP (1), the seasonal effect on bleeding (2) and the \npotential impact of excluded patients from mITT due to not successfully complete the OP and/or not meeting \nthe eligibility criteria to enter ATP (3). The approaches used for each supplementary analysis and sensitivity \nanalyses appear generally appropriate. The start date of the matched ATP period to assess seasonal effect is \ncalculated as start date of OP +365; and the end date of the matched ATP period is calculated as end date of \nOP +365 or the discontinuation date during ATP, whichever is earlier. \nThe planned subgroup analyses, the sample size determination, and the adjustment for multiplicity do not \nraise concerns. \n \n \nEfficacy data and additional analyses \nResults \nBaseline demographics \nOf the 128 non-inhibitor participants in study B7841005, 101 had haemophilia A and 27 had haemophilia B. \n20 of these participants were adolescents (2 on-demand during OP, 18 prophylaxis at OP), 15 of which had \nhaemophilia A, 5 had haemophilia B (all with prophylaxis during OP), based on the all safety set. \nThe number of haemophilia B participants is considered low, especially since very limited previous clinical \nexperience with marstacimab, which constitutes a first in class, is available. \nWhile it is considered acceptable to include both HA and HB patients into the study, a sufficiently large \nnumber of subjects for each haemophilia type is necessary to enable a meaningful extrapolation to the \ngeneral patient population. This was emphasised during EMA scientific advice, where the applicant was \nadvised to “enrol a sufficiently large number of subjects in each stratum to achieve a treatment effect \nestimate with reasonable precision for both haemophilia A and B patients […]”. It is noted that numbers \nprovided for haemophilia B patients are also very limited compared to other clinical programmes, including \nthose for factor replacement therapy for which substantially more clinical experience is available. Further, \nnumbers for adolescents with HB are very low. This issue was initially raised as an MO, but could be resolved \nafter additional data from LTE study 1007 were provided (further discussed below). \nA severe bleeding phenotype was characteristic of the study population. In the on-demand modified intent- \nto-treat (mITT) population at the study entry all participants had one or more target joints and 36% had 3 or \nmore target joints, while in the routine prophylaxis cohort 56.6% of the participants had one or more target \n"
    },
    {
      "page_number": 162,
      "text": "Assessment report \nEMA/464842/2024 \nPage 162/198 \n \njoints at study entry and 15.7% had 3 or more target joints at study entry despite being compliant with \nprophylactic factor replacement therapy. \nIn line with inclusion criteria, the minimum weight reported from participants of the pivotal phase 3 study \nB7841005 was 35.0 kg. No data were available for patients below this weight threshold, and benefit/risk \ncould consequently not be concluded for patients with a body weight <35 kg. A respective MO could be \nresolved after the Applicant agreed to amend the indication and included the body weight threshold of 35 kg \nused in the clinical development programme. \nIn EMA protocol assistance (EMEA/H/SA/3363/2/2017/PA/II), the applicant was advised to obtain data from \nelderly and very elderly patients and the age restriction of adults was consequently increased from <65 years \nof age to <75 years of age. However, data from only 1 patient above 65 years of age were available. \nPrimary endpoint \nThe primary analysis demonstrated non-inferiority of marstacimab prophylaxis compared to routine \nprophylaxis at OP. The mean ABR of treated bleeds in the non-inhibitor cohort was 5.08 (95% CI: 3.40, 6.77) \nduring the active treatment period compared to 7.85 (95% CI: 5.09, 10.61) during the observational period \nwith routine prophylaxis, with a resulting estimated ABR difference of -2.77 (95% CI: -5.37, -0.16). Since \nnon-inferiority was demonstrated, pre-specified statistical testing for superiority was performed and \ndemonstrated superiority with a 2-sided p-value of 0.0376. \nA reduction of the percentage of participants with 0, 1, or 2 bleeds was noted, while the percentage of \nparticipants with ≥3 bleeds was slightly increased (36.1% during routine prophylaxis, 39.8% during \nmarstacimab prophylaxis). \nThe ABR for treated bleeds reported for patients in the routine prophylaxis OP seemed comparably high, and \nan OC was raised in this regard in the D120 LoQ. In the responses, the applicant identified a subpopulation of \n15 patients on routine prophylaxis whose prophylaxis schedule adherence was <80%. For these patients, the \nmodel-derived ABR during OP was 21.54 (95% CI: 11.05, 32.03), and 6.63 (95% CI: 2.59, 10.68) during \nmarstacimab ATP. After exclusion of the poor-adherence participants, an overall model-derived ABR of 4.73 \n(95% CI: 2.89, 6.58) during ATP was reported compared to 4.83 (95% CI: 3.07, 6.59) during the OP. From \nthe provided data, it seems likely that this patient subset was the root cause for a comparably high ABR in \nthe routine prophylaxis observational period of study B7841005. \nFor patients previously on on-demand treatment during OP, marstacimab prophylaxis demonstrated \nsuperiority with a 2-sided p-value of <0.0001, providing support for the prophylaxis OP cohort, which is \nconsidered to be of higher regulatory importance. The mean estimated ABR was 3.18 (95% CI: 2.09, 4.85) \nfor marstacimab prophylaxis compared to 38.00 (95% CI: 31.03, 46.54) for on-demand treatment, with an \nestimated ABR ratio of 0.084 (95% CI: 0.059, 0.119). The percent reduction in the ABR of treated bleeds \nfrom the OP was 91.6%. As the upper bound of the 95% CI for the ABR ratio was less than 0.5, these results \nachieved the predetermined criterion for establishing the superiority with a 2-sided p-value of <0.0001. \nHowever, it is of note that in haemophilia patients without inhibitors, on-demand prophylaxis data can only \nbe considered supportive as it does not reflect the standard of care in many EU countries. \nSubgroup analyses for the primary analysis \nSubgroup analyses for type of haemophilia, age groups, race, ethnicity, and geographic region were \nconducted: \n"
    },
    {
      "page_number": 163,
      "text": "Assessment report \nEMA/464842/2024 \nPage 163/198 \n \nThe ABR for participants with haemophilia A was 5.30 for marstacimab prophylaxis compared to 9.16 for \nroutine prophylaxis during OP. \nThe ABR for participants with haemophilia B was 4.71 for marstacimab prophylaxis compared to 3.26 for \nroutine prophylaxis during OP. \nThe ABR for adult participants was 5.73 for marstacimab prophylaxis compared to 9.06 for routine \nprophylaxis. \nThe ABR for adolescent participants was 2.98 for marstacimab prophylaxis compared to 3.30 for routine \nprophylaxis during OP. Within the subpopulation of adolescent patients, HA adolescents had an ABR of 1.55 \nfor marstacimab prophylaxis compared to 3.56 for routine prophylaxis. HB adolescents had an ABR of 7.62 \nfor marstacimab prophylaxis compared to 2.45 for routine prophylaxis. This result for HB adolescents is \nderived from the results of only 4 patients. Two of which had 0 treated bleeding events during marstacimab \nATP, and two had a substantial increase in treated bleeding events compared to the OP. One patient had 3 \ntreated bleeds during OP and 16 treated bleeds during marstacimab prophylaxis, the majority of which were \ntraumatic bleeds. Another subject had 0 treated bleeds at OP and 11 treated bleeds with marstacimab \nprophylaxis, all of which protocolled as traumatic in nature. Given the small sample of adolescent HB \npatients, results in this patient population are difficult to interpret. \nThe overall number of HB patients included into clinical trials across the clinical investigation programme for \nmarstacimab was very low (n=28). Subgroup analyses in pivotal phase 3 study B7841005 showed that \nmarstacimab prophylaxis trended worse compared to routine prophylaxis during the observation period, with \ncorresponding ABRs of 4.71 and 3.26, respectively. HB patients were also markedly overrepresented in the \npatient subgroup who required dose escalation (HB: 8/25, 32.0%, HA: 6/91, 6.6%). In the very limited HB \nadolescent subpopulation (n=4), ambiguous efficacy results were reported. The safety database for \nhaemophilia B, even taking into account the rarity of the disease, was also extremely limited. These factors \nresulted in uncertainties during the evaluation regarding efficacy and safety in the HB population, which could \nbe resolved after additional data from the LTE study 1007 became available for review. In detail, the \ncomparably worse ABR trend in HB patients was not substantiated in the LTE study 1007, where a lower ABR \nwas reported. The mean estimated ABR in the overall HB population was 2.1 (95% CI: 0.96-4.58), thereof a \nmean ABR 1.77 (95% CI: 0.45-6.93; n=7) was reported for patients who were previously treated with on- \ndemand factor treatment, and a mean ABR of 2.24 (95% CI: 0.88-5.74, n=17) for those previously on \nroutine prophylaxis. Comparably higher ABR reported from the small HB patient sample (n=18) with previous \nroutine prophylaxis was primarily caused by 2 patients with high individual annualised bleeding rates. Both \npatients showed ABR decreases in LTE study 1007 after dose escalation. Additionally provided data reported \na trend for overall continually decreasing ABR values when analysed according to 6-month intervals. \nWhile the proportion of HB participants who received dose escalation was higher in the HB patient population \n(32.0%) compared to HA (6.6%), the difference in patients who reached eligibility criteria for dose escalation \nwas less pronounced between disease types. From newly provided data, overall 38.4% (35/91) of HA \nparticipants met dose escalation criteria compared to 48% (12/25) of HB participants. Since dose escalation \nwas not mandatory and the decision to escalate a participant’s dose was at the discretion of the investigator, \nan element of personal preference of the investigator might have impacted the reported proportion of dose \nescalated patients. In line with this argument, a large proportion of dose escalated HB patients were from \none site. \nRegarding the very limited sample of HB adolescents, all 4 patients rolled over into LTE 1007. 2 patients had \nABRs of 0 during marstacimab ATP in the pivotal study 1005, and both patients maintained ABRs of 0 during \n"
    },
    {
      "page_number": 164,
      "text": "Assessment report \nEMA/464842/2024 \nPage 164/198 \n \nthe LTE study 1007 without dose escalation. For both other patients, increased physical activity was noted \nduring ATP, with a high frequency of traumatic bleeds in both patients, and both patients had lower ABRs \nduring the LTE. The provided new information partly alleviated the concerns raised regarding efficacy in the \nHB adolescent study population. \nDose escalation to 300 mg QW resulted in a reduction in the mean ABR for participants during the ATP in \nboth the prophylaxis (descriptive mean ABR (Q1, Q3) before dose escalation 14.03 (7.69, 19.48) and 3.42 \n(0.00, 4.68) after) and the on-demand groups (descriptive mean ABR (Q1, Q3) before dose escalation 3.57 \n(1.19, 8.03) and 2.98 (0.00, 6.89) after). \nFrom efficacy listings of patients on marstacimab prophylaxis, several non-responders or poor-responders \nwere identified. Upon request, the Applicant identified potential prognostic factors for poor responders to be \nadult age group, a higher percentage of overall haemophilic arthropathy as well as a higher HJHS total score. \nHowever, the analysis was not considered sufficiently robust for the potential prognostic factors to be \nreflected in the SmPC. \nFor patients previously treated with on-demand regimen during OP, improvement with marstacimab \nprophylaxis was evident across all subgroups analysed. Notably, HB patients previously on on-demand \ntherapy responded well to marstacimab prophylaxis, which decreased the ABR of treated bleeds from overall \n28.67 to 1.65. Also, the two adolescent HA patients in the on-demand cohort showed improved control of \nbleeding with marstacimab prophylaxis, with the combined ABR decreasing from 35.12 during on-demand OP \nto 1.52 during marstacimab treatment. \nSensitivity analyses for the primary endpoint \nSensitivity analyses were prospectively defined to investigate the impact of preventative infusions, \nmarstacimab dose escalation (by including data after dose escalation into the analysis), treatment \ndiscontinuation, carryover effect from OP to ATP (by excluding data from the first month of marstacimab \ntreatment), and seasonal effects (by including only the portion of ATP into the analysis that match the \ncalendar time of the OP). \n \n \nProphylaxis at OP cohort \nThe estimate for the treatment effect difference between routine prophylaxis and marstacimab prophylaxis \nwas -2.77. Analysis with inclusion of bleedings during preventative infusions increased the treatment \nestimate difference to -2.82. As prespecified in the SAP, for the primary endpoint data collected after optional \ndose escalation were not included into the analysis. The sensitivity analysis with inclusion of data after dose \nescalation showed an increase in treatment estimate difference to -3.20. Imputing the portion after dose \nescalation using data from before the dose increase led to a comparable delta of -2.74. Sensitivity analysis \ninvestigating the impact of treatment discontinuations was performed via imputing the portion after \ndiscontinuation using data from during the treatment and led to an increased delta of -3.12. Impact of \ncarryover from OP to ATP was investigated by excluding data from the first month after initiation of \nmarstacimab treatment. This analysis led to a decrease in treatment effect differences to -2.56. Seasonal \neffects were investigated by inclusion of only the portion of ATP matching the calendar time of OP, which \nshowed an increase in delta to -4.40 (95% CI: -7.10, -1.70; 2-sided p-value=0.0014). The mean duration of \nmatched ATP was only marginally lower than the duration of OP due to a low discontinuation rate. Across all \nparticipants in the mITT Analysis Set, 3.4% (4/116) did not have a matched ATP period due to early \nwithdrawal. \n"
    },
    {
      "page_number": 165,
      "text": "Assessment report \nEMA/464842/2024 \nPage 165/198 \n \nABRs were lower during the second 6 months of marstacimab compared to the first 6 months, with mean \nABR estimates of 3.54 for the first half of ATP and 2.82 for the second half of ATP, when excluding subjects \nwho required a dose increase. \nSummaries provided based on ABR values at OP (groups: ABRs of 0 to <5, 5 to <10, 10 to <20, or ≥20) \nwere provided with responses. In line with post-hoc sensitivity analyses of the primary analysis, for all \nsecondary bleeding endpoints an increase in mean ABR was reported from the patient group with the lowest \nABRs (0 to <5 at OP). Joint bleeds: 0.94 (SD 1.465) vs 2.88 (SD 4.866), spontaneous bleeds: 0.89 (SD \n1.419) vs 2.61 (SD 5.130), target joint bleeds: 0.29 (SD 0.925) vs 1.66 (SD 4.675), total bleeds: 1.41 (SD \n1.727) vs 4.29 (6.937). For all remaining groups, a mean decrease in ABR was reported under marstacimab \ntreatment. \nTaken together, the provided sensitivity analyses supported the obtained results from the primary analysis in \nnon-inhibitor patients previously on routine prophylaxis. While some carryover from OP to ATP might have \noccurred, the corresponding sensitivity analysis showed a robust treatment effect difference of -2.56. All \nother sensitivity analyses led to an increase in delta, strengthening the obtained result of the primary \nendpoint. The treatment effect was stable over the course of one year of active treatment with marstacimab \nprophylaxis, with lower ABR values in the second half of treatment for those subjects who did not require a \ndose escalation. \n \n \nOn-demand cohort \nThe same set of sensitivity analyses as for patients previously on routine prophylaxis during OP were \nconducted for the patient cohort with on-demand treatment during OP. \nThe ratio estimate for the treatment effect comparison of on-demand treatment/marstacimab prophylaxis \nwas 0.084. Sensitivity analyses regarding preventative infusions, impact of dose escalation, treatment \ndiscontinuations, and impact of carryover showed a comparable result as for the primary analysis (ratios \nbetween 0.082 and 0.084). The analysis to assess the seasonal effect on bleeding via inclusion of only the \nportion of ATP matching the calendar time of OP showed a notable reduction of the treatment effect ratio in \nfavour of marstacimab to 0.062 (95% CI: 0.043, 0.090; 2-sided p-value<0.0001). A comparison of the first \nand second half of the marstacimab active treatment period reported a decrease in ABR during the second six \nmonths, in line with results obtained from the cohort of patients previously on routine prophylaxis. The \ntreated ABR during the matched ATP period was numerically lower than the ABR during the overall ATP \nperiod in both cohorts. These supplementary data support the primary analysis with no concerns raised. \nSecondary endpoints \nSecondary endpoints evaluated incidences of joint bleeds, spontaneous bleeds, target joint bleeds, and total \nbleeds. For all these bleeding related endpoints, in patients previously on routine prophylaxis a reduction of \nthe overall incidence was demonstrated and results of the bleeding related secondary endpoints provide \nsupport for the primary analysis. However, a reduction in 0 bleeders is noted across all bleeding related \nsecondary endpoints. Results for patients previously on routine prophylaxis are summarised below. \nThe incidence of joint bleeds was 4.13 during marstacimab ATP and 5.66 during previous routine prophylaxis. \nAnnualised rates of participants with 0, 1 or 2 joint bleeds decreased (0 joint bleeds: 40/83 [48.2%] during \nroutine prophylaxis to 33/83 [39.8%]), rates of participants with ≥3 joint bleeds increased from 23/83 \n(27.7%) to 27 (32.5%). The incidence of joint bleeds was lower in the second half of the ATP (3.07 vs 2.30). \n"
    },
    {
      "page_number": 166,
      "text": "Assessment report \nEMA/464842/2024 \nPage 166/198 \n \nThe incidence of spontaneous bleeds was 3.78 during marstacimab ATP and 5.86 during previous routine \nprophylaxis. Annualised rates of participants with 0 spontaneous bleeds decreased slightly from 40/83 \n(48.2%) during routine prophylaxis to 35/83 (42.2%) during marstacimab prophylaxis, rates of participants \nwith 1, 2, 3 or more spontaneous bleeds were comparable between treatment courses. The incidence of \nspontaneous bleeds was lower in the second half of the ATP (2.80 vs 2.03). \nThe incidence of treated target joint bleeds was 2.51 (95% CI: 1.25, 3.76) during marstacimab ATP and 3.36 \n(95% CI: 1.59, 5.14) during previous routine prophylaxis. Annualised rates of participants with 0 treated \ntarget joint bleeds decreased from 62/83 (74.7%) during routine prophylaxis to 54/83 (65.1%), rates of \nparticipants with 1, 2, 3 or more treated target joint bleeds were comparable between marstacimab and \nprevious routine prophylaxis. The incidence of treated target joint bleeds was lower in the second half of the \nATP (1.46 vs 1.29). \nThe incidence of total bleeds was 5.97 (95% CI: 4.13, 7.81) during marstacimab ATP and 8.84 (95% CI: \n5.97, 11.72) during previous routine prophylaxis. Annualised rates of participants with 0 total bleeds \ndecreased from 28/83 (33.7%) to 22/83 (26.5%), rates for those with 3 or more total bleeds increased from \n33/83 (39.8%) to 39/83 (47.0%). The incidence of total bleedings was lower in the second half of the ATP \n(3.54 vs 1.29). \nThe key secondary endpoint percentage of participants with 0 bleeds was removed more than 2 years after \nstudy initiation as part of protocol amendment 7. At the time of endpoint removal, 127/128 patients were \nenrolled in study B7841005, of which 104 patients had already received Hympavzi. Taking into account the \nunfavourable outcome reported for marstacimab and the open-label design of pivotal study B7841005, it \nseems likely that the decision to remove the endpoint was data-driven. This is seen critical and raises \nuncertainties regarding study conduct. Since corresponding data on the percentage of participants with no \ntreated bleeds were presented as part of the descriptive summary of the primary endpoint, this issue was \nhowever not further pursued. \nIt is noted that during the marstacimab ATP 5 participants discontinued. All 5 participants were included in \nthe primary and subgroup analyses until discontinuation. 4/5 patients discontinued due to withdrawal by \nsubject, 1 due to an AE (meningioma, unrelated to study drug). Only 2 of the 5 discontinued participants had \nhigher ABRs (treated, joint, spontaneous, target, and total bleeds) during marstacimab treatment. \nThe haemophilia joint health score (HJHS) demonstrated comparable results for previous routine prophylaxis \nand marstacimab prophylaxis. Results after 12 months trended slightly better compared to results after 6 \nmonths, in line with the primary analysis and bleeding related secondary endpoints. \nPROs \nOverall, results from PROs suggested preservation of the benefits of routine prophylaxis under continued \nmarstacimab treatment. However, due to the open-label design and the consequent considerable risk for \nbias, the relevance of PRO data is considered limited. \nDevelopment of antibodies \nNo relevant difference in ABRs was detected between patients with or without ADAs or nABs. \nSupportive studies \nThe Phase 3 OLE Study B7841007, long-term OLE of the pivotal Study B7841005, is still ongoing and, \naccording to the currently available data, in participants with varying lengths of treatment (34.0 to 483.0 \ndays) marstacimab maintained its long-term efficacy with respect to ABR of treated bleeds and the incidence \n"
    },
    {
      "page_number": 167,
      "text": "Assessment report \nEMA/464842/2024 \nPage 167/198 \n \nof spontaneous bleeds, joint bleeds, total bleeds (treated and untreated), target joints, and HRQoL outcomes. \nFeasibility of self-administration using the sponsor’s PFP device was established in a small patient population. \nThe multiple ascending dose study B7841002 showed that marstacimab efficacy across all doses investigated \noverall as well as across individual treatment groups. However, no clear dose/effect correlation could be \ndeduced from the data provided given the small sample size. \nThe phase 2 OLE study B7841003 provided efficacy data in line with the results obtained in phase 3 studies. \n \n \n \n2.6.7. Conclusions on the clinical efficacy \n \nNon-inferiority and statistical superiority regarding the ABR of treated bleeds were shown for weekly \nmarstacimab prophylaxis over a prospectively conducted lead-in observational period on routine factor \nprophylaxis in the overall study population. Generally, this outcome was supported by secondary endpoints \nregarding bleeding incidences and haemophilic joint assessment. \n \n2.6.8. Clinical safety \n \n2.6.8.1. Patient exposure \n \nStudy B7841005 – Pivotal Study \nAs of 17 April 2023, the LPLV for the non-inhibitor cohort: \n• \n37 participants with prior on-demand treatment using factor replacement entered the study, of whom \n34 (91.9%) completed the 6-month OP and 3 (8.1%) discontinued during the OP (2 participants due to \nprotocol deviations and 1 participant due to other reason of moving to a different country). Of the 34 \nparticipants who completed the OP, 33 participants entered the ATP and all 33 (100%) participants \ncompleted the 12 month ATP. No participants discontinued during the ATP. \n• \n91 participants with prior prophylactic treatment using factor replacement entered the study, of \nwhom 84 (92.3%) completed the 6-month OP and 7 (7.7%) discontinued during the OP (5 participants no \nlonger met eligibility criteria and 2 participants due to protocol deviations). Of the 84 participants who \ncompleted the OP, 83 participants entered the ATP, of whom 78 (94.0%) completed the 12-month ATP and 5 \n(6.0%) discontinued (4 participants withdrew and 1 participant due to AE). \n• \n108 of 111 participants who completed the 12-month marstacimab ATP planned to participate in the \nlong-term extension Study B7841007. \n• \n1 participant with prior on-demand treatment and 8 participants with prior prophylactic treatment \nentered the follow-up phase of Study B7841005. Note: participants who planned to participate in the long- \nterm extension Study B7841007 were not required to enter the follow-up phase. \n• \nTwo participants (1 in the prior on-demand cohort and 1 in the prior prophylaxis cohort) completed \nthe OP, but discontinued before entering the ATP and marstacimab dosing due to not meeting eligibility \ncriteria to enter the ATP. \n"
    },
    {
      "page_number": 168,
      "text": "Assessment report \nEMA/464842/2024 \nPage 168/198 \n \nIntegrated Safety Analysis Population \nIn the integrated analyses datasets: \n• \nOf 116 participants without inhibitors who entered the ATP phase of the Study B7841005, 111 \n(95.7%) participants without inhibitors completed the 12-month marstacimab ATP. As of 10 February 2023, \n90 participants completed Study B7841005 and, 88 of these entered Study B7841007 as of 10 March 2023. \nThese 88 were included in the B7841005/B7841007 analysis (29/30 [96.7%] participants with prior on- \ndemand treatment and 59/60 [98.3%] participants with prior prophylaxis). 2 participants without inhibitors \ndid not continue into Study B7841007 due to sponsor decision (1 participant in on-demand treatment at OP \ncohort) and investigator decision (1 participant in routine prophylaxis at OP cohort). \n• \nOf 27 participants who entered Study B7841002, 24 participants completed the study and 2 \nparticipants discontinued due to AEs and 1 participant withdrew from study. Of the participants who \ncompleted Study B7841002, 18 participants were enrolled into the OLE Study B7841003. 2 participants were \nnewly enrolled into Study B7841003 at the 150 mg SC QW dose. Of these 20 participants, 18 (including the 2 \nparticipants enrolled de novo) completed Study B7841003 and 2 participants discontinued due to withdrawal \nby participant. \n \n \nTable 47: Patient exposure Marstacimab Dataset (Data cut-off: Pivotal: April 17, 2023, OLE: March \n10, 2023) \n \nPatients enrolled \nPatients \nexposed* \nPatients exposed \nto the proposed \ndose range \nPatients with \nlong term** \nsafety data \nBlinded studies \n(placebo-controlled) \n- \n- \n- \n- \nBlinded studies \n(active -controlled) \n- \n- \n- \n-- \n26 Phase 1 \n27 Phase 1 \n20 Phase 2 (18 \nOpen studies \n20 Phase 2 (18 \nfrom Ph1 + 2 \nnew subjects) \n118 Phase 3 -> \nfrom Ph1 + 2 \nnew subjects) \n116 Phase 3 -> \n88 OLE \n6 phase 1 \n10 phase 2 \n116 phase 3 \n125 \n88 OLE \n144 unique \nsubjects \nPost marketing \n- \n- \n- \n- \nCompassionate use \n- \n- \n- \n- \n* Received at least 1 dose of active treatment \n** ≥ 12 months continuous exposure data. \n \n \nThe Applicant has provided two different datasets for the safety evaluation. \nThe first is the safety analysis from the pivotal trial (B7841005), where a comparison for the same patients \nwhile receiving their usual haemophilia treatment during the OP (observational period) is possible. \n"
    },
    {
      "page_number": 169,
      "text": "Assessment report \nEMA/464842/2024 \nPage 169/198 \n \nThe second encompasses all patients with haemophilia A or B without inhibitors who received marstacimab in \nmultiple dose studies across the clinical trial programme. In addition, patients with inhibitors from the phase \n1 and phase 2 studies are included in this dataset, but not patients with inhibitors from the respective cohort \nof the pivotal trial. \nData from 144 patients are available in those datasets, with 125 subjects exposed to treatment with \nmarstacimab for a duration of 12 months or longer. 116 of those patients suffered from haemophilia A, while \n28 subjects suffered from haemophilia B. Furthermore, 6 of the haemophilia A patients were displaying \ninhibitors and enrolled in an inhibitor cohort in a phase 1 or phase 2 study. Safety data from the inhibitor \ncohort of the pivotal study were not included in the integrated safety analysis. \nThe majority of subjects were between 18 and 44 years old, with a median age of 31.0 years. The number of \nsubjects ≥65 yoa in the clinical trial programme is extremely limited. Only one patient, aged 66, was enrolled \nin the pivotal trial. The lower age limit for inclusion into the pivotal trial was 12 years, and data from 19 \nadolescents, 15 with HA and 4 with HB are available. \nThe majority of patients were White (50 %), followed by Asian (40.3%) and Black (9.0) subjects. \nThe cut-off date of the safety database was March/April 2023, and the Applicant was asked to submit an \nupdated analysis of all events of death, SAE and AESI reported since, also for the cohorts of patients \nsuffering from haemophilia A or B with inhibitors enrolled in the pivotal trial B7841005/ extension trial \nB7841007. With the responses to the D120 LoQ, the Applicant submitted a safety update with a new cut-off \nof 09 Oct 2023. As the participation of the non-inhibitor cohort in pivotal study 1005 was already complete \nwith the original cut-off, additional data for the non-inhibitor cohort derive from long-term extension study \n1007. In addition, supportive data from the inhibitor cohorts of studies 1005 and 1007 as well as paediatric \nstudy 1008 were made available. \n \n2.6.8.2. Adverse events \n \nTreatment-Emergent Adverse Events \n"
    },
    {
      "page_number": 170,
      "text": "Assessment report \nEMA/464842/2024 \nPage 170/198 \n \nTable 48: Incidence, CTCAE Grade of Treatment-Emergent Adverse Events (All Causalities) by \nSystem Organ Class and Preferred Term - Marstacimab Dataset \n \n \n"
    },
    {
      "page_number": 171,
      "text": "Assessment report \nEMA/464842/2024 \nPage 171/198 \n \n \n \n"
    },
    {
      "page_number": 172,
      "text": "Assessment report \nEMA/464842/2024 \nPage 172/198 \n \n \n \n"
    },
    {
      "page_number": 173,
      "text": "Assessment report \nEMA/464842/2024 \nPage 173/198 \n \n \n \n \n \n \nFrequency of AEs for Participants with Dose Escalation \nFor Studies B7841005/B7841007, of the 18 participants who had a dose escalation from 150 mg QW \nmarstacimab to 300 mg QW marstacimab: \n• \nNo participant experienced an SAE or an AE that led to discontinuation of study intervention. \n• \n8 (44.0%) participants experienced TEAEs (all causalities), the most frequently reported were \narthralgia and COVID-19 infection (2 [11.1%] participants). Other TEAEs reported were joint range of motion \ndecreased, injection site induration, laryngitis, rhinitis nasopharyngitis (each 1 [5.6%] participants). No other \nAEs in the ISR category were reported for Studies B7841005/B7841007. All TEAEs reported while participants \nreceived 300 mg marstacimab QW were mild or moderate in severity. \n• \n10 participants who had their dose escalated did not experience any TEAEs while they remained on \nthe 300 mg QW dose. \nFor Studies B7841002/B7841003, of the participants whose treatment with marstacimab was initiated at 300 \nmg QW marstacimab and maintained on that dose : \n• \nIn Study B7841002, 11 (78.6%) participants treated with 300 mg SC QW dose of marstacimab \nreported TEAEs (31 events, 7 of which were considered treatment-related). 1 participant without inhibitors \nexperienced a SAE (Grade 2 appendicitis, not related to treatment). \n• \nIn Studies B7841002/B7841003, there were 2 (14.3%) participants who reported injection site \nbruising, whilst injection site erythema, injection site haematoma, injection site haemorrhage, injection site \ninduration, injection site pain, injection site pruritus, injection site reaction and injection site swelling were all \nreported in 1 of the 14 (7.1%) participants each. \n"
    },
    {
      "page_number": 174,
      "text": "Assessment report \nEMA/464842/2024 \nPage 174/198 \n \nTreatment-Related AEs \nStudy B7841005 collected “study treatment related AE” where study treatment is defined as marstacimab \nprophylaxis during the ATP. Therefore, there were no treatment-related TEAEs in the OP by design. \nIn the integrated analysis of the studies, treatment-related TEAEs across the integrated studies in the \nMarstacimab Dataset showed: \n• \nIn Study B7841005 during ATP which represents the initial 12 months of exposure, the most \nfrequently reported treatment-related AEs were injection site pruritus and pruritus, each reported in 4 \nparticipants (3.4%), and prothrombin fragment 1.2 increased, and injection site erythema, each reported in 3 \n(2.6%) participants. All other treatment-related TEAEs were reported in <2% participants. All treatment- \nrelated TEAEs were of Grade 1 or 2 severity. \n• \nIn Study B7841007 which represents exposure of >12 to approximately 28 months, the most \nfrequently reported treatment-related AEs were injection site bruising, injection site induration and injection \nsite swelling, all reported in 1 (1.1%) participants. All treatment-related TEAEs were of Grade 1 or 2 severity. \nNo other treatment-related TEAEs were reported. \n• \nIn Studies B7841005/B7841007 where unique participants were combined to present the entire \nmarstacimab experience up to approximately 28 months at the intended dose, the most frequently reported \ntreatment-related AEs were injection site pruritus and pruritus, each reported in 4 (3.4%) participants. All \nother treatment-related TEAEs were reported in <3% participants. All participants had treatment-related \nTEAEs of Grade 1 or 2 severity. \n• \nIn Study B7841002, where all participants received the intended or higher doses (150, 300, 450 mg) \nfor 3 months, the most frequently treatment-related AEs were injection site pain and injection site swelling \n(each reported by 3 [11.5 %] participants). Other frequently reported (≥5%) treatment-related AEs were \ninjection site bruising, injection site induration, and hypertension (each reported by 2 [7.7 %] participants). \nTreatment-related TEAEs were of Grade 1 or 2 in severity for all participants with the exception of 4 (15.4%) \nparticipants who reported treatment-related Grade 3 events which included injection site pain, injection site \nswelling, blood fibrinogen decreased, pruritus and rash erythematous each reported in 1 [3.8%] \nparticipants). \n• \nIn Studies B7841002/B7841003 where unique participants were combined to present the entire \nmarstacimab experience up to 15 months with doses at 150 or 300 mg for 12 months, the most frequently \nreported treatment-related AEs were injection site pain and injection site swelling (each reported in 3 \nparticipants [10.7 %]), injection site bruising, injection site induration, injection site reaction and \nhypertension were each reported in 2 (7.1 %) participants). For the majority (85.7%) of participants, \ntreatment related TEAEs were of Grade 1 or 2 severity and Grade 3 reactions were only reported in 4 \n(14.3%) participants. These included injection site pain, injection site swelling, blood fibrinogen decreased, \npruritus and rash erythematous each reported in 1 [3.6%] participants). \n \n \nTable 47 provides an integrated overview of treatment-related TEAEs across relevant studies in the \nMarstacimab Dataset. \n"
    },
    {
      "page_number": 175,
      "text": "Assessment report \nEMA/464842/2024 \nPage 175/198 \n \nTable 49: Incidence of treatment-emergent adverse events by system organ class and preferred \nterm (treatment related) – marstacimab dataset \n \nNumber (%) of Participants: \nby System Organ Class \nand Preferred Term \nB7841002 \n(N=26) \nn (%) \nB7841002/ \nB7841003 \n(N=28) \nn (%) \nB7841005 \n(N=116) \nn (%) \nB7841007 \n(N=87) \nn (%) \nB7841005/ \nB7841007 \n(N=116) \nn (%) \nWith any AE \n14 ( 53.8) \n16 ( 57.1) 23 ( 19.8) \n3 ( 3.4) \n24 ( 20.7) \nGASTROINTESTINAL DISORDERS \n1 ( 3.8) \n1 ( 3.6) \n1 ( 0.9) \n0 \n1 ( 0.9) \nDyspepsia \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nHaemorrhoids \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nHaemorrhoids thrombosed \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nGENERAL DISORDERS AND ADMINISTRATION SITE \nCONDITIONS \n7 ( 26.9) \n10 ( 35.7) 13 ( 11.2) \n3 ( 3.4) \n15 ( 12.9) \nFatigue \n1 ( 3.8) \n1 ( 3.6) \n1 ( 0.9) \n0 \n1 ( 0.9) \nInjection site bruising \n2 ( 7.7) \n2 ( 7.1) \n1 ( 0.9) \n1 ( 1.1) \n2 ( 1.7) \nInjection site erythema \n1 ( 3.8) \n1 ( 3.6) \n3 ( 2.6) \n0 \n3 ( 2.6) \nInjection site haematoma \n0 \n1 ( 3.6) \n1 ( 0.9) \n0 \n1 ( 0.9) \nInjection site haemorrhage \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nInjection site induration \n2 ( 7.7) \n2 ( 7.1) \n1 ( 0.9) \n1 ( 1.1) \n2 ( 1.7) \nInjection site oedema \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nInjection site pain \n3 ( 11.5) \n3 ( 10.7) \n2 ( 1.7) \n0 \n2 ( 1.7) \nInjection site pruritus \n1 ( 3.8) \n1 ( 3.6) \n4 ( 3.4) \n0 \n4 ( 3.4) \nInjection site reaction \n0 \n2 ( 7.1) \n0 \n0 \n0 \nInjection site swelling \n3 ( 11.5) \n3 ( 10.7) \n2 ( 1.7) \n1 ( 1.1) \n3 ( 2.6) \nInjection site warmth \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nPeripheral swelling \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nINJURY, POISONING AND PROCEDURAL \nCOMPLICATIONS \n1 ( 3.8) \n1 ( 3.6) \n1 ( 0.9) \n0 \n1 ( 0.9) \nContusion \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nOccupational exposure to product \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nINVESTIGATIONS \n5 ( 19.2) \n5 ( 17.9) \n3 ( 2.6) \n0 \n3 ( 2.6) \nBlood fibrinogen decreased \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nFibrin D dimer increased \n1 ( 3.8) \n1 ( 3.6) \n2 ( 1.7) \n0 \n2 ( 1.7) \nProthrombin fragment 1.2 increased \n0 \n0 \n3 ( 2.6) \n0 \n3 ( 2.6) \nProthrombin time prolonged \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \n"
    },
    {
      "page_number": 176,
      "text": "Assessment report \nEMA/464842/2024 \nPage 176/198 \n \nNumber (%) of Participants: \nby System Organ Class \nand Preferred Term \nB7841002 \n(N=26) \nn (%) \nB7841002/ \nB7841003 \n(N=28) \nn (%) \nB7841005 \n(N=116) \nn (%) \nB7841007 \n(N=87) \nn (%) \nB7841005/ \nB7841007 \n(N=116) \nn (%) \nTroponin I increased \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nTroponin increased \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nMUSCULOSKELETAL AND CONNECTIVE TISSUE \nDISORDERS \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nArthralgia \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nNERVOUS SYSTEM DISORDERS \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nHeadache \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nSKIN AND SUBCUTANEOUS TISSUE DISORDERS \n1 ( 3.8) \n1 ( 3.6) \n4 ( 3.4) \n0 \n4 ( 3.4) \nPruritus \n1 ( 3.8) \n1 ( 3.6) \n4 ( 3.4) \n0 \n4 ( 3.4) \nRash erythematous \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nVASCULAR DISORDERS \n2 ( 7.7) \n2 ( 7.1) \n0 \n0 \n0 \nHypertension \n2 ( 7.7) \n2 ( 7.1) \n0 \n0 \n0 \nParticipants are only counted once per treatment per event. \nTotals for the number of participants at a higher level are not necessarily the sum of those at the lower levels since a participant may \nreport two or more different AEs within the higher level category. \nIncludes data from the first dose of marstacimab to the last study contact days. \nMedDRA v25.1 coding dictionary applied. \nTable created by:/Volumes/app/cdars/prod/prjB784/nda1_cdisc/B784_SCS_BLA/saseng/cdisc3_0/macros/aesocpt_t.sas \nPFIZER CONFIDENTIAL Table Generation: 01SEP2023 (04:07) \nStudy B7841005(Data cutoff : 17APR2023;Database snapshot date : 05MAY2023); B7841007(Data cutoff : 10MAR2023;Database \nsnapshot date : 14APR2023) Output File: ./nda1_cdisc/B784_SCS_BLA/t143124 \nTable 14.3.1.2.4 Marstacimab is for Pfizer internal use. \n \n \nThe highest reported CTCAE Grade of an adverse event in the complete dataset was 3 (of 5), with one such \nAE (tympanic membrane perforation) occurring in one adolescent subject. In study 1002/1003, six such AEs \n(one instance each of injection site pain, injection site swelling, blood fibrinogen decreased, pruritus \ngeneralised, rash erythematous, skull fracture, cerebral haemorrhage and arthralgia) were reported in 6 adult \nsubjects. In studies 1005/1007, 8 such AEs, with one instance each of ocular implant exposure, tonsillitis, \ngout, hemarthrosis, pain in extremity, meningioma, headache and calculus urinary were reported in 6 adult \nsubjects. Of these events, the injection site reactions, fibrinogen decreased, pruritus and rash were judged as \ntreatment related by the Applicant, which is supported. \nThe most frequently reported AEs irrespective of causality were COVID-19, headache, contusion and \nhypertension. The most frequent treatment related AEs were injection site reactions and prothrombin \nfragment 1.2 increased. \nThe Applicant was asked to include all AEs regarded as treatment related as ADRs in section 4.8 of the SmPC \nor to justify their omission and has adequately justified the selection of AEs as ADRs, except for \nhypertension. \n"
    },
    {
      "page_number": 177,
      "text": "Assessment report \nEMA/464842/2024 \nPage 177/198 \n \nHypertension SMQ was reported with more than twice frequency in the integrated dataset of Phase 2 studies \n1002 and 1003 than in Phase 3 studies 1005/1007. \nTable 50: Adverse events of special interest – marstacimab dataset \n \nOne participant from the PF-06741086 300 mg SC loading + 150 mg SC QW from study 1002 non-inhibitor \ndose cohort permanently discontinued from study due to a Grade 2 non-serious AE of hypertension, which \nwas considered as treatment related by the investigator. At baseline, this patient had BP values within \nnormal limits, and he experienced an AE of elevated BP at study day 58. The fact that on day 66 blood \npressure values were still hypertensive despite last treatment being administered on day 58 cannot be \nconsidered proof of marstacimab not being causally related to this AE, as the steady state half-life of this \nmonoclonal antibody is expected to be 16-18 days. Further, the AE of hypertension is reported as resolved at \nday 85, which aligns with the expected washout of marsticimab. Two further patients who experienced \nhypertension AEs in study 1002 did not have a medical history of hypertension. \nAccording to the Vital signs chapter of Clinical Safety Summary, 7 patients in Study 1003 experienced SBP \nincrease from baseline ≥30 mm Hg and/or supine DBP increase from baseline ≥20 mm Hg. Overall 10 \npatients experienced ≥ 30 mmHg elevation in their systolic BP, ≥ 20 mmHg elevation in their diastolic BP \nduring the Phase 3 clinical studies 1005 and 1007, and as such, their proportion is remarkably lower \ncompared to those found in the Phase 2 studies 1002 and 1003. Most of the elevations were episodic in \nnature, and they occurred in patients who were normotensive or even low-normotensive at the BL of Study \n1005. \nIn the by-patient line listing, overall 15 patients from the 111 patients eligible to enter the extension study \n1007 had permanent systolic BP elevations reaching the magnitude of 5-30 mmHg. There were two patients \nfrom this subpopulation with hypertension at baseline, but the remaining part of these patients were \nnormotensive or even low-normotensive at the baseline of Study 1005. \nTaking into account the narrative of one subject who discontinued from study B7841002 due to hypertension \nthat resolved after stopping the study drug and the incidence of hypertension in 14% of subjects in phase 2 \n+ extension studies and 7% of subjects in the phase 3 + extension studies, as well as the prolonged BP \nelevations occurring in normotensive patients during the Phase 3 studies it cannot ruled out convincingly that \nhypertension is related to marstacimab treatment, even if taking into account the comorbidity of \nhypertension with haemophilia. \n \n \n \n2.6.8.3. Serious adverse event/deaths/other significant events \n \nAESI \nThromboembolic Events \n"
    },
    {
      "page_number": 178,
      "text": "Assessment report \nEMA/464842/2024 \nPage 178/198 \n \nPivotal Trial \nNo participants reported thromboembolic events during the marstacimab ATP. For participants with prior on- \ndemand treatment, no participants reported thromboembolic events during the OP or ATP. \nFor participants with prior routine prophylaxis, 1 (1.1%) participant reported a device occlusion (blocked \nport-a-cath) during the OP, which required hospitalization for the device to be successfully restored and the \nparticipant allowed to continue the study. \n \n \nIntegrated Safety Analysis Population \nThere were no thromboembolic events across Studies B7841002/B7841003 or Studies B7841005/B7841007 \nduring marstacimab treatment. \nOne healthy participant in Study B7841009 (BE study) experienced a deep vein thrombosis and pulmonary \nembolism 9 days following a single dose of marstacimab (300 mg), and 29 days after vaccination with the \nAstraZeneca (ChAdOx1-S [recombinant] COVID-19 vaccine (second dose). \n \n \nThrombotic microangiopathy \nPivotal Trial \nThere were no reports of thrombotic microangiopathy in any participant in this study. \nIntegrated Safety Analysis Population \nThere were no reports of thrombotic microangiopathy events in any participant in any clinical study across \nthe marstacimab program (including the OP of Study B7841005). \n \n \nDisseminated intravascular coagulation/ consumption coagulopathy \nPivotal Trial \nThere were no reports of disseminated intravascular coagulation/consumption coagulopathy in any participant \nin this study. \nIntegrated Safety Analysis Population \nThere were no reports of disseminated intravascular coagulation/consumption coagulopathy in any participant \nin any clinical study across the marstacimab program (including the OP of Study B7841005). \n \n \nInjection site reactions \nPivotal Trial \nPer protocol, ISRs were only evaluated and reported during the ATP when marstacimab was administered, \ntherefore, comparisons with rate on prior therapy are not feasible. \nFor participants with prior on-demand treatment, 2 (6.1%) participants reported an ISR event during the \nmarstacimab ATP. Both ISRs were of Grade 1 severity. \n"
    },
    {
      "page_number": 179,
      "text": "Assessment report \nEMA/464842/2024 \nPage 179/198 \n \nFor participants with prior routine prophylaxis, 9 (10.8%) participants reported an ISR event during the \nmarstacimab ATP. All ISRs were of Grade 1 (8 [9.6%] participants) or Grade 2 (1 [1.2%] participant) \nseverity. \n1 participant experienced approximately 70 ISRs mostly reported as injection site pruritus, erythema, or \ninduration, Grade 1 or 2. This participant tested positive for ADA (Study Days 60, 120, and 180) and positive \nfor NAb (Study Day 120). \nThere were no discontinuations for the AE of ISR in either cohort. \nIntegrated Safety Analysis Population \nIn Study B7841005 during the ATP which represents the initial 12 months of exposure, 11 (9.5%) \nparticipants reported ISRs with the most frequently reported being injection site pruritus (4 [3.4%]) and \nerythema (3 [2.6%] participants). Most ISRs were mild (8.6%), with few moderate (0.9%) and no severe \nreactions. \nIn Study B7841007 which represents exposure of >12 to approximately 28 months, 3 (3.4%) participants \nreported ISRs. ISRs reported were injection site bruising, injection site induration and injection site swelling \neach in 1 participant [1.1%]. ISRs were mild (2.3%), or moderate (1.1%) with no severe reactions. \nAll participants in Study B7841005 who were administered marstacimab used the PFS exclusively. All \nparticipants transitioning into Study B7841007 were provided the PFP for marstacimab administration. All \nparticipants in Study B7841007 except 2 used the PFP exclusively. ISRs were reported with a lower frequency \nin Study B7841007 than in Study B7841005 which may reflect the method of administration. \nIn Studies B7841005/B7841007 where unique participants were combined to present the entire marstacimab \nexperience up to approximately 28 months at the intended dose, 13 (11.2%) participants reported ISRs. \nMost ISRs were mild (10.3%), with few moderate (0.9%) with no severe reactions. \nIn Study B7841002, where all participants received the intended or higher doses (150, 300, 450 mg) for 3 \nmonths, 9 (34.6%) participants reported ISRs. Most injection site reactions were mild (23.1%), with few \nmoderate (3.8%) or severe (7.7%) reactions. Injection site pain and injection site swelling (both Grade 3) \nwere each reported in 1 participant in the 1.5 mL injection volume, 450 mg SC QW cohort. The participant \nwith injection site pain was down titration to the 1 mL injection volume 300 mg SC QW. The increased \nfrequency and severity of injection site reactions at the 450 mg dose level was considered to be related to \nthe increased injection volume of 1.5 mL, delivered 3 times per dose (whereas the other cohorts received \nmarstacimab injection volumes ≤1 mL). These data indicate that the limits of tolerability were reached for \nsome participants at this injection volume. \nIn Studies B7841002/B7841003 where unique participants were combined to present the entire marstacimab \nexperience up to 15 months with doses at 150 or 300 mg, ISRs were reported in 10 (35.7%) participants. \nMost ISRs were mild (21.4%), with few moderate or severe (7.1%) reactions. Grade 3 events were as \ndescribed in Study B7841002. \n \n \nSevere hypersensitivity and anaphylactic reactions \nPivotal Trial \nNo severe or systemic cases of hypersensitivity or anaphylaxis occurred for participants with prior on-demand \nor routine prophylaxis during the OP or marstacimab ATP. \n"
    },
    {
      "page_number": 180,
      "text": "Assessment report \nEMA/464842/2024 \nPage 180/198 \n \nIntegrated Safety Analysis Population \n2 participants in Study B7841002 reported Grade 3 events in the anaphylactic reaction SMQ of pruritus and \nrash erythematous. \nNo other severe hypersensitivity events were observed in Studies B7841002, B7841003 or the non-inhibitor \ncohort of Studies B7841005/B7841007 including OP in B7841005. No hypersensitivity or anaphylactic \nreactions were reported in the 3 participants who also tested positive for ADA in Studies \nB7841002/B7841003 or in the 23 participants who tested positive for ADA in Studies B7841005/B7841007. \n \n \nCOVID-19 infections \nPivotal Trial \nCOVID-19 (SMQ) occurred in 19 (22.9%) prior routine prophylaxis participants during the ATP compared to 3 \n(3.3%) participants during the OP. Many participants entered the ATP as COVID-19 rates were rising in early \n2022. \n \n \nMarstacimab Dataset \nNo Covid-19 events occurred in subjects from clinical trial 1002/1003, 3 participants of trial 1007 reported \nCovid-19 events. \n \n \nAEs Requiring Continuous Monitoring or Treatment Modification \nPivotal trial \nHypersensitivity and Cutaneous Adverse Reactions \nNo participants with prior on-demand treatment reported hypersensitivity cutaneous adverse reactions during \nthe OP. However, 2 (6.1%) participants with prior on-demand treatment reported cutaneous reactions of \npruritus, both mild or moderate in severity and considered related by the investigator, during the \nmarstacimab ATP. \nFor participants with prior routine prophylaxis, 2 (2.2%) participants during the OP reported mild cases of \ncutaneous reactions of eczema and rhinitis allergic (1 [1.1%] each, not related), while 6 (7.2%) participants \nduring the marstacimab ATP reported mild to moderate cases of cutaneous reactions of pruritus (2 [2.4%], \nrelated) and rhinitis allergic (2 [2.4%], not related), and conjunctivitis, eczema, and rash (1 [1.2%] each, \nnot related). \n \n \nGastrointestinal Varices/Haemorrhoids \nNo participants with prior on-demand treatment reported gastrointestinal varices/haemorrhoids during the \nOP, while 1 (3.0%) participant with a history of hemorrhoids experienced a localised inflammatory Grade 2 \n(moderate) event of haemorrhoids thrombosed during the ATP. The participant's active dosing with \nmarstacimab was not affected by this event. \n"
    },
    {
      "page_number": 181,
      "text": "Assessment report \nEMA/464842/2024 \nPage 181/198 \n \nNo gastrointestinal varices/haemorrhoids events were reported for participants with prior routine prophylaxis \nduring the OP or marstacimab ATP. \nIntegrated Safety Analysis Population \nAll reactions were observed in the pivotal trial and are described above. \n \n \nHypertension \nHypertension also qualifies as an AESI under the definition of AEs requiring continuous monitoring (eg, \nadditional laboratory testing) or requiring treatment modification (eg, delay or discontinuation of study \nintervention). Hypertension was one of the most frequently reported AESI and is further discussed under the \nheading of treatment related AEs above. \n \n \nIn summary, adverse events were defined as AESIs if they were either related to the mode of action or the \nadministration of marstacimab, which is endorsed. \nNo instances of thromboembolic events, thrombotic microangiopathy or DIC were reported in any patient \nsuffering from haemophilia A or B without inhibitors across the clinical investigation programme. One TEE of \ndeep vein thrombosis and pulmonal embolism was observed in a healthy volunteer in the bioequivalence \nstudy B7841009, which led to the early termination of this study. \nThe incidence of injection site reactions and hypersensitivity reactions was low across all clinical trials. \nNotably, one patient who was ADA positive and subsequently Nab positive, reported >70 ISR in the pivotal \ntrial. The patient was nAb negative from study Day 183 and ADA negative from study Day 246. He did not \nreport ISR from this time onward and rolled over into the OLE. \nNo special signals or risk emerge from the analysis of the AESIs for the intended label population. \n \n \nSAE \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTable 51: Summary of serious adverse events (all causalities) by system organ class and \npreferred term – marstacimab dataset \n"
    },
    {
      "page_number": 182,
      "text": "Assessment report \nEMA/464842/2024 \nPage 182/198 \n \nNumber of Participants Evaluable for AEs \nNumber(%) of Participants with Adverse Events: \nby System Organ Class and \nPreferred Term \nB7841002 \n(N=26) \nn (%) \nB7841002/ \nB7841003 \n(N=28) \nn (%) \nB7841005 \n(N=116) \nn (%) \nB7841007 \n(N=87) \nn (%) \nB7841005/ \nB7841007 \n(N=116) \nn (%) \nNumber of participants with Serious AE \n4 ( 15.4) \n7 ( 25.0) \n7 ( 6.0) \n2 ( 2.3) \n9 ( 7.8) \nEAR AND LABYRINTH DISORDERS \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nTympanic membrane perforation \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nGENERAL DISORDERS AND ADMINISTRATION SITE \nCONDITIONS \n0 \n2 ( 7.1) \n2 ( 1.7) \n0 \n2 ( 1.7) \nChest pain \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nInflammation \n0 \n2 ( 7.1) \n0 \n0 \n0 \nPeripheral swelling \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nHEPATOBILIARY DISORDERS \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nCholelithiasis \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nINFECTIONS AND INFESTATIONS \n1 ( 3.8) \n1 ( 3.6) \n1 ( 0.9) \n0 \n1 ( 0.9) \nAppendicitis \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nTonsillitis \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nINJURY, POISONING AND PROCEDURAL COMPLICATIONS \n0 \n0 \n1 ( 0.9) \n1 ( 1.1) \n2 ( 1.7) \nContusion \n0 \n0 \n0 \n1 ( 1.1) \n1 ( 0.9) \nTraumatic haemorrhage \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nMUSCULOSKELETAL AND CONNECTIVE TISSUE \nDISORDERS \n0 \n0 \n1 ( 0.9) \n1 ( 1.1) \n2 ( 1.7) \nHaemarthrosis \n0 \n0 \n1 ( 0.9) \n1 ( 1.1) \n2 ( 1.7) \nNEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED \n(INCL CYSTS AND POLYPS) \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nMeningioma \n0 \n0 \n1 ( 0.9) \n0 \n1 ( 0.9) \nNERVOUS SYSTEM DISORDERS \n0 \n1 ( 3.6) \n0 \n0 \n0 \nGeneralised tonic-clonic seizure \n0 \n1 ( 3.6) \n0 \n0 \n0 \nHaemorrhage intracranial \n0 \n1 ( 3.6) \n0 \n0 \n0 \nSOCIAL CIRCUMSTANCES \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nPhysical assault \n1 ( 3.8) \n1 ( 3.6) \n0 \n0 \n0 \nVASCULAR DISORDERS \n1 ( 3.8) \n1 ( 3.6) \n1 ( 0.9) \n0 \n1 ( 0.9) \nHaemorrhage \n1 ( 3.8) \n1 ( 3.6) \n1 ( 0.9) \n0 \n1 ( 0.9) \nTotal preferred term eventsa \n4 ( 15.4) \n8 ( 28.6) \n8 ( 6.9) \n2 ( 2.3) \n10 ( 8.6) \n"
    },
    {
      "page_number": 183,
      "text": "Assessment report \nEMA/464842/2024 \nPage 183/198 \n \nNumber of Participants Evaluable for AEs \nNumber(%) of Participants with Adverse Events: \nby System Organ Class and \nPreferred Term \nB7841002 \n(N=26) \nn (%) \nB7841002/ \nB7841003 \n(N=28) \nB7841005 \n(N=116) \nn (%) \nB7841007 \n(N=87) \nn (%) \nB7841005/ \nB7841007 \n(N=116) \nn (%) \nn (%) \nTotal Number of Casesb \n4 ( 15.4) \n8 ( 28.6) \n8 ( 6.9) \n2 ( 2.3) \n10 ( 8.6) \nTotal Number of Participants with Serious Adverse Eventsc \n4 ( 15.4) \n7 ( 25.0) \n7 ( 6.0) \n2 ( 2.3) \n9 ( 7.8) \nTotal Number of Participants with Serious Adverse Eventsd 16 \nA case is a single event or a series of related events not separated in time occurring in a single participant. \na. Total number of events per participant per cohort. \nb. Number of cases that started in the cohort. \nc. Total number of participants having an event that started in the cohort. \nd. Overall count of participants that had a Serious adverse Event in any cohort. \nSource of Serious AE is SDW(Safety Data Warehouse) or Argus. \nFor Study B7841003 SAEs reported for 2 participants occurred after their study participation, were not related to study drug by the PI, \nand were reported after the active collection period required by the protocol. Therefore, these SAEs were only recorded in the Safety \ndatabase and not recorded in the Study database (AE record). \nMedDRA v25.1 coding dictionary applied. \n \n \nOnly one SAE during the pivotal trial, peripheral swelling (right calf), was considered possibly related by the \ninvestigator. As it occurred in temporal relationship to initiation of treatment with marstacimab and no other \nalternative aetiology was identified, this assessment is endorsed. The leg swelling subsided spontaneously \nafter 3 days without intervention, a thrombosis above knee was excluded by ultrasound diagnostic imaging. \nThe other reported SAEs occurred during the OP, were bleeding in a target joint or had a different aetiology. \nNo other SAE was considered possibly or probably related to treatment, which can be followed from the \nprovided narratives. \nThe two SAEs of inflammatory response to a spontaneous bleed were reported 30 and 60 days after the end \nof treatment with marstacimab in clinical trial 1003. \nThe SAE “peripheral swelling” was judged as related by investigator and sponsor and has provided \nbackground information on this event and a justification why it is not considered an ADR. The applicant \nexplained that the swelling subsided without treatment and no VTE could be detected. \n \n \nDeaths \nNo deaths were reported in any of the marstacimab studies up to the data cut-off (17 April 2023 for the \npivotal study 1005, 10 March 2023 for its OLE 1007). \n \n2.6.8.4. Laboratory findings \n \nGenerally, review of the change from baseline for blood chemistry and haematology/ other laboratory \nparameters showed no clinically important findings in laboratory values in Studies B7841002/B7841003 or \nthe non-inhibitor cohort of Studies B7841005/B7841007. \n"
    },
    {
      "page_number": 184,
      "text": "Assessment report \nEMA/464842/2024 \nPage 184/198 \n \nCoagulation parameters were evaluated also as PD markers and are discussed in the clinical pharmacology \nsection of this AR. Consistent with the mode of action of marstacimab, an unspecific activation of the \ncoagulation system with increases of prothrombin fragment 1.2 and D-dimer could be shown. \n \n2.6.8.5. In vitro biomarker test for patient selection for safety \n \nNot applicable. \n \n2.6.8.6. Safety in special populations \n \nThe Applicant has provided subgroup analyses with regard to type of haemophilia, age, race, ethnic \nbackground and region. No safety signals are observable in any of the investigated subgroups. \nThe indication of marstacimab is envisaged for patients 12 years or older, and data from a total of 19 \nsubjects between 12 and <18 years of age are available for the safety evaluation in adolescents. The lowest \nweight in any participant in the pivotal trial was 35 kg. \nJust one patient in the safety database was older than 65, thus the clinical experience in elderly subjects is \nextremely limited. \n \n2.6.8.7. Immunological events \n \nTesting ADA positive had no overall impact on the incidence or severity of SAEs, TEAEs, and AESIs. There \nwas no notable pattern with regards to incidences of TEAEs reported for ADA-positive participants compared \nwith ADA-negative participants. The TEAEs were all mild to moderate (Grade 1 or 2) for ADA-positive \nparticipants. No life-threatening events were reported. \nIn Study B7841002, the 3 participants who tested ADA positive for marstacimab had safety findings generally \nconsistent with ADA-negative participants. None of the 3 participants tested NAb positive. All 3 participants \ncontinued into the long-term safety-follow-up Study B7841003, and tested ADA negative from baseline \nthrough the last study visit. No participant tested ADA positive in Study B7841003. \nDuring pivotal Study B7841005, the 23 participants who tested ADA positive for marstacimab, including the 6 \nparticipants who tested NAb positive, had safety findings generally consistent with ADA-negative participants. \n22 of the 23 ADA-positive participants tested ADA negative at the end of the study and 19 of the 23 ADA- \npositive participants continued into Study B7841007, as of the 10 March 2023 data cut-off. One of the 23 \nADA positive participants in Study B7841005 tested ADA positive but NAb negative in Study B7841007. \nIn conclusion, the immunogenicity evaluation showed that most cases of ADA or NAb were low-titre and \ntransient and did not impact the safety profile in a recognisable way. \n \n2.6.8.8. Safety related to drug-drug interactions and other interactions \n \nAs marstacimab is a monoclonal antibody which is expected to undergo the regular IgG catabolism, no PK \ninteractions with other medicinal products are expected. However, PD interactions with other treatments \naiming at the function of the coagulation system can be anticipated. Nonclinical data as well as clinical data \nfrom bleeding events treated with FVIII or FIX concentrates while being on marstacimab prophylaxis provide \n"
    },
    {
      "page_number": 185,
      "text": "Assessment report \nEMA/464842/2024 \nPage 185/198 \n \nreassuring evidence on the safety of treating breakthrough bleedings with lowest possible effective doses of \nFVIII or FIX preparations, as prescribed in the clinical study protocols. \nTFPI is the natural inhibitor of tissue factor (TF), which is the most potent initiator of coagulation. Beyond its \nrole in haemostasis, TF also has signalling activity and promotes pleiotropic inflammatory responses via \nprotease-activated receptors. (Witkowsi et al, DOI: 10.1016/j.tcm.2015.12.001) In pathophysiological \nconditions with increased tissue factor expression, such as infection, sepsis, cancer and crush injuries, \npotentiation of the inflammatory response via concomitant TFPI inhibition could pose a risk of adverse \nreactions, especially thrombosis. \n \n2.6.8.9. Discontinuation due to adverse events \n \nPivotal Trial \nStudy B7841005 compared AEs leading to discontinuation from study participation reported during the 6- \nmonth OP where participants continued their current factor replacement therapy in the form of on-demand or \nprophylactic treatment versus during the subsequent 12-month ATP where participants received marstacimab \nprophylaxis. \n• \nNo participants with prior on-demand treatment discontinued the study during the OP or ATP due to \nAEs. \n• \nFor participants with prior routine prophylaxis, no participants discontinued the study during the OP \ndue to AEs and 1 (1.2%) participant discontinued the study during the ATP due to an SAE of meningioma not \nrelated to study intervention. \n \n \nIntegrated Safety Analysis Population \nAn integrated overview of discontinuations across relevant studies in Marstacimab Dataset showed: \n• \nIn Study B7841005 during the ATP, which represents the initial 12 months of exposure, 1 (0.9%) \nparticipant discontinued from study due to AEs (meningioma, not considered treatment-related). \n• \nIn Study B7841007 which represents exposure of >12 to approximately 28 months, no participants \ndiscontinued from study due to AEs. \n• \nIn Studies B7841005/B7841007 where unique participants were combined to present the entire \nmarstacimab experience up to approximately 28 months at the intended dose, 1 (0.9%) participant \ndiscontinued from study due to AEs (meningioma, not considered treatment-related). \n• \nIn Study B7841002, where all participants received the intended or higher doses (150, 300, 450 mg) \nfor 3 months, 2 (7.7%) participants discontinued from study due to AEs (blood fibrinogen decreased and \nhypertension). These AEs were considered treatment-related. \n• \nIn Studies B7841002/B7841003 where unique participants were combined to present the entire \nmarstacimab experience up to 15 months with doses at 150 or 300 mg for 12 months, 2 (7.1) participants \ndiscontinued from study due to AEs (blood fibrinogen decreased and hypertension). These AEs were \nconsidered treatment-related. \nOnly one subject discontinued from the pivotal trial due to an unrelated AE. \n"
    },
    {
      "page_number": 186,
      "text": "Assessment report \nEMA/464842/2024 \nPage 186/198 \n \nIn general, study discontinuations and dose modifications were rare. \nTwo subjects discontinued a clinical study because of AEs blood fibrinogen decreased and hypertension, \nwhich were considered treatment related by the investigator and sponsor. The Applicant was asked to include \nthese AEs into table 4.8 of the SmPC or to justify their exclusion. After reviewing the narrative for the event \nof “fibrinogen decreased”, it is agreed with the sponsor that a relationship with marstacimab is unlikely. The \nAE of hypertension however, is considered to be an ADR. \n \n2.6.8.10. Post marketing experience \n \nNot applicable. \n \n \n \n2.6.9. Discussion on clinical safety \n \nExposure \nData from 144 unique male patients are available in the safety database, with 125 subjects exposed to \ntreatment with marstacimab for a duration of 12 months or longer. 116 of those patients suffered from \nsevere haemophilia A, while 28 subjects suffered from severe haemophilia B. Furthermore, 6 of the \nhaemophilia A patients were displaying inhibitors and enrolled in an inhibitor cohort in a phase 1 or phase 2 \nstudy. Safety data from the inhibitor cohort of the pivotal study were not included in the integrated safety \nanalysis. \nThe majority of subjects were between 18 and 44 years old, with a median age of 31.0 years. The number of \nsubjects ≥65 yoa in the clinical trial programme is extremely limited. Only one patient, aged 66, was enrolled \nin the pivotal trial. The lower age limit for inclusion into the pivotal trial was 12 years, and data from 19 \nadolescents, 15 with HA and 4 with HB are available. \nThe majority of patients were White (50.0%), followed by Asian (40.3%) and Black (9.0%) subjects. \nPooling strategy \nThe Pooling strategy, where safety data from \n• \npatients with or without inhibitors completing studies 1002 and 1003, \n• \npatients without inhibitors on completing study 1005 and in the ongoing LTE study 1007 \nwere included in the integrated safety analysis and the two prespecified pooled datasets (comparison dataset \nand Marstacimab dataset) were used in the integrated safety analysis, is considered to be adequate for the \nassessment of marstacimab safety in haemophilia A and B patients. \n \n \nAdverse Events \nThe adverse event profile across the multiple dose trials 1002/1003 and 1005/1007 shows that the most \nfrequently reported AEs irrespective of causality were COVID-19, headache, contusion and hypertension. The \nmost frequent treatment related AEs were injection site reactions and prothrombin fragment 1.2 increased. \n"
    },
    {
      "page_number": 187,
      "text": "Assessment report \nEMA/464842/2024 \nPage 187/198 \n \nThe AE profile was comparable in HA and HB and in those subjects who required a dose escalation. No \nspecific safety signal arises from the analysis of TEAEs. \nIn the integrated marstacimab dataset, the overall frequencies of AEs were noticeably higher in the Phase 2 \nstudies (studies 1002 and 1003) compared to both the ATP of Study 1005 and in the combined marstacimab \ndataset of studies 1005/1007. Given the higher marstacimab doses in the dose finding study 1002 this \ndisparity is not unexpected. Furthermore the frequencies of SAEs were also higher in the studies 1002 and \n1003 when contrasted with the integrated marstacimab dataset in studies 1005/1007. \nSAEs \nFrom the overall SAE profile, no specific concerns arise. \nDeaths \nNo deaths occurred during the clinical investigation programme until the data cut-off. \nAESIs \nThe following AESIs were predefined and analysed: Thromboembolic events, thrombotic microangiopathy, \ndisseminated intravascular coagulation/ consumption coagulopathy, injection site reactions, severe \nhypersensitivity and anaphylactic reactions, COVID-19 infections and other AEs requiring continuous \nmonitoring or treatment modification including: haemorrhage, hepatic disorder, drug-induced liver injury, \nliver related investigations (transaminases, aspartate aminotransferase, and alanine aminotransferase), and \nhypertension. \nTEEs/ thrombotic microangiopathy/ DIC/Consumption coagulopathy/ severe hypersensitivity and anaphylactic \nreactions \nNo such events were reported throughout the clinical development programme in subjects with haemophilia. \nOne event of DVT/PE was reported in a healthy volunteer, concomitantly to a vaccination with Vaxzevria. \nA specific warning on thromboembolic events has been added in section 4.4 of the SmPC. The use of other \nanti-tissue factor pathway inhibitor (anti-TFPI) products has been associated with the development of \nthromboembolic complications in patients exposed to additional haemostatic agents (i.e. bypassing agents) in \nclose proximity. The benefit and risk of using Hympavzi in patients with a history of thromboembolic events \nor currently experiencing an acute severe illness should be considered. Patients at risk should be monitored \nfor early signs of thrombosis, and prophylaxis measures against thromboembolism should be instituted \naccording to current recommendations and standard of care. Hympavzi prophylaxis should be interrupted if \ndiagnostic findings consistent with thromboembolism occur and manage as clinically indicated. In addition, \nthromboembolism has been added as an important potential risk in the safety specification of the RMP and a \nPost-Authorisation Safety Study to Evaluate the Safety of Marstacimab Among Patients with Severe \nHaemophilia A or B using Real-World Data in European Haemophilia Registers (B7841016) will be initiated \nwith the objective to evaluate the incidence rate of thromboembolic events among patients with severe \nhaemophilia A or B in the patient cohort treated with marstacimab during routine clinical care, relative to \ncomparator cohorts treated with standard of care, such as factor replacement therapy, and unexposed to \nmarstacimab. \nInjection site reactions \nIn Study B7841005, 11 (9.5%) participants reported ISRs with the most frequently reported being injection \nsite pruritus (4 [3.4%]) and erythema (3 [2.6%] participants). Most ISRs were mild (8.6%), with few \n"
    },
    {
      "page_number": 188,
      "text": "Assessment report \nEMA/464842/2024 \nPage 188/198 \n \nmoderate (0.9%) and no severe reactions. In Study B7841007, 3 (3.4%) participants reported ISRs. ISRs \nreported were injection site bruising, injection site induration and injection site swelling each in 1 participant \n[1.1%]. ISRs were mild (2.3%), or moderate (1.1%) with no severe reactions. All participants in Study \nB7841005 who were administered marstacimab used the PFS exclusively. All participants transitioning into \nStudy B7841007 were provided the PFP for marstacimab administration. All participants in Study B7841007 \nexcept 2 used the PFP exclusively. ISRs were reported with a lower frequency in Study B7841007 than in \nStudy B7841005 which may reflect the method of administration. \nCOVID-19 infections \nCOVID-19 (SMQ) occurred in 19 (22.9%) prior routine prophylaxis participants during the ATP compared to 3 \n(3.3%) participants during the OP. Many participants entered the ATP as COVID-19 rates were rising in early \n2022. No Covid-19 events occurred in subjects from clinical trial 1002/1003, 3 participants of trial 1007 \nreported Covid-19 events. \nHypertension \nHypertension was one of the most frequently reported AESIs and was observed with an incidence of 14% of \nsubjects in phase 2 + extension studies and 7% of subjects in the phase 3 + extension studies and has been \nincluded in the table under section 4.8 of the SmPC. \nDiscontinuation due to an AE \nOnly one subject discontinued from the pivotal trial due to an unrelated AE (meningioma). In general, study \ndiscontinuations and dose modifications were rare. \nSpecial Populations \nSubgroup analyses with regards to type of haemophilia, age, race, ethnic background and region were \nprovided. No safety signals emerged in any of the investigated subgroups. The lower age limit is adequately \nreflected in sections 4.1 and 4.2 of the SmPC. The lower bodyweight limit is mentioned in section 4.2 and \nwas included into section 4.1. \nLaboratory evaluations \nGenerally, review of the change from baseline for blood chemistry and haematology/ other laboratory \nparameters showed no clinically important findings in laboratory values in studies B7841002/B7841003 or \nthe non-inhibitor cohort of studies B7841005/B7841007. Coagulation parameters were evaluated also as PD \nmarkers and are discussed in the clinical pharmacology section of this AR. Consistent with the mode of action \nof marstacimab, an unspecific activation of the coagulation system with increases of prothrombin fragment \n1.2 and D-dimer could be shown. Nonclinical data as well as clinical data from bleeding events treated with \nFVIII or FIX concentrates while being on marstacimab prophylaxis provide reassuring evidence on the safety \nof treating breakthrough bleedings with lowest possible effective doses of FVIII or FIX preparations, as \nprescribed in the clinical study protocols. This recommendation is also accurately reflected in sections 4.2 and \n4.4 of the SmPC. \nIn pathophysiological conditions with increased tissue factor expression, such as infection, sepsis, cancer and \ncrush injuries, potentiation of the inflammatory response via concomitant TFPI inhibition could pose a risk of \nadverse reactions, especially thrombosis. A statement pertaining to the management of patients with acute \nsevere illness has been included in section 4.2 of the SmPC and a more detailed warning statement was \nadded in section 4.4 of the SmPC to alert treating physicians to the potential risks of treatment with \nmarstacimab during such disease states, especially with regards to thrombosis. \n"
    },
    {
      "page_number": 189,
      "text": "Assessment report \nEMA/464842/2024 \nPage 189/198 \n \nADA \nThe immunogenicity evaluation showed that most cases of ADA or nAb were low-titre and transient and did \nnot impact the safety profile in a recognisable way. In the pivotal study, 19.8% of subjects tested positive for \nADA during the trial, with only 1 of 23 patients still ADA positive at the end of the study. All NAbs were \ntreatment induced and transient in nature. No participants were NAb positive at the end of the study. \nDue to the small size of the safety database, only AEs with a frequency of up to “uncommon” can be \ndetected. The cut-off date of the safety database was March/April 2023, and the Applicant was asked to \nsubmit an updated analysis of all events of death, SAE and AESI reported since, also for the cohorts of \npatients suffering from haemophilia A or B with inhibitors enrolled in the pivotal trial B7841005/ extension \ntrial B7841007. A safety update with a new cut-off of 09 Oct 2023 was submitted. As the participation of the \nnon-inhibitor cohort in pivotal study 1005 was already complete with the original cut-off, additional safety \ndata for the non-inhibitor cohort derive from long-term extension study 1007. In addition, supportive data \nfrom the inhibitor cohorts of studies 1005 and 1007 as well as paediatric study 1008 were made available. \nThese new data confirmed the observed safety profile of marstacimab and no new safety signals arose. \nFrom the safety database all the adverse reactions reported in clinical trials have been included in the \nSummary of Product Characteristics. \n \n2.6.10. Conclusions on the clinical safety \n \nThe available safety database for marstacimab as a prophylactic agent in haemophilia without inhibitors \nshows that injection site reactions and ADA development were the most frequently reported adverse events. \nNo thromboembolic events or severe hypersensitivity or anaphylactic reactions were observed during the \nclinical trials. \nA marketing authorisation for Hympavzi can be recommended from a clinical safety perspective. \nThe CHMP considers the following measures necessary to address issues related to safety: \n• \nA Post-Authorisation Safety Study to Evaluate the Safety of Marstacimab Among Patients with Severe \nHaemophilia A or B using Real-World Data in European Haemophilia Registers (B7841016) \n"
    },
    {
      "page_number": 190,
      "text": "Assessment report \nEMA/464842/2024 \nPage 190/198 \n \n2.7. Risk Management Plan \n \n2.7.1. Safety concerns \n \nThe applicant proposed the following summary of safety concerns in the RMP: \n \nTable 52: Summary of safety concerns \n \nSummary of safety concerns \nImportant identified risks \nNone \nImportant potential risks \nThromboembolism \nMissing information \nNone \n \n2.7.2. Pharmacovigilance plan \n \nTable 53: On-going and planned additional pharmacovigilance activities \n \nStudy \nStatus \nSummary of \nobjectives \nSafety concerns \naddressed \nMilestones \nDue dates \nCategory 3 - Required additional pharmacovigilance activities (by the competent authority) \nA Post- \nAuthorisation \nSafety Study \nto Evaluate \nthe Safety of \nMarstacimab \nAmong \nPatients with \nSevere \nHaemophilia \nA or B using \nReal-World \nData in \nEuropean \nHaemophilia \nRegisters \n(B7841016) \nPlanned \nTo evaluate the \nincidence rate of \nthromboembolic events \namong patients with \nsevere haemophilia A \nor B in the patient \ncohort treated with \nmarstacimab during \nroutine clinical care, \nrelative to comparator \ncohorts treated with \nstandard of care, such \nas factor replacement \ntherapy, and \nunexposed to \nmarstacimab. \nThromboembolic \nevents \nProtocol \nsubmission \nWithin 6 months of \napproval for \nmarstacimab \nInterim/Progress \nReports \nInterim Report: 4 years \nafter the start of data \ncollection \nProgress reports to be \nreported with PSURs \nafter start of data \ncollection. \nFinal Report \nWithin 6 months after \nend of data collection, \nanticipated 30 June \n2033. \n \n2.7.3. Risk minimisation measures \n \nTable 54: Description of routine risk minimisation measures by safety concern \n \nSafety concern \nRoutine risk minimisation activities \nThromboembolism \nRoutine risk communication: \n"
    },
    {
      "page_number": 191,
      "text": "Assessment report \nEMA/464842/2024 \nPage 191/198 \n \nSmPC section 4.4 \nPL section 2 \nRoutine risk minimisation activities recommending specific clinical measures to \naddress the risk: \nNone \nOther routine risk minimisation measures beyond the Product Information: \nNone \n \n2.7.4. Conclusion \n \nThe CHMP considers that the risk management plan version 0.3 is acceptable. \n \n2.8. Pharmacovigilance \n \n2.8.1. Pharmacovigilance system \n \nThe CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the \nrequirements of Article 8(3) of Directive 2001/83/EC. \n \n2.8.2. Periodic Safety Update Reports submission requirements \n \nThe requirements for submission of periodic safety update reports for this medicinal product are set out in \nthe list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and \nany subsequent updates published on the European medicines web-portal. \n \n2.9. Product information \n \n2.9.1. User consultation \n \nThe results of the user consultation with target patient groups on the package leaflet submitted by the \napplicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the \nreadability of the label and package leaflet of medicinal products for human use. \n \n2.9.2. Additional monitoring \n \nPursuant to Article 23(1) of Regulation No (EU) 726/2004, Hympavzi (Marstacimab) is included in the \nadditional monitoring list as it contains a new active substance which on 1st January 2011 was not contained \nin any medicinal product authorised in the EU. \nTherefore, the summary of product characteristics and the package leaflet includes a statement that this \nmedicinal product is subject to additional monitoring and that this will allow quick identification of new safety \ninformation. The statement is preceded by an inverted equilateral black triangle. \n"
    },
    {
      "page_number": 192,
      "text": "Assessment report \nEMA/464842/2024 \nPage 192/198 \n \n3. Benefit-Risk Balance \n \n3.1. Therapeutic Context \n \n3.1.1. Disease or condition \n \nThe agreed indication is: Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 \nyears of age and older, weighing at least 35 kg, with: \n• \nsevere haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or \n• \nsevere haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. \n \n3.1.2. Available therapies and unmet medical need \n \nThe current standard of care for haemophilia A and B is replacement of the missing coagulation factor via \nexogenous factor VIII and IX products. Factor prophylaxis has to be administered via intravenous infusion up \nto 3 times weekly. Newer extended half-life products have reduced infusion frequency but still require IV \naccess. For haemophilia A, Hemlibra is an option for prophylactic treatment by a subcutanous route of \nadministration. In addition, for the control of spontaneous or traumatic bleeding events, on demand infusion \nof FVIII or FIX products are frequently necessary despite baseline prophylaxis. Recently, gene therapy \ntreatments have been approved for both haemophilia A (Roctavian) and Haemophilia B (Hemgenix) in \npatients without inhibitors against factors VIII or X respectively. \n \n3.1.3. Main clinical studies \n \nStudy B7841005 is an ongoing, one-way, cross-over, open-label, multi-centre study planned for \napproximately 145 adolescent and adult participants between 12 to <75 years of age with severe haemophilia \nA or moderately severe to severe haemophilia B (defined as FVIII activity <1%, or FIX activity ≤2%, \nrespectively) with or without inhibitor, with approximately 20% of participants as adolescents (ages between \n12 to <18 years old). The non-inhibitor cohort of this study is complete (N=111), whereas the inhibitor cohort \nis ongoing. The study duration for an individual participant is approximately 21 months, which includes a 45- \nday screening period, a 6-month observational phase (on-demand or routine prophylactic treatment), a 12- \nmonth active treatment phase (initial loading dose of 300mg marstacimab followed by prophylactic weekly \ntreatment with 150mg marstacimab), and a 1-month follow-up for safety monitoring. Patients weighing at \nleast 50 kg with 2 or more spontaneous (atraumatic) bleeds treated with infusion(s) of coagulation FVIII or \nFIX over a 6-month period in the absence of confirmed FVIII or FIX inhibitors were eligible for dose escalation \nto weekly 300mg marstacimab. \nStudy B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy \nof prophylaxis treatment with marstacimab in participants who successfully completed the Phase 3 Study \nB7841005. The study will continue until marstacimab is commercially available in each respective country \nor when the participants have completed 7 years of participation in Study B7841007, whichever occurs \nfirst. All participants are provided the pre-filled pen (PFP) for administration of marstacimab in the study. \nFeasibility of the PFP was evaluated in an optional open-label, single arm sub-study in 23 participants. \n"
    },
    {
      "page_number": 193,
      "text": "Assessment report \nEMA/464842/2024 \nPage 193/198 \n \n3.2. Favourable effects \n \nThe primary analysis demonstrated non-inferiority of marstacimab prophylaxis compared to routine \nprophylaxis at OP in a mixed population of HA and HB patients (combined analysis), as the ABR of treated \nbleeds in the non-inhibitor cohort was 5.08 (95% CI: 3.40, 6.77) during the active treatment period \ncompared to 7.85 (95% CI: 5.09, 10.61) during the observational period with routine prophylaxis in the \npivotal trial, with a resulting estimated ABR difference of -2.77 (95% CI: -5.37, -0.16). Since non-inferiority \nwas demonstrated, pre-specified statistical testing for superiority was performed and demonstrated \nsuperiority with a 2-sided p-value of 0.0376. The ABR for participants with haemophilia A was 5.30 for \nmarstacimab prophylaxis compared to 9.16 for routine prophylaxis during OP. The ABR for participants with \nhaemophilia B was 4.71 for marstacimab prophylaxis compared to 3.26 for routine prophylaxis during OP. \nIn patients with insufficient response to 150mg weekly marstacimab, dose escalation to 300mg weekly \nmarstacimab was effective in reducing mean ABR of treated bleeds (14.03 before dose increase, 3.42 after \ndose increase). \nRobustness of results was investigated using supplemental and sensitivity analyses, including investigations \nof the impact of carryover, seasonal effects, dose escalation, and discontinuations, which strengthened the \nprimary analysis. \nThe primary analysis was supported by secondary endpoints, which included investigations of the incidences \nof joint, spontaneous, target joint, and total bleeds. Non-inferiority was established for all bleeding rate \nsecondary endpoints, with reductions in ABRs reported under marstacimab treatment compared to previous \nroutine prophylaxis in all bleeding rate secondary endpoints. \nFor HA and HB patients without inhibitors previously on on-demand treatment during OP, marstacimab \nprophylaxis demonstrated superiority with a 2-sided p-value of <0.0001, providing support for the results of \nthe prophylaxis OP cohort. The mean estimated ABR was 3.18 (95% CI: 2.09, 4.85) for marstacimab \nprophylaxis compared to 38.00 (95% CI: 31.03, 46.54) for on-demand treatment, with an estimated ABR \nratio of 0.084 (95% CI: 0.059, 0.119). The number of participants with 0 treated bleeds increased from 1/33 \n(3.0%) during OP to 10/33 (30.3%) during ATP. \n \n3.3. Uncertainties and limitations about favourable effects \n \nCurrently available data from HB patients is limited (N=28), with particular limitations of the HB adolescent \npopulation (N=4). \nAmong patients treated according to the dose escalation protocol, a marked overrepresentation of HB \nparticipants was noted. However, the proportion of patients eligible for dose escalation was largely \ncomparable between haemophilia types, alleviating this uncertainty. \nThe ABR for treated bleeds reported for HA patients during routine prophylaxis OP was high compared to \nother clinical studies with routine prophylaxis factor VIII treatment arms, seemingly due to poor compliance \nof some participants at baseline. \nDespite the decrease in ABRs across all bleeding rate related endpoints during marstacimab treatment, \nseveral marstacimab non-responders or poor-responders were identified. \nPercentages of 0 bleeders were decreased compared to previous routine prophylaxis for all bleeding types \n(treated bleeds, joint bleeds, spontaneous bleeds, target joint bleeds, and total bleeds). \n"
    },
    {
      "page_number": 194,
      "text": "Assessment report \nEMA/464842/2024 \nPage 194/198 \n \nA small dose finding study (B7841002) was conducted but the results were inconclusive due to the low \nsample size for each treatment group. \n \n3.4. Unfavourable effects \n \nThe adverse event profile across the multiple dose trials 1002/1003 and 1005/1007 shows that the most \nfrequently reported AEs irrespective of causality were COVID-19, headache, contusion and hypertension. The \nmost frequent treatment related AEs were injection site reactions and prothrombin fragment 1.2 increased. \nThe AE profile was comparable in HA and HB and in those subjects who required a dose escalation. \nThe immunogenicity evaluation showed that most cases of ADA or nAb were low-titre and transient and did \nnot impact the safety profile in a recognisable way. In the pivotal study, 19.8% of subjects tested positive for \nADA during the trial, with only 1 of 23 patients still ADA positive at the end of the study. All NAbs were \ntreatment induced and transient in nature. No participants were NAb positive at the end of the study. \nNo specific safety signal arises from the analysis of TEAEs, SAEs and AESIs. \nNo deaths occurred during the clinical development programme. \nThe cut-off date of the safety database was March/April 2023, and the Applicant was asked to submit an \nupdated analysis of all events of death, SAE and AESI reported since, also for the cohorts of patients \nsuffering from haemophilia A or B with inhibitors enrolled in the pivotal trial B7841005/ extension trial \nB7841007. The Applicant submitted a safety update with a new cut-off of 09 Oct 2023. As the participation of \nthe non-inhibitor cohort in pivotal study 1005 was already complete with the original cut-off, additional data \nfor the non-inhibitor cohort derive from long-term extension study 1007. In addition, supportive data from \nthe inhibitor cohorts of studies 1005 and 1007 as well as paediatric study 1008 were made available. These \nnew data confirmed the observed safety profile of marstacimab and no new safety signals arose. \n \n3.5. Uncertainties and limitations about unfavourable effects \n \nDue to the small size of the safety database, only AEs with a frequency of up to “uncommon” can be \ndetected. Few patients with HB are included in the safety population, of whom only 4 were adolescents. Only \none patient older than 65 was enrolled across all trials. \nThe use of other anti-tissue factor pathway inhibitor (anti-TFPI) products has been associated with the \ndevelopment of thromboembolic complications in patients exposed to additional haemostatic agents (i.e. \nbypassing agents) in close proximity. A specific warning on thromboembolic events has been added in section \n4.4 of the SmPC. The benefit and risk of using Hympavzi in patients with a history of thromboembolic events \nor currently experiencing an acute severe illness should be considered. In addition, thromboembolism has \nbeen added as an important potential risk in the safety specification of the RMP and a Post-Authorisation \nSafety Study to Evaluate the Safety of Marstacimab Among Patients with Severe Haemophilia A or B using \nReal-World Data in European Haemophilia Registers (B7841016) will be initiated with the objective to \nevaluate the incidence rate of thromboembolic events among patients with severe haemophilia A or B in the \npatient cohort treated with marstacimab during routine clinical care, relative to comparator cohorts treated \nwith standard of care, such as factor replacement therapy and unexposed to marstacimab. \n"
    },
    {
      "page_number": 195,
      "text": "Assessment report \nEMA/464842/2024 \nPage 195/198 \n \n3.6. Effects Table \n \nTable 55: Effects Table for Hympavzi as routine prophylaxis of bleeding episodes in patients 12 \nyears of age and older with severe haemophilia A or B without inhibitors \n \nEffect \nShort \nDescription \nUnit \nTreatment \nN=83 \nControl \nUncertainties \n/ \nStrength of \nevidence \nReferences \nFavourable Effects \nABR \npEP \ntreated \nbleeds \nMean \n(95% CI) \n5.08 \n(3.40, 6.77) \n7.85 \n(5.09, 10.61) \nroutine prophylaxis \n- Several \nmarstacimab \nnon- \nresponders or \npoor- \nresponders \nwere \nidentified. \n- Percentages \nof 0 bleeders \nwere \ndecreased \ncompared to \nprevious \nroutine \nprophylaxis for \nall bleeding \ntypes \nStudy \nB7841005 \nABR HA \npopulation \nTreated \nbleeds \nMean \n(SD) \n5.30 \n(8.540) \n9.16 \n(14.251) \nroutine prophylaxis \nStudy \nB7841005 \nABR HB \npopulation \nTreated \nbleeds \nMean \n(SD) \n4.71 \n(6.088) \n3.26 \n(3.305) \nroutine prophylaxis \nAvailable data \nfrom HB \npatients is \nlimited \n(N=28), with \nparticular \nlimitations of \nthe HB \nadolescent \npopulation \n(N=4) \nStudy \nB7841005 \nUnfavourable Effects \nInjection site \nreactions \nIncluding \npain, swelling, \nbruising, \npruritus, \nerythema \n% \nB7841005: \n9.5 % \nB7841002/B7 \n841003: 35.7 \n% \n- \nsmall size of \nthe safety \ndatabase(n=8 \n3) \nClinical safety \nsection 2.6.8 \nAnti-drug \nantibodies \n% \nB7841005: \n19.8 % \nB7841007: \n2.3 % \n- \nClinical safety \nsection 2.6.8. \nNeutralising \nantibodies \n% \nB7841005: \n5.2 % \nB7841007: \n0.0 % \n- \nClinical safety \nsection 2.6.8. \nAbbreviations: ABR annualised bleeding rate \n"
    },
    {
      "page_number": 196,
      "text": "Assessment report \nEMA/464842/2024 \nPage 196/198 \n \n3.7. Benefit-risk assessment and discussion \n \n3.7.1. Importance of favourable and unfavourable effects \n \nCurrently, the standard of care for patients with haemophilia A or B without inhibitors is replacement therapy \nwith FVIII or FIX products, which necessitates treatment with regular intravenous infusions every 2 to 3 \ndays. For newer extended half-life products, IV infusion intervals every week or even every 14 days can be \nsufficient, and for patients with haemophilia A, a subcutaneous prophylaxis option exists with Hemlibra. \nHympavzi is administered via flat dose weekly subcutaneous injections (300mg initial loading followed by \n150mg QW) for HA and HB patients ≥12 years of age above 35kg bodyweight). The proposed posology and \nmethod of administration are considered an important benefit, which are likely to increase treatment \ncompliance, especially as venous access, which is often difficult to achieve, is not necessary. \nThe MAA for Hympavzi is mainly based on results from the single pivotal study B7841005 conducted in \npatients with severe HA or HB without inhibitors ≥12 years of age. Hympavzi effectively reduced the \nfrequencies of bleeding events in the overall patient population when compared to routine FVIII or FIX \nreplacement prophylaxis during a run-in period of at least 6 months in the same subjects. Non-inferiority and \nstatistical superiority over routine prophylaxis were shown in the combined analysis. Further, superiority over \non-demand treatment was established. These results were robust, as demonstrated with informative \nsensitivity analyses investigating impact of various potential sources of bias. In patients experiencing \ninsufficient response to Hympavzi, dose escalation to 300 mg QW was effective in lowering the ABR of treated \nbleeds. The number of HB patients across the clinical programme was low (n=28), with particularly low \nnumbers for adolescent HB patients (n=4), with ambiguous efficacy results reported from the pivotal study. \nHowever, updated efficacy data for HB patients from LTE study 1007 provided reassuring additional data, \nalleviating initially raised concerns regarding efficacy in HB patients. \nWith the currently available safety data, no specific safety signal arose from the analysis of TEAEs, SAEs, and \nAESIs, and the safety profiles of patients with HA and HB were comparable. Also, no specific safety signals \nwere detected in the patient population who required a dose escalation. However, the size of the safety \ndatabase is small, allowing only detection of adverse events up to the frequency rare. Updated safety data as \nwell as supportive safety data for the inhibitor cohort of the pivotal trial and the ongoing paediatric trial \nconfirmed the observed safety profile. \n \n3.7.2. Balance of benefits and risks \n \nTreatment response in HA and HB patients is considered sufficiently characterised. \nWhile the number of HB patients across the clinical programme was low, with particularly low numbers of \nadolescents with HB, an update from the LTE study 1007 provided reassuring new data on the efficacy in HB \npatients, alleviating initially raised concerns regarding the treatment response in HB patients. \nThe observed safety profile is benign with comparable safety results in patients with HA and HB. \nThe wording in section 4.1 of the SmPC was amended versus originally proposed in order to account for the \nfact that no dose recommendation can be made for patients below 35 kg body weight since these patients \nwere excluded from the trials. \n"
    },
    {
      "page_number": 197,
      "text": "Assessment report \nEMA/464842/2024 \nPage 197/198 \n \nWeighing the established effect of Hympavzi treatment in patients with HA and HB and taking into account \nremaining uncertainties due to a limited patient sample of HB patients against the overall benign safety \nprofile reported from both HA and HB patients, the benefits of Hympavzi treatment are considered to exceed \nany risks. \n \n3.7.3. Additional considerations on the benefit-risk balance \n \nNot applicable. \n \n3.8. Conclusions \n \nThe overall benefit/risk balance of Hympavzi is positive, subject to the conditions stated in section \n‘Recommendations’. \n \n4. Recommendations \nSimilarity with authorised orphan medicinal products \nThe CHMP by consensus is of the opinion that Hympavzi is not similar to Alprolix, Idelvion, Roctavian and \nHemgenix within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000. See Appendix on \nSimilarity. \nOutcome \nBased on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the \nbenefit-risk balance of Hympavzi is favourable in the following indications: \nHympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, \nweighing at least 35 kg, with: \n• \nsevere haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or \n• \nsevere haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. \nConditions or restrictions regarding supply and use \nMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product \nCharacteristics, section 4.2). \nOther conditions and requirements of the marketing authorisation \n• \nPeriodic Safety Update Reports \nThe requirements for submission of periodic safety update reports for this medicinal product are set out in \nthe list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and \nany subsequent updates published on the European medicines web-portal. \nConditions or restrictions with regard to the safe and effective use of the medicinal product \n• \nRisk Management Plan (RMP) \nThe marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and \n"
    },
    {
      "page_number": 198,
      "text": "Assessment report \nEMA/464842/2024 \nPage 198/198 \n \ninterventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any \nagreed subsequent updates of the RMP. \nAn updated RMP should be submitted: \n• \nAt the request of the European Medicines Agency; \n• \nWhenever the risk management system is modified, especially as the result of new information \nbeing received that may lead to a significant change to the benefit/risk profile or as the result of an \nimportant (pharmacovigilance or risk minimisation) milestone being reached. \nConditions or restrictions with regard to the safe and effective use of the medicinal product to be \nimplemented by the Member States \nNot applicable. \nNew Active Substance Status \nBased on the CHMP review of the available data, the CHMP considers that marstacimab is to be qualified as a \nnew active substance in itself as it is not a constituent of a medicinal product previously authorised within the \nEuropean Union. \nRefer to Appendix on new active substance (NAS). \nPaediatric Data \nFurthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric \nInvestigation Plan P/0443/2022 and the results of these studies are reflected in the Summary of Product \nCharacteristics (SmPC) and, as appropriate, the Package Leaflet. \n"
    }
  ]
}